,source,target,edge
0,ClinicalTrials.gov,data,processed
1,Theresearchers,patients,recruit
2,ClinicalTrials.gov,data,processed
3,binge,disorders,Obese patients with
4,Criteria:-patients,lockdown period,experiment
5,ClinicalTrials.gov,data,processed
6,ClinicalTrials.gov,data,processed
7,Information,medication,includes
8,Parent,<16 years,Inclusion Criteria:-Children part
9,ClinicalTrials.gov,data,processed
10,ClinicalTrials.gov,data,processed
11,second swab,afterfor use,taken
12,consentthe research team,anonymised data case record form,complete
13,ClinicalTrials.gov,data,processed
14,ClinicalTrials.gov,data,processed
15,short term mortality,greatest potential toimprove outcomes,has
16,Known clinically suspected elevated intracranial pressure,strict control,necessitating
17,Patient,ECMO,receiving
18,ClinicalTrials.gov,data,processed
19,Inclusion Criteria:-Men,18 to 75 years,aged
20,ClinicalTrials.gov,data,processed
21,the World Health Organization,pandemic,declaredCOVID-19
22,ClinicalTrials.gov,data,processed
23,A Feasibility Study,design,has
24,ClinicalTrials.gov,data,processed
25,blood samples,Serological microbiological samples,collected within
26,ClinicalTrials.gov,data,processed
27,investigators,HCPs,define
28,investigators,physiological markers,evaluate
29,suicidal,pre - enrollment)-Previous instruction,survey
30,ClinicalTrials.gov,data,processed
31,COVID-19 pandemic prevention strategise,family lives,impacted
32,ClinicalTrials.gov,data,processed
33,China,use,recentlyapproved
34,Inclusion Criteria:-Males,> 18 years;-Patients,aged
35,ClinicalTrials.gov,data,processed
36,patients,theirvisual acuity,proposed for
37,EHR)and,password protected deidentified Excel document,collected from
38,ClinicalTrials.gov,data,processed
39,Renin,angiotensinogen,stimulates
40,studies,Angiotensin II,shown
41,ClinicalTrials.gov,data,processed
42,signs,inflammatory response activation,prescribed for
43,ClinicalTrials.gov,data,processed
44,Investigators,Project,start
45,Investigators,random permuted block size,use
46,patient population,adult patient,include
47,patients,access,get
48,Investigators,patient,refer
49,patients,access,get
50,Investigators,patient,contact
51,dietician,protein rich nutrition supplements,prescribe
52,Investigators,patient,refer
53,patients,access,get
54,patients,elevated risk score,have
55,Investigators,patient,refer
56,patients,access,get
57,ClinicalTrials.gov,data,processed
58,ClinicalTrials.gov,data,processed
59,the COVID-19 Outbreak,world transition,made
60,COACH,health directed behaviour,improve
61,ClinicalTrials.gov,data,processed
62,ClinicalTrials.gov,data,processed
63,Post - intervention measurements,place,take
64,ClinicalTrials.gov,data,processed
65,Patients,following criteria,be
66,The Program of All-Inclusive Care for the Elderly,comprehensive medical andsupportive services,provides
67,ClinicalTrials.gov,data,processed
68,ClinicalTrials.gov,data,processed
69,Patients,fourto hour treatment,receive
70,device,signs,returned to
71,Established central access,recent hemodialysis,received
72,Biopsy,cancer,proven
73,ClinicalTrials.gov,data,processed
74,Laboratory,infection,confirmed
75,ClinicalTrials.gov,data,processed
76,donationCollected plasma,procedures,undergo
77,ClinicalTrials.gov,data,processed
78,federal government,tocontrol,implemented
79,ClinicalTrials.gov,data,processed
80,tobacco use,damage tothe cardiovascular respiratory systems,cause
81,Inclusion Criteria:-Hong Kong resident,25,aged
82,ClinicalTrials.gov,data,processed
83,size,approach,recognized
84,Exploratory Clinical Study,health,poses
85,Albumin,6000.v,assessedusing
86,ClinicalTrials.gov,data,processed
87,Theinvestigation,effectiveness,testing
88,ClinicalTrials.gov,data,processed
89,Potentialparticipants,letter,receive
90,study questionnaire,following:1,include
91,ClinicalTrials.gov,data,processed
92,ClinicalTrials.gov,data,processed
93,reduction,proportion ofpatients,determine
94,ClinicalTrials.gov,data,processed
95,Group B,intervention,receive
96,ClinicalTrials.gov,data,processed
97,60 participants,hospital stay,whohave
98,investigators,investigators,arrange
99,MRI scan,60-70 minutes,take
100,investigators,participants,ask
101,ClinicalTrials.gov,data,processed
102,ClinicalTrials.gov,data,processed
103,Coronavirus,protective ventilation,requires
104,detection,pressure volume curve,need
105,Berlin criteria,EIT,equipped
106,ClinicalTrials.gov,data,processed
107,Nationwide Prospective Study,critical information,provide
108,ClinicalTrials.gov,data,processed
109,Coronavirus crisis,disturbance,caused
110,pediatric dentistry coursecoordinators,modifications,made
111,ClinicalTrials.gov,data,processed
112,Participants,survey link,alsoreceived
113,ClinicalTrials.gov,data,processed
114,Sinus Rinse,Viral Load,Reduce
115,arm,number,have
116,trial,endedfor,have
117,ClinicalTrials.gov,data,processed
118,ClinicalTrials.gov,data,processed
119,ClinicalTrials.gov,data,processed
120,TCZ treatment,mortality,reduce
121,ClinicalTrials.gov,data,processed
122,The World Health Organization,coronavirus disease,declared
123,ClinicalTrials.gov,data,processed
124,subjectivemeasures,psychometrics:1,include
125,ClinicalTrials.gov,data,processed
126,Systemic Sclerosis,multiple organsystems,affect
127,over 50%,psychologicalimpact,found
128,SSc,multipleorgan systems,affect
129,People,hand function,experience
130,SPIN Cohort participants,online assessments uponenrolment,complete
131,linear mixed model,random effectto account,include
132,ClinicalTrials.gov,data,processed
133,ClinicalTrials.gov,data,processed
134,multi - center prospective observational study,20 adult ARDS patients undermechanical ventilation,enroll
135,Contraindication,1,monitoring
136,ClinicalTrials.gov,data,processed
137,ClinicalTrials.gov,data,processed
138,Subject or Subject,one of the following:1,excluded
139,one of the novel coronavirus laboratory test results,positive.3,show
140,ClinicalTrials.gov,data,processed
141,23 foreign countries,new coronavirus pneumoniacases,reported
142,people panicand anxiety,prevention,affected
143,ClinicalTrials.gov,data,processed
144,tohave,trends,presumed tohave
145,Wewill,impact,examine
146,tohave,trends,presumed tohave
147,visitscan,patients,put
148,ClinicalTrials.gov,data,processed
149,Research,use,projectsrequire
150,ClinicalTrials.gov,data,processed
151,ClinicalTrials.gov,data,processed
152,TheINSPIRE ICOPE CARE program,evidence,provide
153,the FrenchPresidential Plan Grand Age,implementation,aligned with
154,TheINSPIRE ICOPE CARE program,self assessment,involves
155,onset,world,change
156,limited availability,control,hindering
157,Thesepatients,Thesepatients health status,lose
158,screening,polar questions,includes
159,ICOPE Monitor,identification andinformed consent,includes
160,score,robustness,indicate
161,Table,sample size calculation,2shows
162,ICOPE Apps,intrinsic capacityassessment,include
163,Frailtyhas,association,shown
164,ClinicalTrials.gov,data,processed
165,ClinicalTrials.gov,data,processed
166,theevaluation,priority,represents
167,ClinicalTrials.gov,data,processed
168,Recent evidence,higher levels,revealed
169,outbreak,publichealth crisis,causes
170,the World HealthOrganization,disease,named
171,Recent evidence,higher VEGF levels,revealed
172,Numerousstudies,key role,confirmed
173,ClinicalTrials.gov,data,processed
174,Obtained,informed consentExclusion,written
175,ClinicalTrials.gov,data,processed
176,ClinicalTrials.gov,qualitative interview data,processed
177,ClinicalTrials.gov,data,processed
178,ClinicalTrials.gov,data,processed
179,The Coronavirus,major influence,has
180,ClinicalTrials.gov,data,processed
181,Scientific societies,treatment modifications,recommended
182,withthe study,clinical impact,evaluates
183,onquality,metastatic colorectal cancer,made
184,Inclusion,digestive tumor Ongoing treatment,proven
185,ClinicalTrials.gov,data,processed
186,ClinicalTrials.gov,data,processed
187,global population andhealth care systems,unprecedented challenges,facing
188,present research proposal,oninflammation,focuses
189,thinningand destructuration,hidden endothelial surface adhesion moleculeslike,reveal
190,Recent advances,theaccurate differentiation,enabled
191,Infectionprevention measures,handhygiene,include
192,Current evidence,increased viability,shown
193,findings,potential,underline
194,pronounced inflammation,pulmonary microbiome,disrupt
195,Visible opposition,verbally orthrough behavior,Criteria:•
196,ClinicalTrials.gov,data,processed
197,ClinicalTrials.gov,data,processed
198,people,risk,increased
199,ClinicalTrials.gov,data,processed
200,studies,"the "" Post-intensive care Syndrome",described
201,ClinicalTrials.gov,data,processed
202,cross - sectional observational multi - centric study,single center internal control study design,utilize
203,purpose,use,compare
204,ClinicalTrials.gov,data,processed
205,the World Health Organisation,COVID-19a pandemic,declared
206,Childhood obesity,health,threatens
207,underlying drivers,manycommon factors,share
208,current evidence,clear dose response effect,shows
209,online KKH Sports Singapore program,4 weekly online sessions,involves
210,investigators,the following aims:1,address
211,ClinicalTrials.gov,data,processed
212,investigateddevice,30 second video,record
213,Subject,informed consent3,provided
214,ClinicalTrials.gov,data,processed
215,ClinicalTrials.gov,data,processed
216,novel coronavirus,international outbreak,caused
217,patients,severe kidneyabnormalities,show
218,ClinicalTrials.gov,data,processed
219,12 patients,ibrutinib,receive
220,Patients,ibrutinib,receive
221,Patients,usual care,receive
222,ClinicalTrials.gov,data,processed
223,study,family members,includes
224,ClinicalTrials.gov,data,processed
225,ClinicalTrials.gov,data,processed
226,Factors,withburnout,associated
227,ClinicalTrials.gov,data,processed
228,The RIsk Stratification,ICU Registry,RegistryCOVID-19
229,Risk stratification,emerging SARS CoV-2 pandemic,foundedduring
230,thatfar,health care systems capacity,exceeded
231,ClinicalTrials.gov,data,processed
232,ClinicalTrials.gov,data,processed
233,Physicalexercise,effects,has
234,ClinicalTrials.gov,data,processed
235,proposed Allo Prime universal viral protection mechanism,vaccination,involves
236,ClinicalTrials.gov,data,processed
237,ClinicalTrials.gov,data,processed
238,article,protocol,presents
239,About 10%,perinatal depression,experience
240,ClinicalTrials.gov,data,processed
241,ClinicalTrials.gov,data,processed
242,patient,supplemental oxygen,requires
243,patient guardian legal representative,written IRB approved informed consentExclusion,signed
244,Platelet,"75,000 mm3",count
245,ClinicalTrials.gov,data,processed
246,related data,infection,confirmed
247,ClinicalTrials.gov,related data,processed
248,Coronavirus,containment,caused
249,ThisDental Surgery questionnaire,16 questions,includes
250,Inclusion,dental surgeons associates volunteers,Criteria:-All
251,ClinicalTrials.gov,data,processed
252,pandemic,health caresystems,affected
253,patients,hydroxychloroquine HCL treatment,receive
254,Groups 1 and 2,patients,admitted
255,ClinicalTrials.gov,data,processed
256,ClinicalTrials.gov,data,processed
257,Inclusion Criteria:-Community dwelling adults,≥,aged
258,ClinicalTrials.gov,data,processed
259,COVID 19 pandemic,healthcare capacity,overwhelmed
260,Component 2- Case control,data elements,studycaptures
261,ClinicalTrials.gov,data,processed
262,Chest CT scan,specificity,alsodemonstrated
263,Voluntary,informed consent,written
264,ClinicalTrials.gov,data,processed
265,ClinicalTrials.gov,data,processed
266,double sampling,direct impact onconventional patient management,has
267,ClinicalTrials.gov,data,processed
268,Inclusion Criteria:-Adolescents,11 18 years old Previous consultation,aged
269,ClinicalTrials.gov,data,processed
270,strategy,highest percentage,conducted to
271,second aim,national perspectives,assess
272,Wewill,survey,administer
273,NIH,surveysfrom,recommended
274,surveys,Psychological StressAssociated,include
275,ClinicalTrials.gov,data,processed
276,investigators,extravascular lung water index,assesswhether
277,ClinicalTrials.gov,data,processed
278,COVID-19)Secondary Objectives:-To,time,evaluate
279,ClinicalTrials.gov,data,processed
280,Findings,future supportive interventions,inform
281,ClinicalTrials.gov,data,processed
282,ClinicalTrials.gov,data,processed
283,Participant,18,aged
284,ClinicalTrials.gov,data,processed
285,ClinicalTrials.gov,data,processed
286,ClinicalTrials.gov,data,processed
287,people,increasedstress,experiencing
288,COVID-19 publichealth crisis,resources,requires
289,Hospitals,visitor restrictions,instituting
290,healthcare changes,OB Gyn patients level,impacting
291,participants,baseline survey,complete
292,ClinicalTrials.gov,data,processed
293,people,increasedstress,experiencing
294,investigators,prospective evaluation,proposea
295,COVID-19 publichealth crisis,resources,requires
296,ClinicalTrials.gov,data,processed
297,"2019-nCoV),medical workers",enormous stress,facing
298,severe situation,mentalhealth problems,causing
299,Gutmicrobiota,brain function,influence
300,brain,gut microbiota trough neuronal andendocrine pathways,influence
301,reseaches,relevance,support
302,ClinicalTrials.gov,data,processed
303,COVID-19 pandemics,lives,changed
304,ClinicalTrials.gov,data,processed
305,Patients,time,seen
306,ClinicalTrials.gov,data,processed
307,ClinicalTrials.gov,data,processed
308,ClinicalTrials.gov,data,processed
309,Favipiravir,anti - viral activity,shown
310,unit,250 mL beer,History of
311,ClinicalTrials.gov,data,processed
312,About 20%,chronic disease,have
313,ClinicalTrials.gov,data,processed
314,Salaried staff,carrying,opposing
315,Underage,staff,salaried
316,ClinicalTrials.gov,data,processed
317,ClinicalTrials.gov,data,processed
318,ClinicalTrials.gov,data,processed
319,ClinicalTrials.gov,data,processed
320,diabetic complications,answers,provide
321,ClinicalTrials.gov,data,processed
322,Inclusion Criteria:-Able,informed consentExclusion Criteria:-None,provide
323,ClinicalTrials.gov,data,processed
324,ClinicalTrials.gov,data,processed
325,ClinicalTrials.gov,data,processed
326,Healthcare professionals,psychological burden,experience
327,ClinicalTrials.gov,data,processed
328,organizations,free access mobile applications,created
329,investigators,random sample,ask
330,ClinicalTrials.gov,data,processed
331,ClinicalTrials.gov,data,processed
332,ClinicalTrials.gov,data,processed
333,ClinicalTrials.gov,data,processed
334,ClinicalTrials.gov,data,processed
335,mandateddirectives,routine daily activities,disruptthe
336,Participants,questionnaires,complete
337,structured questionnaire,coveredseveral areas,consists of
338,Physical symptom variables,fever,included
339,Contacthistory variables,close contact,include
340,"Questions 3, 5",depression subscale,form
341,Questions,anxiety subscale,form
342,18 will,stresssubscale,"Questions 1, 6, 8, 11, 12, 14"
343,ClinicalTrials.gov,data,processed
344,ClinicalTrials.gov,data,processed
345,production,theinflammatory cascade,exacerbate
346,ClinicalTrials.gov,data,processed
347,SARS CoV-2,4 million people,infected
348,Human infections,major human public health threats,pose
349,"with3131,545 deaths",aparticularly high mortality rate,has
350,™ vaccine,Sf9 platform,manufacturedusing
351,ClinicalTrials.gov,data,processed
352,COVID-19 outbreak,public panic,caused
353,rapidly changinginformation,elicitedfear,have
354,people,information,consume
355,indirect exposure,wide range,has
356,Corriganand,important ingredients,identified
357,ClinicalTrials.gov,data,processed
358,Prosocial Behavior,Mental Health Foster Emotional,Safeguard
359,Prosocial Behavior,Mental Health Foster Emotional,Safeguard
360,research teamwill,participants emotional,measure
361,researchers,participants,At
362,research team,experimental effectsusing multiple linear regression,assess
363,models,indicator variables forexperimental conditions,include
364,research team,baseline survey,post
365,meansrespondents,their first three days,finish
366,SPI calculations,optional items.2,exclude
367,respondent,at least half,complete
368,respondent,topic non - sensical non - English responses,provides
369,ClinicalTrials.gov,data,processed
370,case,dates,diagnosed
371,ClinicalTrials.gov,data,processed
372,coronaviruses,high seasonality,exhibited
373,chronic hypovitaminosis D,pulmonary fibrosis,induces
374,biological measures,Social demographic measures,arecollected
375,ClinicalTrials.gov,data,processed
376,ClinicalTrials.gov,data,processed
377,ClinicalTrials.gov,data,processed
378,ClinicalTrials.gov,data,processed
379,Study,800 subjects,randomize
380,Subjectswill,itolizumab,receive
381,ClinicalTrials.gov,data,processed
382,SARS CoV-2,human cells,invades
383,ClinicalTrials.gov,data,processed
384,Mitochondrial Disease,poor growth,cause
385,Participants,questionnaire,complete
386,Participants,blood sample,give
387,Participants,diagnosis,have
388,Supportive evidence,genetic testing,include
389,Laboratory,positive testing,confirmed
390,Participants,diagnosis,have
391,Supportive evidence,genetic testing,include
392,participants,evidence,have
393,Participants,greater 4 kilograms.3,weigh
394,ClinicalTrials.gov,data,processed
395,patients,RT PCR positive nasopharyngeal swab results,hadpositive
396,Hypoxic,Non - severe COVID,intubated
397,ClinicalTrials.gov,data,processed
398,ClinicalTrials.gov,data,processed
399,genetic analysis,new coronavirus,indicated
400,analysis,existence,shows
401,ClinicalTrials.gov,data,processed
402,ClinicalTrials.gov,data,processed
403,questionnaire,arepart,contains
404,ClinicalTrials.gov,data,processed
405,ClinicalTrials.gov,data,processed
406,ClinicalTrials.gov,data,processed
407,emergency confinement measures,impact,tolimit
408,ClinicalTrials.gov,data,processed
409,ClinicalTrials.gov,data,processed
410,control group participants,sentences,unscramble
411,Participants,feedback,get
412,groups,psycho education video,watch
413,ClinicalTrials.gov,data,processed
414,ClinicalTrials.gov,data,processed
415,Randomized Phase,Clinical Trial,IIa
416,Phase,clinical trial,IIa
417,Secondary endpoints,safety,include
418,The United States,2.5 million cases,seen
419,Current data,incubation period,suggest
420,SOC)for,patients,considered in
421,CSA,hyperimmune states,suppresses
422,CSA,coronavirus replication,inhibits
423,Spain,universal relationship,Another study of
424,The PI,thorough discussions,undertaken
425,ClinicalTrials.gov,data,processed
426,ClinicalTrials.gov,data,processed
427,brief verbal survey,confidential questionsregarding basic demographics,entail
428,ClinicalTrials.gov,data,processed
429,Inclusion Criteria:-The selection criteria,staff nurses,working
430,ClinicalTrials.gov,data,processed
431,ClinicalTrials.gov,data,processed
432,Public Health England,ongoing sero prevalence programme,has
433,ClinicalTrials.gov,data,processed
434,ClinicalTrials.gov,data,processed
435,ClinicalTrials.gov,data,processed
436,ClinicalTrials.gov,data,processed
437,ClinicalTrials.gov,data,processed
438,Confinement,lives,changes
439,ClinicalTrials.gov,data,processed
440,the World Health Organization,SARS CoV-2,declared
441,the World Health Organization,coronavirus disease(COVID-19,declared
442,fear,higher rates,causes
443,chloroquine,promise,shown
444,CQ,virus infection,shown
445,ClinicalTrials.gov,data,processed
446,ClinicalTrials.gov,data,processed
447,ClinicalTrials.gov,data,processed
448,T2 patients,spirometry,undergo
449,ClinicalTrials.gov,data,processed
450,prospective randomised open label study,standard clinical care,verses
451,Participants,exit,willstudy
452,ClinicalTrials.gov,data,processed
453,cohort,20 participants,have
454,participants,standard,receive
455,ClinicalTrials.gov,data,processed
456,addition,themechanisms,promotes
457,ClinicalTrials.gov,data,processed
458,ClinicalTrials.gov,data,processed
459,Inclusion,American older adults,Criteria:-African
460,deficit,English,read
461,ClinicalTrials.gov,data,processed
462,Patients,topical antifungals,receiving
463,patients,systemic corticosteroids,using
464,ClinicalTrials.gov,data,processed
465,Danishgovernment,social distancing,recommends
466,factors,thequality,affect
467,newpandemic situation,concerns,cause
468,Patients,cancer treatment,receiving
469,ClinicalTrials.gov,data,processed
470,ClinicalTrials.gov,data,processed
471,ClinicalTrials.gov,data,processed
472,ClinicalTrials.gov,data,processed
473,ClinicalTrials.gov,data,processed
474,global pandemic,atremendous impact,had
475,patients,information,"Further, a better understand on"
476,Patients,functional graft,transplantedwith
477,ClinicalTrials.gov,data,processed
478,Restoringhomeostasis,effective functioning,involves
479,ancillary study,study,complement
480,ClinicalTrials.gov,data,processed
481,ClinicalTrials.gov,data,processed
482,ClinicalTrials.gov,data,processed
483,Patient and/or family,data collection,decline
484,ClinicalTrials.gov,data,processed
485,(SCD,"100,000 people",affects
486,secondary objectives,attitudes,Secondary Objectives
487,opening,fromfourth wave,analyses
488,ClinicalTrials.gov,data,processed
489,tenth woman hasdepressive symptoms,major depression,suffer
490,easilyaccessible eHealth support,fast resource effective care,provide
491,ClinicalTrials.gov,data,processed
492,History,14,pointes
493,ClinicalTrials.gov,data,processed
494,ClinicalTrials.gov,data,processed
495,ClinicalTrials.gov,data,processed
496,Immunocompromised persons,high titers,shed
497,ClinicalTrials.gov,data,processed
498,Doxycycline,specimens,based on
499,ClinicalTrials.gov,data,processed
500,ClinicalTrials.gov,data,processed
501,Caregivers,Technologies,Using
502,Caregivers,Technologies,Using
503,Spanish government,social distancing,hasenforced
504,inadequate access,chronic conditions,aggravate
505,ClinicalTrials.gov,data,processed
506,Disclosure,participants,unblind
507,ClinicalTrials.gov,data,processed
508,Project,impact,studies
509,interventionthat,personalized feedback,provides
510,Peer Resilience Champions,evidence based principles,follow
511,study design,controlled comparison,provides
512,cluster,support,receive
513,the Express Survey,email address,collects
514,the Express Survey,measures,includes
515,Enriched T1 toT6 surveys,about 10-20 minutes,take
516,ClinicalTrials.gov,data,processed
517,depression,effects,increase in
518,Form,socio demographic features,templateincluded
519,ClinicalTrials.gov,data,processed
520,Colorectal cancer patients,19 pandemic,subjected to
521,ClinicalTrials.gov,30 day post operative outcome data,processed
522,Community health workers,emotionalsupport,offer
523,community health workers,psychosocial impact,reduce
524,ClinicalTrials.gov,data,processed
525,Patients,rintatolimod IV,receive
526,ClinicalTrials.gov,data,processed
527,the WorldHealth Organization,COVID-19,declared
528,COVID-19 manifests,respiratory illness,reported
529,Cardiovascular disease,early diagnosis,allow for
530,ClinicalTrials.gov,data,processed
531,ClinicalTrials.gov,data,processed
532,project,data,collect
533,dialysis Patients,Chronic dialysis,Inclusion
534,ClinicalTrials.gov,data,processed
535,subjects,gender,havethe
536,investigators,demand,willassess
537,investigators,information,obtain
538,ClinicalTrials.gov,data,processed
539,Cross-Sectional Observation Telephone Survey Study,Changes,Understand
540,ClinicalTrials.gov,data,processed
541,COVID-19,large number,causes
542,virus,total,caused
543,house,limitation,notleaving
544,approximately45%,recommended level,meet
545,Individuals,healthy diets,report
546,ClinicalTrials.gov,data,processed
547,1 5 women,mentalillness,estimated
548,study,national required dataprotection standards,follow
549,pandemic,fear,causing
550,Pregnant women,mothers,Participants
551,number,minimum group size,estimate
552,study,deception,include
553,online survey,changes,elicit
554,ClinicalTrials.gov,data,processed
555,ClinicalTrials.gov,data,processed
556,ClinicalTrials.gov,data,processed
557,research subjects,online.1,participate
558,Brief demographics,questions,survey
559,Individuals,videos,see
560,individuals,video,see
561,ClinicalTrials.gov,data,processed
562,ClinicalTrials.gov,data,processed
563,ClinicalTrials.gov,data,processed
564,50 ofthem,intensive care,admitted to
565,study,theeffect,investigate
566,"10E9 L,-lymphocyte",0.6,count
567,ClinicalTrials.gov,data,processed
568,Wehave,data,collected
569,Eligibility,patients,150
570,Patients,riskthat,reduced
571,patients,Dexamethasone 4 mg/kg/day,received
572,patients,informed consent,provided
573,ClinicalTrials.gov,data,processed
574,cases,one million,confirmed
575,important relationships,betweeninfection cardiovascular diseases,emerge
576,COVID-19 patients,severe course,have
577,impact,new possible prognostic risk,Explore
578,ClinicalTrials.gov,data,processed
579,Healthy males,≥,aged
580,ClinicalTrials.gov,data,processed
581,ClinicalTrials.gov,data,processed
582,Additional studies,promisingoutcome,shown
583,Secondary factors,evaluation,willinclude
584,ClinicalTrials.gov,data,processed
585,ClinicalTrials.gov,data,processed
586,Evaluation,FHU,the Management of Patients With Inflammatory and Dysimmune Diseases Followed in
587,Evaluation,End,Lock Down
588,ClinicalTrials.gov,data,processed
589,ClinicalTrials.gov,data,processed
590,Physician burnout,significant impact,has
591,virtual delivery platform,proposed intervention,renders
592,ClinicalTrials.gov,data,processed
593,ClinicalTrials.gov,data,processed
594,ClinicalTrials.gov,data,processed
595,Acute Respiratory Tract Infection,adouble blind randomized design comparing supplementation,follow
596,exclusion,upwards adjustment,conducted to
597,ClinicalTrials.gov,data,processed
598,ClinicalTrials.gov,data,processed
599,bindings,dendritic cells,activate
600,TLR7 andTLR8,simple-chain RNA,recognize
601,ClinicalTrials.gov,data,processed
602,Mindfulness,significant results interms,done
603,ClinicalTrials.gov,data,processed
604,dentist,weight,check
605,ClinicalTrials.gov,data,processed
606,ClinicalTrials.gov,data,processed
607,PTX,HR-QoL,improve
608,reduced number,direct cost,decreasethe
609,Introduction Paroxysmal atrial fibrillation,increasedrisk,induce
610,majority,symptoms,have
611,duration andfrequencies,patient suffering,causes
612,andan,risk,increased
613,willparticipation,symptoms,allowed to
614,Study,multi centre randomised controlled trial Patients,design
615,ClinicalTrials.gov,data,processed
616,Studies,demonstratedthe systemic local effects,have
617,ClinicalTrials.gov,data,processed
618,Preliminary evidence,worse outcomes,suggests
619,Preliminary evidence,worse outcomes,suggests
620,ClinicalTrials.gov,data,processed
621,Brazilian Multicenter Study,information,provide
622,ClinicalTrials.gov,data,processed
623,Respiratory infection,mechanical ventilation,require
624,Patient,over 18 years,aged
625,ClinicalTrials.gov,data,processed
626,patients.-Patients,immunomodulators,Acute Respiratory Distress Syndrome
627,ClinicalTrials.gov,data,processed
628,purpose,presence,detect
629,ClinicalTrials.gov,data,processed
630,ClinicalTrials.gov,data,processed
631,second,sera,collect
632,second,sera,collect
633,ClinicalTrials.gov,data,processed
634,ClinicalTrials.gov,data,processed
635,110 mmHg Patient,history,reported
636,ClinicalTrials.gov,data,processed
637,ClinicalTrials.gov,data,processed
638,large epidemic,available hospital capacity,challengethe
639,participants,participants treatment allocation,receive
640,allhealth care providers,information,performed to
641,Data,medical history,includes
642,Data,eligibility confirmation,includes
643,participants,unsolicited AEs,report
644,individual,s41586,found in
645,participants,symptoms,be
646,exclusion category,subjects,subjects with
647,ClinicalTrials.gov,data,processed
648,Virtual Eye Movement Desensitisation,Psychological Outcome,Improve
649,patients,related critical illness,survived
650,Eye-Movement Desensitisation,incidence,reduced
651,Small studies,Small studies,shown
652,ClinicalTrials.gov,data,processed
653,research,plaque reductionneutralizing test,conduct
654,Investigators,approximately 10 patients,enroll
655,convalescent plasma,cell infected virus,neutralize
656,recipients,eligibility criteria,enrolled
657,Investigators,mean difference,find
658,Investigators,potential expected andtheoretical risks,weighing
659,donor,plasmadraw,revoke
660,ClinicalTrials.gov,data,processed
661,ClinicalTrials.gov,data,processed
662,Modelling,strategies,informing
663,Blood,Nasal,samples
664,ClinicalTrials.gov,data,processed
665,Informed Consent Forms,patients,forenrolled
666,screening visit,includemedical history,will
667,Daily safety labs,CBC chemistry panel,include
668,Patients,follow visits,have
669,visitsmay,place,take
670,patient,ability,has
671,Chronic liver failure,exclusion criterion,tests not
672,ClinicalTrials.gov,data,processed
673,ClinicalTrials.gov,data,processed
674,DESIGN,clinical trial,randomized
675,ClinicalTrials.gov,data,processed
676,The World Health Organization,comprehensive guidelines underscoringpersonal hygiene measures,presented
677,ClinicalTrials.gov,data,processed
678,Patients,special demographic characteristics,have
679,patient,morethan 120 kg,increased
680,ClinicalTrials.gov,data,processed
681,studies,potential role,indicated
682,Hydroxychloroquine,potentinhibition,demonstrated
683,approximately 50%,form,currentlyreceiving
684,smallstudies,potential role,indicated
685,OSF Data Analytics,reports,inflammatories
686,Study staff,highest degree,maintain
687,ClinicalTrials.gov,data,processed
688,SOC,provider,treating
689,ClinicalTrials.gov,data,processed
690,patients,care,taken
691,ClinicalTrials.gov,data,processed
692,High flow nasal cannula,intubation,prevent
693,SpO2 FiO2,consent.-Beneficiary,equivalent).-Informed
694,ClinicalTrials.gov,data,processed
695,the MGH,outpatient testing,began
696,Managers,necessary team structures andmedian salaries,shared
697,actual worldwide context,stressful factor,isa
698,causes,lengh,Assess
699,ClinicalTrials.gov,data,processed
700,ClinicalTrials.gov,data,processed
701,ClinicalTrials.gov,data,processed
702,source population,patients,represents
703,ClinicalTrials.gov,data,processed
704,use,important advantages,has
705,conditions,it).-<48 hours,sought
706,ClinicalTrials.gov,data,processed
707,Exclusion CriteriaThe volunteer,open label non - randomized clinical trial study,enter
708,ClinicalTrials.gov,data,processed
709,Pan et al,fibrous stripes,observed
710,ClinicalTrials.gov,data,processed
711,progressive endothelial thromboinflammatory syndrome,themicrovascular bed,involve
712,someinvestigators,patients,reported
713,participating center,separate computer generated randomizationschedule,has
714,Contrast CT,positive,scan
715,arterial venous malformations,veins,esophageal
716,ClinicalTrials.gov,data,processed
717,VPM1002 vaccination,partial protection,assumed
718,total,single dose,receive
719,Theinvestigators,outcome safety data,review
720,ClinicalTrials.gov,data,processed
721,children,clinical consequences,present
722,children,clinical consequences,present
723,V4).Main analyses,analyses,comprise
724,ClinicalTrials.gov,data,processed
725,HCQ,efficacyagainst SARS CoV-1,has
726,reported effects,suppressionof fungi,include
727,neitheragent,consistent efficacy,demonstrated
728,Anunderpowered n=30 study,clinical benefit,demonstrateany
729,long history ofclinical failure,low probability,suggests
730,patients,access,is
731,ClinicalTrials.gov,data,processed
732,Patients,emergency department,visiting
733,ClinicalTrials.gov,data,processed
734,ClinicalTrials.gov,data,processed
735,virus,theirgenome,is
736,Thecoronavirus surface protein spike,entry,mediates
737,CoV-2-S protein,2,utilizes
738,ClinicalTrials.gov,data,processed
739,histology,non pancreatic3,showed
740,ClinicalTrials.gov,data,processed
741,ClinicalTrials.gov,data,processed
742,COVID-19 Pandemic,new challenges,brought
743,reminders,incase,send
744,ClinicalTrials.gov,data,processed
745,ClinicalTrials.gov,data,processed
746,"2,3 COVID-19pandemic",services.4,affected
747,reduction,anincrease,cause
748,ClinicalTrials.gov,data,processed
749,Male female subjects,18 to 45 years,aged
750,Vital signs,abnormalities,show
751,Subjects,fertility plan,have
752,ClinicalTrials.gov,data,processed
753,ClinicalTrials.gov,data,processed
754,ClinicalTrials.gov,data,processed
755,-CoV-2,diagnosis,confirmed
756,ClinicalTrials.gov,Data,processed
757,Presence,PTSD symptoms,predict
758,questions,theoretically driven selections,given
759,study,Cross - sectional survey design,involves
760,Public service providerswere,trough Facebook,recruited
761,investigators,items,combined
762,conservative estimates,1900.Statistical models,included
763,way ANOVA Kruskal Wallis test,toexploratory investigate differences,conducted
764,investigatorswill,test,used
765,ClinicalTrials.gov,data,processed
766,Epidemiologicalstudies,biological myocardial involvement,report
767,ClinicalTrials.gov,data,processed
768,Inclusion Criteria:-Participant,body mass index,have
769,investigators,potential,evaluate
770,ClinicalTrials.gov,data,processed
771,334 million people,asthma,estimated
772,ClinicalTrials.gov,data,processed
773,ClinicalTrials.gov,data,processed
774,ClinicalTrials.gov,data,processed
775,wait list design,controlled trial,randomised
776,Investigators,symptoms,monitor
777,Specific study objectives,uncertainties,address
778,findings,choice,inform
779,participants,Intervention,willreceive
780,tele rehabilitation programme,aninitial assessment,comprise
781,EQ-5D-5L anxiety depression domain,insight,provide
782,STST,good correlation,hasshown
783,Significant comorbid physical mental illness,engagement,prevent
784,ClinicalTrials.gov,data,processed
785,Subjects,ibudilast 100 mg d,receive
786,ClinicalTrials.gov,data,processed
787,semi - partial correlation,biased easiestinterpretable estimate,gives
788,survey,mandatory fields,includes
789,ClinicalTrials.gov,data,processed
790,ClinicalTrials.gov,data,processed
791,epidemiological reports,disproportionate low rate,unveiled
792,activation,inhibitors,androgensynthesis
793,Inclusion Criteria:-Male,SARS CoV-2 infection,confirmed
794,ClinicalTrials.gov,data,processed
795,multicenter study,fixed dose combination,provides
796,ClinicalTrials.gov,data,processed
797,ClinicalTrials.gov,data,processed
798,Patients,markedly varied clinicalpresentations,have
799,ClinicalTrials.gov,data,processed
800,hospitals,incredible challenges,facing
801,ClinicalTrials.gov,data,processed
802,brief online delivered cognitive behavioralintervention,degree,is to
803,ClinicalTrials.gov,data,processed
804,Efficacy,Strengthening,Via
805,Data,protection,demonstrated
806,Arecent study,- vaccination,showed
807,recent ecological observations,inversecorrelation,suggest
808,Participants,single dose,receive
809,Analysis,placeafter M6 visits,take
810,ClinicalTrials.gov,data,processed
811,professional,experience,Secondary variables
812,contact,aforementioned variables,provide
813,ClinicalTrials.gov,data,processed
814,unit,250 mL beer,History of
815,ClinicalTrials.gov,data,processed
816,COVID-19,high mortality.-Patients,have
817,oncological benign pathologies,high morbidity,have
818,ClinicalTrials.gov,data,processed
819,therapy,progression,test
820,donor compound S nitroso N acetylpenicillamine increased survival rate inan model,epithelial cells,infected
821,Laboratory,COVID19 infection,confirmed
822,ClinicalTrials.gov,data,processed
823,ClinicalTrials.gov,data,processed
824,understanding,considerableknowledge,gained
825,Complex anddelicately balanced interaction,cellular andhumoral components,involve
826,ClinicalTrials.gov,data,processed
827,ClinicalTrials.gov,data,processed
828,The World Health Organization,coronavirus disease,declared
829,health care workers,internet,using
830,ClinicalTrials.gov,data,processed
831,ClinicalTrials.gov,data,processed
832,process,health status,affected
833,ISL)lymphedema,classification,evaluated by
834,ClinicalTrials.gov,data,processed
835,patient,complete hospitalization record,has
836,ClinicalTrials.gov,data,processed
837,study,eligible patients,enrol
838,Criteria:-,diagnosis,Confirmed
839,ClinicalTrials.gov,data,processed
840,Corona virus,primarily deep hypoxia,causes
841,critical illness,long termneurocognitive functioning,affects
842,investigators,single centre,conduct
843,ClinicalTrials.gov,data,processed
844,people,state anxiety transitions,elevated
845,Previous activities,significantreductions,predicted
846,ClinicalTrials.gov,data,processed
847,study,effectiveness,compares
848,Secondary outcomes,rates,include
849,Exploratory outcomes,stress related affect reactivity salivaryinflammatory markers,include
850,Online oral fluid toxicology testing,innovative data collection modalities,represent
851,ClinicalTrials.gov,data,processed
852,Contact,persons,infected
853,Reactive IgG,rapid test).8,standardize
854,Subjects,vaccination,receive
855,ClinicalTrials.gov,data,processed
856,ClinicalTrials.gov,data,processed
857,ClinicalTrials.gov,data,processed
858,Lactobacillus,CECT,plantarum
859,Lactobacillus,CECT,plantarum
860,Lactobacillus,CECT,plantarum
861,ClinicalTrials.gov,data,processed
862,ClinicalTrials.gov,data,processed
863,Patients,Patients general practitioner,contact
864,Cluster Randomized Trial,French regions,involve
865,ClinicalTrials.gov,data,processed
866,ClinicalTrials.gov,data,processed
867,Inclusion Criteria:-Patients,positive (PCR,tested
868,ClinicalTrials.gov,data,processed
869,Diabetes,significant additional risk,confers
870,DPP-4,variouseffects,has
871,aimsto,safety,assess
872,trial,theeffects,assess
873,ClinicalTrials.gov,data,processed
874,ClinicalTrials.gov,data,processed
875,Severe courses,lungs,affect
876,Coronavirus disease,hospitalization,requires
877,hospitalization rate disease severity,elderly,increases
878,thesepatients,prolonged activated partial thromboplastin time,have
879,studygroup,patients,examine
880,Pneumologic tests,lung function test,include
881,urine tests,kidney parameters,include
882,ClinicalTrials.gov,data,processed
883,Cordio App,vocal data,upload
884,ClinicalTrials.gov,data,processed
885,infectious diseases,ahuge impact,shown in
886,Fundació Lluita contra SIDA,questions,The surveyis
887,ClinicalTrials.gov,data,processed
888,COM COVID survey study,presence,examines
889,ClinicalTrials.gov,data,processed
890,identification,emergence,follows
891,Severe disease,supplemental oxygen administration,requires
892,ClinicalTrials.gov,data,processed
893,Timing mode ofpresentation,length,depend
894,ClinicalTrials.gov,data,processed
895,ClinicalTrials.gov,data,processed
896,COVID-19,hospitals,fills
897,ClinicalTrials.gov,data,processed
898,Favipiravir,anti - viral activity,shown
899,unit,250 mL beer,History of
900,ClinicalTrials.gov,data,processed
901,Coronavirus disease,global pandemic,causing
902,Coronavirus disease,global pandemic,causing
903,ClinicalTrials.gov,data,processed
904,ClinicalTrials.gov,data,processed
905,ClinicalTrials.gov,data,processed
906,ClinicalTrials.gov,data,processed
907,Patients,death,expected
908,ClinicalTrials.gov,data,processed
909,patientswill,clinical pharmacological measures,receive
910,patients,clinical pharmacological measures,receive
911,Patientsin,CBD,receive
912,ClinicalTrials.gov,data,processed
913,Patients,withdrawal program,perform
914,withdrawal program,abrupt interruption,includes
915,ClinicalTrials.gov,data,processed
916,investigators,novelbinding receptors,develop
917,ClinicalTrials.gov,data,processed
918,ClinicalTrials.gov,data,processed
919,Health Care professionals,line withcoronavirus disease COVID-19 patients,working
920,ClinicalTrials.gov,data,processed
921,ClinicalTrials.gov,data,processed
922,post - exposure prophylaxis,symptomatic COVID-19 disease,test
923,trial,5 groups,targeting
924,ClinicalTrials.gov,data,processed
925,Outbreak,rapid - shaping,requires
926,patients,elbow flexion extension,involving
927,Therehabilitation intervention,30 rehabilitation sessions,include
928,patients,arehabilitation treatment,receive
929,experiments,written consent;-compliance,Inclusion Criteria:-first ischemic or hemorrhagic stroke
930,ClinicalTrials.gov,data,processed
931,ClinicalTrials.gov,Exclusion Criteria:-incomplete data,processed
932,Nintedanib Nintedanib cloth,soft capsule treatment,sulfonate
933,109 L,≥100 ×,platelets
934,ClinicalTrials.gov,data,processed
935,ClinicalTrials.gov,data,processed
936,Intensive Care Unit,patients,admitted
937,ClinicalTrials.gov,data,processed
938,Patient,diagnosis,received
939,Patient,at least one,possess
940,ClinicalTrials.gov,data,processed
941,ClinicalTrials.gov,data,processed
942,ClinicalTrials.gov,data,processed
943,ClinicalTrials.gov,data,processed
944,Theinvestigators,effect sizes,examine
945,analyses,different sources ofinformation,include
946,pre - registered planned analyses,multipleregression,include
947,survey,mandatory fields,includes
948,ClinicalTrials.gov,data,processed
949,investigators,multi - center observational longitudinal cohort study,propose
950,consenting participants,survey assessment,undergo
951,ClinicalTrials.gov,data,processed
952,comers,departments,echocardiography
953,echocardiogram,informed consent,HF symptoms-Referral from
954,ClinicalTrials.gov,data,processed
955,ClinicalTrials.gov,data,processed
956,sector,patient demographics,includes
957,ClinicalTrials.gov,data,processed
958,exclusion,48 hours,take
959,Survival,active medical treatment,expected
960,ClinicalTrials.gov,data,processed
961,virus,factors,assess
962,Screeningfor specific antibodies,exposure,determine
963,patients,hospitalization,set up
964,patients,weekly clinical follow,had
965,investigation,atransmission rate,shows
966,reading,30 minutes,exceed
967,ClinicalTrials.gov,data,processed
968,ClinicalTrials.gov,data,processed
969,ClinicalTrials.gov,data,processed
970,ClinicalTrials.gov,data,processed
971,ClinicalTrials.gov,data,processed
972,COVID-19,clustering morbidity trend,has
973,ClinicalTrials.gov,data,processed
974,reasons,high scientific value,identfy
975,Alveolar edema,causedisruption,may
976,alveolar exudate organization andpulmonary interstitial fibrosis,process,accompany
977,novel coronavirus,positive stranded RNA nucleic acid,has
978,novel coronavirus,non - structural proteins,has
979,hemoglobin,heme metabolism,inhibits
980,ClinicalTrials.gov,data,processed
981,ClinicalTrials.gov,data,processed
982,Infection,treatment,undergo
983,ClinicalTrials.gov,data,processed
984,protocol,convenience sample,utilizes
985,DGMC COVIDScreening Tent personnel,aninformational flyer,provide
986,study team member,lab coat,wear
987,participantwill,copy,keep
988,study team member,lab coat,wear
989,participant,bagged specimen,thenplace
990,Thestudy team member,double bagged saliva sample,place
991,study team member,code,record
992,Via RT-PCR,N gene,target
993,participant,sample,taken to
994,ClinicalTrials.gov,data,processed
995,- attendance,toany,referred
996,Inclusion Criteria:-Patients,16 years old Confirmed diagnosis,aged
997,ClinicalTrials.gov,data,processed
998,ClinicalTrials.gov,data,processed
999,ClinicalTrials.gov,data,processed
1000,SARS CoV-2).The World Health Organization,coronavirus disease,declared
1001,management,focusedprimarily,has
1002,Patients,2:1,randomized
1003,Patients withSARS-CoV-2 PCR,infection,confirmed
1004,ClinicalTrials.gov,data,processed
1005,ClinicalTrials.gov,data,processed
1006,COVID-19 Pneumonia COVID Study,global health crisis,causing
1007,COVID-19 epidemic,majorreorganization,imposed
1008,scenario,implementation,requires
1009,ClinicalTrials.gov,data,processed
1010,ClinicalTrials.gov,data,processed
1011,Novel Coronavirus,2019-nCoVacute respiratory disease,causes
1012,The NovelCoronavirus,2019-nCoVacute respiratory disease,causes
1013,ClinicalTrials.gov,Data,processed
1014,randomized clinical trial,maternal neonatal infections,reducedselected
1015,treatment,primary hypotheses,includes
1016,single prophylactic intrapartumoral dose,maternal death,reduce
1017,Second single prophylactic intrapartum oral dose,intrapartum neonatal death,reduce
1018,ClinicalTrials.gov,data,processed
1019,management,major healthcare burden,represents
1020,ClinicalTrials.gov,data,processed
1021,COVID19 Pandemic,crisis,represents
1022,Necessary adjustments,reduction,include
1023,N 30 employees,bymeans,interviewed about
1024,ClinicalTrials.gov,data,processed
1025,Inclusion Criteria:-We,individuals,identify
1026,Inclusion Criteria:-We,individuals,exclude
1027,ClinicalTrials.gov,data,processed
1028,ClinicalTrials.gov,data,processed
1029,Liberal use,number,increase
1030,The World Health Organisation,oxygen therapy,recommends
1031,ClinicalTrials.gov,data,processed
1032,Patients,sequelae,had
1033,patients,radiological sequelae,had
1034,ClinicalTrials.gov,data,processed
1035,one,episode,Exclusion Criteria:-Use of
1036,child,potential,(SaO2 < 90% for
1037,ClinicalTrials.gov,data,processed
1038,China,70635 confirmed cases,has
1039,ClinicalTrials.gov,data,processed
1040,Secondary Aims:-To,reproducibility,demonstrate
1041,ClinicalTrials.gov,data,processed
1042,ClinicalTrials.gov,data,processed
1043,ClinicalTrials.gov,data,processed
1044,Participants,access,have
1045,participants,consent,completed
1046,group,baseline final questionnaires,complete
1047,labemployee,interviews,complete
1048,Participants,access,have
1049,ClinicalTrials.gov,data,processed
1050,study,feasibility,evaluate
1051,patient,testing,undergo
1052,Alternative anatomic sites,lower sensitivity,have
1053,subjects,additional tests.3.2 Specific Aim,+ subjects
1054,healthcare provider,patient,evaluate
1055,ClinicalTrials.gov,data,processed
1056,ClinicalTrials.gov,data,processed
1057,ClinicalTrials.gov,data,processed
1058,sub study,characteristic profile,reported
1059,ClinicalTrials.gov,data,processed
1060,studies,asignificant difference,reported
1061,theory,gender difference,fits
1062,androgen expression,significantvariation,demonstrates
1063,SARS CoV-2,type II pneumocytes,infects
1064,investigators,preliminary observational study,conducted
1065,12 (29%,clinical signs,classified
1066,ClinicalTrials.gov,data,processed
1067,Recruit Blood Donors,SMS,Via
1068,Recruit Blood Donors,SMS,Via
1069,number,todecline,continuing
1070,placebo group donors,SMS,receive
1071,ClinicalTrials.gov,data,processed
1072,ClinicalTrials.gov,data,processed
1073,ClinicalTrials.gov,data,processed
1074,Scientific evidence,better understanding,achieved
1075,complex situation,aspects,affect
1076,selected pregnant women,an Informed Consent,sign
1077,Women,general advice,received
1078,pregnant women,thesensations,intended for
1079,ClinicalTrials.gov,data,processed
1080,prophylactic weekly hydroxychloroquine,incidence,Determine
1081,weekly prophylactic hydroxychloroquine,severity,determine
1082,ClinicalTrials.gov,data,processed
1083,investigators,sample size,select
1084,investigators,Covid 19 patients,include
1085,ClinicalTrials.gov,data,processed
1086,ClinicalTrials.gov,data,processed
1087,ClinicalTrials.gov,data,processed
1088,Secondary outcomes,participant reported health status,include
1089,aproportion,sufficiently severe symptoms,have
1090,ClinicalTrials.gov,data,processed
1091,ClinicalTrials.gov,data,processed
1092,Retrospective Propensity,An International Observational Study of Outpatients With SARS-CoV-2 Infection,Matched
1093,300 or lung infiltrates > 50% of the lung field).3,> 50%,infiltrates
1094,ormore 100 F,> 48 hours,defined
1095,patients,standard protocol,received
1096,ClinicalTrials.gov,data,processed
1097,primary outcome,besymptomatology,will
1098,Healthcare workers,high levels,present
1099,investigators,expressions,collect
1100,Secondary outcomes,posttraumatic stress,include
1101,Healthcare workers,healthcare,provided
1102,ClinicalTrials.gov,data,processed
1103,Lopinavir ritonavir,inhibitory role,has
1104,ClinicalTrials.gov,data,processed
1105,Nitazoxanide,powerful antiviral effects,has
1106,current pandemic,world best health systems,challenging
1107,ClinicalTrials.gov,data,processed
1108,pragmatic approachwill,swift initiation,enable
1109,ClinicalTrials.gov,data,processed
1110,2020 NCT04308668,2020 NCT04308668 primary outcome tosymptomatic improvement,changed
1111,Study,enrollment forthe primary ordinal outcome,continues
1112,ClinicalTrials.gov,data,processed
1113,Group,Polish surgeons,included
1114,ClinicalTrials.gov,data,processed
1115,Thecohort,new incidental cases,carried
1116,ClinicalTrials.gov,data,processed
1117,Hospital health workers,challengessuch,facing
1118,Hospital health workers,challengessuch,facing
1119,ClinicalTrials.gov,data,processed
1120,thrombophilic mutations,patients clinical response,is
1121,study protocol,following steps:• Collected data,cover
1122,ClinicalTrials.gov,data,processed
1123,ClinicalTrials.gov,data,processed
1124,Patients,care(one,receive
1125,Participants,online questionnaire,filled
1126,ClinicalTrials.gov,data,processed
1127,ClinicalTrials.gov,data,processed
1128,data,ofanti SARS CoV-2 antibodies,exist to
1129,serological test,result,provides
1130,The NG-Biotechtest,CE IVD mark,has
1131,ClinicalTrials.gov,data,processed
1132,"RedHill Biopharma, Ltd.",opaganib,offered
1133,Patients,andStandard,received
1134,Patients,opaganib,eitherreceived
1135,cohorts,similar median age,had
1136,ClinicalTrials.gov,data,processed
1137,sequential changes,difference,remainsunclear
1138,emergency,sudden cardiac arrest,includes
1139,ClinicalTrials.gov,data,processed
1140,ClinicalTrials.gov,data,processed
1141,ClinicalTrials.gov,data,processed
1142,Human Study,Safety,Evaluate
1143,A PHASE 1B,SAFETY,EVALUATE
1144,ClinicalTrials.gov,data,processed
1145,organ functions,circulation,include
1146,ClinicalTrials.gov,data,processed
1147,Pandemic,routine hospital services,disrupted
1148,Pandemic,routine hospital services,disrupted
1149,overarching aim,secondaryobjectives,raises
1150,ClinicalTrials.gov,data,processed
1151,COVID-19 outbreak,changes,caused
1152,Environmentalstressors,atoll,take
1153,English speaking adults,18 and olderDesign,ages
1154,Participants,email address,give
1155,Participants,username,get
1156,participants,online study surveys,complete
1157,participants,email reminders,willget
1158,surveys,set,willcomplete
1159,Participants,links,get
1160,NIH research study,relationship,describe
1161,ClinicalTrials.gov,data,processed
1162,studies,significant reduction,reported
1163,community pharmacy,challenge,facing
1164,Inclusion Criteria:-Inclusion criteria,males,included
1165,ClinicalTrials.gov,data,processed
1166,epidemic,toEurope,spread
1167,patient,civilsde Lyon,hospices
1168,ClinicalTrials.gov,data,processed
1169,ClinicalTrials.gov,data,processed
1170,ClinicalTrials.gov,data,processed
1171,Theoriginal design,limitations,has
1172,Retrospective Observational Cohort Study,manikin,employ
1173,Intubation,high risk,poses
1174,recentstudy,patient,simulated
1175,simulated cough,macroscopic contamination,Examination ofthe laryngoscopist
1176,Canelli et al,observation,concluded
1177,ClinicalTrials.gov,data,processed
1178,female athletes,negativelyto attempts,respond
1179,Allparticipants,information,receive
1180,ClinicalTrials.gov,data,processed
1181,ClinicalTrials.gov,data,processed
1182,participants,initial questionnaire,obtained
1183,participants,collections,complete at
1184,participants,collections,complete at
1185,participants,collections,complete at
1186,ClinicalTrials.gov,data,processed
1187,Patients,risk,required
1188,ClinicalTrials.gov,data,processed
1189,immunosuppressive status(patients,immunosuppressants,using
1190,ClinicalTrials.gov,data,processed
1191,asthe test,information,provide
1192,ClinicalTrials.gov,data,processed
1193,theinvestigators,recombinant human thrombomodulin,add
1194,ClinicalTrials.gov,data,processed
1195,measures,stress,add
1196,study population,family members,consenting
1197,ClinicalTrials.gov,data,processed
1198,"103,573 cases","32,292 hospitalized cases",wereconfirmed
1199,unprecedented health crisis,repercussions,has
1200,ClinicalTrials.gov,data,processed
1201,ClinicalTrials.gov,data,processed
1202,recommandations,potential sourceof viral transmission,is
1203,ClinicalTrials.gov,data,processed
1204,ClinicalTrials.gov,data,processed
1205,Patient,major issue,stratificationremains
1206,ClinicalTrials.gov,data,processed
1207,Clinical status,tapering,allow
1208,ClinicalTrials.gov,data,processed
1209,ClinicalTrials.gov,data,processed
1210,kit,tonucleic acid isolates,wasapplied
1211,RdRpgene targeted Wuhan RdRp oligonucleotide set,positive results,gives
1212,ClinicalTrials.gov,Demographic epidemiological clinical data,processed
1213,ClinicalTrials.gov,data,processed
1214,ClinicalTrials.gov,data,processed
1215,andto,impact,measure
1216,ClinicalTrials.gov,data,processed
1217,ClinicalTrials.gov,data,processed
1218,Virus Outbreak,Antimicrobial Resistance,How COVID-19
1219,Virus Outbreak,Antimicrobial Resistance,How COVID-19
1220,previous study,high incidence,showed
1221,ClinicalTrials.gov,data,processed
1222,Exclusion Criteria:-active cigarette smoker chronic rhinosinusitis head trauma,English previous hyposmia anosmia complaint pregnancy previous sinus skull base,understand
1223,ClinicalTrials.gov,data,processed
1224,ClinicalTrials.gov,data,processed
1225,ClinicalTrials.gov,data,processed
1226,Subject,Day 22,evaluated after
1227,female subject,tubal ligation,used
1228,ClinicalTrials.gov,data,processed
1229,ClinicalTrials.gov,data,processed
1230,World Health Organization,epidemicdisease,declared
1231,Total number,"1,800,000",approached
1232,COVID-19patients,physical fitness,have
1233,ClinicalTrials.gov,data,processed
1234,the World Health Organization,outbreak ofcoronavirus disease,declared
1235,ClinicalTrials.gov,data,processed
1236,current situation,core aspectsof people lives,changing
1237,ClinicalTrials.gov,data,processed
1238,ClinicalTrials.gov,data,processed
1239,Noradrenaline,0.5 micrograms/ kg minute)3,dose
1240,ClinicalTrials.gov,data,processed
1241,Multicentric Retrospective Observational Study of Thoracic Scanner Performance,141 participants,recruit
1242,ClinicalTrials.gov,data,processed
1243,caring contact group,usual discharge related care,receive
1244,ClinicalTrials.gov,data,processed
1245,Multicentric Retrospective Observational Study of Thoracic Scanner Performance,SARS CoV-2-uninfectedindividuals,includes
1246,ClinicalTrials.gov,data,processed
1247,investigators,limited,havea
1248,ClinicalTrials.gov,data,processed
1249,ClinicalTrials.gov,data,processed
1250,ESOGER informationand,ESOGER databank,create
1251,ClinicalTrials.gov,data,processed
1252,Multicentric Retrospective Observational Study of Thoracic Scanner Performance,participants,randomize
1253,ClinicalTrials.gov,data,processed
1254,Hemodialysiscentres,specific setting,represents
1255,Dialysis patients,susceptible population,constitute
1256,impactof,frequency,reduced
1257,ClinicalTrials.gov,data,processed
1258,ClinicalTrials.gov,data,processed
1259,ClinicalTrials.gov,data,processed
1260,investigators,different parts,measure
1261,ClinicalTrials.gov,data,processed
1262,principal investigator,dedicated electronic case report form,provides
1263,ClinicalTrials.gov,data,processed
1264,ClinicalTrials.gov,data,processed
1265,ClinicalTrials.gov,data,processed
1266,ClinicalTrials.gov,data,processed
1267,ClinicalTrials.gov,data,processed
1268,ClinicalTrials.gov,data,processed
1269,immune,the Virus,produced
1270,ClinicalTrials.gov,data,processed
1271,Covid-19 pneumonia,similar clinicaloutlook,has
1272,ClinicalTrials.gov,data,processed
1273,ClinicalTrials.gov,data,processed
1274,Childrenwill,access,have
1275,Investigators,gamified social emotional learningand nutrition games,creating
1276,ClinicalTrials.gov,data,processed
1277,COVID-19 Pandemic,people withpre existing health conditions,impacts
1278,ClinicalTrials.gov,data,processed
1279,Tocilizumab,COVID-19 Pandemic,kill
1280,theU.S. FDA theU.S. FDA,Tocilizumab,approved
1281,Expected life span,7 days.9,exceed
1282,ClinicalTrials.gov,data,processed
1283,International Multicenter,Double Blind Placebo Controlled Trial,Randomized
1284,SOC,remdesivir,include
1285,primary endpoint,7 mutually exclusive categories capturingthe range,includes
1286,limiting symptoms,time,include
1287,ClinicalTrials.gov,data,processed
1288,compressor,alarms,powered by
1289,ClinicalTrials.gov,data,processed
1290,patients,intensive care treatment,need
1291,ClinicalTrials.gov,data,processed
1292,studies,shorter hospitalstay lower mortality,showed
1293,use,important advantages,has
1294,ClinicalTrials.gov,data,processed
1295,ClinicalTrials.gov,data,processed
1296,afferent fibers,thebrain,enter
1297,ClinicalTrials.gov,data,processed
1298,NHS testing service,individuals,added to
1299,NNUH staff,patients,approach in
1300,investigators,2more sample sets,collect
1301,ClinicalTrials.gov,data,processed
1302,authors,"the ""Inhaled Sedation for COVID-19-related ARDS",designed
1303,ClinicalTrials.gov,data,processed
1304,investigators,toadminister UCMSCs,propose
1305,UCMSCs,different specific antibodies,characterizedusing
1306,Inclusion Criteria:-Provide,informed consent Male female subjects age,written
1307,ClinicalTrials.gov,data,processed
1308,ClinicalTrials.gov,data,processed
1309,target population,women,includes
1310,ClinicalTrials.gov,data,processed
1311,ClinicalTrials.gov,data,processed
1312,Oncology,Pathway Modifications Impact,Care
1313,Oncology,Pathway Modifications Impact,Care
1314,ClinicalTrials.gov,data,processed
1315,ClinicalTrials.gov,data,processed
1316,study,evolution,evaluate
1317,nutritional support system,complications,reducethe
1318,distribution,normality criteria,performed
1319,cases,hoc tests,post
1320,systematic randomized allocation,sequence,With
1321,ClinicalTrials.gov,data,processed
1322,Study,measures,outcomesinclude
1323,theresults,efficacy,support
1324,Engaging regular physical activity confers,risk,reduced
1325,vigorous activity,computer,has at
1326,ClinicalTrials.gov,data,processed
1327,Thepandemic,risk factors,worsened
1328,ClinicalTrials.gov,data,processed
1329,ClinicalTrials.gov,data,processed
1330,ClinicalTrials.gov,data,processed
1331,Vasopressin,intravenous fluid resuscitation,received
1332,Vasopressin,screening multi - organ dysfunction score,have
1333,Thrombocytopenia,"150,000µ/L",defined
1334,Vasopressin,chest compressions,had
1335,Vasopressin,acute myocardial infarction,had
1336,platelet,"30,000 cells mm3",count
1337,Vasopressin,extensive degree burns,sustained
1338,condition,subject,preclude
1339,ClinicalTrials.gov,data,processed
1340,ClinicalTrials.gov,data,processed
1341,ClinicalTrials.gov,data,processed
1342,Chinese scientists,genomeinformation,shared
1343,ClinicalTrials.gov,data,processed
1344,SARS CoV-2,global pandemic,caused
1345,Older age,role,play
1346,researchers,toassess,want
1347,Design,place,take
1348,Participants,website,visit
1349,Participants,survey,fill out
1350,Clinical Study,less than 30minutes,take
1351,Participants,questions,answer
1352,Participants,survey,repeat
1353,protocol,information,collect
1354,ICU,related death,stay
1355,ICU,related death,stay
1356,Study Population,people,include
1357,Somemembers,cognitive impairment,performed
1358,ClinicalTrials.gov,data,processed
1359,Coronavirus,containment,caused
1360,spread,significant challenges,posed
1361,Thisquestionnaire,39 questions,includes
1362,ClinicalTrials.gov,data,processed
1363,Additional experiential self compassion,Assignment,exercises
1364,ClinicalTrials.gov,data,processed
1365,andinform,surgical resources,is
1366,investigators,otherdemographic characteristics,gather
1367,investigators,SARS CoV-2 carrier,captureasymptomatic
1368,investigators,surgical approach,capture
1369,investigators,existing definitions,use
1370,investigators,convenient sample size,plan
1371,multivariable Cox model,presence,include
1372,investigators,patients,include
1373,ClinicalTrials.gov,data,processed
1374,Patients,tocilizumab,receive
1375,clinical recovery,1 or 2 on the 7-category ordinal scale,prohibited until
1376,ClinicalTrials.gov,data,processed
1377,ClinicalTrials.gov,data,processed
1378,ClinicalTrials.gov,data,processed
1379,Patient,aminotransferase,aspartate
1380,Patient,bilirubin level,has
1381,Exceptions,following noninvasive malignancies,include
1382,ClinicalTrials.gov,data,processed
1383,different information sourcesto,information,obtain
1384,multiple studies usinglatent variable paradigms,relationship,established
1385,investigators,differences,investigate
1386,survey,mandatory fields,includes
1387,ClinicalTrials.gov,data,processed
1388,Exclusion Criteria:-Participants,detailed medical history,lacked
1389,ClinicalTrials.gov,data,processed
1390,Cell Therapy,Umbilical Cord derived Mesenchymal Stromal Cells,Using
1391,Mesenchymal stem cells,attractive characteristics,feature
1392,therapeutic effectsof,excellent tolerance,havedemonstrated
1393,disease,microvasculature,accumulated
1394,ClinicalTrials.gov,data,processed
1395,pneumonia,dysregulated immune system,present
1396,NK cells,use,proposes
1397,investigators,quick recovery,expect
1398,investigators,previous successful experience,have
1399,ClinicalTrials.gov,data,processed
1400,ClinicalTrials.gov,data,processed
1401,ClinicalTrials.gov,data,processed
1402,contamination,question,raises
1403,the French Armed Forces Health Service,simplemanagement plan,proposed
1404,ClinicalTrials.gov,data,processed
1405,Voluntary physicians,eligible participants,refer
1406,ClinicalTrials.gov,data,processed
1407,Baseline measures,questionnaires,include
1408,Inclusion Criteria:-Aged,traumatic event,ward)-Experienced
1409,ClinicalTrials.gov,data,processed
1410,ClinicalTrials.gov,data,processed
1411,health system,unscheduledurgent care,centralizes
1412,ClinicalTrials.gov,data,processed
1413,study,20 % ofdepressive anxious troubles,reported
1414,confinement,about 8 weeks,lasted
1415,ClinicalTrials.gov,data,processed
1416,ClinicalTrials.gov,data,processed
1417,Prior research,link,established
1418,urgency,investigation,necessitates
1419,ClinicalTrials.gov,data,processed
1420,PwSCI,supports,require
1421,MO community,collaborations,have
1422,ClinicalTrials.gov,data,processed
1423,ClinicalTrials.gov,data,processed
1424,Vitamin C,antioxidant properties,has
1425,Vitamins,duration,shorten
1426,patients,betterprognosis,show
1427,ClinicalTrials.gov,data,processed
1428,ClinicalTrials.gov,data,processed
1429,mental health experts,concerns,raise
1430,ClinicalTrials.gov,data,processed
1431,ClinicalTrials.gov,data,processed
1432,evolution,clinically different phases,showstwo
1433,phase,patients,affects
1434,data,important role,indicate
1435,studies,expression,analyzed
1436,ClinicalTrials.gov,data,processed
1437,physicians,access,receive
1438,protocol,retrospective data input,allows
1439,ClinicalTrials.gov,data,processed
1440,ClinicalTrials.gov,data,processed
1441,ClinicalTrials.gov,data,processed
1442,FMF,commoncharacteristics,have
1443,ClinicalTrials.gov,data,processed
1444,Patients,investigatedtherapy,get
1445,Change,COVID,score
1446,signed inform,COVID 19,consent
1447,patient,mechanical ventilation,need
1448,ClinicalTrials.gov,data,processed
1449,COVID-19pandemic,aspects,affected
1450,proposed mixed methods explanatory study,retrospective prospective datacollection,Methods
1451,ClinicalTrials.gov,data,processed
1452,controlled trial,efficacy,assess
1453,results,useful information,provide
1454,Kg,body weight,predicted
1455,medical staff,extubation,treated with
1456,blood samples,andseveral chemical variables,alsocollected
1457,occurrence,specificparagraph,see
1458,DSMC,safety,analyze
1459,statistician,access,have
1460,steering committeewill review study integrity safety risk benefit issues,patients,included
1461,ClinicalTrials.gov,data,processed
1462,respiratória Aguda Grave Por COVID-19 patients,higher incidence ofthromboembolic events,indicate
1463,events,ICU admissions,increase
1464,ClinicalTrials.gov,data,processed
1465,Pandemic,people lives,affecting
1466,ClinicalTrials.gov,data,processed
1467,Glasgow Coma Scale,10Contraindication,score
1468,ClinicalTrials.gov,data,processed
1469,Pilot Study,remote consultations,utilises
1470,ClinicalTrials.gov,data,processed
1471,researchers,treatments,compared
1472,2020Exclusion,patients,treated
1473,ClinicalTrials.gov,data,processed
1474,ClinicalTrials.gov,data,processed
1475,information,ideas,give
1476,Participants,blood sample,give
1477,Recovered participants,material,have
1478,Recovered participants,echocardiogram,have
1479,Participation,1-2 days,lasts
1480,Documented history,7g/,draw
1481,ClinicalTrials.gov,data,processed
1482,medical personnel,protective suits,wear
1483,Inclusion Criteria:-Give voluntary consent,criteria Wrist low diseases,meet
1484,ClinicalTrials.gov,data,processed
1485,ClinicalTrials.gov,data,processed
1486,Jude patients,Covid-19.Exclusion Criteria:-NA,confirmed
1487,ClinicalTrials.gov,data,processed
1488,new kind,unprecedented impact,generating
1489,new kind,unprecedented impact,generating
1490,Potentialparticipants,type,include
1491,ClinicalTrials.gov,data,processed
1492,ClinicalTrials.gov,data,processed
1493,Thislongitudinal study,prevalence,investigates
1494,Previousstudies,significant burden,demonstrated
1495,Participants,monthly online survey,receive
1496,ClinicalTrials.gov,data,processed
1497,Observational data,potential benefit,suggest
1498,ClinicalTrials.gov,data,processed
1499,Informed Consent Form,voluntarilyExclusion Criteria:-1,signed
1500,ClinicalTrials.gov,data,processed
1501,ClinicalTrials.gov,data,processed
1502,ClinicalTrials.gov,data,processed
1503,Aerosolized,Adenosine Treatment,Inhaled
1504,Aerosolized,Adenosine Treatment,Inhaled
1505,ClinicalTrials.gov,data,processed
1506,International outbreak,intense attention ofspecialists,raised
1507,ClinicalTrials.gov,data,processed
1508,world,pandemic,facing
1509,world health organization,disease,coined
1510,6,crudemortality rate,infected with
1511,ClinicalTrials.gov,data,processed
1512,instance treatment,oxygenotherapy,includes
1513,prone positioning,survival improvement,shown
1514,COVID,increasing rate,patientsrequire
1515,patients,instruction,begiven
1516,ClinicalTrials.gov,data,processed
1517,teleconsultation,physicalvisit,assessed
1518,ClinicalTrials.gov,data,processed
1519,ClinicalTrials.gov,data,processed
1520,collected data,unique insights,provides
1521,Inclusion Criteria:-a,type 2 diabetes,diagnosed
1522,ClinicalTrials.gov,collected data,processed
1523,ClinicalTrials.gov,data,processed
1524,public,boredom,experience
1525,Infected patients,severe fatal respiratory diseases(e.g,develop
1526,public,boredom,experience
1527,contact information,2 parts,includes
1528,ClinicalTrials.gov,data,processed
1529,contact information,better understanding,allow
1530,neurological disorders,form,epilepsy
1531,ClinicalTrials.gov,data,processed
1532,contact information,impact,explore
1533,patients,experiences,recall during
1534,ClinicalTrials.gov,data,processed
1535,COVID-19 pandemic,dramatic effects,had
1536,ClinicalTrials.gov,data,processed
1537,ClinicalTrials.gov,data,processed
1538,situation,negativeimpact,have
1539,ClinicalTrials.gov,data,processed
1540,the World Health Organization,current corona virusdisease,announced
1541,incidence ofinfection,gradual increase,follows
1542,ClinicalTrials.gov,data,processed
1543,Repeated surveys,data,missing
1544,interactions representtests,change,predicting
1545,pre - registered planned analyses,multipleregression,include
1546,sample size,representative random selection 10 084 adultparticipants,included
1547,ClinicalTrials.gov,data,processed
1548,subjects,weekly study visits,complete
1549,subjects,final safety follow visit,complete
1550,Effective methods,condoms,include
1551,subject,significant risk,has
1552,subject,1 suicidal attempts withreference,had
1553,Investigator,concomitant use,allow
1554,ClinicalTrials.gov,data,processed
1555,emerging infectious diseases,impact,caused
1556,an Emergency Department,double triage telemedicine method totreat non - critical patient,used
1557,application,exposuretime,reduced
1558,ClinicalTrials.gov,data,processed
1559,cardiac causes,toTnc kinetic,lead
1560,work,hypothesis,test
1561,Exclusion Criteria:-patients,> 72h,hospitalized
1562,ClinicalTrials.gov,data,processed
1563,Phase 2a Open label Study,approval,received
1564,ClinicalTrials.gov,clinical data,processed
1565,Prolongedadministration,patients,benefit
1566,prolonged regimen,increase,allow
1567,admission,asignificant strain,poses
1568,only Remdesivir,benefits,shown
1569,ClinicalTrials.gov,data,processed
1570,individual,criteria,meet
1571,ClinicalTrials.gov,data,processed
1572,ClinicalTrials.gov,data,processed
1573,10µL,2 drops,apply
1574,ClinicalTrials.gov,data,processed
1575,the COVID-19 Epidemic,major impact,has
1576,sites,visits,authorize
1577,concern,patients,toprotect
1578,early identification,establishment,allow
1579,SMS email,reminder mode,scheduled on
1580,ClinicalTrials.gov,data,processed
1581,Quarantine,persons,separates
1582,study,research gap,undertaken
1583,Institutional quarantine,persons,separates
1584,study,research,undertaken
1585,ClinicalTrials.gov,data,processed
1586,mg single dose,every three weeks,repeated
1587,mg single dose,every three weeks,repeated
1588,ClinicalTrials.gov,data,processed
1589,investigators,stakeholders knowledge,assess
1590,investigators,stakeholders knowledge,assess
1591,ClinicalTrials.gov,data,processed
1592,ClinicalTrials.gov,data,processed
1593,ClinicalTrials.gov,data,processed
1594,ClinicalTrials.gov,data,processed
1595,investigators,knowledge,gain
1596,hospitals,obstetric care,provide
1597,Clinical recordsand,data,included in
1598,authors,SAS 9.4 software,analysis
1599,ClinicalTrials.gov,data,processed
1600,ClinicalTrials.gov,data,processed
1601,ClinicalTrials.gov,data,processed
1602,Phase,Nasogastric Tube,Acalabrutinib Tablet Suspension Delivered
1603,ClinicalTrials.gov,data,processed
1604,investigators,tolerability,investigating
1605,investigators,nasal administration,test
1606,single dose phase,acute tolerability,test
1607,ClinicalTrials.gov,data,processed
1608,ClinicalTrials.gov,data,processed
1609,Participants,app,download
1610,level,educational information,provides
1611,ClinicalTrials.gov,data,processed
1612,Separation,mentalhealth,affect
1613,conditions ofconfinement,social support,harm
1614,ClinicalTrials.gov,data,processed
1615,Current position,routine use,recommend
1616,ClinicalTrials.gov,data,processed
1617,ClinicalTrials.gov,data,processed
1618,breath collection,within24 hours,occur
1619,ClinicalTrials.gov,data,processed
1620,the World Health Organization,COVID-19,declared
1621,"1,346,299 individuals",confirmedCOVID-19 infection,had
1622,ClinicalTrials.gov,data,processed
1623,ClinicalTrials.gov,data,processed
1624,helplines,emotional orinformational support,offer
1625,Additional support avenues,online support groups,include
1626,ClinicalTrials.gov,data,processed
1627,Investigators,caspase-3system,analyzed
1628,ClinicalTrials.gov,data,processed
1629,Patients,therapy,getinvestigated
1630,patient,mechanical ventilation,20 ml/ min-physician judgment
1631,ClinicalTrials.gov,data,processed
1632,COVID-19pandemic,"7.1 million cases and>400,000 deaths",caused
1633,ClinicalTrials.gov,data,processed
1634,ClinicalTrials.gov,data,processed
1635,investigator,potential,evaluate
1636,WOCBP,negative highly sensitive pregnancy test,have
1637,ClinicalTrials.gov,data,processed
1638,ClinicalTrials.gov,data,processed
1639,governments,unprecedentedmeasures,spread across
1640,China,Movement Control Order,enforced
1641,Criteria:-All,participants,consenting
1642,ClinicalTrials.gov,data,processed
1643,ClinicalTrials.gov,data,processed
1644,Thefirst clinical observations,situations,reported
1645,ClinicalTrials.gov,data,processed
1646,ClinicalTrials.gov,data,processed
1647,administration,development,reduce
1648,ClinicalTrials.gov,data,processed
1649,research,criteria,fulfil
1650,focus groups,user groups opinions,collate
1651,wide spectrum,increased generalizability,allow
1652,patient,copy,keep
1653,Training,form,take
1654,ClinicalTrials.gov,data,processed
1655,Patients,randomization schemata,know
1656,The DSMBCharter,processes,outline
1657,APACHE II,205,score
1658,medically acceptable method,intrauterine devices,includes
1659,-End stage malignancy,treatment,undergoing
1660,ClinicalTrials.gov,data,processed
1661,ClinicalTrials.gov,data,processed
1662,Coronavirus,Acute Kidney Injury,Induced
1663,data,virus,show
1664,ClinicalTrials.gov,data,processed
1665,ClinicalTrials.gov,data,processed
1666,Analysis,monthly records,include
1667,representative age stratifiedsample 2000 subjects,questionnaire assessment,undergo
1668,Analysis,monthly records,include
1669,representative age stratifiedsample 2000 subjects,questionnaire assessment,undergo
1670,ClinicalTrials.gov,data,processed
1671,ClinicalTrials.gov,data,processed
1672,physical mental economic health burden,poor,affects
1673,ClinicalTrials.gov,data,processed
1674,ClinicalTrials.gov,data,processed
1675,Secondary outcomes,polysomnography,conducting
1676,ClinicalTrials.gov,data,processed
1677,Patients,poor prognosis,havea
1678,consecutive patients,beincludedExclusion Criteria:- Patients,admitted to
1679,ClinicalTrials.gov,data,processed
1680,Laboratory,infection,confirmed
1681,ClinicalTrials.gov,data,processed
1682,current coronavirus disease pandemic,problem,posed
1683,ClinicalTrials.gov,data,processed
1684,ClinicalTrials.gov,data,processed
1685,Phase II Randomised Study,SARS CoV-2-uninfectedindividuals,includes
1686,ClinicalTrials.gov,data,processed
1687,Participants,assessmentsbefore,have
1688,resides,history,have
1689,COVID stress scale,worry repetitive negative thinking,score
1690,ClinicalTrials.gov,data,processed
1691,world,pandemic,lives
1692,new context,lockdown time,emergesduring
1693,health workers,PTSD,ispredictable
1694,ethicalCommittee,protocol,approve
1695,budget,theestimation,have
1696,program,groups,A numberwill assign to
1697,results,bytelephone,communicate
1698,sleep.4.- Principal Investigator,sleep.4.- Principal Investigator work,participated in
1699,Bravo Navarro,doctorate,has
1700,Bravo Navarro,Bravo Navarro doctoral thesis,carried out
1701,Bravo Navarro,project,led
1702,Bravo Navarro,numerous publications,has
1703,ClinicalTrials.gov,data,processed
1704,professional personal distress,burnout,is
1705,Open 2020).Professional burnout,significant threat,represents
1706,"2006),individual factors",susceptibility,increase
1707,ClinicalTrials.gov,data,processed
1708,ClinicalTrials.gov,data,processed
1709,the COVID-19 Pandemic,healthcare workers,impacted
1710,the COVID-19 Pandemic,healthcare workers,impacted
1711,ofthese factors,ofthese factors menstrual cycle,affect
1712,researcher,thecharacteristics,investigates
1713,exclusion criteria,pregnancy,includes
1714,ClinicalTrials.gov,data,processed
1715,ClinicalTrials.gov,data,processed
1716,ClinicalTrials.gov,data,processed
1717,widespread message,lives,save
1718,ClinicalTrials.gov,data,processed
1719,ClinicalTrials.gov,data,processed
1720,Patients,atelectasis indorsal lung regions,develop
1721,ClinicalTrials.gov,data,processed
1722,laboratory confirmed COVID-19-Must,severe,have
1723,ClinicalTrials.gov,data,processed
1724,COVID-19,world wide epidemic,cause
1725,ClinicalTrials.gov,data,processed
1726,Hospital staff,questions,have
1727,Studies,figures,suggest
1728,staff,serological test,benefit
1729,ClinicalTrials.gov,data,processed
1730,Woebot,Disorders,Use
1731,ClinicalTrials.gov,data,processed
1732,adult,infectious syndrome,presents
1733,ClinicalTrials.gov,data,processed
1734,ClinicalTrials.gov,data,processed
1735,study vaccine administration Participant,body mass index,have
1736,ClinicalTrials.gov,data,processed
1737,current COVID19 pandemic,globe,afflicted
1738,current COVID19 pandemic,globe,afflicted
1739,ER,acute cardiovascular event,All comers to
1740,Thepatient,physical social stress,reporting
1741,ClinicalTrials.gov,data,processed
1742,ClinicalTrials.gov,data,processed
1743,arms,sedation,receive
1744,Thecontrol arm,sedation,receive
1745,sedative agents,benzodiazepines,include
1746,brain,majority,provides
1747,recent meta analysisshowed clonidine use,length,reduce
1748,extensive search,ofpropranolol,reveal
1749,Observational studies,andpossibly lower mortality risk,haveshown
1750,meta analysisof 10 randomized controlled trials,propranolol reducedhospital length,found
1751,established data safetymonitoring committee,adverse events,evaluate
1752,treating team,treating team usual betablocker,resume
1753,ClinicalTrials.gov,data,processed
1754,Osteosarcopenia,simultaneous presence,designates
1755,induced lock,- start,prevented
1756,ClinicalTrials.gov,data,processed
1757,patients,single infusion,receive
1758,Patients,treatments,receive
1759,Patients,standard,Note
1760,ClinicalTrials.gov,data,processed
1761,ClinicalTrials.gov,data,processed
1762,precautions,daily practice,changed
1763,Thisexogenous hospital tension,caregivers,impacts
1764,Caregivers,respond,have
1765,ClinicalTrials.gov,data,processed
1766,ClinicalTrials.gov,data,processed
1767,symptoms,negative Elecsys Anti - SARS CoV-2 immunoassay antibody test,Have
1768,ClinicalTrials.gov,data,processed
1769,unexpected onset,practices,modified
1770,ClinicalTrials.gov,data,processed
1771,MSCs,innovative approach,constitute
1772,Large animal studies,beneficial effects,alsoreplicated
1773,ARDS,inapproximatel 20 % cases,is
1774,fully anonymised minimal dataset,reasons,berecorded on
1775,appropriately trained doctor,consent,take
1776,Trial guidelines,detailed information,provide
1777,The NICTU,training,provide
1778,betweenthe ORBCEL C,groups,treated
1779,Patient,invasive mechanical ventilation3,receiving
1780,ClinicalTrials.gov,data,processed
1781,total enrollment,102 patients,enroll
1782,subjects,inhalation,receive
1783,patients,level,Weaning from
1784,Physician,institutional weaningprotocols,follow
1785,Laboratory,infection,confirmed
1786,ClinicalTrials.gov,data,processed
1787,ClinicalTrials.gov,data,processed
1788,ClinicalTrials.gov,data,processed
1789,reports,higherlevels,predict
1790,Increased positive metacognitions,lower levels,predict
1791,reports,higherlevels,predict
1792,Increased positive metacognitions,lower levels,predict
1793,Exploratory,differences,investigate
1794,survey,mandatory fields,includes
1795,ClinicalTrials.gov,data,processed
1796,ClinicalTrials.gov,data,processed
1797,subjects,axatilimab,receive
1798,ClinicalTrials.gov,data,processed
1799,ClinicalTrials.gov,data,processed
1800,Excessive amounts ofNETs,rigidity,increase
1801,ClinicalTrials.gov,data,processed
1802,ClinicalTrials.gov,data,processed
1803,ClinicalTrials.gov,data,processed
1804,isan,problem,Thedelayed treatment for
1805,investigators,safety,investigate
1806,novel severe acute respiratory syndrome coronavirus,2019 novel coronavirus,provisionallynamed
1807,researches,conclusion,suspected
1808,ClinicalTrials.gov,data,processed
1809,Subjects,Subjects height,have
1810,ClinicalTrials.gov,data,processed
1811,investigators,pandemic affectedSyrian patients,know
1812,ClinicalTrials.gov,data,processed
1813,appointment,mole,make
1814,ClinicalTrials.gov,data,processed
1815,Adult male female patients,18-85 years,aged
1816,ClinicalTrials.gov,data,processed
1817,ClinicalTrials.gov,data,processed
1818,neuromuscular,agents.-Ventilated patient,Inclusion Criteria:-ICU admission for
1819,ClinicalTrials.gov,data,processed
1820,Computertomography,ground glass opacity,revealed
1821,reports,coronavirus,emerged of
1822,ClinicalTrials.gov,data,processed
1823,ClinicalTrials.gov,data,processed
1824,ClinicalTrials.gov,data,processed
1825,thisprotective ventilation,deep sedation,requires
1826,ClinicalTrials.gov,data,processed
1827,Approximately 50%,Critical COVID-19,develop
1828,tointravenous Aviptadil,escalating doses,randomized
1829,ATII,only 5%,cellscomprise
1830,ClinicalTrials.gov,data,processed
1831,study,maxillo facial activity,compare
1832,ClinicalTrials.gov,data,processed
1833,study,maximum,include
1834,study,maximum,willinclude
1835,ClinicalTrials.gov,data,processed
1836,COVID19-associated disease,different clinical aspects,have
1837,ClinicalTrials.gov,data,processed
1838,Vitamin D,profound effects,has
1839,100,COVİD-19 patients,confirmed
1840,ClinicalTrials.gov,data,processed
1841,ClinicalTrials.gov,data,processed
1842,TXA,theinfectivity,hypothesized
1843,patients,daily anticoagulation,receive
1844,ClinicalTrials.gov,data,processed
1845,ClinicalTrials.gov,data,processed
1846,ClinicalTrials.gov,data,processed
1847,ClinicalTrials.gov,data,processed
1848,50 kg body mass index,BMI weight,Note
1849,ClinicalTrials.gov,data,processed
1850,ClinicalTrials.gov,data,processed
1851,Evaluation,Safety,Hospitalized
1852,ClinicalTrials.gov,data,processed
1853,ClinicalTrials.gov,data,processed
1854,partial pressure,> 50%,v. lung infiltrates
1855,Patients,heparin,receive
1856,HIV infection,immunosuppressive therapy,receiving
1857,ClinicalTrials.gov,data,processed
1858,Vitamin C,immune system,increases
1859,high body,unbearable environment,temperaturecauses
1860,body temperature,important functions,has
1861,Vitamin C,immune system,increases
1862,combination treatment,faster results,achieves
1863,experts,prevalence,interpret
1864,i. Asia,peaks,pronounced
1865,Middle East,low cases,have
1866,ClinicalTrials.gov,data,processed
1867,ClinicalTrials.gov,data,processed
1868,combination,development,prevent
1869,ClinicalTrials.gov,data,processed
1870,posphodiesterase-4,key role,plays
1871,pentoxifylline,multipurpose generally safe adjuvant therapy forCOVID-19 patients,constitute
1872,ClinicalTrials.gov,data,processed
1873,Evelo,safety,investigate
1874,Patient,systemic immunosuppressive agent,taking
1875,Patient,diagnosed primary immunodeficiency.7,has
1876,Patient,diagnosis,has
1877,Patient,pre - existing known significant liver disease,has
1878,Patient,pre - existing known substantially impaired cardiac function,has
1879,ClinicalTrials.gov,data,processed
1880,Aggrenox,Acute Covid-19,Treat
1881,Participants,standard care,receive
1882,investigators,demographic,collect
1883,ClinicalTrials.gov,data,processed
1884,patient,theantibiotic azithromycin,received
1885,16 patients,significantreduction,observed
1886,ClinicalTrials.gov,data,processed
1887,ClinicalTrials.gov,data,processed
1888,ClinicalTrials.gov,data,processed
1889,complications,main causes,arethe
1890,Nointra patient dose escalation,place,take
1891,MTD.The study,thestandard cohort,employ
1892,intra - patientescalation,place,take
1893,ClinicalTrials.gov,data,processed
1894,ClinicalTrials.gov,data,processed
1895,ClinicalTrials.gov,data,processed
1896,subjects,informed consent,provide
1897,Subjects,thefirst dose,receive
1898,Close contact,air space,share
1899,patient,criteria,Note
1900,ClinicalTrials.gov,data,processed
1901,ClinicalTrials.gov,data,processed
1902,PCR test resultswill,PCR test resultswill medical records studies,have
1903,ClinicalTrials.gov,data,processed
1904,48%,co - morbidity,had
1905,ClinicalTrials.gov,data,processed
1906,Exclusion Criteria:-People,mobile app,use
1907,ClinicalTrials.gov,data,processed
1908,ClinicalTrials.gov,data,processed
1909,Group 1):-A,diagnosis,Inclusion Criteria
1910,ClinicalTrials.gov,data,processed
1911,French authorities,ivermectin,approved
1912,ClinicalTrials.gov,data,processed
1913,ClinicalTrials.gov,data,processed
1914,ClinicalTrials.gov,data,processed
1915,ClinicalTrials.gov,data,processed
1916,Participants,Short Form Health Survey,willcomplete
1917,Subjects,Inclusion Criteria,meet
1918,Subject,cells,banked
1919,Subject,written informed consent,provides
1920,ClinicalTrials.gov,data,processed
1921,ClinicalTrials.gov,data,processed
1922,TACTIC R,efficacy,assess
1923,trial,immunomodulatoryagents,compare
1924,TACTIC R,algorithm,iterate
1925,ClinicalTrials.gov,data,processed
1926,Moderate Hypoxemia,Supplemental Oxygen,To
1927,ClinicalTrials.gov,data,processed
1928,Small clinical trials andobservational studies,possibleclinical benefit,suggested
1929,ClinicalTrials.gov,data,processed
1930,SARS CoV2 infection,severe pneumonia,produces
1931,APACHE II,risk,carried out
1932,I. BackgroundThe SARS CoV-2 virus,a positive-sense RNA,has
1933,application,levels,reduces
1934,application,levels,reduces
1935,ClinicalTrials.gov,data,processed
1936,ClinicalTrials.gov,data,processed
1937,25 subjects,3 doses,treatedwith
1938,Provide,informed consent,written
1939,ClinicalTrials.gov,data,processed
1940,investigators,association ofvarious critical care interventions,examine
1941,ClinicalTrials.gov,data,processed
1942,results,310 people,identified
1943,peopleinfected,highly variable IgG antibody titers,observed
1944,majority,drop,showed
1945,ClinicalTrials.gov,data,processed
1946,early investigation,high levels ofinflammatory cytokines,revealed
1947,Viral replication triggers,inflammatory signalingcascades,downstream
1948,effects,outcomes,toimprove
1949,ClinicalTrials.gov,data,processed
1950,Mild Symptoms,choloroquinE Compounds,PRophylaxis of
1951,ClinicalTrials.gov,data,processed
1952,nebulized heparin,theseverity,"Randomized, placebo"
1953,Research interventions,place,take
1954,participating site,theirown IND,have
1955,latent TB,TB,treated
1956,Chronic recent corticosteroid,> 10 mg/day9,use
1957,women,highly effective methods,Women of
1958,ClinicalTrials.gov,data,processed
1959,ClinicalTrials.gov,data,processed
1960,study population,sample,comprise
1961,ClinicalTrials.gov,data,processed
1962,Researchers,100 participants,recruiting
1963,ClinicalTrials.gov,data,processed
1964,optimal management,health risks,minimize
1965,Major rapid changes,negative consequences,induce
1966,Major,curator trusteeship,protected
1967,ClinicalTrials.gov,data,processed
1968,nebulized heparin,theseverity,"Furthermore, Randomized, placebo controlled study to"
1969,virus,respiratory symptoms,reported in
1970,ClinicalTrials.gov,data,processed
1971,Main outcomes,cause mortality,include
1972,ClinicalTrials.gov,data,processed
1973,investigators,data,utilize
1974,investigators,predictors,select
1975,investigators,predictors,select
1976,ClinicalTrials.gov,data,processed
1977,ClinicalTrials.gov,data,processed
1978,ClinicalTrials.gov,data,processed
1979,study,structure,provide
1980,ClinicalTrials.gov,data,processed
1981,the Egyptians,rituals,have
1982,ClinicalTrials.gov,data,processed
1983,Case series,sepsis,suggest
1984,ClinicalTrials.gov,data,processed
1985,ClinicalTrials.gov,data,processed
1986,Quick SOFA,seriously ill patients,identify
1987,ClinicalTrials.gov,data,processed
1988,ClinicalTrials.gov,data,processed
1989,Seroprevalence Study,effectiveness,evaluate
1990,ClinicalTrials.gov,data,processed
1991,ClinicalTrials.gov,data,processed
1992,natural history,withCOVID-19 infection,known about
1993,ClinicalTrials.gov,data,processed
1994,ClinicalTrials.gov,data,processed
1995,Lopinavir ritonavir,equivocal possibly positive efficacy,showed
1996,ClinicalTrials.gov,data,processed
1997,ClinicalTrials.gov,data,processed
1998,ClinicalTrials.gov,data,processed
1999,RESPIRE Study,design,has
2000,patients,standard,receive
2001,Current,bacterial infection,documented
2002,ClinicalTrials.gov,data,processed
2003,Presence,MAP,maintain
2004,Platelet,"< 50,000/ml2",count
2005,Patient,Extracorporeal Membrane Oxygenation,receiving
2006,ClinicalTrials.gov,data,processed
2007,use,obese cases,help
2008,use,obese cases,help
2009,ClinicalTrials.gov,data,processed
2010,ClinicalTrials.gov,data,processed
2011,children:-Age,visit,between birth and 15 years-Carrying out
2012,ClinicalTrials.gov,data,processed
2013,ClinicalTrials.gov,data,processed
2014,English acronym,coronavirus disease,is
2015,ClinicalTrials.gov,data,processed
2016,number,number,reached
2017,patients,conjunctival swab,receive
2018,objective,purpose,has
2019,ClinicalTrials.gov,data,processed
2020,investigators,aftercare ambulatory unit,created
2021,investigators,data,export
2022,ClinicalTrials.gov,follow data,processed
2023,SAR Cov-2 infection,cardiovascular system,include
2024,ClinicalTrials.gov,data,processed
2025,ClinicalTrials.gov,data,processed
2026,Rapidly emerging evidence,foundolfactory taste disturbances,have
2027,study population,subjects,draw
2028,Cases: Laboratory,COVID-19 infection,confirmed
2029,ClinicalTrials.gov,data,processed
2030,ClinicalTrials.gov,data,processed
2031,patients,medical consultation,seek
2032,Physicians,useddifferent therapeutic approaches,have
2033,ClinicalTrials.gov,data,processed
2034,guidelines,conservative fluid strategy,advocate
2035,ClinicalTrials.gov,data,processed
2036,ClinicalTrials.gov,data,processed
2037,ClinicalTrials.gov,data,processed
2038,ClinicalTrials.gov,data,processed
2039,ClinicalTrials.gov,data,processed
2040,policies,grief,The investigatorshypothesize
2041,ClinicalTrials.gov,data,processed
2042,Early PP,spontaneous breathing patientswith AHRF,benefit
2043,ClinicalTrials.gov,data,processed
2044,ClinicalTrials.gov,data,processed
2045,investigators,EuRopean Study,undertook
2046,ClinicalTrials.gov,data,processed
2047,Patients,lower respiratory tract,orfrom
2048,ClinicalTrials.gov,data,processed
2049,Recruited subjects,adult patients,include
2050,subjects,written informed consent,give
2051,potential additional future testing,immune response,Willingness to
2052,ClinicalTrials.gov,data,processed
2053,ClinicalTrials.gov,data,processed
2054,ClinicalTrials.gov,data,processed
2055,the COVID-19,recovered patient,infected
2056,ClinicalTrials.gov,data,processed
2057,ClinicalTrials.gov,data,processed
2058,ClinicalTrials.gov,data,processed
2059,patients,68Ga]Ga DOTA-(RGD)2 PET CT scan,Intervention
2060,ClinicalTrials.gov,data,processed
2061,ClinicalTrials.gov,data,processed
2062,ClinicalTrials.gov,data,processed
2063,ClinicalTrials.gov,data,processed
2064,Modulation,virus,counteract
2065,ClinicalTrials.gov,data,processed
2066,ClinicalTrials.gov,data,processed
2067,China,cases,reported
2068,mortality,1.4 and 42%,rangesbetween
2069,cases,finding countries,increasing
2070,ClinicalTrials.gov,data,processed
2071,ClinicalTrials.gov,data,processed
2072,Combination,COVID-19 Infection-,Promising
2073,Combination,COVID-19 Infection-,Promising
2074,IsotretinoinCould,COVID-19,Promising
2075,B38-CAP homolog,structural similarity,shares
2076,Therapeutic efficacy,investigation,warrant
2077,increased generation,counter - regulatoryprotective effects,triggers
2078,recombinant,therapeutic approachesin patients,promising
2079,B38-CAP homolog,structural similarity,shares
2080,Invitro recombinant B38-CAP protein,conversion,catalyzed
2081,Therapeutic efficacy,investigation,warrant
2082,ClinicalTrials.gov,data,processed
2083,Earlymobilization,risk,reduce
2084,tertiary referral centers,participants,recruit
2085,postural positioning,patient Non - invasively ventilated O2 high fluxes,Weaned off
2086,ClinicalTrials.gov,data,processed
2087,nation wide prospective cohort study,main issues:1,addresses
2088,nation wide prospective cohort study,onchildren,focuses
2089,ClinicalTrials.gov,data,processed
2090,ClinicalTrials.gov,data,processed
2091,study,periods,consistsof
2092,patients,qualitative determination,undergo
2093,patients,1 tablet,receive
2094,Patients,KBILD questionnaire,complete
2095,adequate contraception methods,use,include
2096,use,transfusion,plasma
2097,ClinicalTrials.gov,data,processed
2098,ClinicalTrials.gov,data,processed
2099,selective blockade,pulmonary inflammatory response inthe subject,modulate
2100,investigators,randomized controlled open label intervention study,propose
2101,Diabetic patients,treatment,begin
2102,ClinicalTrials.gov,data,processed
2103,ClinicalTrials.gov,data,processed
2104,ClinicalTrials.gov,data,processed
2105,ClinicalTrials.gov,data,processed
2106,nonCOVID-19 diagnosis,out.-Patient,ruled
2107,ClinicalTrials.gov,data,processed
2108,ClinicalTrials.gov,data,processed
2109,Inclusion Criteria:-Adults,18,aged
2110,ClinicalTrials.gov,data,processed
2111,SARS Cov-2 Infection COVID-19,severe clinicalcourse,develop
2112,ClinicalTrials.gov,data,processed
2113,Chloroquine,activity againstSARS coronaviruses,demonstrated
2114,ClinicalTrials.gov,data,processed
2115,subject,trial,advised to
2116,ClinicalTrials.gov,data,processed
2117,study patients,7 to up to 14 days of defibrotide,receive
2118,millimeters,voluntary written informed consent,300 mmHg
2119,ClinicalTrials.gov,data,processed
2120,ClinicalTrials.gov,data,processed
2121,ClinicalTrials.gov,data,processed
2122,ClinicalTrials.gov,data,processed
2123,the World Health Organization,COVID-19 outbreak,declared
2124,preliminary results,moderateto severe degree psychological impact,showed
2125,ClinicalTrials.gov,data,processed
2126,ClinicalTrials.gov,data,processed
2127,duration,time,include
2128,Evidence,vascular access,occluded
2129,ClinicalTrials.gov,data,processed
2130,Religousleaders,mask use,encourage
2131,ClinicalTrials.gov,data,processed
2132,exclusion category,1,includes
2133,ClinicalTrials.gov,data,processed
2134,kidney histology,severe acute tubularnecrosis,showed
2135,Non - specific mechanisms,hypovolemia,include
2136,Pharmaceutical industries,lot,made
2137,ClinicalTrials.gov,data,processed
2138,successive complement system,massive local release,activationcauses
2139,Functional implications,progressive worsening,includea
2140,negligible,high D dimerlevel,presents
2141,CT,positive,scan
2142,ClinicalTrials.gov,data,processed
2143,ClinicalTrials.gov,data,processed
2144,SARS CoV-2 Outcomes,Rehabilitation,Recovery Profiles in
2145,COVID19 patients survivors,lung function andreduced ability,reduced
2146,patients,program,areoffered
2147,Patients,abattery,undergo
2148,ClinicalTrials.gov,data,processed
2149,pulmonary coronarvirus disease,theattention,stated
2150,studies,broad spectrum antimicrobial effect,demonstrated
2151,ClinicalTrials.gov,data,processed
2152,International guidelines,anticoagulation,recommendprophylactic
2153,Theformer,large implications,have
2154,Region Östergötland/Östergötland County,population,has
2155,ClinicalTrials.gov,data,processed
2156,130 Patients,effect,evaluate
2157,ClinicalTrials.gov,data,processed
2158,olderpeople,IFN β deficiency,shown
2159,Addition,lung cells,protects
2160,Synairgen,randomised placebo,conducted
2161,patient,SNG001or placebo,receive
2162,ClinicalTrials.gov,data,processed
2163,ClinicalTrials.gov,data,processed
2164,primaryoutcome,main ventilator settings,includes
2165,Healthcare workers,best care,struggling
2166,data,tointensive care units,admitted
2167,patients,invasive ventilation,berestricted to
2168,ClinicalTrials.gov,data,processed
2169,total duration,visit,is
2170,recent diagnostic test,SARS CoV-2,positivefor
2171,Admission,continuous positive airway pressure,required
2172,ClinicalTrials.gov,data,processed
2173,ClinicalTrials.gov,data,processed
2174,High resolution CT,pulmonary fibrosis,indicates
2175,ClinicalTrials.gov,data,processed
2176,Provide,informed consent2,written
2177,Female subjects,blood pregnancy test,undergo
2178,ClinicalTrials.gov,data,processed
2179,patients,severe sleep disruption,experience
2180,Sleepdisruption sleep alteration,influence,have
2181,Patients,marked fragmentation,experience
2182,sleep deprivation,negative impact,shown
2183,factors,quality,influence
2184,ClinicalTrials.gov,data,processed
2185,ClinicalTrials.gov,data,processed
2186,ClinicalTrials.gov,data,processed
2187,dual role,considerable challenge,poses
2188,ClinicalTrials.gov,data,processed
2189,Remote,Glucose Monitoring,Continues
2190,Male,over 18 years,aged
2191,ClinicalTrials.gov,data,processed
2192,investigators,longitudinal study,perform
2193,severe form,poor prognosis,mayhave
2194,test ofpolyfunctionality,intracellular cytokine expression,characterize
2195,ClinicalTrials.gov,data,processed
2196,immune system,corticosteroids,includes
2197,ClinicalTrials.gov,data,processed
2198,Genitourinary Tumors,COVID-19 Infection,Observational Retrospective-prospective Study in
2199,greatest severity Treatments,Negative presence,Present symptoms
2200,ClinicalTrials.gov,data,processed
2201,ClinicalTrials.gov,data,processed
2202,study team,randomized controlled trial,proposes
2203,ClinicalTrials.gov,data,processed
2204,ClinicalTrials.gov,data,processed
2205,Cyclosporin,replication,blocks
2206,alisporivir,replication,inhibits
2207,Severe renal impairment,haemodialysis,requiring
2208,ClinicalTrials.gov,data,processed
2209,ClinicalTrials.gov,data,processed
2210,Chinese scientists,genomeinformation,shared
2211,randomized controlled double blind trial,ofremdesivir,evaluate
2212,Chinese scientists,genomeinformation,shared
2213,randomized controlled double blind trial,ofremdesivir,evaluate
2214,Laboratory,COVID-19.3,confirmed
2215,e.g. Child Pugh,≥ C,Severe liver disease
2216,ClinicalTrials.gov,data,processed
2217,ClinicalTrials.gov,data,processed
2218,Patients,surveys,follow up
2219,ClinicalTrials.gov,data,processed
2220,Criteria:-Newly,patients,diagnosed
2221,ClinicalTrials.gov,data,processed
2222,Participants,information,provided
2223,Inclusion Criteria:-Subjects,18,aged
2224,ClinicalTrials.gov,data,processed
2225,20 / min,60,diastolic
2226,ClinicalTrials.gov,data,processed
2227,COVID-19,hospitalization,requires
2228,ClinicalTrials.gov,data,processed
2229,Randomized Clinical Trial,short term,evaluate
2230,ClinicalTrials.gov,data,processed
2231,Covid-19,increasing threat,poses
2232,ClinicalTrials.gov,data,processed
2233,investigators,prospective randomized double blind placebo controlled study,propose
2234,firstly 3 patients,MTX LDE IV,receive
2235,9 patients,MTX LDE IV 30 mg,receive
2236,Patients,clinical laboratory safety evaluations,undergo
2237,ClinicalTrials.gov,data,processed
2238,Investigators,prospective cohort study,conduct
2239,ClinicalTrials.gov,data,processed
2240,review,followingfetal complications,demonstrate
2241,prospective randomized double blind placebo controlled study,pregnant women,follow
2242,ClinicalTrials.gov,data,processed
2243,patientsmay,prophylaxis,require
2244,ClinicalTrials.gov,data,processed
2245,attention,onmode,focused
2246,emphasis,post- acute care,involve
2247,COVID-19,major impact,anticipated
2248,Inclusion,cases,confirmed
2249,ClinicalTrials.gov,data,processed
2250,Outcomes,safety,include
2251,ClinicalTrials.gov,data,processed
2252,ClinicalTrials.gov,data,processed
2253,HCQ,theirtreatment,interrupted
2254,Patients,corticosteroids,receive
2255,ClinicalTrials.gov,data,processed
2256,TypeIII IFNs,restricted receptor expression,have
2257,clinical status,immediateconsent,obtained from
2258,ClinicalTrials.gov,data,processed
2259,ClinicalTrials.gov,data,processed
2260,Investigators,Registry(COREG,Methods
2261,McMaster Multi Regional COVID-19 Hospital Case Registry,data,includes
2262,McMaster,REDCap,stored in
2263,Datacollectors,standardized training,undergo
2264,COREG,consensus recommendations,shape
2265,ClinicalTrials.gov,data,processed
2266,investigator,instructions,give
2267,ClinicalTrials.gov,data,processed
2268,immunomodulatory therapies,potential long term effects onmale fertility,provoke
2269,cytokine microenvironment,tumorigenic adverse effects,have
2270,ClinicalTrials.gov,data,processed
2271,largest published registry,disease,describes
2272,literature search,myocardialinjury,reported
2273,confirmed COVID-19,3biomarkers high sensitivity troponin T,be
2274,Patients,positive realtime reverse transcription,have
2275,COVID-19 disease,thoracic X - ray imaging findings,confirmed on
2276,ClinicalTrials.gov,data,processed
2277,number,total number,calculated
2278,surveillance,execution,involves
2279,ClinicalTrials.gov,data,processed
2280,toCOVID-19,symptomatic COVID 19 infections,prevent
2281,Limited physical assessment,visit,collectedduring
2282,ClinicalTrials.gov,data,processed
2283,ClinicalTrials.gov,data,processed
2284,Ability,valid email address,have
2285,ClinicalTrials.gov,data,processed
2286,carrierdiagnosis,false negatives,present
2287,Caregivers,onlypartial access,have
2288,ClinicalTrials.gov,data,processed
2289,ofthese patients,secondary bacterial infections,develop
2290,Patients,WMT,underwent
2291,Fungal,pathogens infection6,identified
2292,ClinicalTrials.gov,data,processed
2293,Herd Immunity Study,history,aiming at
2294,ClinicalTrials.gov,data,processed
2295,Adults,18 years of age,aged
2296,investigators,hydroxychloroquine,prescribe
2297,ClinicalTrials.gov,data,processed
2298,Neuromuscular Blockade Agents,COVID-19 Patients,The Use of
2299,patients,inintensive care units,hospitalized
2300,ClinicalTrials.gov,data,processed
2301,ClinicalTrials.gov,data,processed
2302,Chinese scientists,novel coronavirus,isolated
2303,The WHO,later virus,designated
2304,West Algerian CORODIAB-13 study,answers,provide
2305,ClinicalTrials.gov,data,processed
2306,ClinicalTrials.gov,data,processed
2307,ClinicalTrials.gov,data,processed
2308,Participants,routine clinical data,have
2309,ClinicalTrials.gov,data,processed
2310,study,thefeasibility,explore
2311,password protected study website,dynamic programmatic content,provides
2312,ClinicalTrials.gov,data,processed
2313,ClinicalTrials.gov,data,processed
2314,ClinicalTrials.gov,Participants socio demographic data,processed
2315,response,question3,respond
2316,absence,unprotected exposure,constituted
2317,ClinicalTrials.gov,data,processed
2318,patients,chain reaction,undergopolymerase
2319,ClinicalTrials.gov,data,processed
2320,study,design,has
2321,ClinicalTrials.gov,data,processed
2322,researchteam,Eligible patients,visit
2323,ClinicalTrials.gov,data,processed
2324,ClinicalTrials.gov,data,processed
2325,ClinicalTrials.gov,data,processed
2326,25%,risk score.2,-Use
2327,sample,risk score,validate
2328,ClinicalTrials.gov,data,processed
2329,ClinicalTrials.gov,data,processed
2330,ClinicalTrials.gov,data,processed
2331,Subject,medical history,1
2332,Subject,history,1
2333,ClinicalTrials.gov,data,processed
2334,ofthe investigator clinical team,Murray scores,perform
2335,ClinicalTrials.gov,data,processed
2336,Neutralizing antibodies,important role,play
2337,SARS-CoV -2 specific NAbs,SARS CoV specific NAbs peak,reached
2338,ClinicalTrials.gov,data,processed
2339,ClinicalTrials.gov,data,processed
2340,group,4 weeks,complete
2341,ClinicalTrials.gov,data,processed
2342,Hopelessness,issue,compounds
2343,study team,225 hopeless IHDpatients from a large community teaching hospital in the Midwest,enroll
2344,ClinicalTrials.gov,data,processed
2345,clinical trial isto,safety,test
2346,Project,proper approvals,received
2347,Diagnostic criteria,1,includes
2348,Liver disease,grade C,score
2349,ClinicalTrials.gov,data,processed
2350,pandemic,tremendous stress,placed
2351,ClinicalTrials.gov,data,processed
2352,Sarcopenia,major inpatients,seems
2353,rehabilitation ofthese patients,nutritional support,requires
2354,IRS Care,assessments,needs
2355,ClinicalTrials.gov,data,processed
2356,Measurement,Software,Collect
2357,study staff member,brief set ofdemographic medical history questions,complete
2358,study team,set,complete
2359,study staff,post - measurement observation questions,complete
2360,ClinicalTrials.gov,data,processed
2361,ClinicalTrials.gov,data,processed
2362,volume,bycompliance,computed
2363,Participants,initially deep sedation andneuromuscular blockers,receive
2364,ClinicalTrials.gov,clinical data,processed
2365,investigators,prognosisand outcomes,study
2366,investigators,toevaluate hospital length,propose
2367,CVD,outcomes,influence
2368,study,male female patients,include
2369,ClinicalTrials.gov,data,processed
2370,Preliminary data,hypothesis,support
2371,Preliminary data,hypothesis,support
2372,ClinicalTrials.gov,data,processed
2373,ClinicalTrials.gov,data,processed
2374,healthcare workers,second option,adopt
2375,ClinicalTrials.gov,data,processed
2376,Viral RNA extraction,large volume,Ab
2377,ClinicalTrials.gov,data,processed
2378,ClinicalTrials.gov,data,processed
2379,ofretrospective studies,older age,The results
2380,ill individuals,CoViD-19 disease requiringmechanical ventilation,confirmed
2381,ClinicalTrials.gov,data,processed
2382,French,national containment,In
2383,Sleep disorders,major impact,have
2384,socio demographic factors,influence,is
2385,Child,7 to 11 years,aged
2386,ClinicalTrials.gov,data,processed
2387,difference,Freestyle Libre CGM,glucose
2388,theinvestigators,difference,noted
2389,ClinicalTrials.gov,data,processed
2390,ClinicalTrials.gov,data,processed
2391,COVID-19,children,studied in
2392,A Feasibility Study,safety,determine
2393,A Feasibility Study,safety,determine
2394,ClinicalTrials.gov,data,processed
2395,ClinicalTrials.gov,data,processed
2396,study,study effectiveness,investigate
2397,ClinicalTrials.gov,data,processed
2398,New developments,understanding,improve
2399,ClinicalTrials.gov,data,processed
2400,Participantswill,Participantswill standard medical treatment,continue
2401,study andcheck,physicians suitability,study
2402,Participantswill,Participantswill standard medical treatment,continue
2403,Permanent sterilization methods,tubal ligation,include
2404,ClinicalTrials.gov,data,processed
2405,virus infection,non-specificurticaria,includes
2406,Pathological findings,thrombocytic lymphocytic vasculitis,showed
2407,SAVI,acral skin,associates
2408,Production ofautoantibodies,thrombogenic properties,have
2409,ClinicalTrials.gov,data,processed
2410,ClinicalTrials.gov,data,processed
2411,ClinicalTrials.gov,data,processed
2412,ClinicalTrials.gov,data,processed
2413,experiments,direct impact,have
2414,screening tool,presence,beadministered in
2415,ClinicalTrials.gov,data,processed
2416,attending proceduralist,the SGB,perform
2417,Nurse,patientmonitoring,provide
2418,SGB perineural catheter,standard sterile technique,placedusing
2419,ClinicalTrials.gov,data,processed
2420,hyperinflammatory responses,acute lung injury,drive
2421,ClinicalTrials.gov,data,processed
2422,the World Health Organization,pandemic,outbreak
2423,positive patients andto,role,clarify
2424,ClinicalTrials.gov,data,processed
2425,ClinicalTrials.gov,data,processed
2426,ClinicalTrials.gov,data,processed
2427,ClinicalTrials.gov,data,processed
2428,Uncaria Tomentosa)has,potent anti - viral immunomodulatory activity,Cats Claw
2429,TNF alpha,monocyte culture supernatants,ininfected
2430,alkaloidal fraction,strongimmunomodulation,decreased
2431,Glutamine,forimmune suppressed individuals,recommended
2432,Magnesium Gluconate,immunomodulatory effects,shown
2433,herb,potentialantiviral immunomodulatory properties,believed
2434,Giloy,normal functioning,supports
2435,Itspharmacological activities,cardioprotective activity,include
2436,herb,antiviral activity,believed
2437,minerals,immune boosting activities,Studiesshow
2438,Damanaka,potential anti - malarial properties,has
2439,ClinicalTrials.gov,data,processed
2440,Ono Pharmaceutical,mesylate tablets,provideCamostat
2441,gelatin,Size,capsules
2442,arm,100 subjects,have
2443,patients,treatment,receive
2444,ClinicalTrials.gov,data,processed
2445,Study participation,onevisit,includes
2446,consented patient,screening questions,answer
2447,study statistician,block randomization schedule,create
2448,participants,known COVID+ status,alreadyhave
2449,study,only one 70-90 minute,requires
2450,ClinicalTrials.gov,data,processed
2451,Aninterim analysis,proportion,showed
2452,ClinicalTrials.gov,data,processed
2453,The Fleming [FMTVDM,Treatment Protocol,Directed
2454,VARIANCE,values,provide
2455,ClinicalTrials.gov,data,processed
2456,long term disabilities,dependence,lead to
2457,old;-Membership,consent,provides
2458,ClinicalTrials.gov,data,processed
2459,eligible patients,severe symptoms,with
2460,Subjects,18 to 79 years of age2,aged
2461,ClinicalTrials.gov,data,processed
2462,ClinicalTrials.gov,data,processed
2463,Study,actual situation,explores
2464,the Section,information,Section one obtains information from
2465,ClinicalTrials.gov,data,processed
2466,repurposed new drugs,antimalarials(chloroquine,include
2467,ClinicalTrials.gov,data,processed
2468,ClinicalTrials.gov,data,processed
2469,unknown role,study,necessitates
2470,ClinicalTrials.gov,data,processed
2471,ClinicalTrials.gov,data,processed
2472,Study,real time observational data,collects
2473,ClinicalTrials.gov,data,processed
2474,Patients,havenon - specific symptoms,may
2475,Platelets,"less than 70,0000",count
2476,ClinicalTrials.gov,data,processed
2477,fact,cytokine stormsyndrome,generate
2478,ClinicalTrials.gov,data,processed
2479,ClinicalTrials.gov,data,processed
2480,Male female subjects,18 to 45 years,aged
2481,body,no less than 50 kg,weight
2482,Previous viral gene sequencing,high homology,showed
2483,Medical history,following diseases,suggest
2484,ClinicalTrials.gov,data,processed
2485,novel coronavirus,respiratory symptoms,reported in
2486,Clinical studies,incidence rate,show
2487,Clinical studies,trail respiratory symptoms,precede
2488,pooled analysis,overallpercentage,revealed
2489,SARS CoV-2,angiotensin converting enzyme 2(ACE2,uses
2490,ClinicalTrials.gov,data,processed
2491,previous Asian epidemics,lasting impact,had
2492,study,psychological impact,assessed
2493,ClinicalTrials.gov,data,processed
2494,study,non - randomisedcomparator condition,comprises
2495,ClinicalTrials.gov,data,processed
2496,ClinicalTrials.gov,data,processed
2497,pandemic,relationship,andreveal
2498,42.463.119 individuals,criterion,cover
2499,ClinicalTrials.gov,data,processed
2500,ClinicalTrials.gov,data,processed
2501,Project,surgeon patient telemedicine perspectives,assess
2502,ClinicalTrials.gov,data,processed
2503,ClinicalTrials.gov,data,processed
2504,population,persons,include
2505,ClinicalTrials.gov,data,processed
2506,convalescent plasma,clinical laboratory clearance conditions,improve
2507,fresh plasma,negative prognostic factors,Assess
2508,patients,response points,evaluated
2509,ClinicalTrials.gov,data,processed
2510,antibodies,ashort term passive immunization,provide
2511,Thesecases,symptoms,showed
2512,Preclinical studies,remdesivir,suggested
2513,ClinicalTrials.gov,data,processed
2514,Functional testing,olfaction testing,include
2515,ClinicalTrials.gov,data,processed
2516,Patients,single dose ivermectin of12 mg,receive
2517,ClinicalTrials.gov,data,processed
2518,majority,acute respiratory distress syndrome,CoV-2)developed
2519,airway pressures,impact,reflect
2520,Elastance,values,influence
2521,ClinicalTrials.gov,data,processed
2522,study,aplacebo comparator group,comprise
2523,Humanity,new pandemic,experiencing
2524,small open label trial,viralcontainment,treated with
2525,randomized clinical studies,28-day survival benefit,shown
2526,ClinicalTrials.gov,data,processed
2527,study population,COVID-19 pateints,include
2528,ClinicalTrials.gov,data,processed
2529,Criteria:-,diabetic patients,enrolled
2530,ClinicalTrials.gov,data,processed
2531,Pregnant women,cov-2 positives,SARS
2532,ClinicalTrials.gov,data,processed
2533,ClinicalTrials.gov,data,processed
2534,Platelet,"70,000 or known functional platelet disorder 4",count
2535,ClinicalTrials.gov,data,processed
2536,pandemic,epidemiologicaldata,generated
2537,"Approximately 200,000 children",witha,living
2538,The French Society of Cardiology,recommendations,issued
2539,ClinicalTrials.gov,data,processed
2540,ClinicalTrials.gov,data,processed
2541,Cohorts,anapproximately equal number,include
2542,Examples,1,include
2543,ClinicalTrials.gov,data,processed
2544,change,impacton follow,have
2545,change,impact,have
2546,ClinicalTrials.gov,data,processed
2547,Patient,clinical criteria,meets
2548,ClinicalTrials.gov,data,processed
2549,ECG,left ventricular ejection fraction,carried out
2550,ClinicalTrials.gov,data,processed
2551,Inclusion,confirmed diagnosis,Criteria:-having
2552,ClinicalTrials.gov,data,processed
2553,current COVID-19 pandemic,healthcare organizations,providing
2554,arapidly expanding body,pattern,identified
2555,ClinicalTrials.gov,data,processed
2556,people,mild moderate symptoms,develop
2557,ClinicalTrials.gov,data,processed
2558,ClinicalTrials.gov,data,processed
2559,the COVID-19 Pandemic,major impact,had
2560,hydroxychloroquine,viral replication,prevent
2561,ClinicalTrials.gov,data,processed
2562,Inclusion Criteria:-COVID-19 PCR,patients,"positive,-Hospitalized"
2563,ClinicalTrials.gov,data,processed
2564,RTB101,Severity,Phase 3 Study to
2565,ClinicalTrials.gov,data,processed
2566,Patient,SARS CoV-2 infection,confirmed
2567,ClinicalTrials.gov,data,processed
2568,ClinicalTrials.gov,data,processed
2569,healthcare systems,unprecedented challenges,facing
2570,largest case series,"72,314 case records",reported
2571,putativemechanisms,direct myocardial injury,include
2572,COVID-19,asignificant impact,have
2573,myocarditis,contributing role,attributed to
2574,Imaging,imaging,is
2575,unique property,directquantification,allows
2576,CTCA,excellent sensitivity,has
2577,major,use,guidelinesadvocate
2578,Age,healthy control,matched
2579,ClinicalTrials.gov,data,processed
2580,UK,app,developed
2581,ClinicalTrials.gov,data,processed
2582,Pandemic,fears,created
2583,information,different types,had
2584,single respondent,survey responseto,set
2585,Minimum,personal details Section II,required
2586,6 Questions,following,carried
2587,Section II & III,closed ended questions,contained
2588,ClinicalTrials.gov,data,processed
2589,sample size,duration,dependon
2590,ClinicalTrials.gov,data,processed
2591,Phase Ib,Exploratory Trial,Controlled
2592,52 to,resolution,taken at
2593,ClinicalTrials.gov,data,processed
2594,Evaluation methods,laboratory investigationsand CT chest,include
2595,0.2 cm2.Patients,session,receive
2596,50 mW cm2,phototoxic response,increased
2597,ClinicalTrials.gov,data,processed
2598,ClinicalTrials.gov,data,processed
2599,ClinicalTrials.gov,data,processed
2600,ClinicalTrials.gov,data,processed
2601,treatment,clinical efficacy,demonstrated
2602,ClinicalTrials.gov,data,processed
2603,Infection,tremendous socialimpact,has
2604,interim analysis,place,took
2605,53 % decrease,80%,reached
2606,ClinicalTrials.gov,data,processed
2607,investigators,risk,eliminate
2608,ClinicalTrials.gov,data,processed
2609,ClinicalTrials.gov,data,processed
2610,Domains,Mood/Energy,include
2611,Domains,Mood/Energy,include
2612,PD,Clinical diagnosis,subjects
2613,ClinicalTrials.gov,data,processed
2614,ClinicalTrials.gov,data,processed
2615,ClinicalTrials.gov,data,processed
2616,Virchow triad,major risk factors,describes
2617,ClinicalTrials.gov,data,processed
2618,ClinicalTrials.gov,data,processed
2619,Study,distribution,evaluates
2620,Mothers,proven infection,have
2621,ClinicalTrials.gov,data,processed
2622,The BreastfeedingReport Card,slow improvements,indicates
2623,Hospital staff,breastfeeding,encourage
2624,Information,demography,include
2625,Participating physicians,2-hour Zoom sessions,attend
2626,Demography,guideline items,COVID-19
2627,Infant feeding growth pattern,charts,andgrowth
2628,ClinicalTrials.gov,data,processed
2629,ClinicalTrials.gov,data,processed
2630,SARS Covid-19 virus pandemic,big impact,had
2631,ClinicalTrials.gov,data,processed
2632,patient,enteral routeExclusion criteria1,tolerates
2633,ClinicalTrials.gov,data,processed
2634,COVID-19,aglobal pandemic,caused
2635,pregnant women,intensive care,required
2636,study,increase,observed
2637,theinvestigators,samples,stratify
2638,ClinicalTrials.gov,data,processed
2639,ClinicalTrials.gov,data,processed
2640,recent COVID-19 pandemic,aspects,affected
2641,Theinvestigators,the Online Psychotherapy Tool,use
2642,method,care capacity,increase
2643,Exclusion criteria,active psychosis,include
2644,The SW,pre - designed therapy module,assign
2645,SWs,standard care pathway,learn
2646,Training,webinars,occurthrough
2647,OPTT,identifiable personalinformation,collect
2648,ClinicalTrials.gov,data,processed
2649,ClinicalTrials.gov,data,processed
2650,outbreak,significant strain,put
2651,pandemicExclusion Criteria:-Patients,surgical intervention,undergoing
2652,ClinicalTrials.gov,data,processed
2653,survey,aims,address to
2654,ClinicalTrials.gov,data,processed
2655,ClinicalTrials.gov,data,processed
2656,ClinicalTrials.gov,data,processed
2657,bedside investigations,utmost importance,have
2658,SARS CoV-2)infection,background,leads to
2659,90%,invasive mechanicalventilation,require
2660,investigations,utmost importance,have
2661,theratio,atelectatic/overdistended alveoli,estimated
2662,ClinicalTrials.gov,data,processed
2663,ClinicalTrials.gov,data,processed
2664,study,diagnostic performance,investigates
2665,RT-PCR,COVID-19 positive2,confirmed
2666,RT-PCR,COVID-19 negative3,confirmed
2667,ClinicalTrials.gov,data,processed
2668,ClinicalTrials.gov,data,processed
2669,hospitals,ethical approach upstream,institutionalized
2670,study,2 weekly meetings,set up
2671,ClinicalTrials.gov,data,processed
2672,Participants,blood sample,give
2673,Participants,Participants history,discuss
2674,machine,plasma,willseparate
2675,Participation,up to 240 days,last
2676,Enrolled subjects,baselinephysical laboratory examination,receive
2677,Provide,informed consent,written
2678,Females,screening,have
2679,ClinicalTrials.gov,data,processed
2680,Post - acute COVID-19 patients,convalescents).Sample size calculation,discharged from
2681,healthcare professionals,clinical recommendations,give to
2682,Patients,new recommendations,receive
2683,ClinicalTrials.gov,data,processed
2684,itremains,seroprevalence,unclear
2685,ClinicalTrials.gov,data,processed
2686,ClinicalTrials.gov,data,processed
2687,ClinicalTrials.gov,data,processed
2688,Patients,hospital,leave
2689,local ethics committee,thisstudy,approved
2690,Investigators,frequency,analysed
2691,ClinicalTrials.gov,data,processed
2692,Patients,leflunomide,receive
2693,Patients,QD,receive
2694,Cycles,28 days,repeatevery
2695,Cycles,28days,repeat
2696,Patients,completion,receiveSOC.After
2697,Inclusion,consent,informed
2698,Subjects,following therapies,received
2699,ClinicalTrials.gov,data,processed
2700,Pandemic,fears,created
2701,dental treatment procedures,aerosols,generate
2702,Pandemic,fears,created
2703,google form,compulsory consent,alsosought for
2704,ClinicalTrials.gov,data,processed
2705,Coronavirus Emergency,Italian Healthcare National System,affected
2706,ClinicalTrials.gov,data,processed
2707,ClinicalTrials.gov,data,processed
2708,chosen adult subject,physician independent consent,permitted to
2709,ClinicalTrials.gov,data,processed
2710,ClinicalTrials.gov,data,processed
2711,ClinicalTrials.gov,data,processed
2712,COVID19 pandemic,public health emergency,represents
2713,ClinicalTrials.gov,data,processed
2714,cytokine storm,increase,induces
2715,MSCs,positive role,play
2716,ClinicalTrials.gov,data,processed
2717,Respiratory Control Center Anomalies,Lack,Explain
2718,attenuation,clinicians,deprives
2719,ClinicalTrials.gov,data,processed
2720,ClinicalTrials.gov,data,processed
2721,HOPECOVID19,new respiratory virus,generatedby
2722,ClinicalTrials.gov,data,processed
2723,pandemic,fromWuhan Province,emerged
2724,ClinicalTrials.gov,data,processed
2725,ClinicalTrials.gov,data,processed
2726,ClinicalTrials.gov,data,processed
2727,SARS CoV-2 infection,dysregulation,causes
2728,Therelease,positivefeedback loop,facilitate
2729,cardinal features,constant fever,include
2730,Endogenous viral protein,virus specific CD8 T cells,canactivate
2731,Therapeutic options,steroids intravenous immunoglobulin selective cytokine blockade(eg Anakinra Tocilizumab JAK inhibition vaccines reinfusion,include
2732,Patients,TCZ treatment,received
2733,China,astudy,conducting
2734,18 years or older-Diagnosis of SARS,≥ 30 breaths min,increase in
2735,vasopressors,mean arterial pressure,respiratory failure
2736,ClinicalTrials.gov,data,processed
2737,phase,efficacy,evaluate
2738,ClinicalTrials.gov,data,processed
2739,250 patients,nitazoxanide 500mg 8 / 8 hours,received
2740,250 patients,placebo,received
2741,Population,suggestive,scan
2742,ClinicalTrials.gov,data,processed
2743,studies,outinside,carried
2744,Wuhan Hospitals,presence,showed
2745,etc.).Its mechanism,virus adsorption,preventing
2746,ClinicalTrials.gov,data,processed
2747,Patient,extracorporeal membrane oxygenation,receiving
2748,Patient,history,has
2749,ClinicalTrials.gov,data,processed
2750,theclinical efficacy,significant effects,described
2751,ClinicalTrials.gov,data,processed
2752,Arandomized study,role hydrochloride,clarify
2753,ClinicalTrials.gov,data,processed
2754,body,systemic adaptation response,undergoes
2755,triad,toend organ failure,lead
2756,ClinicalTrials.gov,data,processed
2757,Arandomized study,to:1,seeks
2758,ClinicalTrials.gov,18y available data,processed
2759,ClinicalTrials.gov,data,processed
2760,ClinicalTrials.gov,data,processed
2761,investigators,correlationbetween clinical immunovirological data,study
2762,investigator,correlation,study
2763,Research interventions,prospective collection,include
2764,Recruitment,priority,datais
2765,ClinicalTrials.gov,data,processed
2766,ClinicalTrials.gov,data,processed
2767,ClinicalTrials.gov,data,processed
2768,ClinicalTrials.gov,data,processed
2769,Hospitalization,delayed resuscitation,require
2770,ClinicalTrials.gov,data,processed
2771,ClinicalTrials.gov,data,processed
2772,COVID-19 patients,coagulopathy,develop
2773,patients,severe thrombotic complications,develop
2774,Patients,typical Covid-19 manifestation,showing
2775,ClinicalTrials.gov,data,processed
2776,Bats,dampened Nod like receptorfamily,have
2777,intervention groupwill,capsules,receive
2778,non - intervention group,placebopills,receive
2779,ClinicalTrials.gov,data,processed
2780,WOCBP,negative highly sensitive pregnancy test,have
2781,screening visit.-Has,vaccine,received
2782,ClinicalTrials.gov,data,processed
2783,ClinicalTrials.gov,data,processed
2784,ClinicalTrials.gov,data,processed
2785,Guo colleagues meta analysis,thatARBs,showed
2786,Our proposed ARBs CORONA II Phase 3 RCT,losartancan decrease mortality,establish
2787,Primary - Losartan,mortality,decreases
2788,ClinicalTrials.gov,data,processed
2789,Participants,one of two aromas to inhale with one beingactive and the other a control comparison,receive
2790,pending-adults age,informed consentExclusion Criteria:-Smoker,participated in
2791,ClinicalTrials.gov,data,processed
2792,ClinicalTrials.gov,data,processed
2793,specific effect,use,justifies
2794,ClinicalTrials.gov,data,processed
2795,ClinicalTrials.gov,data,processed
2796,ClinicalTrials.gov,data,processed
2797,patient,consent,given
2798,ClinicalTrials.gov,data,processed
2799,ClinicalTrials.gov,data,processed
2800,Covid 19 pandemia,millions of deaths worldwide,causing
2801,ofCOVID-19,cytokine storm syndrome,have
2802,Inclusion,clinical diagnosis,Criteria:-documented
2803,ClinicalTrials.gov,data,processed
2804,Patients,hospitalized)8,treated in
2805,ClinicalTrials.gov,data,processed
2806,ClinicalTrials.gov,data,processed
2807,ClinicalTrials.gov,data,processed
2808,ClinicalTrials.gov,data,processed
2809,metformin,severity,Determine
2810,metformin,symptomatic COVID-19,Determine
2811,metformin,SARS CoV-2 infection,Determine
2812,ClinicalTrials.gov,data,processed
2813,ClinicalTrials.gov,data,processed
2814,study,impact,compare
2815,ClinicalTrials.gov,data,processed
2816,ClinicalTrials.gov,data,processed
2817,ClinicalTrials.gov,data,processed
2818,ClinicalTrials.gov,data,processed
2819,therapeuticmanagement,empiric antimicrobial therapy,includes
2820,Usual biology,procalcitonin measurement,includes
2821,Empirical antimicrobialtherapy,generation cephalosporin,combines
2822,ClinicalTrials.gov,data,processed
2823,patients,supplemental oxygen,need
2824,retesting,Current hospitalization,allowed
2825,ClinicalTrials.gov,data,processed
2826,Sulforaphane,lungs frominflammatory pathology,derived from
2827,ClinicalTrials.gov,data,processed
2828,patient consents,baseline demographic details,collect
2829,Patients,≥18 years2,aged
2830,ClinicalTrials.gov,data,processed
2831,study,association,evaluate
2832,study,collection,involves
2833,ClinicalTrials.gov,data,processed
2834,CORIMUNO19-COAG,efficacy,evaluate
2835,ClinicalTrials.gov,data,processed
2836,oxygen.-Score,oxygen,hospitalized
2837,ClinicalTrials.gov,data,processed
2838,signs,dehydrogenase,lactate
2839,ClinicalTrials.gov,data,processed
2840,Subjects,open label screened plasma,receive
2841,infection.-Severe DIC,factor replacement,needing
2842,ClinicalTrials.gov,data,processed
2843,Cases,criteria,meeting
2844,ClinicalTrials.gov,data,processed
2845,ClinicalTrials.gov,data,processed
2846,Patients,impact,investigate
2847,ClinicalTrials.gov,data,processed
2848,double blind placebo controlled study,efficacy,toassess
2849,double blind placebo controlled study,efficacy,obtained
2850,ClinicalTrials.gov,data,processed
2851,ClinicalTrials.gov,data,processed
2852,Laboratory,SARS CoV-2 infection,confirmed
2853,ClinicalTrials.gov,data,processed
2854,ClinicalTrials.gov,data,processed
2855,ClinicalTrials.gov,data,processed
2856,ClinicalTrials.gov,data,processed
2857,Patients,routine care,receive
2858,ClinicalTrials.gov,data,processed
2859,ClinicalTrials.gov,data,processed
2860,Inclusion Criteria:-Males,12yrs,aged
2861,ClinicalTrials.gov,data,processed
2862,60 - 80 years of age,indesignated hotspots,Intervention study Study population
2863,Investigators,Red & Orange zones,include
2864,information,incommunity organizations,presented
2865,immunological biomarkeranalysis,additional blood samples,provide
2866,Detection,ICMR validated SARS CoV-2 Antibody Test,performedusing
2867,Presence,presence,willindicate
2868,primary variables,percentage,bethe
2869,Inclusion,60 years of age or older,Criteria:-Adults
2870,ClinicalTrials.gov,data,processed
2871,dateapproximately 600 individuals,IMU-838,received
2872,trial,adaptive sequential design,uses
2873,An IDMC,unblinded data,review
2874,thefinal analysis,approximately 230 patients,expected
2875,IA1,indicateactivity,extended to
2876,Barrier methods,cap,include
2877,1.0 109 L,"100,000 mm³",count
2878,ordinary activity,fatigue,Less
2879,ClinicalTrials.gov,data,processed
2880,An Independent Data SafetyMonitoring Board,participating subjects,supervise
2881,clinical endpoints,life threateningrespiratory disease,include
2882,ClinicalTrials.gov,data,processed
2883,study,thepredictors,assessed
2884,ClinicalTrials.gov,data,processed
2885,study,300 participants,enroll
2886,ClinicalTrials.gov,data,processed
2887,ClinicalTrials.gov,data,processed
2888,diagnosis,thepresence,include
2889,Patient,supportive oxygen therapy4,requires
2890,ClinicalTrials.gov,data,processed
2891,ClinicalTrials.gov,data,processed
2892,thekilling,awareness,raised
2893,ClinicalTrials.gov,data,processed
2894,considerable,intensive care treatment forCovid-19 associated pneumonia,require
2895,ClinicalTrials.gov,data,processed
2896,BackgroundCOVID-19,lower case fatality rate,shown
2897,common cause,theactivation,promote
2898,MVs,increasingattention,received
2899,Outpatients,byGeneral Practitioners,recruited
2900,ClinicalTrials.gov,data,processed
2901,caregivers,severalissues,facing
2902,current period,profoundreorganization,necessitated
2903,ClinicalTrials.gov,data,processed
2904,ClinicalTrials.gov,data,processed
2905,the Food and Drug Administration (FDA,severalplatforms,approved
2906,clinicallaboratory improvement amendments,complexity,designated
2907,ClinicalTrials.gov,data,processed
2908,depression,relationship,aimed
2909,42.463.119 individuals,criterion,cover
2910,ClinicalTrials.gov,data,processed
2911,improve,toenhance,contribute
2912,ClinicalTrials.gov,data,processed
2913,kit,regulatoryapproval,obtained
2914,ClinicalTrials.gov,data,processed
2915,ClinicalTrials.gov,data,processed
2916,ClinicalTrials.gov,data,processed
2917,outcomes,islittle information,tend to
2918,ClinicalTrials.gov,data,processed
2919,Research interventions,place,take
2920,latent TB,TB,treated
2921,Chronic recent corticosteroid,> 10 mg/day9,use
2922,women,highly effective methods,Women of
2923,ClinicalTrials.gov,data,processed
2924,NFS liver tests,biomarkers,lymphocyte
2925,Chest,tomography,computed
2926,ClinicalTrials.gov,data,processed
2927,ClinicalTrials.gov,data,processed
2928,patients,week afterillness onset,deteriorate
2929,Pal pulmonary,rehabilitation program,focused
2930,ClinicalTrials.gov,data,processed
2931,researchers,infodemic,haveobserved
2932,investigators,single stage,propose
2933,researchers,data quality interms,explore
2934,ClinicalTrials.gov,data,processed
2935,Coronavirus Artificial Antigen,Cell Vaccine,Presenting
2936,basedon,domains,conserved
2937,2019,new coronavirus,is
2938,Covid-19,threat,pose
2939,subjects,total,receive
2940,ClinicalTrials.gov,data,processed
2941,People,changes,haveexperienced
2942,Common co - existing comorbidities,patients,place
2943,change,distress,exacerbate
2944,rapid changes,shifting risk benefit ratio forpatients,reflected
2945,use,tothe fore,come
2946,electronic Patient,Outcome Measures,Reported
2947,ClinicalTrials.gov,data,processed
2948,household,intervention,receive
2949,Symptomatic,concomitant use,exclude
2950,ClinicalTrials.gov,data,processed
2951,ClinicalTrials.gov,data,processed
2952,participants,symptom questionnaire,complete
2953,10 participants,clinic home visit,provided to
2954,a current EC,informed consent form2,Signed
2955,ClinicalTrials.gov,data,processed
2956,ClinicalTrials.gov,data,processed
2957,ClinicalTrials.gov,data,processed
2958,Investigator,pilot phase,concluded
2959,Investigator,consecutive SARS COV-2 negative tests,collect up
2960,Lung,> 50%,infiltrates
2961,ClinicalTrials.gov,data,processed
2962,URL,dayspost randomization,Major secondary outcome measure:(1
2963,myocardial injury,major impact,is
2964,investigators,strong rationale andworld leading expertise,have
2965,70%,28-day time point,estimated on
2966,Planned subgroup analyses,1)Diabetes,include
2967,ClinicalTrials.gov,data,processed
2968,lower intracellular cholesterol concentration,SREBP 2 upregulating LDL receptor synthesis,leads to
2969,intracellularcholesterol homeostasis,new physiological equilibrium,achieves
2970,intracellular cholesterol content seemsto,virus uptake,influence
2971,Recently anobservational study,theprotective effect,showed
2972,ClinicalTrials.gov,data,processed
2973,Previousexperiences,need,highlight
2974,Previous vivoantiviral studies,Previous vivoantiviral studies activity,showed
2975,Laboratory,infection,confirmed
2976,ClinicalTrials.gov,data,processed
2977,Cincinnati,Cincinnati,had
2978,confirmed case,spread,avoided
2979,ClinicalTrials.gov,data,processed
2980,investigator led non - commercial non - interventional study,patient identifiable information,collect
2981,lab test,COVID-19 infection ii clinicaldiagnosis,confirmed
2982,investigator led non - commercial non - interventional study,surgery patients,capture:-emergency
2983,participating site,data,provided with
2984,collaborators,data,registered
2985,Reports,description,include
2986,toCovidVAS protocol,risk factors,identify
2987,lab test,COVID-19 infection ii clinical diagnosis,confirmed
2988,study,surgery patients,capture:-emergency
2989,ClinicalTrials.gov,data,processed
2990,Troponin leak,direct cardiacinvolvement,signify
2991,myocyte,portalfor viral infection,provide
2992,ClinicalTrials.gov,data,processed
2993,Time,48 hours,exceed
2994,Patients,alcohol,abusing
2995,ClinicalTrials.gov,data,processed
2996,Comorbidities,susceptibility,increase
2997,ClinicalTrials.gov,data,processed
2998,Peng,usefulness,accentuate
2999,researchers team,good correlation,found
3000,ClinicalTrials.gov,data,processed
3001,ClinicalTrials.gov,data,processed
3002,Severe infiltrationof pulmonary tissue,alveolar gas exchange,affects
3003,ClinicalTrials.gov,data,processed
3004,ClinicalTrials.gov,data,processed
3005,ClinicalTrials.gov,data,processed
3006,ClinicalTrials.gov,data,processed
3007,Severe CoVID-19 identifiedin Wuhan Pneumonia,ECMO,Clinical Scores for
3008,significance,clinical prognostic cores,ofestablished
3009,accuracy,prediction,assessed
3010,ClinicalTrials.gov,data,processed
3011,Patients,withfever,present
3012,5 % 10 % amonghospitalized patients,ICU admission,require
3013,increasing number,healthcare systems,challenged
3014,Inclusion Criteria:-COVID,patients,confirmed
3015,ClinicalTrials.gov,data,processed
3016,longitudinal follow,positive negative RT PCR test,carried out
3017,ClinicalTrials.gov,data,processed
3018,Antibody tests,humanantibodies,detect
3019,MethodsThe Weil Lab research group,special interest,has
3020,rapid format antibody,evaluated andantibody test results,compared with
3021,reader,vote,thedeciding
3022,ClinicalTrials.gov,data,processed
3023,ClinicalTrials.gov,data,processed
3024,Visits,detailed interview,include
3025,investigators,individuals,enroll
3026,ClinicalTrials.gov,data,processed
3027,sample turn times,hours to several days,take
3028,final format,dry conjugate,attached to
3029,ClinicalTrials.gov,data,processed
3030,spread,significant challenges,posed
3031,Dentist,bachelor,having
3032,Inclusion Criteria:-Dentist,bachelor,having
3033,ClinicalTrials.gov,data,processed
3034,patient,following criteria,meet
3035,ClinicalTrials.gov,data,processed
3036,investigators,odds ratios,compare
3037,automated analyzer,complete blood count,count
3038,investigators,theodds ratios,compared
3039,BSMMU fever clinic,1200 COVID-19 positive cases,alreadytreated
3040,titre,desired level,collected on
3041,Dr. Fazle RabbiChowdhury,necessary permission,have
3042,laboratory medicine team,clinical team,support
3043,Patients,years.2,below18
3044,ClinicalTrials.gov,data,processed
3045,Septic isolation,contact isolation,includes
3046,relationship,better understanding,are
3047,ClinicalTrials.gov,data,processed
3048,2 types,risk,been
3049,commonly prescribed blood pressuremedications,risk,increase
3050,ClinicalTrials.gov,data,processed
3051,ClinicalTrials.gov,data,processed
3052,ClinicalTrials.gov,data,processed
3053,ClinicalTrials.gov,data,processed
3054,Misr International University(MIU,established online learning system,has
3055,ClinicalTrials.gov,data,processed
3056,ClinicalTrials.gov,data,processed
3057,subjectwill,assigned treatment,receive
3058,ClinicalTrials.gov,data,processed
3059,ClinicalTrials.gov,data,processed
3060,Ciclesonide,low rate,has
3061,ClinicalTrials.gov,data,processed
3062,ClinicalTrials.gov,data,processed
3063,Patients,treatment,receive
3064,ClinicalTrials.gov,data,processed
3065,ClinicalTrials.gov,data,processed
3066,pathogenesis,prominent role,recognizes
3067,ongoing study,enrollment,involves
3068,ClinicalTrials.gov,data,processed
3069,ClinicalTrials.gov,data,processed
3070,Renal impairment,15 mL min/1.73 m²,measured
3071,ClinicalTrials.gov,data,processed
3072,tamoxifen,redistribution,A studydemonstrated
3073,cysteine,inhibitor E64d,firstidentified by
3074,Tamoxifen exposures,cathepsin D activity,decreased
3075,Angiotensin II,intracellular calcium activity,increases
3076,nicardipine,Ang II mediated[Ca2,influence
3077,interleukin-6,AT1 protein,regulated
3078,Prostate cancer cell lines,TMPRSS2 expression,stronglyupregulated
3079,cancers,distinct set ofrisk factors,have
3080,men,higher risk,have
3081,Tamoxifen,therate,decreased
3082,Organellaracidification disruption,formany,required for
3083,cysteine,inhibitor E64d,firstidentified by
3084,Tamoxifen,cathepsin D activity,exposuresdecreased
3085,Age,the followingconditions:1,have
3086,16 1-anti coagulation,active cervicitis,use
3087,ClinicalTrials.gov,data,processed
3088,ClinicalTrials.gov,data,processed
3089,investigators,preparedstatements,have
3090,ClinicalTrials.gov,data,processed
3091,pandemic,massive threat,poses
3092,initial interventional studies,minimalimprovement,approved
3093,CLOCC trial,efficacy,willevaluate
3094,ClinicalTrials.gov,data,processed
3095,Research interventions,place,take
3096,Inclusion Criteria,all):1,meet
3097,latent TB,TB,treated
3098,Chronic recent corticosteroid,> 10 mg/day9,use
3099,women,highly effective methods,Women of
3100,ClinicalTrials.gov,data,processed
3101,ClinicalTrials.gov,data,processed
3102,new strain,inDecember,called
3103,The World HealthOrganization,disease,named
3104,Clinical features,respiratory symptoms,include
3105,Partial pressure,> 50%,infiltrates
3106,Recovery,COVID-19 diagnosis,confirmed
3107,ClinicalTrials.gov,data,processed
3108,randomized controlled trial,Study Design trialwith estimates,inform
3109,investigators,record pulse oximetry,continuous
3110,ClinicalTrials.gov,data,processed
3111,human coronavirus,novel coronavirus disease,caused
3112,Common symptoms,fever,include
3113,Surface marker analysis,presence,confirmed
3114,completed sequencing,miRNA,expressed
3115,property,therapeutic potential,demonstrates
3116,Provide,informed consent2,written
3117,Individuals,COVID-19 symptoms,severe
3118,Female subjects,blood urine pregnancy test,undergo
3119,ClinicalTrials.gov,data,processed
3120,ClinicalTrials.gov,data,processed
3121,ClinicalTrials.gov,data,processed
3122,ClinicalTrials.gov,data,processed
3123,Circulating bio - adrenomedullin,vascular tone,regulates
3124,ClinicalTrials.gov,data,processed
3125,syndrome coronavirus,disease,causes
3126,investigators,knockout,discovered
3127,senicapoctreatment,anti - inflammatory effects,possesses
3128,senicapoc,antiviral properties,is
3129,Aarhus University,senicapoc,haspatented
3130,ClinicalTrials.gov,data,processed
3131,ClinicalTrials.gov,data,processed
3132,ClinicalTrials.gov,data,processed
3133,Risk,infectionsas,transmitted
3134,preparation,steps,includes
3135,ClinicalTrials.gov,data,processed
3136,the Lifespan Cancer Institute,over 50%,serves
3137,investigators,Blackstone Valley Community Health Center,engagethe
3138,investigators,staff,engage
3139,ClinicalTrials.gov,Data,processed
3140,ClinicalTrials.gov,data,processed
3141,clinical diagnosis,SARS CoV-2 infection,confirmed
3142,ClinicalTrials.gov,data,processed
3143,ClinicalTrials.gov,data,processed
3144,ClinicalTrials.gov,data,processed
3145,Knowledge,implementation,achieve
3146,ClinicalTrials.gov,data,processed
3147,ClinicalTrials.gov,data,processed
3148,investigator,nature,explain
3149,laboratory,COVID-193,have
3150,ClinicalTrials.gov,data,processed
3151,ClinicalTrials.gov,data,processed
3152,ClinicalTrials.gov,data,processed
3153,Low dose radiation,anti - inflammatory effects thatare,selected
3154,patients,standard national protocol,receive
3155,available)-↑,Criteria:-Lack,CRPExclusion
3156,ClinicalTrials.gov,data,processed
3157,patients,oxygen,need
3158,ClinicalTrials.gov,data,processed
3159,quantitative assessment,reliable predictionmodel,establish
3160,project research period,6 months,have
3161,End time,AI model,2020.2.1 Establish
3162,collection,chest HRCTexamination,underwent
3163,ClinicalTrials.gov,data,processed
3164,study,health related quality,investigates
3165,ClinicalTrials.gov,data,processed
3166,Inclusion Criteria:-Having,COVID-19 illness PCR test,suffered
3167,ClinicalTrials.gov,data,processed
3168,ClinicalTrials.gov,data,processed
3169,ClinicalTrials.gov,data,processed
3170,clinical trial,highlysensitive blood biomarkers,examines
3171,ClinicalTrials.gov,data,processed
3172,Inclusion,professionals,Criteria:-All
3173,ClinicalTrials.gov,data,processed
3174,ClinicalTrials.gov,data,processed
3175,Study of Efficacy and Safety of DV890,efficacy,assess
3176,Participants,receiveSoC,will
3177,End,place,take
3178,ClinicalTrials.gov,data,processed
3179,Lung,> 50%,infiltrates
3180,ClinicalTrials.gov,data,processed
3181,ClinicalTrials.gov,data,processed
3182,Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,antibodies,alsoinvestigates
3183,pandemic,importantconsequences,has
3184,investigators,toassess children,aim
3185,Pneumonia,ongoing coordinated efforts,complements
3186,ClinicalTrials.gov,data,processed
3187,mode,highcontagiousness rate2,induces
3188,study,clinical characteristics,published
3189,patients,rapid ventilatory assistance,required
3190,ClinicalTrials.gov,data,processed
3191,currentglobal death toll,"37,000 people",exceeds
3192,survivors,functional,showed
3193,common computed tomographic changes,bilateral subpleural milk glass opacity,include
3194,ClinicalTrials.gov,data,processed
3195,Inclusion Criteria:-Patient,Patient,confirmed
3196,ClinicalTrials.gov,data,processed
3197,antiviral studies,efficacy,evaluate
3198,patient,40 kg;3,weighs
3199,ClinicalTrials.gov,data,processed
3200,ClinicalTrials.gov,data,processed
3201,Surveyingco morbid lung diseases,interstitial lung diseases,done
3202,kVp mA perslice,patient clinical indication,weightof
3203,percentage ofpatients,criteria,Statistical analysis
3204,multi center double blind placebo controlled randomized Phase 2/3 trial,safety,studythe
3205,multi center double blind placebo controlled randomized Phase 2/3 trial,safety,studythe
3206,Phase 2,safety,has
3207,whetherbardoxolone methyl,probability,designed to
3208,Patients,ofdosing,follow
3209,Assessments,clinicalstatus assessments,include
3210,An independent Data and Safety MonitoringBoard,study leadership,advise
3211,Known,ventricular ejection fraction,left
3212,ClinicalTrials.gov,data,processed
3213,Patients,Indirect Inhibition,Via
3214,Patients,Indirect Inhibition,Via
3215,Patients,Indirect Inhibition,Via
3216,respiratory,currently approved treatments,has
3217,inPCO patients,inlevels,resulted in
3218,ClinicalTrials.gov,data,processed
3219,ClinicalTrials.gov,data,processed
3220,ClinicalTrials.gov,data,processed
3221,ClinicalTrials.gov,data,processed
3222,person immune system,SARS CoV-2,remembers
3223,thirdof patients,imaging findings,have
3224,patients,exercise capacity,reduced
3225,proposed mechanisms ofmyocardial injury,cytokine storm,include
3226,Infection,complex systemicinflammatory responses,initiates
3227,Activation,subsequent activation,resultsin
3228,Existence,prediction ofvaccination frequency,help
3229,Thecolloidal gold,anti-human IgG,conjugated
3230,ClinicalTrials.gov,data,processed
3231,recent evidence,therapy,suggests
3232,X ULN,outcomes,improves
3233,ClinicalTrials.gov,data,processed
3234,ClinicalTrials.gov,data,processed
3235,Swiss population,period,underwent
3236,Swiss population,period,underwent
3237,COVID-19 pandemic,health care,affected
3238,ClinicalTrials.gov,data,processed
3239,positive pressure fans,negative pressure models,replaced
3240,ClinicalTrials.gov,data,processed
3241,SARS Cov-2 Infection,ages,affects
3242,ClinicalTrials.gov,data,processed
3243,total,transfusion,receive
3244,Recipient,criteria,meet
3245,ClinicalTrials.gov,data,processed
3246,multicenter prospective cohort study,substudies,have
3247,multicenter prospective cohort study,CT,includes
3248,ClinicalTrials.gov,data,processed
3249,ClinicalTrials.gov,data,processed
3250,ANDhave,symptoms,developed
3251,ClinicalTrials.gov,data,processed
3252,Exclusion Criteria:-A,SARS CoV-2 infection,confirmed
3253,ClinicalTrials.gov,data,processed
3254,patient,patient,defend
3255,ClinicalTrials.gov,data,processed
3256,Subjects,specific antiviral drugs,received
3257,Combined organ failure,ICU monitoring,requires
3258,L,×,platelets
3259,ClinicalTrials.gov,data,processed
3260,novel coronavirus,access,changed
3261,RCT participants,berecruited)Inclusion criteria:1,BLUE CORAL eligibility
3262,ClinicalTrials.gov,data,processed
3263,ClinicalTrials.gov,data,processed
3264,ClinicalTrials.gov,data,processed
3265,seropositivity,IgM IgG responses,rateof
3266,ClinicalTrials.gov,data,processed
3267,patients,specific neuro cognitiverehabilitation,require
3268,ClinicalTrials.gov,data,processed
3269,discovery,public health emergencies,causing
3270,recovered plasma,successful results,show
3271,study,improved clinical pictures,showed
3272,ClinicalTrials.gov,data,processed
3273,ClinicalTrials.gov,data,processed
3274,Nutritional Habits,Coronavirus Disease,Affect
3275,patients,Hydroxychloroquine,receive
3276,ClinicalTrials.gov,data,processed
3277,ClinicalTrials.gov,data,processed
3278,recent inception,thousands of deaths globally,caused
3279,ClinicalTrials.gov,data,processed
3280,ClinicalTrials.gov,data,processed
3281,ClinicalTrials.gov,data,processed
3282,study,comparison betweenplacebo,include
3283,exclusion category,1,includes
3284,ClinicalTrials.gov,data,processed
3285,Inclusion Criteria:-Adults patients,75 years COVID-19 diagnosis,aged
3286,ClinicalTrials.gov,data,processed
3287,ClinicalTrials.gov,data,processed
3288,colchicine,improveoutcomes,Weextrapolate
3289,ClinicalTrials.gov,data,processed
3290,ClinicalTrials.gov,data,processed
3291,Patients,SymptomTracker Insight(TM,use
3292,ClinicalTrials.gov,data,processed
3293,Rapidly emerging evidence,foundolfactory taste disturbances,have
3294,Laboratory,COVID-19 infection,confirmed
3295,ClinicalTrials.gov,data,processed
3296,critically ill patients,criteria forthe definition,present
3297,ClinicalTrials.gov,data,processed
3298,ClinicalTrials.gov,data,processed
3299,ClinicalTrials.gov,data,processed
3300,people,mild symptoms,have
3301,Participants,MRI,have
3302,Participants,dye,receive
3303,Participants,ultrasound,have
3304,Participants,blood urine samples,provide
3305,Participants,nasal swabs,provide
3306,Participants,bronchoscopy,have
3307,Participants,spinal fluid sample,provide
3308,Participants,lung heart function tests,have
3309,Adults,group,represent
3310,ClinicalTrials.gov,longitudinal study usinggranular clinical laboratory imaging data,processed
3311,ClinicalTrials.gov,data,processed
3312,stratification,measurement,requires
3313,ClinicalTrials.gov,data,processed
3314,Natural products,outcomes,showed
3315,ClinicalTrials.gov,longitudinal study usinggranular clinical laboratory imaging data,processed
3316,increase,risk,reduce
3317,ClinicalTrials.gov,data,processed
3318,ClinicalTrials.gov,data,processed
3319,Cancer Patients and Survivors,psychological financial physical social,impacted
3320,AYA cancer survivors,inferior long term survival,have
3321,ClinicalTrials.gov,data,processed
3322,Inclusion,applicable,enrolled in
3323,ClinicalTrials.gov,data,processed
3324,pandemic,health systems,challenging
3325,melatonin receptors,lower mortality rates afterpolymicrobial sepsis,mediate
3326,Melatonin agonism,clinical role inindividuals,investigated
3327,Ministério da Saúde,Brasil,do
3328,Melatonin,apoptosis,antagonizes
3329,Melatonin receptors,improvements,mediate
3330,Mathes AM,liver function,improves
3331,imaging,signs,show
3332,ClinicalTrials.gov,data,processed
3333,patients,routine blood samples,have
3334,ClinicalTrials.gov,data,processed
3335,Natural supplementations,reported effects,have
3336,blackseed supplementation,chelation effect,exerts
3337,black seed,antiviral effect,exerts
3338,manynatural sources,antimalarial effect,exerts
3339,ClinicalTrials.gov,data,processed
3340,ClinicalTrials.gov,data,processed
3341,Health Canada,Steriwave™ Nasal Decolonization,The study willuse
3342,Health Canada,Steriwave™ Nasal Decolonization,approved
3343,PDF,Methylene Blue MB nasal spray,uses
3344,ClinicalTrials.gov,data,processed
3345,oflife,difference,Follow up
3346,ClinicalTrials.gov,data,processed
3347,Concept Study investigators,pneumonia,hypothesize
3348,SARS CoV,viral detection systems,inhibits
3349,SARS CoV,T cell apoptosis,induces
3350,ClinicalTrials.gov,data,processed
3351,ClinicalTrials.gov,data,processed
3352,Infections Study,association,assess
3353,mortality,management,is
3354,influenza,mortality,H1N1had
3355,likelyto,pleural effusion,"p<0.001),higher frequency of"
3356,patients,demographical socio economic strata,comefrom
3357,ClinicalTrials.gov,data,processed
3358,andwhether rapid 24 48h turnaround,impact,has
3359,Identical genomes,evidence,provide
3360,Inclusion Criteria:-Participants,COVID-19 infection,confirmed
3361,ClinicalTrials.gov,data,processed
3362,subgroup,ahyperinflammatory HI syndrome,is
3363,Trials,tocilizumab,using
3364,ClinicalTrials.gov,projectspecific data,processed
3365,SARS CoV-2,greater diseaseseverity,are
3366,innate immune response,induction,involves
3367,Common respiratory viral infections,viral pathology,promote
3368,Human coronavirus infections,immunopathology,induce
3369,signsthat secondary invasive fungal infections,increasingly complication inpatients,present
3370,Interferon dependent endothelial dysfunction,pathogenicity,drives
3371,Evaluation,peripheral blood immune responses,vivo
3372,STUDY,24 month prospective longitudinal multicentre,DESIGNThrough
3373,study team,clinical information includingdemographics,collect
3374,ClinicalTrials.gov,data,processed
3375,Patient,willingness,expressed
3376,Patient,unwillingness,expressed
3377,ClinicalTrials.gov,data,processed
3378,non - interventional observational study,vitamin D levels,measure
3379,ClinicalTrials.gov,data,processed
3380,COVID-19 pandemic,major imminent challenge,poses
3381,derive validate personalized risk prediction models,pathophysiological mechanisms,explore
3382,personalized risk prediction models,clinicians,support
3383,COVID-19 pandemic,major imminent challenge,poses
3384,ClinicalTrials.gov,data,processed
3385,ClinicalTrials.gov,data,processed
3386,ClinicalTrials.gov,data,processed
3387,ClinicalTrials.gov,data,processed
3388,ClinicalTrials.gov,data,processed
3389,ClinicalTrials.gov,data,processed
3390,110 hospitals,patients,treating
3391,ClinicalTrials.gov,data,processed
3392,Methodology Hospitalized patients,clinical criteria,meeting
3393,Secondary outcomes,time,include
3394,pragmatic project,major gap,fill
3395,Release,revision,necessitated
3396,manufacturers,clinical trials,used
3397,Relevance,high mortality rate,has
3398,ifthe patient goals,intubation,included
3399,ClinicalTrials.gov,data,processed
3400,studies,chest X ray,include
3401,ClinicalTrials.gov,data,processed
3402,Short bi weekly brief follow surveys,additional assessment,provide
3403,substantial,mental health services,require
3404,symptoms,available resources,using
3405,Calculation,95%CI of 0.025 for asample proportion of 0.20,ensures
3406,participants,explicit informed consent,provide
3407,consent questionsThe Qualtrics survey platform,three of the most important security certifications,has
3408,complies,relevant regulations,withall
3409,Physicalsecurity measures,strict control,include
3410,Inclusion,cases,isolated
3411,ClinicalTrials.gov,data,processed
3412,Analysis,statistics,includedescriptive
3413,The HERO Registry,HCWs,include
3414,Participants,inclusioncriteria,meet
3415,ClinicalTrials.gov,data,processed
3416,ClinicalTrials.gov,data,processed
3417,reports,procoagulant state,postulated
3418,ClinicalTrials.gov,data,processed
3419,recent pandemic,national health emergency,caused
3420,observational studies,small samples,have
3421,maintenance,60 mmHg,MAP
3422,Inclusion,18 years of age,Criteria:-patients over
3423,ClinicalTrials.gov,data,processed
3424,ClinicalTrials.gov,data,processed
3425,ClinicalTrials.gov,data,processed
3426,the Strasbourg University Hospital,suddenincrease,resulted from
3427,Strasbourg hospital workers,SARS CoV-2infection,presented
3428,ClinicalTrials.gov,data,processed
3429,age,Child,Child from
3430,ClinicalTrials.gov,data,processed
3431,ClinicalTrials.gov,data,processed
3432,ClinicalTrials.gov,data,processed
3433,COVID-19 infection,respiratory system,evidenceseems to
3434,diabetic mice,prolonged illness,had
3435,positive patients,stimulation test,undergo
3436,basal,at(0 minutes,practiced in
3437,ClinicalTrials.gov,data,processed
3438,ClinicalTrials.gov,data,processed
3439,Postpartum depression,around 15%,represent
3440,ClinicalTrials.gov,data,processed
3441,ClinicalTrials.gov,data,processed
3442,Infection,Corona Virus Disease,causes
3443,participants,the Aeonose,breathedthrough
3444,ClinicalTrials.gov,data,processed
3445,animal andclinical trials,efficacy,is
3446,ClinicalTrials.gov,data,processed
3447,ClinicalTrials.gov,data,processed
3448,Inclusion Criteria:-Clinical diagnosis,48 hours ago.-Virological confirmation,started
3449,ClinicalTrials.gov,data,processed
3450,investigators,clinical andbiological characteristics,reported
3451,Clinical characteristics,age,include
3452,ClinicalTrials.gov,data,processed
3453,fever reduction,effect,had
3454,ibuprofen,cardiac fibrosis,based on
3455,fever reduction,effect,had
3456,meta analysis,difference,found
3457,ClinicalTrials.gov,data,processed
3458,China,70635 confirmed cases,has
3459,China,70635 confirmed cases,has
3460,ClinicalTrials.gov,data,processed
3461,Criteria:-PCR confirmed Covid-19 pneumonia respiratory failureExclusion,cancer,Criteria:-diagnosed
3462,ClinicalTrials.gov,data,processed
3463,ClinicalTrials.gov,data,processed
3464,ClinicalTrials.gov,data,processed
3465,ClinicalTrials.gov,data,processed
3466,health system,urgent care,centralizesunscheduled
3467,ClinicalTrials.gov,data,processed
3468,ClinicalTrials.gov,data,processed
3469,ClinicalTrials.gov,data,processed
3470,nc MCE system,remote control workstation,added
3471,investigators,gastric examination time,choosethe
3472,ClinicalTrials.gov,data,processed
3473,Patients,aVR HMD,receive
3474,Patient,indication,has
3475,Patient,history,has
3476,Patient,severe hearing visual impairment,has
3477,Patient,high risk,has
3478,ClinicalTrials.gov,data,processed
3479,ClinicalTrials.gov,data,processed
3480,male patient,sperm,donate
3481,patient,history,has
3482,ClinicalTrials.gov,data,processed
3483,18 65 years old Patient,the Berlin Definition,fulfil
3484,ClinicalTrials.gov,data,processed
3485,16 % patients,admission,need
3486,the WHO,outbreak,declared
3487,Patients,fever orrespiratory symptoms,show
3488,About 16%patients,admission,need
3489,the NUTRIC,association,estimated to
3490,ClinicalTrials.gov,data,processed
3491,Investigators,research study,propose
3492,depression anxiety,the Hospital Anxiety and Depression Scale,measuredby
3493,ClinicalTrials.gov,data,processed
3494,VIP,NMDA induced caspase-3 activation,observed in
3495,Six,hospitaland,left
3496,Irreversible underlying conditionwith,fatal course,treatment for
3497,ClinicalTrials.gov,data,processed
3498,Prior immunosuppressive therapies,bacterial,Suspected
3499,ClinicalTrials.gov,data,processed
3500,ClinicalTrials.gov,data,processed
3501,severe burn,death,injuries)-Expected
3502,ClinicalTrials.gov,data,processed
3503,ClinicalTrials.gov,data,processed
3504,ill patients,intensivecare resources,strained
3505,ClinicalTrials.gov,data,processed
3506,odontology service,beenresponsible,has
3507,COVID19 Crisis,organization,changed
3508,course,place,take
3509,1st figures,average attendance,indicate
3510,investigators,nominative data,entered into
3511,ClinicalTrials.gov,data,processed
3512,Inclusion Criteria:-Have,acute illness,had
3513,ClinicalTrials.gov,data,processed
3514,Telephone consultations,visual cues,provide
3515,ClinicalTrials.gov,data,processed
3516,ClinicalTrials.gov,data,processed
3517,About 1,IBD,have
3518,ClinicalTrials.gov,data,processed
3519,ClinicalTrials.gov,data,processed
3520,Recruit Blood Donors,SMS,Via
3521,Recruit Blood Donors,SMS,Via
3522,number,todecline,continuing
3523,ClinicalTrials.gov,data,processed
3524,ClinicalTrials.gov,data,processed
3525,ClinicalTrials.gov,data,processed
3526,ClinicalTrials.gov,data,processed
3527,inclusion criteria,patients,regarded
3528,study protocol,Standards forReporting,followed
3529,operator,TCD,performing
3530,Variations,deformations,cause
3531,Arteries,proximal segments,analyzed
3532,automated Brain4care Analytics system,collected data,verify
3533,ClinicalTrials.gov,data,processed
3534,treatment group,ofparticipants,consist
3535,Women,negative serum pregnancy test,have
3536,History,participant safety,affect
3537,ClinicalTrials.gov,data,processed
3538,Early reports,presence,indicate
3539,recent data,high incidence,reveal
3540,ClinicalTrials.gov,data,processed
3541,French government,nationalcontainment measures,implemented
3542,unique identifieris,separate email,sent in
3543,ClinicalTrials.gov,data,processed
3544,SARS CoV2 virus,severe fatal disease,causes
3545,Stress,immune response,modulates
3546,Inclusion Criteria:-Patient,Criteria:-Patient,admitted to
3547,ClinicalTrials.gov,data,processed
3548,TheWorld Health Organization,coronavirus disease,declared
3549,ClinicalTrials.gov,data,processed
3550,Data,form,collected
3551,ClinicalTrials.gov,data,processed
3552,ClinicalTrials.gov,data,processed
3553,1.-To create risk stratification scales,SARS CoV-2,infectedby
3554,ClinicalTrials.gov,data,processed
3555,ClinicalTrials.gov,data,processed
3556,dopatients,nursing care,value
3557,ClinicalTrials.gov,data,processed
3558,IFN-β 1a,disease,evaluated
3559,ClinicalTrials.gov,data,processed
3560,DaeguCatholic university hospital psychiatry department,active psychiatric counselingfor medical patients,conducted
3561,ClinicalTrials.gov,data,processed
3562,ClinicalTrials.gov,data,processed
3563,Novel Coronavirus,2019-nCoVacute respiratory disease,causes
3564,Novel Coronavirus,the2019-nCoV acute respiratory disease,causes
3565,ClinicalTrials.gov,Data,processed
3566,outbreak ofSRAR COV,social impact,caused
3567,IFN-α2β,inhibitory effects,has
3568,Lopinavir remdesivir single polyclonal antibodies,mosteffective antiviral treatment options,explore
3569,phase,efficacy,assess
3570,treatment,discharge standard,reach
3571,patients,hospital,performed by
3572,ClinicalTrials.gov,data,processed
3573,enrolled patients,CT scanning session,have
3574,imaging,mathematical modeling todetermine regional differences,uses
3575,PBM,parenchymal lung function changes,detect
3576,Participants,consent,provideinformed
3577,Participants,one inspiration-expiration CT,undergo
3578,ClinicalTrials.gov,data,processed
3579,ClinicalTrials.gov,data,processed
3580,sample size,574 participants,included
3581,"Hays & DiMatteo,1987)which",frequency,measures
3582,ClinicalTrials.gov,data,processed
3583,ClinicalTrials.gov,data,processed
3584,ClinicalTrials.gov,data,processed
3585,research,association,investigatethe
3586,research,association,investigate
3587,investigators,significance level,defined
3588,conservative estimates,2530 individuals,included
3589,investigators,equal opportunity,reached out
3590,survey,random selection,reached
3591,clinicaltrials.gov,data,processed
3592,Mindfulness training,popularity,gaining
3593,"Birnie, Speca & Carlson",strong associations,found
3594,ClinicalTrials.gov,data,processed
3595,mitigating factors,rate,are
3596,Participants,follow upquestionnaires,receive
3597,followup questionnaires,burnout,measure
3598,Response,medical trainees,ratesby
3599,ClinicalTrials.gov,data,processed
3600,Bariatric patients,peculiar frail subset,represent
3601,ClinicalTrials.gov,data,processed
3602,ClinicalTrials.gov,data,processed
3603,FDA FDA,PCRtesting,approved
3604,ClinicalTrials.gov,data,processed
3605,ClinicalTrials.gov,data,processed
3606,Childhood Measles,Mortality Rate,Decrease
3607,Childhood Measles,Mortality Rate,Decrease
3608,ClinicalTrials.gov,CFR data,processed
3609,ClinicalTrials.gov,data,processed
3610,regular users,regular users,exceeded
3611,regular Botox Cosmetic users,asecondary gain desire,have
3612,ClinicalTrials.gov,data,processed
3613,ClinicalTrials.gov,data,processed
3614,investigators,combination,use
3615,focus,X - ray,use
3616,ClinicalTrials.gov,data,processed
3617,ClinicalTrials.gov,data,processed
3618,COVID-19 pandemic,millions of people,affected
3619,people,psychotic symptoms,are
3620,Participants,surveyagain,complete
3621,T3,informed consent,provide
3622,investigators,torecruit,hope
3623,ClinicalTrials.gov,data,processed
3624,hoursimulation session,scenarios,include
3625,Eachparticipant,scenarios,complete
3626,ClinicalTrials.gov,data,processed
3627,andwill,comparative rates,assess
3628,Drug interventions,Spanish law,follow
3629,ClinicalTrials.gov,data,processed
3630,novel coronavirus,respiratory syndrome coronavirus,severeacute
3631,guidelines,weak recommendation,provide
3632,23 25 patients,supplementaloxygen,required
3633,ClinicalTrials.gov,data,processed
3634,Patients,injections,have
3635,ClinicalTrials.gov,data,processed
3636,study population,cancer patients,comprise
3637,ClinicalTrials.gov,data,processed
3638,World Health Organization(WHO,pandemic disease,designated
3639,influenza,mortality,H1N1had
3640,studies,tomographic findings,correlate
3641,likelyto,pleural effusion,"p<0.001),higher frequency of"
3642,Patients,working class,represent
3643,ClinicalTrials.gov,data,processed
3644,anxiety,country,rateswithin
3645,ClinicalTrials.gov,data,processed
3646,Prospective registry,new insights,provide
3647,Inclusion,longitudinal prognostic evaluationof diagnostic therapeutic interventions,permit
3648,ClinicalTrials.gov,data,processed
3649,ClinicalTrials.gov,data,processed
3650,threat,stress,cause
3651,Participants,username,get
3652,Participants,finger tapping task,complete
3653,Participants,key certainnumber,press
3654,theywill,survey,complete
3655,research,study website,use
3656,research,risk,identify
3657,ClinicalTrials.gov,data,processed
3658,ClinicalTrials.gov,data,processed
3659,Available shreds,promising use,support
3660,Anti - viralactivity,treatment option,constitute
3661,Chinese government,transmission,confirmed
3662,the WHO,outbreak,declared
3663,Early detection andstrategies,major difference forinfected patients,make
3664,People,symptoms,have
3665,Selected Drugs Hesperidin,anti - viral activity,exhibited
3666,Toxicity studies,high safety profile,confirmed
3667,Results,absence,showed
3668,host cellular receptors,possiblelines,provide
3669,Immunity,major role,plays
3670,anti - viral activity,itsrole,involves
3671,Cytokine storm,release,involves
3672,proposed mechanism,theoccurrence,involves
3673,effects,stomach pain,include
3674,Selected Drugs Hesperidin,absorption,reduce
3675,Selected Drugs Hesperidin,absorption,reduce
3676,Selected Drugs Hesperidin,absorption,increase
3677,Selected Drugs Hesperidin,risk,is
3678,patients,standardized care,receive
3679,RT PCR negative Secondary Outcome Measures,changes,include
3680,parallel groups,Masking,asserted
3681,Patients,Patients,Both sexesExclusion Criteria
3682,Patients,Patients,Both sexesExclusion Criteria
3683,ClinicalTrials.gov,data,processed
3684,total enrollment,prevalence,assess
3685,data,dealingwith patients,prove
3686,study,patients,enroll
3687,ClinicalTrials.gov,data,processed
3688,ClinicalTrials.gov,data,processed
3689,ClinicalTrials.gov,data,processed
3690,placebo group,Bromhexine,receive
3691,ClinicalTrials.gov,data,processed
3692,ClinicalTrials.gov,data,processed
3693,Participants,online survey,willcomplete
3694,ClinicalTrials.gov,data,processed
3695,ClinicalTrials.gov,data,processed
3696,subjects,follow,undergo
3697,ClinicalTrials.gov,data,processed
3698,role,investigation,requires
3699,CV risk factors,vulnerability,enhance
3700,ClinicalTrials.gov,data,processed
3701,randomized clinical study,arms,comprises
3702,Arm,oraldisinfection,undergo
3703,ClinicalTrials.gov,data,processed
3704,a Pilot Study,safety,evaluate
3705,ClinicalTrials.gov,data,processed
3706,Analysis,calls,examine
3707,a Directed Acyclic Graph,identification,willallow
3708,Analysis,covariates,examine
3709,Inclusion,ambulance attendance,requested
3710,ClinicalTrials.gov,data,processed
3711,medical frontline staffs,high risk,have
3712,medical frontline staffs,similar symptoms,acuminated
3713,ClinicalTrials.gov,data,processed
3714,adults,surgical intervention,thatrequire
3715,ClinicalTrials.gov,data,processed
3716,amajor disagreement,amajor disagreement,happened
3717,presentedas,standard deviation,means
3718,ClinicalTrials.gov,data,processed
3719,novel coronavirus infectious disease,inWuhan city,broke out
3720,ClinicalTrials.gov,data,processed
3721,patients,hydroxychloroquine,receive
3722,ClinicalTrials.gov,data,processed
3723,step,demographic characteristics,includethe
3724,survey,mandatory fields,includes
3725,ClinicalTrials.gov,data,processed
3726,Network Centrality,Overall Depression Symptom Reduction,Predict
3727,Overall Symptom Reduction,Social Distancing Protocols,Lifted
3728,Thedissemination procedure,information,involved
3729,Thesemutlivariate analyses,large samples,require
3730,Wehave,network analysis,avoided
3731,ClinicalTrials.gov,data,processed
3732,Recruit Blood Donors,SMS,Via
3733,Recruit Blood Donors,SMS,Via
3734,number,todecline,continuing
3735,placebo group donors,SMS,onlyreceive
3736,ClinicalTrials.gov,data,processed
3737,ClinicalTrials.gov,data,processed
3738,current situation,fears,generates
3739,ClinicalTrials.gov,data,processed
3740,Meet criteria,ongoing need,had
3741,ventilation,known concurrent respiratory,Have
3742,female subject,one of the following conditions,meet
3743,Provides,informed consent,signed
3744,ClinicalTrials.gov,data,processed
3745,® 2000 device,19 to 64 years,aged
3746,subjects,Week 1 visit,reviewed by
3747,Once thefirst five subjects Group,Week 1 visit,reviewed by
3748,48,2nd vaccination,followed for
3749,subjects,vasectomy,wait
3750,ClinicalTrials.gov,data,processed
3751,ClinicalTrials.gov,data,processed
3752,Patients,polyvalent,treated in
3753,Inclusion Criteria:-Patients,polyvalent,treated in
3754,ClinicalTrials.gov,data,processed
3755,Convalescent plasma,specific actions,offer
3756,sample size,verificationof,enable
3757,ClinicalTrials.gov,data,processed
3758,monitoring methods,improvements,enable
3759,supplemental O2,SpO2,need for
3760,ClinicalTrials.gov,data,processed
3761,Management,great challenge,presents
3762,Pharmaceutical interventions,desiredeffects,achieve
3763,ClinicalTrials.gov,data,processed
3764,Treatment,oxygenation,improves
3765,ClinicalTrials.gov,data,processed
3766,Items,possible answers,have
3767,ClinicalTrials.gov,data,processed
3768,Participation,about one hour,take
3769,Withyour permission,results,release
3770,Brain Health,healthcare assistance,provide
3771,ClinicalTrials.gov,data,processed
3772,Individuals withsmaller social networks,healthy diets,report
3773,Sedentary life,diseases,invites
3774,sedentary lifestyle,health problems,causes
3775,peoplehave,sports,included
3776,Technology,benefits,brought
3777,ClinicalTrials.gov,data,processed
3778,studies,raised levels,haverevealed
3779,ClinicalTrials.gov,data,processed
3780,ClinicalTrials.gov,data,processed
3781,Secondary outcomes,score change,mean
3782,ClinicalTrials.gov,data,processed
3783,VHTs,IECmaterials,distribute
3784,villages)that,study districts,span
3785,theinvestigators,15 villages,select
3786,the VHT,project administrator ofparticipants,inform
3787,Previous studies,thepost test questionnaires,administered
3788,nature,randomization,makes
3789,investigators,frequencies,report
3790,Members,visit,make
3791,ClinicalTrials.gov,data,processed
3792,world,coronavirus,experiencing
3793,use,promise,shown
3794,ClinicalTrials.gov,data,processed
3795,publications,performance,report
3796,patient opposition,prospective COVID-19 sub - population,(
3797,ClinicalTrials.gov,data,processed
3798,Covid-19 patients,massive deprogramming,reinforced
3799,the French Department of Health and Human Services,generalguidelines,given
3800,ClinicalTrials.gov,data,processed
3801,ClinicalTrials.gov,data,processed
3802,modality,25 patients,allow
3803,literature,efficacy ofwithdrawal,confirm
3804,emergency,patients,performed
3805,literature,theuse,promote
3806,ClinicalTrials.gov,data,processed
3807,COVID isunique,abetter understanding,provide
3808,ClinicalTrials.gov,data,processed
3809,ClinicalTrials.gov,data,processed
3810,Participants,sameintervention,receive
3811,ClinicalTrials.gov,data,processed
3812,Demographics,gender,measured with
3813,sample size,2880 participants,Sample size
3814,ClinicalTrials.gov,data,processed
3815,IBD,patients risk,increase
3816,ClinicalTrials.gov,data,processed
3817,Initial studies,numerous severe courses,described
3818,ClinicalTrials.gov,and(previously unpublished data,processed
3819,theincreased patient flow,additional pressure,creates
3820,patient,both chest CT,undergo
3821,participants,online questionnaire,completed
3822,ClinicalTrials.gov,data,processed
3823,ClinicalTrials.gov,data,processed
3824,severe,asa novel human pathogen,emerged
3825,Prevention measures,distancing,included
3826,nearly 60%,viruspre,shed
3827,study,onprevention,focuses
3828,data,sound safety profile forthe planned intervention,support
3829,ClinicalTrials.gov,data,processed
3830,ClinicalTrials.gov,data,processed
3831,Repeated surveys,high drop,have
3832,ClinicalTrials.gov,data,processed
3833,Medical management,evolvingtreatment regimens,include
3834,ClinicalTrials.gov,data,processed
3835,social distancing measures,closure,include
3836,ClinicalTrials.gov,data,processed
3837,Professional Peer Resilience Initiative,Exclusion Criteria:1,study
3838,Treatment Sub,Inclusion,study
3839,ClinicalTrials.gov,data,processed
3840,Specific target genes,"SLC6A4,NR3C1",include
3841,ClinicalTrials.gov,data,processed
3842,old;-Laboratory,2019-nCoV infection,confirmed
3843,ClinicalTrials.gov,data,processed
3844,psychological distress,healthcare,is
3845,Inclusion Criteria Healthcare professionals,officeemployee,nurses
3846,ClinicalTrials.gov,data,processed
3847,SARS CoV-2 disease,Public Health emergency,represents
3848,ClinicalTrials.gov,data,processed
3849,Exerciseinterventions,adverse health effects,reduce
3850,ClinicalTrials.gov,data,processed
3851,ClinicalTrials.gov,data,processed
3852,the World HealthOrganization,SARS CoV-2 disease,described
3853,RT PCR).-Meet,toseveral countries,SARS-CoV-2 disease
3854,ClinicalTrials.gov,data,processed
3855,participant,access,have
3856,ClinicalTrials.gov,data,processed
3857,ClinicalTrials.gov,data,processed
3858,infection,pneumonia,cause
3859,researchers,40 hospitalized patients,invite
3860,ClinicalTrials.gov,data,processed
3861,ClinicalTrials.gov,data,processed
3862,ClinicalTrials.gov,data,processed
3863,strictphysical distancing government,physical distancing protocols,initiated
3864,survey,mandatory fields,includes
3865,ClinicalTrials.gov,data,processed
3866,reportedquarantine,post traumatic stress symptoms,reviewed
3867,Bacteria,high reads,included
3868,Over 80%,exceptionally highbacterial load,exhibited
3869,secondpart,validated general anxiety disorder scale,included
3870,ClinicalTrials.gov,data,processed
3871,COVID-19,threat,posedgreat
3872,ClinicalTrials.gov,data,processed
3873,Randomized Double Blind Placebo Controlled Phase,Study,IIa
3874,ClinicalTrials.gov,data,processed
3875,ClinicalTrials.gov,data,processed
3876,Eligible patients(111,criteria,fulfilled
3877,55 patients,55 patients standard therapy(anthracycline containing chemotherapy,received
3878,Eligible patients(111,criteria,fulfilled
3879,55 patients,55 patients standard therapy(anthracycline containing chemotherapy,received
3880,coronaviruses,iron overload,induce
3881,ketotifen,potentialbeneficial effect,has
3882,ClinicalTrials.gov,data,processed
3883,Current recommendations,large scale tests,include
3884,ClinicalTrials.gov,data,processed
3885,ClinicalTrials.gov,data,processed
3886,ClinicalTrials.gov,data,processed
3887,Simple mindfulness,healthier ways,practicesprovide
3888,researchers,mindfulness practices,introducemodified
3889,ClinicalTrials.gov,data,processed
3890,Thesesymptoms,significant impact,have
3891,1 Critical Care Family,Inventory,Needs
3892,investigators,survey responses,review
3893,ClinicalTrials.gov,data,processed
3894,2019 2020 coronavirus pandemic,far reaching consequences,had
3895,ClinicalTrials.gov,data,processed
3896,ClinicalTrials.gov,data,processed
3897,The World Health Organization,emergence,declared in
3898,data,increasing rapidly exponential number,Francereported
3899,ClinicalTrials.gov,data,processed
3900,37.0ºC.-Negative SARS CoV-2 test,negative serum β hCG,have
3901,age ≥18,acute illness,had
3902,screening.-Have,acute illness,had
3903,ClinicalTrials.gov,data,processed
3904,Shingrix vaccination,acute trained,associated with
3905,Secondary outcomes,differencesin hospitalization,include
3906,ClinicalTrials.gov,data,processed
3907,infected people,novel approach,propose
3908,ClinicalTrials.gov,data,processed
3909,ClinicalTrials.gov,data,processed
3910,patients,chronic respiratory failure,develop
3911,ClinicalTrials.gov,data,processed
3912,online survey,measures implications,assesses
3913,questionnaires,psychometric variables,evaluate
3914,ClinicalTrials.gov,data,processed
3915,Acute respiratory distresssyndrome,common complication,represents
3916,ClinicalTrials.gov,data,processed
3917,ClinicalTrials.gov,data,processed
3918,Tumor cells,host recognition,evade
3919,immune imbalance,similarities tumors,has
3920,COPD,home oxygen therapy6,requires
3921,ClinicalTrials.gov,data,processed
3922,women,pregnancy outcomes,regardless
3923,ClinicalTrials.gov,data,processed
3924,ClinicalTrials.gov,data,processed
3925,These ARFC,optimal security,masksprovide
3926,ClinicalTrials.gov,data,processed
3927,CoVID-19 patients,acute respiratory distresssyndrome,develop
3928,prospective study,thekinetics,described
3929,ClinicalTrials.gov,data,processed
3930,ClinicalTrials.gov,data,processed
3931,ClinicalTrials.gov,data,processed
3932,work,both the Everett Clinic,serve
3933,ClinicalTrials.gov,data,processed
3934,Bronchoalveolar lavage samples,highest sensitivity,showed
3935,cardinal features,constant fever,include
3936,China,elevated ferritin,included
3937,Injury,vascular inflammation,andassociated
3938,Low Flow,case,Washed Oxygen
3939,ClinicalTrials.gov,data,processed
3940,Participants,glue ear,have
3941,member,atelephone/ video consultation,arrange
3942,family,frequent support,carried out
3943,families,queries).2,direct
3944,website,information,was
3945,ClinicalTrials.gov,data,processed
3946,Investigators,complex links betweenrespiratory infections,studied
3947,ClinicalTrials.gov,RICO survey data,processed
3948,A feasibility RCT,groups:1,comprising
3949,ClinicalTrials.gov,data,processed
3950,analyses,patients perspectivetowards colonoscopy,explore
3951,ClinicalTrials.gov,data,processed
3952,thisresearch study,changes,describes
3953,COVID-19,aspects,impacted
3954,ClinicalTrials.gov,data,processed
3955,ClinicalTrials.gov,data,processed
3956,ClinicalTrials.gov,data,processed
3957,program,effectivenessand safety,evaluating
3958,ClinicalTrials.gov,data,processed
3959,Serologic Profile,Patients,CoV2 in
3960,ClinicalTrials.gov,data,processed
3961,Socialdistancing,social isolation,exacerbated
3962,ClinicalTrials.gov,data,processed
3963,COVID-19 outbreak,blend,entails
3964,ClinicalTrials.gov,data,processed
3965,primary aim,global objective data driven analysis,deliver
3966,ClinicalTrials.gov,data,processed
3967,Inclusion,previous clinical records,diabetes
3968,ClinicalTrials.gov,data,processed
3969,ClinicalTrials.gov,data,processed
3970,shortage,high quality protectivemasks,affects
3971,ClinicalTrials.gov,data,processed
3972,treatments,survival,improve
3973,20 mg,qd,prednisone
3974,ClinicalTrials.gov,data,processed
3975,Surgical sterilization,minimum,occurred
3976,confirmatory follicle,hormone levels,Females
3977,Male participants,1,have
3978,ClinicalTrials.gov,data,processed
3979,Therapid increase,great benefit,proved
3980,Inclusion,professionals,Criteria:-healthcare
3981,ClinicalTrials.gov,data,processed
3982,ClinicalTrials.gov,data,processed
3983,number,indolent clinical course,have
3984,Patients,continuous physiological monitoring,undergo
3985,Diagnosis,one of the following criteria,meeting
3986,ClinicalTrials.gov,data,processed
3987,Patients,higher serumlevels,have
3988,CT imaging,viral pneumonia,with
3989,ClinicalTrials.gov,data,processed
3990,usefulness,appropriate strategies,allow
3991,ClinicalTrials.gov,data,processed
3992,Indication,histological confirmation)Objective,require
3993,Rationale,significant benefits,emphasised
3994,Treatment plans,risk,revised
3995,ClinicalTrials.gov,data,processed
3996,COVID-19 outbreak,aconsiderable proportion,highlighted
3997,ClinicalTrials.gov,data,processed
3998,unit,250 mL beer,History of
3999,ClinicalTrials.gov,data,processed
4000,Subjects,one of the following conditions,fulfill
4001,ClinicalTrials.gov,data,processed
4002,ClinicalTrials.gov,data,processed
4003,classical subsequent treatment regimen,patients susceptibility,increase
4004,Eltrombopag,good safety,demonstrated
4005,Clinically,corticosteroid resistant relapsed immune thrombocytopenic purpura,confirmed
4006,Fertile patients,effective contraception,use
4007,ClinicalTrials.gov,data,processed
4008,ClinicalTrials.gov,data,processed
4009,Prone position,mortality,reduced
4010,control group,conventional positioning,have
4011,ClinicalTrials.gov,data,processed
4012,investigators,profile,study
4013,investigators,genome wide miRNA andtranscriptome screens,perform
4014,Alltypes,pivotal roles,play
4015,investigators,profile,study
4016,ClinicalTrials.gov,data,processed
4017,ClinicalTrials.gov,data,processed
4018,Prognostic Factors,Track,Keeping
4019,nearly half,old age,reported
4020,nearly half,old age,reported
4021,NK cells,cytolysis orapoptosis,mediate
4022,Lipids,pro - inflammatory anti - inflammatory activities,show
4023,Covid-19 pneumonia,transition,defined
4024,Secondary endpoints,liver,include
4025,subject,informedconsent,sign
4026,Cin,way,anonymized
4027,50%,one of theabove-mentioned complications,the assumption
4028,ClinicalTrials.gov,data,processed
4029,The World Health Organization,outbreak apandemic,declared
4030,ClinicalTrials.gov,data,processed
4031,ClinicalTrials.gov,data,processed
4032,Inclusion Criteria:-Patient,18 years;-Hospitalized,aged
4033,ClinicalTrials.gov,data,processed
4034,Low-flow Extracorporeal Carbon Dioxide Removal,Renal Replacement Therapy Platform,Using
4035,early implementing,escalation,preventfurther
4036,ClinicalTrials.gov,data,processed
4037,ClinicalTrials.gov,data,processed
4038,ClinicalTrials.gov,data,processed
4039,data,thenature,inform
4040,Previous epidemics,unique medical syndromes,created
4041,Criteria Development phase,data driven research consensus,develop
4042,results,novel insights,provide
4043,current version,details,provides
4044,data,thenature,inform
4045,Previous epidemics,unique medical syndromes,created
4046,Criteria Development phase,data driven research consensus,develop
4047,results,novel insights,provide
4048,ClinicalTrials.gov,data,processed
4049,study,safety,evaluate
4050,ClinicalTrials.gov,data,processed
4051,countries,policy,implementing
4052,study,outcomes,evaluate
4053,Adult,dispensing,eligiblefor
4054,ClinicalTrials.gov,data,processed
4055,Clinical trial,parallel groups,withtwo
4056,Clinical trial,parallel groups,withtwo
4057,ClinicalTrials.gov,data,processed
4058,study,unique opportunities,exploit
4059,ClinicalTrials.gov,data,processed
4060,Coronaviruses,large family,make up
4061,data,"43,000 confirmedcases",reported
4062,Inclusion Criteria:-Being,ages,continue
4063,ClinicalTrials.gov,data,processed
4064,local health facilities,clusters,reported
4065,investigators,commercial RT qPCR assay kit,used
4066,local health facilities,clusters,reported
4067,investigators,real time,established
4068,Clinical manifestations1,imaging characteristics,has
4069,ClinicalTrials.gov,data,processed
4070,ClinicalTrials.gov,data,processed
4071,ClinicalTrials.gov,data,processed
4072,conditions,mask,includeno
4073,Outcome variables,exercise duration,include
4074,ClinicalTrials.gov,data,processed
4075,COVID-19 epidemic,global health crisis,causing
4076,COVID-19 epidemic,majorreorganization,imposed
4077,The World Health Organization,incidents,recommends
4078,scenario,implementation,requires
4079,ClinicalTrials.gov,data,processed
4080,group,200 participants,include
4081,ClinicalTrials.gov,data,processed
4082,infection,neurological deficits,documented
4083,ClinicalTrials.gov,data,processed
4084,ClinicalTrials.gov,data,processed
4085,treatment strategies,risk,carry
4086,Patients,additionalinvestigations,undergo
4087,ClinicalTrials.gov,data,processed
4088,ClinicalTrials.gov,data,processed
4089,Infectious disease outbreaks,psychological effect,have
4090,healthcare workers,importantresponsibilities,assumed
4091,ClinicalTrials.gov,data,processed
4092,ClinicalTrials.gov,data,processed
4093,person based approach,development,inspired
4094,ClinicalTrials.gov,data,processed
4095,Patients,l,count
4096,339306)miRCURY LNA SYBR Green PCR Kit,LNA SYBR Green PCR Kit,miRCURY
4097,ClinicalTrials.gov,data,processed
4098,reliable evidence based medicine basis,bynew coronavirus infection,caused
4099,ClinicalTrials.gov,data,processed
4100,Favipiravir,anti - viral activity,shown
4101,unit,250 mL beer,History of
4102,ClinicalTrials.gov,data,processed
4103,situation,challenges,creates
4104,ClinicalTrials.gov,data,processed
4105,investigators,universities,inviting
4106,investigators,multivariate regressions,run
4107,ClinicalTrials.gov,data,processed
4108,REMAP CAP,adaptive research platform,provides
4109,domain,additional eligibility criteria,Previous participation in
4110,ClinicalTrials.gov,data,processed
4111,healthcare workers,second option,adopt
4112,ClinicalTrials.gov,data,processed
4113,Studies,admission,shown
4114,the Royal Free Hospital,500 patients,admitted
4115,ClinicalTrials.gov,data,processed
4116,Healthy volunteers,portion,make up
4117,ClinicalTrials.gov,data,processed
4118,ClinicalTrials.gov,data,processed
4119,ClinicalTrials.gov,data,processed
4120,ClinicalTrials.gov,data,processed
4121,Viral Global Pandemic,pulmonaryalveolar structure,damaging
4122,The U.S.,U.S. outbreak,has
4123,Viral Global Pandemic,pulmonaryalveolar structure,damaging
4124,The U.S.,U.S. outbreak,has
4125,Sporadic reports,positiveclinical outcomes,revealed
4126,ClinicalTrials.gov,data,processed
4127,Five percent,extracorporeal circulation ECMO techniques,require
4128,experimental design,phases,comprises
4129,numberof samples,quantity,surpasses
4130,budget,material,includes
4131,Thisquantification,guidance,provide
4132,ClinicalTrials.gov,data,processed
4133,ClinicalTrials.gov,data,processed
4134,Investigators,data,collect
4135,ClinicalTrials.gov,data,processed
4136,disease,China,spreadsin
4137,Patients,mild,have
4138,Patients,non - specific symptoms,have
4139,ClinicalTrials.gov,data,processed
4140,intensive care unit,particular place,occupies
4141,ClinicalTrials.gov,data,processed
4142,ClinicalTrials.gov,data,processed
4143,ClinicalTrials.gov,data,processed
4144,Leronlimab(PRO,phases,have
4145,Child-Pugh,12);5,score
4146,ClinicalTrials.gov,data,processed
4147,ClinicalTrials.gov,data,processed
4148,ClinicalTrials.gov,data,processed
4149,ClinicalTrials.gov,data,processed
4150,ClinicalTrials.gov,data,processed
4151,ClinicalTrials.gov,data,processed
4152,Patients,ahigher risk,have
4153,ClinicalTrials.gov,data,processed
4154,study,level,measure
4155,research,level ofanti SARS CoV-2 antibodies,measure
4156,ClinicalTrials.gov,data,processed
4157,ClinicalTrials.gov,data,processed
4158,COVID-19,respiratory system,affects
4159,severe acute respiratory distress syndrome,respiratory system,affects
4160,SARS CoV-2 infection,tothrombotic disease,lead
4161,ClinicalTrials.gov,data,processed
4162,patients,background current standard,willreceive
4163,ClinicalTrials.gov,data,processed
4164,ClinicalTrials.gov,data,processed
4165,ClinicalTrials.gov,data,processed
4166,ClinicalTrials.gov,data,processed
4167,patients,skin manifestations,develop
4168,ClinicalTrials.gov,data,processed
4169,Statistical analysis,Statistical Package,performedusing
4170,Inferential statistics,Pearson coefficient,included
4171,ClinicalTrials.gov,data,processed
4172,ClinicalTrials.gov,data,processed
4173,ofCOVID-19.Small observational studies,findings,used in
4174,Otherobservational studies,presence,described
4175,Inclusion Criteria:-COVID-19,cardiopulmonary ultrasound,Received
4176,Criteria:-Did,positive,receive
4177,ClinicalTrials.gov,data,processed
4178,patients,capacity,provided with
4179,12 consented patients,Nebulised Rt-PA,receive
4180,second group,SOC,receive
4181,the DMC,reports,receiveweekly
4182,Patients,following criteria,meet
4183,Patients,following criteria,meet
4184,ClinicalTrials.gov,data,processed
4185,ClinicalTrials.gov,data,processed
4186,adults,theirmoderate intensity physical activities,increase
4187,ClinicalTrials.gov,data,processed
4188,ClinicalTrials.gov,data,processed
4189,ClinicalTrials.gov,data,processed
4190,cases,contemporaneouslywith,occurred
4191,study,to:1,aim
4192,inclusion,serological test,collected around day 15
4193,Inclusion Criteria:-Adult patients,informed consent,signed
4194,ClinicalTrials.gov,data,processed
4195,COVID-19,high infection rate,has
4196,COVID-19,high infection rate,has
4197,recent article,total,analyzed
4198,study,138 COVID-19 patients,included
4199,Multiple viruses,myocarditis,cause
4200,autopsy reports,SARS CoV RNA,found
4201,McLellan team,novel coronavirus,uploaded
4202,pharmacological studies,aspirin,found
4203,subjects,aspirin,taken
4204,ClinicalTrials.gov,data,processed
4205,ClinicalTrials.gov,data,processed
4206,Tele health,Clinical Trial,Enabled
4207,Tele health,Clinical Trial,Enabled
4208,Laboratory,SARS CoV-2 infection,confirmed
4209,ClinicalTrials.gov,data,processed
4210,the WHO,global pandemic,declared
4211,older adults,presentation,described
4212,common symptoms,headache,include
4213,ClinicalTrials.gov,data,processed
4214,Social isolation,negative impacts,is
4215,older adults,50 % higher healthcare costs,have
4216,telephone program,kind,provide
4217,Theinvestigators,mental health outcomes,assess
4218,investigators,qualitativeanalyses focus groups,perform
4219,ClinicalTrials.gov,data,processed
4220,Substudyspecific assessments,optional sample collection,collected
4221,ClinicalTrials.gov,data,processed
4222,Participants,blood,willhave
4223,visit,about 30 minutes,take
4224,visit,about 30 minutes,take
4225,Male,18 - 65 years,aged
4226,ClinicalTrials.gov,data,processed
4227,prevalence,significantly withincreasing age,increases
4228,approximately 45%,recommended level,notmeet
4229,ClinicalTrials.gov,data,processed
4230,ClinicalTrials.gov,data,processed
4231,study,presence,examined
4232,investigators,presence,determine
4233,ClinicalTrials.gov,data,processed
4234,ClinicalTrials.gov,data,processed
4235,COVID-19 Pandemic,high incidence,suggest
4236,tointensive care units,mechanical ventilation,admitted
4237,initial ICU Recovery Clinic recovery clinic appointmentpatients,initial ICU recovery clinic appointmentpatients 8-week physical therapy program,begin
4238,ClinicalTrials.gov,data,processed
4239,Adult,18,aged
4240,ClinicalTrials.gov,data,processed
4241,ClinicalTrials.gov,data,processed
4242,ClinicalTrials.gov,data,processed
4243,Initial studies,numerous severe courses,described
4244,ClinicalTrials.gov,and(previously unpublished data,processed
4245,ClinicalTrials.gov,data,processed
4246,conventional medicines,oxygentherapy,involve
4247,becausethe prevention,estimated enrollment,performed
4248,ClinicalTrials.gov,data,processed
4249,ClinicalTrials.gov,data,processed
4250,ClinicalTrials.gov,data,processed
4251,ClinicalTrials.gov,data,processed
4252,ClinicalTrials.gov,data,processed
4253,intervention group,access,thatreceives
4254,Subjects,private group,canjoin
4255,AAFA navigator,telephonicfollow,offer
4256,follow survey,closed open ended questionsabout implementation outcomes,ask
4257,investigators,30 % loss,assume
4258,Findings,CONSORT reporting guidelines,reportedusing
4259,ClinicalTrials.gov,data,processed
4260,pandemic situation,mother,study
4261,biobank Swedish linkage tohealth registers,futureresearch,enable
4262,ClinicalTrials.gov,data,processed
4263,hospitalized patient,Informed Consent form,signed
4264,ClinicalTrials.gov,data,processed
4265,response,social isolation distancing,means
4266,response,social isolation distancing,means
4267,ClinicalTrials.gov,data,processed
4268,participating patients,complete blood count,undergo
4269,hospital stay patients,continuous vital sign monitoring,receive
4270,ClinicalTrials.gov,data,processed
4271,ClinicalTrials.gov,data,processed
4272,patients,care,need
4273,Males,18,aged
4274,Patients,aminotransferase AST);9,aspartate
4275,ClinicalTrials.gov,data,processed
4276,Patients,tocilizumab,receive
4277,Patients,standardof care,receive
4278,Patients,standard,receive
4279,ClinicalTrials.gov,data,processed
4280,Patients,studysupplements,take
4281,DiarrheaWomen,potential:1,bearing
4282,ClinicalTrials.gov,data,processed
4283,High throughput screening studies,Abl kinase inhibitors,identified
4284,Secondaryendpoint,progression,include
4285,ClinicalTrials.gov,data,processed
4286,investigators,changes,evaluate
4287,ClinicalTrials.gov,data,processed
4288,novel coronavirus,world,brought
4289,patients,brunt,face
4290,ClinicalTrials.gov,data,processed
4291,Coronavirus disease,significant threat,poses
4292,patient,anothermedical visit,make
4293,ClinicalTrials.gov,data,processed
4294,current guidelines,use ofexercise,support
4295,recent small non - randomized study,feasibility,analyses
4296,ClinicalTrials.gov,data,processed
4297,ClinicalTrials.gov,data,processed
4298,ClinicalTrials.gov,data,processed
4299,recent small non - randomized study,5 patients,included
4300,endophthalmitis,infection,Inclusion Criteria:-Patients with
4301,ClinicalTrials.gov,data,processed
4302,whatthe investigators,non - specific effects,called
4303,Indonesian trial,vaccination,reported
4304,Immunological studies,explanation,provided
4305,BCG recipients,release,increased
4306,vaccinationcan,trained immunity phenotype,induce
4307,numerous clinical trials,effect,investigating
4308,HYPOTHESIS BCG vaccination,risk,reduce
4309,Participants,BCG vaccine,receive
4310,participants,injection,receive
4311,treatment,place,take
4312,subject,followingcriteria,meet
4313,-Previous Mycobacterium tuberculosis,COVID-19 infection,subjects
4314,ClinicalTrials.gov,data,processed
4315,Participationmay,visits,include
4316,ClinicalTrials.gov,data,processed
4317,catchment area,2000 transplantedpatients,includes
4318,ClinicalTrials.gov,data,processed
4319,Coronavirus disease,requirement,brought about
4320,ClinicalTrials.gov,data,processed
4321,ClinicalTrials.gov,data,processed
4322,practitionner,modalities,performed to
4323,ClinicalTrials.gov,data,processed
4324,Coronavirus COVID-19 infection,global pandemic withhigh morbidity,causing
4325,child,little orno,appears
4326,ClinicalTrials.gov,data,processed
4327,real pandemic,unprecedented threat,posing
4328,section,socio demographic characteristics,investigates
4329,second section,clinical features,investigates
4330,sixth section,behaviours,investigates
4331,LazzaroSpallanzani,EPICOVID19 study protocol,approved
4332,theyfirst,platform,informed of
4333,Exclusion,consent,provide on
4334,ClinicalTrials.gov,data,processed
4335,Lahore General Hospital,abroad spectrum antiviral activity,has
4336,ClinicalTrials.gov,data,processed
4337,students,students,include
4338,ClinicalTrials.gov,data,processed
4339,sequencing,place,take
4340,men,interest,Databases
4341,ClinicalTrials.gov,data,processed
4342,ClinicalTrials.gov,data,processed
4343,ClinicalTrials.gov,data,processed
4344,Study,SARS CoV-2 nucleic acids,test
4345,ClinicalTrials.gov,data,processed
4346,ClinicalTrials.gov,data,processed
4347,ClinicalTrials.gov,data,processed
4348,Lahore General Hospital patients,survive,have
4349,Inclusion Criteria:-Have,written informed consent,given
4350,ClinicalTrials.gov,data,processed
4351,factors,patient diet,include
4352,patients,electronic informed consent form,receive
4353,Participants,document,sign
4354,Data management activities,standard operating procedures,follow
4355,patient,collection,maintained in
4356,Source,information,datais
4357,xCures,source records,retain
4358,ClinicalTrials.gov,DATA,processed
4359,MS patients,immunosuppressive immunomodulatory therapies,receive
4360,MS patients,social support,lose
4361,MS patients,social support,lose
4362,ClinicalTrials.gov,data,processed
4363,ClinicalTrials.gov,data,processed
4364,ClinicalTrials.gov,data,processed
4365,ClinicalTrials.gov,data,processed
4366,study,research questions,poses
4367,Patients,- assessment,undergo
4368,ClinicalTrials.gov,data,processed
4369,ClinicalTrials.gov,data,processed
4370,investigators,age 13 or older,recruit
4371,ClinicalTrials.gov,data,processed
4372,ClinicalTrials.gov,data,processed
4373,ClinicalTrials.gov,data,processed
4374,ClinicalTrials.gov,data,processed
4375,ClinicalTrials.gov,data,processed
4376,corticosteroid therapy,ACR EULAR 2010 classification criteria Patients,meeting
4377,ClinicalTrials.gov,data,processed
4378,followingglobal spread,210 countries,involved
4379,ClinicalTrials.gov,data,processed
4380,ClinicalTrials.gov,data,processed
4381,ClinicalTrials.gov,data,processed
4382,ClinicalTrials.gov,data,processed
4383,Argentina,total,reported
4384,Patient Safety Climate inHealthcare Organizations PSCHO,ORMAQ and Safety Climate Scale,modified
4385,ClinicalTrials.gov,data,processed
4386,pregnant women,worrisome outcomes,have
4387,ClinicalTrials.gov,data,processed
4388,subjects,written informed consent,give
4389,Recruited subjects,adult patients,include
4390,subjects,written informed consent.6,give
4391,potential additional future testing,immune response,Willingness to
4392,ClinicalTrials.gov,data,processed
4393,Validation,Ophthalmic Telephone Consultations,Aid
4394,Eye problems,regular monitoring toprevent permanent visual impairment,require
4395,ClinicalTrials.gov,data,processed
4396,Exclusion Criteria:-patient refusal,test questions,understanding
4397,ClinicalTrials.gov,data,processed
4398,current pandemic COVID-19,challenges,alsoexacerbated
4399,ClinicalTrials.gov,data,processed
4400,ClinicalTrials.gov,data,processed
4401,couldhelp,effective vaccines,make
4402,Healthy people,18 and olderDesign,Eligibility
4403,Participants,9 visits,have
4404,visits,blood tests,include
4405,Participants,gettingthe vaccine,get
4406,Participants,optional extra study visits,have
4407,Participants,study,repeat
4408,subjectsmay,blood,give
4409,Evaluations,vaccine antibody titers,include
4410,Additional evaluations,includeperipheral immune cell phenotyping,may
4411,Subjects,stool samples,provide
4412,subjects,study participation,continue
4413,Current alcohol,disorders,use
4414,ClinicalTrials.gov,data,processed
4415,ClinicalTrials.gov,data,processed
4416,ClinicalTrials.gov,data,processed
4417,Itwould,epidemiological surveillance,provide
4418,metropolitan area,"6,700 agents",has
4419,ClinicalTrials.gov,data,processed
4420,Obesity,important role,plays
4421,Thesefactors,low grade chronic inflammation,include
4422,scan Surgical,consent1,informed
4423,SICOB,informed consent,2
4424,ClinicalTrials.gov,data,processed
4425,ClinicalTrials.gov,data,processed
4426,ClinicalTrials.gov,data,processed
4427,Bangladesh,case,struggling
4428,Hydroxychloroquine,goodeffect,shown
4429,ClinicalTrials.gov,data,processed
4430,ClinicalTrials.gov,data,processed
4431,ClinicalTrials.gov,data,processed
4432,Exploratory Study,Severe Pneumonia,Caused
4433,ClinicalTrials.gov,data,processed
4434,Moderate severity,1 unit,given
4435,the Federal Food and Drug Agency,process,made
4436,ClinicalTrials.gov,data,processed
4437,Medically,acute illness,attended
4438,ClinicalTrials.gov,data,processed
4439,World Health Organization,outbreak,announced
4440,questionnaire,theinformation,includes
4441,ClinicalTrials.gov,data,processed
4442,2020-Patient,2020-Patient,Criteria:-Patients over 18 years of
4443,ClinicalTrials.gov,data,processed
4444,rapid spread,unprecedented challenge forhealthcare systems,represents
4445,the Federal Council,electiveinterventions,prohibited
4446,project population,consecutive patients,comprises
4447,ClinicalTrials.gov,data,processed
4448,Objectives,levels,Investigate
4449,Objectives,levels,Investigate
4450,Study design,mental health status,weinvestigated
4451,demographic variables,sex,include
4452,Clinicaltrials.gov,data,processed
4453,investigators,supportive text messages,developed
4454,investigators,supportive text messages,send
4455,investigators,message bank,generated
4456,50 % messages,differentcoping skills,involve
4457,Participants,one of these messages per day between 9:00 am and6:00 pm,receive
4458,Clinicaltrials.gov,data,processed
4459,perceptions,critical point,take
4460,Inclusion Criteria:-18 years old older Access,purpose study procedures,understand
4461,Clinicaltrials.gov,data,processed
4462,containment,unprecedented societalsituation,creates
4463,Discontinuation,patient major risk,exposes
4464,Burgundian cohorts,healthimpact,study
4465,Clinicaltrials.gov,data,processed
4466,questionnaire,20 questions,included
4467,Clinicaltrials.gov,data,processed
4468,Clinicaltrials.gov,data,processed
4469,Clinicaltrials.gov,data,processed
4470,PrescribeWellness,collaboration,facilitates
4471,PrescribeWellness,medication riskmitigation program,expands
4472,Clinicaltrials.gov,data,processed
4473,ill covid-19 patients,respiratory support,require
4474,Clinicaltrials.gov,data,processed
4475,healthcare facilities,telemedicine services,started
4476,Inclusion Criteria:-Patients,18 year Diagnosis,aged
4477,Clinicaltrials.gov,data,processed
4478,study,thehealth care resources,describe
4479,The Pediatric Emergency Research Networks,largestinternational acute pediatric care collaboration,represents
4480,Project Team,pediatric emergency medicineand infectious disease clinicians,includes
4481,Team members,expertise,have
4482,Clinicaltrials.gov,data,processed
4483,Clinicaltrials.gov,data,processed
4484,Clinicaltrials.gov,data,processed
4485,process,serine protease,requires
4486,Clinicaltrials.gov,data,processed
4487,Criteria:-patients,hydroxychloroquine,used
4488,Clinicaltrials.gov,data,processed
4489,display,length,assess
4490,Adult,COVID19,hospitalized
4491,Clinicaltrials.gov,data,processed
4492,Covid-19 Pandemic,changes,makes
4493,Covid-19 Pandemic,changes,makes
4494,Clinicaltrials.gov,data,processed
4495,way ANOVA Kruskal Wallis test,toexploratory investigate differences,conducted
4496,investigators,test,used
4497,interactions,tests,represent
4498,Theseinteractions,tests,represent
4499,ClinicalTrials.gov,data,processed
4500,Epidemic Disease,great impact,has
4501,Healthcare workers,essential role,play
4502,3109 healthcare workers,national internet based cross - sectional45-item survey,completed
4503,ClinicalTrials.gov,data,processed
4504,ClinicalTrials.gov,data,processed
4505,ClinicalTrials.gov,data,processed
4506,definition isa,case,suspected
4507,the WHO,pandemiccaused,declares
4508,subgroup,cytokine storm syndrome,evidencesuggests
4509,ClinicalTrials.gov,data,processed
4510,the COVID-19 Pandemic,undoubtedly elevated levels,has
4511,ClinicalTrials.gov,data,processed
4512,quarantine,daily routine,changed
4513,Participants,questions,complete
4514,group,exercise program,follow
4515,ClinicalTrials.gov,data,processed
4516,Ghurki trust teaching hospital,SMARTSTRATEGY SMART hospital lockdown,adopted
4517,Pakistan federal government,knownas,initiated
4518,orthopaedic team,orthopaedic team,started
4519,Strict asepsis,period,observedduring
4520,ClinicalTrials.gov,data,processed
4521,previous thoracic RT,pulmonary toxicity,chemoinduced
4522,ClinicalTrials.gov,data,processed
4523,ClinicalTrials.gov,data,processed
4524,ClinicalTrials.gov,data,processed
4525,ClinicalTrials.gov,data,processed
4526,ClinicalTrials.gov,data,processed
4527,ClinicalTrials.gov,data,processed
4528,ClinicalTrials.gov,data,processed
4529,ClinicalTrials.gov,data,processed
4530,Patient,consent,informed
4531,ClinicalTrials.gov,data,processed
4532,donor compound S nitroso N acetylpenicillamine increased survival rate inan model,eukaryotic cells,infected
4533,Laboratory,COVID19 infection,confirmed
4534,ClinicalTrials.gov,data,processed
4535,ClinicalTrials.gov,data,processed
4536,prospective data,number,increases
4537,transthoracic echocardiography,time,commonlyused
4538,Qatar Cardiovascular COVID-19 Registry,-19 positive patients,include
4539,ClinicalTrials.gov,1,processed
4540,drug,marketing authorisation,have
4541,ClinicalTrials.gov,data,processed
4542,antibodies,seasonal long term immunity,provides
4543,study,initial online survey,involves
4544,ClinicalTrials.gov,data,processed
4545,ClinicalTrials.gov,data,processed
4546,current situation,fears,generates
4547,ClinicalTrials.gov,data,processed
4548,patients,eligibility criteria,meeting
4549,ClinicalTrials.gov,data,processed
4550,Current practice,period,involves
4551,ClinicalTrials.gov,data,processed
4552,Early evaluation,future scale,enable
4553,approach,clinician scientist engagement,has
4554,Participants,updates,receive
4555,ClinicalTrials.gov,data,processed
4556,ClinicalTrials.gov,data,processed
4557,present study,dose escalation phase cancer treatment expansions,willinclude
4558,present study,approximately 140 participants,enroll
4559,participants,treatment,continue
4560,Nonsterilized female participants,effective methods,use
4561,ClinicalTrials.gov,data,processed
4562,Immuomedulator,risk,emerged
4563,Patient,IL6,receive
4564,ClinicalTrials.gov,data,processed
4565,ClinicalTrials.gov,data,processed
4566,Registry on Characteristics,the Intensive Care Unit,hospitalizedin
4567,ClinicalTrials.gov,data,processed
4568,online learning,umbrella term,involves
4569,new shifts,equality gaps,widen
4570,Online learning,umbrella term,involves
4571,New shifts ineducation approaches,equality gaps,widen
4572,22 countries,announcedpartial localized closures,have
4573,socioeconomic,student achievement,factorsaffecting
4574,studies,students perception,examined
4575,selected courses,courses,learned
4576,self administrated instrument,dimensions,identified
4577,Students,course topics,movethrough
4578,Facilitate Interaction,"hands activities,-Organize Online Courses",Provide
4579,ClinicalTrials.gov,data,processed
4580,issignificant difference,andlength,stay
4581,ClinicalTrials.gov,data,processed
4582,ClinicalTrials.gov,data,processed
4583,safety,phases,have
4584,ClinicalTrials.gov,data,processed
4585,ClinicalTrials.gov,data,processed
4586,the World Health Organization,NHF,list
4587,ClinicalTrials.gov,data,processed
4588,DEPLOY helpsto,timely conduct,facilitate
4589,ClinicalTrials.gov,data,processed
4590,ClinicalTrials.gov,data,processed
4591,digitalversion,beneﬁts,demonstrated
4592,Process measures,Goal Attainment,include
4593,consultationsand,COVID eWHELD intervention,cost
4594,Analyses,CONSORT guidance,follow
4595,ClinicalTrials.gov,data,processed
4596,Participants,online daily diaryfirst thing,complete
4597,ClinicalTrials.gov,data,processed
4598,BACKGROUND Health care workers,elevated risk,face
4599,Participants,short questionnaire,fill in
4600,counts,Bayesian negative binomial regression,analysed
4601,ELVIS COVID-19 study,ben,has
4602,ClinicalTrials.gov,data,processed
4603,specificantibodies,passive protectiveimmunity,provide
4604,ClinicalTrials.gov,data,processed
4605,anticipated impact,voice biomarker features,defining
4606,Voice biomarkers,key role,play
4607,study population,men,includes
4608,ClinicalTrials.gov,data,processed
4609,ClinicalTrials.gov,data,processed
4610,Maternal fetal transmission,late fetal losses,explain
4611,ClinicalTrials.gov,data,processed
4612,ClinicalTrials.gov,data,processed
4613,Screening,sensitive discussion abouteconomic difficulties,open
4614,Theinvestigators,waiver,requested
4615,Parent,CommUnity Care centers,specified
4616,Inclusion Criteria:-Any parent,CommUnity Care centers,specified
4617,ClinicalTrials.gov,data,processed
4618,pandemic,life,affected
4619,Healthcare workers,withhigh levels,working
4620,COVID-19 Pandemic,daily life,affecting
4621,ClinicalTrials.gov,data,processed
4622,family practitioners,patient information,value
4623,ClinicalTrials.gov,data,processed
4624,Modern quarantine strategies,short- andmedium term deadlocks,include
4625,ClinicalTrials.gov,data,processed
4626,ClinicalTrials.gov,data,processed
4627,study,objective,has
4628,study,objective,has
4629,ClinicalTrials.gov,data,processed
4630,ClinicalTrials.gov,data,processed
4631,nationwide registrystudy,important findings,identified
4632,ClinicalTrials.gov,data,processed
4633,ClinicalTrials.gov,data,processed
4634,clinical researcher,responses,collect
4635,duration,maximum,takes
4636,ClinicalTrials.gov,data,processed
4637,wellas,cancer patients,explored
4638,itwas,severe acute respiratory syndrome coronavirus,renamed
4639,ClinicalTrials.gov,data,processed
4640,Patients,single dose ofexebacase,receive
4641,Exebacase Phase 3 study sites,inthis Expanded Access study,participate
4642,ClinicalTrials.gov,data,processed
4643,ClinicalTrials.gov,data,processed
4644,VPM1002 vaccination,partial protection,assumed
4645,questionnaires,outcome safety data,review
4646,Subject,access,has
4647,Previous positive SARS CoV-2 test,10,result
4648,ClinicalTrials.gov,data,processed
4649,ClinicalTrials.gov,data,processed
4650,ClinicalTrials.gov,data,processed
4651,ClinicalTrials.gov,data,processed
4652,COVID-19 Pandemic,world medical community,provided
4653,data,non,was
4654,Patients,February 1st,admitted
4655,ClinicalTrials.gov,data,processed
4656,ClinicalTrials.gov,data,processed
4657,The Coronavirus,containment,caused
4658,self administered questionnaire,9 specific questions,includes
4659,ClinicalTrials.gov,data,processed
4660,participants,hybrid dentures,received
4661,ClinicalTrials.gov,data,processed
4662,new respiratory syndrome,withclinical signs,emerged
4663,Tests,theappearance,showed
4664,otherstrains,severe respiratory illnesses,caused
4665,early paper,41 patients withlaboratory confirmed COVID-19 infection,reported
4666,98%,multiplelobular,had
4667,ClinicalTrials.gov,data,processed
4668,Participants,sessions,receive
4669,Participants,self help psychotherapy,receive
4670,Separation,significant impact,have
4671,participants,acode number,have
4672,protocol.-Can,written informed consent,Able to
4673,certified clinical psychologist,invitation e link,send
4674,Al Ghafri et,applicability,alexamined
4675,cut score,thebest trade,gave
4676,currentstudy researchers,total score,take
4677,Pfizer Inc.,permission,states
4678,recruitment,period,taking
4679,Potential participant,theirparticipation,discuss
4680,Data,unique cod serial number,willreceive
4681,Omanis,18-65 years,aging
4682,protocol.-Can,written informed consent,≥ 10.-Has access to
4683,ClinicalTrials.gov,data,processed
4684,ClinicalTrials.gov,data,processed
4685,Women,higher depressive levels,report
4686,Younger subjects,poorer mental health symptoms,report
4687,Individuals,depressive symptoms,experience
4688,investigators,sufficient access,hypothesize
4689,following,protective variables,included in
4690,Younger subjects,poorer mental health symptoms,report
4691,investigators,education,hypothesize
4692,investigators,sufficient access,hypothesize
4693,following,protective variables,included in
4694,investigators,altruism,hypothesize
4695,questions,theoretically driven selections,given
4696,survey,random selection,reached
4697,pre - registered planned analyses,multiple regression,include
4698,clinicaltrials.gov,data,processed
4699,Respiratory virus outbreaks,major impacts,have
4700,Participants,blood sample,give
4701,kit containsgauze,instructions,containsdetailed
4702,kit containsgauze,80ul of blood and mail 80ul of blood to the the NIH Clinical Center lab,collect
4703,Participants,up to 4,enroll in
4704,knowledge,response tocurrent,impact
4705,clinicaltrials.gov,data,processed
4706,SARS CoV-2,1 million number,crossed
4707,COVID-19,case intradomestic contact definition,confirmed
4708,fever,symptoms,have
4709,clinicaltrials.gov,data,processed
4710,clinicaltrials.gov,data,processed
4711,clinicaltrials.gov,data,processed
4712,clinicaltrials.gov,data,processed
4713,clinicaltrials.gov,data,processed
4714,current pandemic,majorglobal health challenge,represents
4715,Secondary safety outcomes,prolongation,include
4716,clinicaltrials.gov,data,processed
4717,personnel,measures onstrict precaution,observe
4718,clinicaltrials.gov,data,processed
4719,WOCBP,negative urinary pregnancy test,have
4720,clinicaltrials.gov,data,processed
4721,Human study,role,evaluate
4722,patients,steroids,receive
4723,Patients,daily CRP measurements,receive
4724,patients,daily CRP measurements,receive
4725,clinicaltrials.gov,data,processed
4726,noval coronavirus disease,physical psychologicaldysfunctions,cause
4727,clinicaltrials.gov,data,processed
4728,ClinicalTrials.gov,data,processed
4729,ClinicalTrials.gov,data,processed
4730,percentage,between 10 and 30%,isevaluated
4731,ClinicalTrials.gov,data,processed
4732,herpes,types,viruses
4733,Studies,intense andrapid pharyngeal multiplication,show
4734,molecule,viricidal effect,shown
4735,ClinicalTrials.gov,data,processed
4736,approach,option,provides
4737,ClinicalTrials.gov,data,processed
4738,Isotretinoin therapy,anti - inflammatory anti - platelet fibrinolytic activities,proven
4739,Angiotensin II,intracellular calcium activity,increases
4740,nicardipine,Ang II mediated[Ca2,influence
4741,interleukin-6,AT1 protein,regulated
4742,Disease,significantlyhigher levels,have
4743,maturationprocess,initiation,affects
4744,Productive replication,innate immune response,modulates
4745,lung DCs,expression,found
4746,Retinoic acid,spontaneous apoptosis,inhibit
4747,13-cis RA,Th2 cytokine production,activates
4748,ATRA,anti - inflammatory immunoregulatory effects,reported
4749,Intracellular cholesterol levelis,amajor role,plays
4750,Retinoic acid,HIV infection,inhibit
4751,retinoic Acid,significant upregulation oftoll like receptor,induced
4752,study,thrombin platelet aggregation inhibitoryactivities,investigated
4753,retinoic acid,highest inhibition,showed
4754,Prostate cancer cell lines,TMPRSS2 expression,stronglyupregulated
4755,cancers,distinct set ofrisk factors,have
4756,men,higher risk,have
4757,Age,the followingconditions:1,have
4758,ClinicalTrials.gov,data,processed
4759,ClinicalTrials.gov,data,processed
4760,protocol,patients,studies
4761,ClinicalTrials.gov,data,processed
4762,SarsCoV2,20 million people,infected
4763,fall,positive treatment effect,beconsidered
4764,ClinicalTrials.gov,data,processed
4765,investigatorwill,national study,perform
4766,Corona virus,deleterious effects,have
4767,transneuronal transport,directinjury,induce
4768,Cytokines,blood brain barrier,cross
4769,mechanism,host immune response effects,fromunintended
4770,ill patients,neurologic,develop
4771,PNS)symptoms,impaired taste,The most common peripheral nervous system
4772,patients,lowerlymphocyte levels,had
4773,Systematic brain imaging,knowledge,mayincrease
4774,Severe COVID-19 infection,neurological manifestations,predicts
4775,Severe COVID-19 infection,neuropsychiatric psychiatric disorders,predicts
4776,Severe COVID-19 infection,neuropsychological sequelae,predicts
4777,ClinicalTrials.gov,data,processed
4778,ClinicalTrials.gov,data,processed
4779,ClinicalTrials.gov,data,processed
4780,limited telemedicine access,observeddisparities,exacerbating
4781,Black,video visits,patientsused
4782,Patients,algorithmic assessment,triggerthe
4783,patients,clinical support,receive
4784,Patients,thealgorithmic assessment,trigger
4785,nearly 80%,withthe program,engaged
4786,RNs,600 calls,managed
4787,early medicalinterventions,clinical outcomes,based on
4788,practices,topatients concerns,respond
4789,unnecessary escalations,whenmanaging patients,occur
4790,patients,low oxygen saturation,have
4791,the Vermont Department of Public Health,program,implemented
4792,ClinicalTrials.gov,data,processed
4793,ClinicalTrials.gov,data,processed
4794,general recommendations,andmistrust,create
4795,ClinicalTrials.gov,data,processed
4796,France,sanitary crisis,knows
4797,ClinicalTrials.gov,data,processed
4798,term,attention,captured
4799,Signed,informed consent,written
4800,ClinicalTrials.gov,data,processed
4801,Thequestion bank,demographics,includes
4802,Salivaspecimens,nasal swab specimen,replace
4803,Participants,theopportunity,have
4804,investigators,specimen collection materials instructions forcollection,provide
4805,Theinvestigators,results,return
4806,Individual return,following principles,willfollow
4807,the MURDOCK Study,"12,526residents from 20 Zip Codes in the Cabarrus County/Kannapolis region",recruited
4808,ClinicalTrials.gov,data,processed
4809,studieswill,minimum core dataset,collect
4810,Individualstudies,specific outcome measures,have
4811,ClinicalTrials.gov,data,processed
4812,Hydroxychloroquine Chemoprophylaxis,Trial,PHYDRA
4813,ClinicalTrials.gov,data,processed
4814,lot,role,proved
4815,Corona viruses,diseases,cause
4816,dividedinto groups,protocol,classified
4817,lobar collapse,byECHO,excluded
4818,ClinicalTrials.gov,data,processed
4819,investigative teamas results,2 stages,involves
4820,stage,2 3 doses,include
4821,Investigational drugs,investigative teamas results,enter
4822,ClinicalTrials.gov,data,processed
4823,ClinicalTrials.gov,data,processed
4824,Percentage,COVID-19 IgG Antibodies,Study to
4825,serosurveillance,asymptomatic employees,tested for
4826,ClinicalTrials.gov,data,processed
4827,ClinicalTrials.gov,data,processed
4828,Emergency general surgical care,unique set ofconsiderations,presents
4829,Patients,higher risk,have
4830,ClinicalTrials.gov,data,processed
4831,Survivors,significant input,require
4832,ClinicalTrials.gov,data,processed
4833,ClinicalTrials.gov,data,processed
4834,patients,detailedabove,examined by
4835,Subject,COVID-19 infection,confirmed
4836,Lung,> 50%,infiltrates
4837,Prospective study patients,informed consent,provides
4838,Subject,COVID-19 infection,confirmed
4839,Lung,> 50%,infiltrates
4840,Subject,COVID-19 infection,confirmed
4841,Lung,> 50%,infiltrates
4842,ClinicalTrials.gov,data,processed
4843,ClinicalTrials.gov,data,processed
4844,functional imaging PET,followingadvantages,has
4845,functional imaging PET molecular probe,upmolecular events,pick
4846,gender,COVID-19 drug,received
4847,gender,COVID-19 drug,received
4848,ClinicalTrials.gov,data,processed
4849,to10 centers,study,conduct
4850,to10 centers,study,conduct
4851,Patients,therapy,initiate
4852,Patients,continued standard care,receive
4853,National Kidney Foundation,3B 5 chronic renal dysfunction,stages
4854,ClinicalTrials.gov,data,processed
4855,Mechanically ventilated patients,mortality,have
4856,NETs,mortality,found in
4857,Inclusion,patients,ventilated
4858,ClinicalTrials.gov,data,processed
4859,DEPLOY helpsto,timely conduct,facilitate
4860,ClinicalTrials.gov,data,processed
4861,ClinicalTrials.gov,data,processed
4862,Phase,Clinical Trial,IIb
4863,ClinicalTrials.gov,data,processed
4864,ClinicalTrials.gov,data,processed
4865,ClinicalTrials.gov,data,processed
4866,ClinicalTrials.gov,data,processed
4867,Specific Aim,potential efficacy,determine
4868,lung,50%-Written informed consent,obtained before
4869,ClinicalTrials.gov,data,processed
4870,ClinicalTrials.gov,data,processed
4871,ClinicalTrials.gov,clinical biological data,processed
4872,thrombotic complications,inpatients,develop
4873,ClinicalTrials.gov,data,processed
4874,Exclusion Criteria:-Vulnerable populations,individual,institutionalized
4875,ClinicalTrials.gov,data,processed
4876,Prehospital providers,patients,encounter
4877,observational prospective study,COVID-19 status,document
4878,patients,headset,have
4879,ClinicalTrials.gov,data,processed
4880,spleen,injection contraindication Faint,cause
4881,ClinicalTrials.gov,data,processed
4882,Adult,≥18years,aged
4883,Laboratory,COVID-19 infection,confirmed
4884,heparin,thrombocytopenia,induced
4885,anticipated total blood volume,450,allowed
4886,ClinicalTrials.gov,data,processed
4887,andto,extent,investigate
4888,ClinicalTrials.gov,data,processed
4889,online expressive writingintervention,distress,A randomised controlled trial
4890,LIO-C,distress,improve
4891,world,unprecedented challenges,pandemic
4892,ClinicalTrials.gov,data,processed
4893,Platelet disorder,injection contraindication,cause
4894,Prior administration,vaccines,vectored
4895,ClinicalTrials.gov,data,processed
4896,Combined treatment,incidence,lowers
4897,Combined treatment,need,decreases
4898,ClinicalTrials.gov,data,processed
4899,Previous members,respiratory,caused
4900,ClinicalTrials.gov,data,processed
4901,numerous patients,olfactory teste disorders,described
4902,ClinicalTrials.gov,data,processed
4903,total,cases,reported
4904,trials,place,taking
4905,Clinical experience,withpromising results,came up
4906,ClinicalTrials.gov,data,processed
4907,ClinicalTrials.gov,data,processed
4908,subjects,guidelines,receive
4909,Studyvisits,place,take
4910,ClinicalTrials.gov,data,processed
4911,interim safety review,place,take
4912,ClinicalTrials.gov,data,processed
4913,activation,immunesystem,skewes
4914,investigators,SARS CoV-2infection induced immune activation,hypothesize
4915,ClinicalTrials.gov,data,processed
4916,ClinicalTrials.gov,data,processed
4917,Continuous biomonitoring,layer,provides
4918,ClinicalTrials.gov,data,processed
4919,nearly 13 million people,COVID-19,contracted
4920,Observational analyses,use,suggested
4921,subsequent analysis,similar associations,demonstrated
4922,analyses,pronounced benefit withtherapeutic,suggest
4923,legal guardian,written informed consentExclusion Criteria:-Age,provides
4924,18 years Mechanical ventilation,<72 hours-Treatment,stay
4925,ClinicalTrials.gov,data,processed
4926,hemodynamic pressors,blood pressure).6,Hypotension
4927,Anemia,<75%,defined
4928,ClinicalTrials.gov,data,processed
4929,Inclusion Criteria:-Signs,confirmed SARS CoV-2 infection,suggestive of
4930,ClinicalTrials.gov,data,processed
4931,Thisdaily monitoring,quality,improve
4932,Patient,COVID,diagnosed
4933,ClinicalTrials.gov,data,processed
4934,Containment,boredom,provides
4935,ClinicalTrials.gov,data,processed
4936,ClinicalTrials.gov,data,processed
4937,Voluntary signature,Informed Consent2,approved
4938,ClinicalTrials.gov,data,processed
4939,Parents,Parents children Parents owndietary lifestyle habits,reported
4940,world,new disease,facing
4941,unprecedented situation,causedchanges,have
4942,online survey,3 sections,had
4943,Parents,informed consent form,signed
4944,ClinicalTrials.gov,data,processed
4945,studies,potential clinical benefit,suggested
4946,ClinicalTrials.gov,data,processed
4947,ClinicalTrials.gov,data,processed
4948,ClinicalTrials.gov,data,processed
4949,difference,effect size,willallow
4950,ClinicalTrials.gov,data,processed
4951,ClinicalTrials.gov,data,processed
4952,disease inChina,variable disease course,have
4953,patients,pulmonary fibrosis,developed
4954,ClinicalTrials.gov,data,processed
4955,Inclusion Criteria:-Patients,≥,aged
4956,ClinicalTrials.gov,data,processed
4957,ClinicalTrials.gov,data,processed
4958,ClinicalTrials.gov,data,processed
4959,epidemic,major therapeutic challenge,represents
4960,study(health students internship,entire duration,are
4961,ClinicalTrials.gov,data,processed
4962,People,similarly frightening public health emergency,experienced
4963,anxiety,following additional issues:-Fear,canhave
4964,Patients,English,read
4965,ClinicalTrials.gov,data,processed
4966,trials,minimum core dataset,collect
4967,Individual studies,specific outcome measures,have
4968,ClinicalTrials.gov,data,processed
4969,ClinicalTrials.gov,data,processed
4970,SARS CoV-2,inflammatory cascade,triggers
4971,≤ 100 cGy,anti - inflammatoryresponse lowering levels,induces
4972,LD-RT,therapeutic,afford
4973,ClinicalTrials.gov,data,processed
4974,figure,nearly 2 million hospital admissions,imply
4975,IONIC Intervetion,patients,inhospitalised
4976,8.4 mg dL)-Renal impairment,disease,uncontrolled
4977,ordinary activity,fatigue,Less
4978,ClinicalTrials.gov,data,processed
4979,Male,≥,aged
4980,ClinicalTrials.gov,data,processed
4981,24-weekhome based telerehabilitation program,prescribed endurance exercises,includesindividualized
4982,single blinded randomized control trial study,6-monthhome telerehabilitation program,evaluate
4983,intervention,individualized prescribed upper lower extremity enduranceexercises,includes
4984,expertphysiotherapist,possible exercise,record
4985,ClinicalTrials.gov,data,processed
4986,Inclusion Criteria:-Suspected,≥,COVID-19-Aged
4987,fraction,oxygen fraction,inspired
4988,ClinicalTrials.gov,data,processed
4989,plasticity,inflammation,regulates
4990,plasticity,inflammation,regulates
4991,Bothstudies,marked reversal,reveal
4992,ClinicalTrials.gov,data,processed
4993,study,adults,enroll
4994,Participants,plasma,receiveconvalescent
4995,ClinicalTrials.gov,data,processed
4996,ClinicalTrials.gov,data,processed
4997,ClinicalTrials.gov,data,processed
4998,Study participants,opaganib 2 250 mg capsules,receive
4999,patient,written informed consent,signed
5000,Platelet,"75,000 mm3",count
5001,ClinicalTrials.gov,data,processed
5002,ClinicalTrials.gov,data,processed
5003,Platelet,"75,000 mcl Metabolic criteria",count
5004,ClinicalTrials.gov,data,processed
5005,ClinicalTrials.gov,data,processed
5006,ClinicalTrials.gov,data,processed
5007,Patient,score,has
5008,Patient,treatment,requires
5009,ClinicalTrials.gov,data,processed
5010,Infected individuals,severe respiratory difficultiesand pneumonia,experience
5011,ClinicalTrials.gov,data,processed
5012,IL-1ra,patientsurvival improvement,demonstrated
5013,ClinicalTrials.gov,data,processed
5014,ClinicalTrials.gov,data,processed
5015,Therapeutic anticoagulationwith heparin,clinical outcomes,improve
5016,adaptive design,response adaptiverandomization,includes
5017,History,thrombocytopenia,induced
5018,ClinicalTrials.gov,data,processed
5019,endothelial dysfunction,significant traction,gain
5020,studies,signaling,emphasized
5021,Nebivolol,non - adrenergic vasodilating properties,shown
5022,Severe symptoms,symptom,include
5023,ClinicalTrials.gov,data,processed
5024,study,efficacy,evaluate
5025,ClinicalTrials.gov,data,processed
5026,ClinicalTrials.gov,data,processed
5027,Actual data,unexpectedly high incidence ofpartially fatal complications,show
5028,ClinicalTrials.gov,data,processed
5029,ClinicalTrials.gov,data,processed
5030,ClinicalTrials.gov,data,processed
5031,ClinicalTrials.gov,data,processed
5032,study,relationship,explore
5033,shared pathogenetic mechanisms,act,suggested
5034,ClinicalTrials.gov,data,processed
5035,Demographic summaries,gender,include
5036,regression model,prognostic factors,explore
5037,software,v26,beSPSS
5038,ClinicalTrials.gov,data,processed
5039,ClinicalTrials.gov,data,processed
5040,patients,standard,willreceive
5041,ClinicalTrials.gov,data,processed
5042,ClinicalTrials.gov,data,processed
5043,Evaluation,SARS CoV-2,infectedwith
5044,open controlled trial,efficacy,evaluate
5045,ClinicalTrials.gov,data,processed
5046,Inclusion Criteria:-Able,informed consent,provide
5047,ClinicalTrials.gov,data,processed
5048,ClinicalTrials.gov,data,processed
5049,ClinicalTrials.gov,data,processed
5050,ClinicalTrials.gov,data,processed
5051,physicians,rt PCR test,screened
5052,anyother,tests,ordered
5053,physicians,rt PCR test,screened
5054,anyother,tests,ordered
5055,ClinicalTrials.gov,data,processed
5056,ClinicalTrials.gov,data,processed
5057,total,elective surgery,assigned in
5058,Data distribution,Shapiro Wilk D'Agostino tests,assessedusing
5059,ClinicalTrials.gov,data,processed
5060,Prospective Observational Study,approximately 500 patients,include
5061,Participants,sampling,undergo
5062,Plasma suPAR levels,assay,determinedusing
5063,suPAR level,non - survivors,discriminates
5064,Sampling laboratory measurementsParticipants,sampling,undergo
5065,Sample sizeThis study,500 patients,include
5066,ClinicalTrials.gov,data,processed
5067,Ambulatory patients,treatment,willreceive
5068,Male,≥,aged
5069,ClinicalTrials.gov,data,processed
5070,ClinicalTrials.gov,data,processed
5071,ClinicalTrials.gov,data,processed
5072,patient,COVID-19infectionInclusion criteria,confirmed
5073,ClinicalTrials.gov,data,processed
5074,ClinicalTrials.gov,data,processed
5075,Current local quarantine policy,practicality,undermine
5076,virus,"108,618 infections",reportedlycaused
5077,ClinicalTrials.gov,patient passive physiological data,processed
5078,ClinicalTrials.gov,data,processed
5079,single center prospective open label,efficacy,blind for
5080,patient,diagnosis,confirmed
5081,patient,instructions,follow
5082,ClinicalTrials.gov,data,processed
5083,Opaganib,Oxygen,With
5084,patient,written IRB approved informed consent.4,signed
5085,Platelet,"≥75,000",count
5086,EKG,QTc prolongationExclusion,showing
5087,ClinicalTrials.gov,data,processed
5088,adult group,follow 7 days afterfirst vaccination,recruited
5089,ClinicalTrials.gov,data,processed
5090,The Republic of Korea,sharp increase,experiences
5091,ClinicalTrials.gov,data,processed
5092,ClinicalTrials.gov,data,processed
5093,Group D n=10 patients,2 % hypertonic saline gargleand nasal lavage,use
5094,randomgroup allocation,distribution,ensure
5095,ClinicalTrials.gov,data,processed
5096,investigators,NIOD,Procedure
5097,investigators,expiratory tidal volume,document
5098,investigators,necessary sample size,estimate
5099,Radiographic findings,ground glass opacities,include
5100,NIOD,patient cooperation,requires
5101,OBJECTIVES & RESEARCH QUESTIONS ObjectivesThis project,objectives:1,has
5102,the NIOD,kinds ofphysiological positive effects,provide on
5103,randomized pilot study,valuable knowledge,provide
5104,Eligible Patients,section,see
5105,Caregivers,positioningas,change
5106,Theinvestigators,membrane,use
5107,investigators,40Hz,apply
5108,Theinvestigators,following variables,record
5109,Patients,the standard ICU care ineach center.4.9 Statistical Analyses,receive
5110,investigators,analyses,repeatthe
5111,Patients,grouprelative,alsoreceive
5112,randomized pilot study,Proulx MD,will
5113,DSMB,study completion,follow
5114,wewill,CPT,exclude
5115,ClinicalTrials.gov,data,processed
5116,clinical trial,safety,evaluates
5117,ongoing COVID-19pandemic,increased risk,demonstrated
5118,ClinicalTrials.gov,data,processed
5119,results,national andglobal policies,inform
5120,study investigators,job title,belinking
5121,Second psychosocial e.g. job demand control,departmental level policy information onpersonal protective equipment,link
5122,study investigators,variable census information,integratecommunity
5123,study,travel distance,include
5124,ClinicalTrials.gov,data,processed
5125,ClinicalTrials.gov,data,processed
5126,ClinicalTrials.gov,data,processed
5127,consecutive patients,eligibility criteria,meeting
5128,ClinicalTrials.gov,data,processed
5129,HBOT,blood transport,onlypromotes
5130,ClinicalTrials.gov,data,processed
5131,Deconfinement,triage,complicate
5132,ClinicalTrials.gov,data,processed
5133,Chloroquine,benefit,shown
5134,ClinicalTrials.gov,data,processed
5135,convalescent plasma,mortality,Prior findings in
5136,ClinicalTrials.gov,data,processed
5137,Metabolomics,change,detect
5138,metabolomics,place,have
5139,Inclusion,over 18 years of age-affiliated,Criteria:-patient
5140,ClinicalTrials.gov,data,processed
5141,Patients,COVID disease,confirmed
5142,ClinicalTrials.gov,data,processed
5143,ClinicalTrials.gov,data,processed
5144,new type,great pressure,puts
5145,Klok FA et al,the Post-COVID-19 Functional Status Scale,developed
5146,Research permissionto,validity,investigate
5147,ClinicalTrials.gov,data,processed
5148,Male female subjects,18 to 80 years,aged
5149,Subjects,informed consent form,sign
5150,ClinicalTrials.gov,data,processed
5151,ClinicalTrials.gov,data,processed
5152,people,thisvirus,know
5153,randomized pilot study,3 groups,include
5154,Participants,minimum,complete
5155,ClinicalTrials.gov,data,processed
5156,ClinicalTrials.gov,data,processed
5157,ClinicalTrials.gov,data,processed
5158,ClinicalTrials.gov,data,processed
5159,ClinicalTrials.gov,data,processed
5160,ClinicalTrials.gov,data,processed
5161,ClinicalTrials.gov,data,processed
5162,ClinicalTrials.gov,data,processed
5163,Criteria:-Previous COVID-19 diagnosis,-No access,documented in
5164,ClinicalTrials.gov,data,processed
5165,group,higher risk,beat
5166,ClinicalTrials.gov,data,processed
5167,ClinicalTrials.gov,data,processed
5168,Pilot study,use,assess
5169,Patients,LDN,receive
5170,ClinicalTrials.gov,data,processed
5171,ClinicalTrials.gov,data,processed
5172,approximately 50%,cytokine storm phenotype2,demonstrate
5173,SARS CoV-2 rapid global spread,likely protracted influence,transmissionindicate
5174,McNagny,technology,developed
5175,method,data,yields
5176,log2,change,fold
5177,ClinicalTrials.gov,data,processed
5178,Participants,daily visits,receive
5179,ClinicalTrials.gov,data,processed
5180,Surfactant replacement therapy,oxygenation,improves
5181,ClinicalTrials.gov,data,processed
5182,testing,diagnostic,allowcommunity
5183,POCT,small disposable kits,possibleusing
5184,sample,kit.3,centrifuged
5185,PCR,COVID-19 infection,confirmed
5186,ClinicalTrials.gov,data,processed
5187,Multifocal interstitial pneumonia,common cause,represents
5188,Inclusion Criteria:-SARS CoV2 Infection,interstitial pneumonia Hospital admission,confirmed
5189,ClinicalTrials.gov,data,processed
5190,Phase 1 patients,visits,draws
5191,factor,significant safety issue,considered
5192,ClinicalTrials.gov,data,processed
5193,registry,SARS CoV-2 antibodies,conducted
5194,ClinicalTrials.gov,blood test data,processed
5195,ClinicalTrials.gov,data,processed
5196,trial participants,SOC*.Randomization,receive
5197,ClinicalTrials.gov,data,processed
5198,ClinicalTrials.gov,data,processed
5199,1 ug k min SOFA,15 points,score
5200,ClinicalTrials.gov,data,processed
5201,ClinicalTrials.gov,data,processed
5202,NET,role,plays
5203,Men,≥18,aged
5204,ClinicalTrials.gov,data,processed
5205,helmet like interfacesystem,theapplication,allow
5206,chest CT,25irpm;-Gasometric parameters,scan with
5207,ClinicalTrials.gov,data,processed
5208,Researchers,participantsover,analyze
5209,andif Participantsmedical records,positive PCR test,monitored for
5210,Anothersubpopulation study,participants,recruit
5211,ClinicalTrials.gov,data,processed
5212,Individualswill,10 dollar incentive,see
5213,ClinicalTrials.gov,data,processed
5214,ClinicalTrials.gov,data,processed
5215,ClinicalTrials.gov,data,processed
5216,ClinicalTrials.gov,data,processed
5217,patient,peak specific IgM,showed
5218,NETs,potential,have
5219,elevated levels,worseoutcomes,investigated
5220,T cell responses,regulatory role,are
5221,NE inhibitors,expression,induced
5222,presence,maturation,promoted
5223,presence,antibody based immunity.(24,improves
5224,trans retinoic acid,beneficial effects,has
5225,RA,neutrophil mediated endothelial cell injury,modulate
5226,effects,reduction,underlie
5227,continuedproduction,negative effect,has
5228,T cells,significantlyhigher levels,have
5229,maturationprocess,initiation,affects
5230,atRA)can,spontaneous apoptosis,Retinoic acid
5231,ATRA,anti - inflammatory immunoregulatory effects,reported
5232,Intracellular cholesterol levelis,amajor role,plays
5233,ion.(62)Angiotensin II,intracellular calcium activity,increases
5234,nicardipine,Ang II mediated[Ca2,influence
5235,interleukin-6,AT1 protein,regulated
5236,Age,the followingconditions:1,have
5237,ClinicalTrials.gov,data,processed
5238,hemodynamic pressors,blood pressure).6,Hypotension
5239,Anemia,<75%,defined
5240,ClinicalTrials.gov,data,processed
5241,Subjects,fingerstick lancing 1 venous blood draw,undergo
5242,Male female subjects,years.2,aged
5243,Subject,documented SARS CoV-2 PCR test,have
5244,ClinicalTrials.gov,data,processed
5245,ClinicalTrials.gov,data,processed
5246,Coronavirus disease-19 COVID-19,unprecedented effect,had
5247,Increased number,enormous load,put
5248,Population,confirmed cases,consists
5249,ClinicalTrials.gov,data,processed
5250,ClinicalTrials.gov,data,processed
5251,Patients,survey,complete
5252,ClinicalTrials.gov,data,processed
5253,ClinicalTrials.gov,data,processed
5254,Identify,antigenic binding,confirm
5255,Active coronavirus disease Inclusion criteriaParticipants,following criteria,satisfy
5256,CriteriaThe presence,participant,exclude
5257,ClinicalTrials.gov,data,processed
5258,clinical course,thedegree of NETosis activity,andevaluate
5259,plasma,process,evaluated
5260,clinical course,thedegree of NETosi activity,andevaluate
5261,plasma,the NETosisprocess,evaluated
5262,Covid-19 patients,≥,aged
5263,ClinicalTrials.gov,data,processed
5264,arterial blood gas and/or lung imagingto,probability,assess
5265,swab,Nasopharyngeal,betaken for
5266,time point,themonitoring measurement,replace
5267,hospital,measurement,replace
5268,normal cell turnover,nucleic acid content,results in
5269,Permanent sterilisation methods,hysterectomy,include
5270,ClinicalTrials.gov,data,processed
5271,ClinicalTrials.gov,data,processed
5272,Brazilian Chiropractors,COVID-19 Pandemic,Facing
5273,Brazil,Latin America largest coronavirus outbreak,has
5274,ClinicalTrials.gov,data,processed
5275,willbe,50 cancer patients candidates,enrolled
5276,ClinicalTrials.gov,data,processed
5277,Post Exposure Prophylaxis,Patients,Healthcare Workers Exposed to
5278,viruses,host cells,enter
5279,group,investigational drug,receive
5280,Researchers,differentmedications,researching
5281,ClinicalTrials.gov,data,processed
5282,Inclusion Criteria:-Adults medical paramedical staff,emergency room,working
5283,ClinicalTrials.gov,data,processed
5284,investigators,open randomizedclinical trial,propose
5285,disease spectrum includesasymptomatic stage,point,constituting
5286,ClinicalTrials.gov,data,processed
5287,investigators,prospective double blind multicentre randomised trial toassess treatment,do
5288,60 patients,i.v. transfusion 3times,receive
5289,30 patients,placebo,receive
5290,4)pulmonary imaging,interstitial damage,revealed
5291,ClinicalTrials.gov,data,processed
5292,ClinicalTrials.gov,data,processed
5293,nospecific treatment,efficacy,proven
5294,HBOT mechanisms,thesefindings,explain
5295,outbreakstarted,the World Health,recognized
5296,170moderate,cases,admitted
5297,Poor prognosis,highlevels,include
5298,Chen et al.,case series,reported
5299,cases,increase,reported
5300,increased,binding,increases
5301,HBOT,following inflammatory cytokines,reduces
5302,ClinicalTrials.gov,data,processed
5303,patients,dyspnea,have
5304,effects,improvement,resultin
5305,ClinicalTrials.gov,Non - parametric data,processed
5306,ClinicalTrials.gov,data,processed
5307,positive patients,placebo doses,receive
5308,patients,oral,time from
5309,Control group,placebo,receiving
5310,participant,participant medication box,estimated by
5311,risk,be20%,modified
5312,%,hospital management,required
5313,fetal toxicity studies,notshow embryo fetal toxic effects,recommended
5314,the World Medical Association,the Helsinki Declaration,haspromulgated
5315,ClinicalTrials.gov,data,processed
5316,ClinicalTrials.gov,data,processed
5317,Patients,wide range,exhibit
5318,ground glass opacification,more than 50%,found
5319,andcan,drug-induced LQT,cause
5320,ClinicalTrials.gov,data,processed
5321,x upper limit,"50,000/µL.3",platelets
5322,ClinicalTrials.gov,data,processed
5323,stage renal disease,cirrhosis,confirmed
5324,ClinicalTrials.gov,data,processed
5325,ClinicalTrials.gov,data,processed
5326,Efficacy and Safety of Nitazoxanide,Mild Ambulatory COVID-19 Patients,Treat
5327,Investigator,treatment duration,extend
5328,ClinicalTrials.gov,data,processed
5329,community health workers,households,educate
5330,Inclusion Criteria:-Youth,18 to 30 years,aged
5331,ClinicalTrials.gov,data,processed
5332,ClinicalTrials.gov,data,processed
5333,investigators,utility,demonstrated
5334,ClinicalTrials.gov,data,processed
5335,Plasma,variety,contains
5336,ClinicalTrials.gov,data,processed
5337,SARS)-CoV-2 real time RT-PCR,nasopharyngeal swab sample,Confirmed COVID-19 disease
5338,patient,capacity,obtained from
5339,protocol,pregnant subjects,exclude
5340,ClinicalTrials.gov,data,processed
5341,Common Medications,Course,Alter
5342,the WHO,recommendation,reversed
5343,NSAID use,bacterial pneumonia,is
5344,case control study,association,explore
5345,ClinicalTrials.gov,data,processed
5346,Comparison,IM,administered
5347,ClinicalTrials.gov,data,processed
5348,patients,pneumonia,develop
5349,Excessiveand,immune system response,uncontrolled
5350,"AT2),which",development,determines
5351,Cytokinerelease syndrome,emergence,threatens
5352,key components,disruption,include
5353,ClinicalTrials.gov,data,processed
5354,vitamin D,hard endpoints,Wehypothesize
5355,ClinicalTrials.gov,data,processed
5356,24 patients,0.5 10E6 UC MSCs,received
5357,other24 patients,conventional treatment,received
5358,ClinicalTrials.gov,data,processed
5359,Hypercapnia,NIV,indicating
5360,ClinicalTrials.gov,data,processed
5361,activity,role inprevention,play
5362,Participants,treatment,receive
5363,Mosthealth agencies,careful approach,suggest
5364,Exposureof HCW,risk stratification,necessitates
5365,patient,facemask,The CDCdefines
5366,patient,facemask,wear
5367,HCWs safety,thepossibility,makes
5368,intervention group,oral hydroxychloroquine,receive
5369,400 mg,treatment,receive
5370,primary analysis,randomized participants,include
5371,ClinicalTrials.gov,data,processed
5372,Score,supplemental oxygen,requires
5373,condition,participant,put
5374,ClinicalTrials.gov,data,processed
5375,ClinicalTrials.gov,data,processed
5376,Fourteen patients,dose level,receive
5377,Patients,total,receive
5378,Patients,identical IV infusions,receive
5379,Patients,available supportive antiviral therapies,receive
5380,exploratory endpoints,time,include
5381,ClinicalTrials.gov,data,processed
5382,ClinicalTrials.gov,data,processed
5383,pandemicwill,capacity,exceed
5384,health carepersonnel,valuable resource,represent
5385,Elfiky et al.,SARS CoV-2 model,made
5386,duration,lower temperature,presented
5387,Study,triple blinded multicentric clinical trial,designRandomized
5388,central pharmacist,thecorrespondence,know
5389,participants,follow visits,have
5390,ClinicalTrials.gov,data,processed
5391,1)improves V Q ratio,PVR,reduces
5392,ClinicalTrials.gov,data,processed
5393,ClinicalTrials.gov,data,processed
5394,Corona virus disease,parts,involving
5395,pandemic,parts,involving
5396,ClinicalTrials.gov,data,processed
5397,patients,arthritis,withrheumatoid
5398,ClinicalTrials.gov,data,processed
5399,Emergency departments,important,carried out
5400,Emergency departments,important,carried out
5401,ClinicalTrials.gov,data,processed
5402,ClinicalTrials.gov,data,processed
5403,ClinicalTrials.gov,data,processed
5404,ClinicalTrials.gov,data,processed
5405,ClinicalTrials.gov,data,processed
5406,apatient,criteria,The treating physician/investigator contacts
5407,ClinicalTrials.gov,data,processed
5408,ClinicalTrials.gov,data,processed
5409,endpoints,current COVID-19-based precautions impacttreatment related outcomes,establish
5410,ClinicalTrials.gov,data,processed
5411,ClinicalTrials.gov,data,processed
5412,study,minimum number,developed with
5413,BPCO,Quick Walk Test respiratory symptoms,95% in
5414,ClinicalTrials.gov,data,processed
5415,criteria,rational use,support
5416,lipophilic nature,toinhibit viral replication,allow
5417,ClinicalTrials.gov,data,processed
5418,ClinicalTrials.gov,data,processed
5419,target zones,set,cover
5420,Herbs,Herbs,prove
5421,protocol,treatment model,presents
5422,ClinicalTrials.gov,data,processed
5423,I. Future correlative biomarker objectives,assessment,include
5424,Adult,quality,complete
5425,ClinicalTrials.gov,data,processed
5426,questionnaire,women,trained to
5427,ClinicalTrials.gov,data,processed
5428,15-20%,hospitalization,require
5429,ClinicalTrials.gov,data,processed
5430,ClinicalTrials.gov,data,processed
5431,questionnaire,39 questions,included
5432,investigators,interviews,Qualitative survey
5433,interview guide,onstructural organizational human factors,focused
5434,ClinicalTrials.gov,data,processed
5435,pandemic,considerabledisruption,caused
5436,cohort study,exposed cohort,willcomprise
5437,ClinicalTrials.gov,data,processed
5438,agentsare,pressure,lesson
5439,Ideal,tidal volume,estimated
5440,ClinicalTrials.gov,data,processed
5441,ClinicalTrials.gov,data,processed
5442,"200,000 have",succumbed,diagnosed
5443,Specific questions,presence,include
5444,study team,detailed investigations,prioritise
5445,Study participants,medical assistance,seek
5446,ClinicalTrials.gov,data,processed
5447,Evaluation,New Detection Approaches,Approaches
5448,issues,thequality,reduce
5449,ClinicalTrials.gov,data,processed
5450,fatigue)-Initial treatment plan,hospitalization Presence,include
5451,ClinicalTrials.gov,data,processed
5452,Phase,Double blind Randomized Controlled Trial,IIa
5453,conventional treatment,ARDS:-Either Wharton Jelly MSCs,randomized
5454,ClinicalTrials.gov,data,processed
5455,antiviral activity,patientswith,willevaluate
5456,ClinicalTrials.gov,data,processed
5457,ClinicalTrials.gov,data,processed
5458,features,fundamentallydifferent phenotypes,show
5459,ClinicalTrials.gov,data,processed
5460,upregulation,increasedsusceptibility,explain
5461,ClinicalTrials.gov,data,processed
5462,Autologous Peripheral Blood,CD34 + Cells,CLBS119
5463,randomized interventional comparative Phase IIII trial,safety,explore
5464,Eligible subjects,single administration,receive
5465,ClinicalTrials.gov,data,processed
5466,ClinicalTrials.gov,data,processed
5467,Platelets,"50,0006",<
5468,ClinicalTrials.gov,data,processed
5469,Unblinded study pharmacist orresearch nurse,investigational products,prepare
5470,symptoms,disease,offebrile
5471,central research coordinator,localdedicated study personnel,train
5472,Patient,formal role,plays
5473,steering committee,primary outcomes,review
5474,number,uneven,isfind
5475,patients,rtPCR test,expected
5476,ClinicalTrials.gov,data,processed
5477,clinical characteristics,respiratorysymptoms,include
5478,outbreak hasalready,global alarm,caused
5479,Fujifilm Toyama Chemical,Phase III clinical trial,hasstarted
5480,Avigan,RNA,blocks
5481,the new Phase IIItrial,Avigan safety,assess
5482,type,China,donein
5483,patients,tothe treatments,estimated
5484,Data Collectors,data collection sheet,fill up
5485,Standard TreatmentStandard treatment,oxygen inhalation,included
5486,Onprolong treatment Onprolong treatment,inflammation,develop
5487,RT-PCR,respiratory samples,done by
5488,clinical characteristics,respiratorysymptoms,include
5489,ClinicalTrials.gov,data,processed
5490,ClinicalTrials.gov,data,processed
5491,Lang andcolleagues,role,investigated
5492,Secondary objectives,safety,evaluated
5493,Secondary objectives,safety,evaluated
5494,Group 2a,liposomal lactoferrin,received
5495,Blood samples,T1,werecollected at
5496,ClinicalTrials.gov,data,processed
5497,Acute Kidney Injury,Renal Replacement Therapy,", Randomized, Case Controlled, Double-blind, Ascending-dose Study of"
5498,ClinicalTrials.gov,data,processed
5499,Early reports,overall cardiac arrhythmia incidence,suggested
5500,ClinicalTrials.gov,data,processed
5501,Sex,individual susceptibility,influence
5502,Inclusion Criteria:-Patients,SARS Cov-2 infection,confirmed
5503,ClinicalTrials.gov,data,processed
5504,Colchicine treatment,initial dose,includes
5505,Patients,standard therapy,receive
5506,ClinicalTrials.gov,data,processed
5507,lucinactant,duration,decrease
5508,Lucinactant,extensive safety profile,has
5509,lucinactant,respiratory status,hypothesized
5510,ICF;-Age 18 75 inclusive);-Real time polymerase chain reaction,positive,assay
5511,ClinicalTrials.gov,data,processed
5512,ClinicalTrials.gov,data,processed
5513,Current standard,invarious North American hospitals,differs
5514,ClinicalTrials.gov,data,processed
5515,Platelet,Fl5,count
5516,History,thrombocytopenia,induced
5517,ClinicalTrials.gov,data,processed
5518,Clinical Validation,Flocked Nasopharyngeal Swabs,Molded
5519,Clinical Validation,Flocked Nasopharyngeal Swabs,Molded
5520,ClinicalTrials.gov,data,processed
5521,becausethese drugs,action mechanism,counteract
5522,ClinicalTrials.gov,data,processed
5523,ClinicalTrials.gov,data,processed
5524,ClinicalTrials.gov,data,processed
5525,ClinicalTrials.gov,data,processed
5526,ClinicalTrials.gov,data,processed
5527,open controlled trial,efficacy,evaluate
5528,ClinicalTrials.gov,data,processed
5529,interim safety review,place,take
5530,ClinicalTrials.gov,data,processed
5531,current gold standard method,high analytical sensitivityand specificity,has
5532,ClinicalTrials.gov,data,processed
5533,lack,bias,cause
5534,ClinicalTrials.gov,data,processed
5535,ClinicalTrials.gov,data,processed
5536,Theinvestigators,Redcap platform,use
5537,Arms & InterventionsThe investigators,information,document
5538,Data collection Arms,participant sex,collect
5539,Arms & InterventionsThe investigators,data,collect
5540,ClinicalTrials.gov,data,processed
5541,Recent studies,ofvitamin C Zinc administration,shown
5542,patient,informed consent,give
5543,patients,standard routine medical care,receive
5544,study,principle,follow
5545,online graph padcalculator,patients,distributed
5546,random numbers,aspatients code number,assigned
5547,person,distinct sets,allocated
5548,ClinicalTrials.gov,data,processed
5549,ClinicalTrials.gov,data,processed
5550,ClinicalTrials.gov,data,processed
5551,global pandemic,considerable morbidity andmortality,caused
5552,China,elevated D dimer level greater than1 ug,observed
5553,association,modifiable risk factor,represent
5554,risk stratification,blood count,complete
5555,P F,D dimer,ratio<100)-Elevated
5556,ClinicalTrials.gov,data,processed
5557,Hospitalmortality,45%,affects
5558,Administration,elimination ofthe virus,delay
5559,Contraindication,QT prolongation,documented
5560,ClinicalTrials.gov,data,processed
5561,ClinicalTrials.gov,data,processed
5562,ClinicalTrials.gov,data,processed
5563,Autopsy reports,micro macro vascular thrombosis,noted
5564,75%,pulmonary,had
5565,Patients,23.3-fold higher risk,had
5566,ClinicalTrials.gov,data,processed
5567,patients,follow visit,have
5568,ClinicalTrials.gov,data,processed
5569,ClinicalTrials.gov,data,processed
5570,Absolute lymphocyte,500 cells,count
5571,ClinicalTrials.gov,data,processed
5572,colchicine treatment,initial dose,includes
5573,Patients,standard therapy,receive
5574,ClinicalTrials.gov,data,processed
5575,ClinicalTrials.gov,data,processed
5576,patients,sequelae,have
5577,patients,organization,changed
5578,the clinician,clinician twoquestions,ask
5579,method,better results,Is
5580,COVID-19 patients,sequelae,have
5581,COVID-19 patients,dyspnea,bephysical
5582,COVID-19 patients,recovery,indicated in
5583,telemedicine,developed inaffected industrial countries,beeing
5584,clinician,clinician questions,ask
5585,method,betterresults,Is
5586,study,methods,evaluates
5587,ClinicalTrials.gov,data,processed
5588,RT PCRpanel,SARS CoV-2 Ribonucleic acid,detects
5589,approach,false positives,generateany
5590,case control study,120 samples,analyze
5591,The PI,activities,coordinate
5592,organizations,collaborative work,is
5593,IEDCR,different kits,uses
5594,A*Star Fortitude Kit,false positive false negative results,known
5595,IEDCR,A*Star Fortitude Kit,uses
5596,IEDCR,collaborative work,doing
5597,Kappa,K=(Observed Agreement,coefficient
5598,Principal Investigator,evaluation data analysis,coordinating
5599,The PI,activities,coordinate
5600,ClinicalTrials.gov,data,processed
5601,ClinicalTrials.gov,data,processed
5602,Bothtreatment groups,established treatment regimen,receive
5603,ClinicalTrials.gov,data,processed
5604,Pilot Study,Effect,Evaluate
5605,ClinicalTrials.gov,data,processed
5606,Blockade,deterioration,prevent
5607,Pilot Study,Effect,Evaluate
5608,ClinicalTrials.gov,data,processed
5609,Thymalfasin,COVID-19 Infection,Treat
5610,Larger clinical trials,shownsignificant efficacy,have
5611,1.6 mg,immune system homeostasis,restores
5612,ClinicalTrials.gov,data,processed
5613,Nasal lavage consistsof,salt water,running
5614,Patients,significant risks,involve
5615,Pilot Study,Effect,Evaluate
5616,ClinicalTrials.gov,data,processed
5617,Pilot Study,Effect,Evaluate
5618,ClinicalTrials.gov,data,processed
5619,ClinicalTrials.gov,data,processed
5620,Pilot Study,Effect,Evaluate
5621,ClinicalTrials.gov,data,processed
5622,ClinicalTrials.gov,data,processed
5623,FDA,standard blood donation,approved
5624,(P:F) ratio <300 -Pulmonary,> 50%,defined
5625,ClinicalTrials.gov,data,processed
5626,ClinicalTrials.gov,data,processed
5627,studypatients,standard,receive
5628,Patients,continuous intravenous i.v infusion,receivea
5629,ClinicalTrials.gov,data,processed
5630,emergence,significant challenge,poses
5631,ClinicalTrials.gov,data,processed
5632,SOC treatment,adult subjects,inhospitalized
5633,greater 5 upper limit,100 109 L,platelets
5634,ClinicalTrials.gov,data,processed
5635,DM,investigator,question
5636,Statistical analysis,Statistical analysis plan,See
5637,statistician,Statistical analysis plan,finalize
5638,secondary efficiency indicators,negative conversion ratio,include
5639,2.4Analysis software,the software SAS,Use
5640,Nomodification,original data,overwrite
5641,study sites,study drugs,manage
5642,Subjects Inclusion Criteria:1 legal representatives,informed consent,agree not
5643,ClinicalTrials.gov,data,processed
5644,ClinicalTrials.gov,data,processed
5645,Patients inthe test group,convalescent plasma,receive
5646,200ml,blood bank records,issuedmaintaining
5647,partial pressure,> 50%,v. lung infiltrates
5648,Clinical status,infusion,precluding
5649,ClinicalTrials.gov,data,processed
5650,National early warning score,quickly determiningthe degree,helps in
5651,National early warning score,likelihood,provides
5652,Field,lungs,covering
5653,Gantry,lateral chest,rotated to
5654,Gantry,0 degree,opened
5655,ClinicalTrials.gov,data,processed
5656,ClinicalTrials.gov,data,processed
5657,ClinicalTrials.gov,data,processed
5658,weeks).A lab technician,blood,collected
5659,exercise,moderate intensity aerobic exercises,groupperformed
5660,Participants,weeks aerobic exercise program,performed
5661,Inclusion patient,mild,has
5662,ClinicalTrials.gov,data,processed
5663,ARB,Usage,DRi
5664,ClinicalTrials.gov,data,processed
5665,new coronavirus,seriouspneumonias,cause
5666,Hydroxychloroquine,efficacy,shown
5667,ClinicalTrials.gov,data,processed
5668,ClinicalTrials.gov,data,processed
5669,study,patients,enroll
5670,potential,potential risk,given
5671,Patient,informed consent,provide
5672,ClinicalTrials.gov,data,processed
5673,Serum Samples,samples,andbronchoscopy
5674,patients,impact,havesignificant
5675,ClinicalTrials.gov,data,processed
5676,ClinicalTrials.gov,data,processed
5677,adult patients,emergency laparotomy surgery,included
5678,ClinicalTrials.gov,data,processed
5679,Current standard PPE equipment,afit tested N95 mask,includes
5680,Ultimately decreased levels,therisk,reduce
5681,ClinicalTrials.gov,data,processed
5682,human antigen presenting cells,process COVID-19 target antigen protein,take up
5683,ClinicalTrials.gov,data,processed
5684,investigators,center 225 patient longitudinalprospective cohort study,propose
5685,Researchers,depth evaluation,perform
5686,Pre - existing cognitive language impairment,clinical outcomes,prohibiting
5687,ClinicalTrials.gov,data,processed
5688,Studies,similar findings,show
5689,CITY,particular demographic composition,has
5690,ClinicalTrials.gov,data,processed
5691,ClinicalTrials.gov,data,processed
5692,Satisfaction Scale,level,assesses
5693,BRUMS,about one to two minutes,takes
5694,24 indicators,subscales,comprise
5695,person,1 minute,defined
5696,Fluctuations inHRV patterns,early sensitive diagnosis,provide
5697,balls,circles,touched
5698,offers,feedback,hit
5699,ClinicalTrials.gov,data,processed
5700,Subjects,inclusion criteria,meet
5701,Laboratory,infection,confirmed
5702,e.g. Child Pugh,≥ C,Severe liver disease
5703,ClinicalTrials.gov,data,processed
5704,Convalescent plasma,clinical outcome,significantlyimproves
5705,Multicenter,double blind placebo.controlled clinical trial,randomized
5706,Study,Primary objective,objectives
5707,ClinicalTrials.gov,data,processed
5708,ClinicalTrials.gov,data,processed
5709,SARS CoV-2 displays,efficient transmission pattern,amore
5710,incidence,the general Population,40%among
5711,ClinicalTrials.gov,data,processed
5712,the WHO,global situation,described
5713,respiratory difficulties,tohospitalization,lead
5714,ClinicalTrials.gov,data,processed
5715,scientific community,little knowledge,has
5716,SARS-CoV-2 Quercetin,antiviral activity,have
5717,Bromelain,natural killer cells,activates
5718,ClinicalTrials.gov,data,processed
5719,ClinicalTrials.gov,data,processed
5720,ClinicalTrials.gov,data,processed
5721,Inclusion,time period,represent
5722,Trained research staff,data,abstract
5723,Individual participant data willinclude baseline data,exposure data,COVID-19
5724,"Approximately 24,400 deliveries",COVID-19 infections,confirmed
5725,ClinicalTrials.gov,data,processed
5726,Comparison,IM,administered
5727,US Infectious Cohort,oncology patients,excludes
5728,Men,≥,aged
5729,1000 cells,HOSPITALIZATION:4,following
5730,ClinicalTrials.gov,data,processed
5731,ClinicalTrials.gov,data,processed
5732,Transfusion,standard treatment modality,plasmais
5733,Transfusion,standard treatment modality,plasmais
5734,Studies,reduction viralload,reported
5735,Body weight,>50 kg,cut off
5736,Lung,> 50%,infiltrates
5737,ClinicalTrials.gov,data,processed
5738,Disease.the World Health Organization,non - blinded clinical trial,launched
5739,Study,research,advocates
5740,Doxycycline,promising results,showed
5741,Ivermectin,good efficacy,showed
5742,Doxycycline Doxycycline,anti viral role,has
5743,co - principle investigators,computer,managed by
5744,experimental,available standard,receive
5745,ClinicalTrials.gov,data,processed
5746,study site standard aftercare program,education sessions andphysical exercise,includes
5747,"8,5 million populated countries",to23'574,raised
5748,about 13.8% to 35%,severe course,suffering
5749,lung,>50%,infiltrates
5750,patients,oxygen therapy,require
5751,patients,intensive care,require
5752,patients,invasive ornon invasive mechanical ventilation,require
5753,8-week pulmonary rehabilitation program,significantlyexercise capacity,improved
5754,the American Thoracic Society,respiratoryrehabilitation,recommends
5755,Wölfel,virus,isolated
5756,duration,interquartile range,showed
5757,current knowledge,duration,shows
5758,average time,ranged,found
5759,evidence,high risk,points out
5760,patient,signs,reports
5761,ClinicalTrials.gov,data,processed
5762,Patients,4 study visits,attend
5763,ClinicalTrials.gov,data,processed
5764,current pandemic,urgent reorganization,demands
5765,participants,allrecommendations,received
5766,ClinicalTrials.gov,data,processed
5767,ClinicalTrials.gov,data,processed
5768,investigators,biorepository,created
5769,ClinicalTrials.gov,data,processed
5770,common manifestations,fever,included
5771,ClinicalTrials.gov,data,processed
5772,ClinicalTrials.gov,data,processed
5773,Laboratory,COVID-19 infection,confirmed
5774,ClinicalTrials.gov,data,processed
5775,SOC)versus SOC,SARS CoV-2 infection,confirmed
5776,ClinicalTrials.gov,data,processed
5777,ECDC risk factors,elderly people,include
5778,requiredintensive care treatment,high circulating cytokines,In
5779,study,important information,provide
5780,data,important implications,have
5781,ClinicalTrials.gov,data,processed
5782,Patients,single double plasma units,receive
5783,Cedars-Sinai Medical CenterPatients,single double plasma units,receive
5784,ClinicalTrials.gov,data,processed
5785,Data,beneficialrole,showed
5786,ClinicalTrials.gov,data,processed
5787,ClinicalTrials.gov,data,processed
5788,90%,supplemental oxygen tomaintain,requiring
5789,Patient,resuscitate DNR,has
5790,Patient,severe chronic obstructive pulmonary disease,has
5791,Patient,known pregnancy,has
5792,ClinicalTrials.gov,data,processed
5793,ClinicalTrials.gov,patient clinical data,processed
5794,Multiple large series,high rates ofmyocardial injuries,reported
5795,findings,raisedconcerns,have
5796,COVID CMR,120 patients,willinclude
5797,ClinicalTrials.gov,data,processed
5798,ClinicalTrials.gov,data,processed
5799,ClinicalTrials.gov,data,processed
5800,ClinicalTrials.gov,data,processed
5801,patients,abnormally high carbon dioxide,have
5802,patients,carbon dioxide levels,oxygenand
5803,ClinicalTrials.gov,data,processed
5804,ClinicalTrials.gov,data,processed
5805,SARS CoV-2,patients,affects
5806,AECII,thealveolar capillary barrier permeability,regulate
5807,ClinicalTrials.gov,data,processed
5808,ClinicalTrials.gov,data,processed
5809,Signed,informed consentExclusion Criteria:-Contra indication,written
5810,ClinicalTrials.gov,data,processed
5811,Droplets,route,beanother
5812,Researchers,SARS cov-2,detected
5813,One of two studies have reportedSARS-CoV-2 RNA in semen from six infected patients,reportedSARS RNA,have
5814,pandemic,major changes,created
5815,Northwell Health,elective surgeries,postponed
5816,Anotherretrospective non - operative hospital cohort,34 102 adult patients,found
5817,Bariatric Surgical Practice,Apr,published
5818,Patients,< 18 years.2,age
5819,ClinicalTrials.gov,data,processed
5820,patients,casefatality rate,have
5821,definition,therapies,tailorestablished
5822,ATS Insubria archives,missingdata,provides
5823,ClinicalTrials.gov,data,processed
5824,companies,kits,offering
5825,ClinicalTrials.gov,data,processed
5826,Transmission,throughdroplets,occurs
5827,ClinicalTrials.gov,data,processed
5828,Donors,anti - SARS CoV2 antibodies,have
5829,ClinicalTrials.gov,data,processed
5830,group,study drug,receive
5831,group,standard,receive
5832,ClinicalTrials.gov,data,processed
5833,participant,total,receive
5834,HIV positive subjects,regimen,using
5835,ClinicalTrials.gov,data,processed
5836,Quarantining individualswill,standard,have
5837,ClinicalTrials.gov,data,processed
5838,ClinicalTrials.gov,data,processed
5839,SARS CoV-2 pandemic,unprecedented burden,puts
5840,smartwatch,severalphysiological parameters,collects
5841,ClinicalTrials.gov,collected data,processed
5842,tissue,marked shift incellular metabolism,indicated
5843,ClinicalTrials.gov,data,processed
5844,Cardiovascular Renal Biomarkers,Acute Heart or Kidney Injury,Predict
5845,ClinicalTrials.gov,data,processed
5846,investigator led non - commercial non - interventional study,patient,collect
5847,ClinicalTrials.gov,data,processed
5848,a head CT,evidence,demonstrating
5849,ClinicalTrials.gov,data,processed
5850,ClinicalTrials.gov,data,processed
5851,passive antibodytherapy,protection,is
5852,largest,treatment,studyinvolved
5853,ClinicalTrials.gov,data,processed
5854,pandemic,topic,brought
5855,angiotensin,2(ACE2,identified
5856,ClinicalTrials.gov,data,processed
5857,ClinicalTrials.gov,data,processed
5858,ClinicalTrials.gov,data,processed
5859,Bio Rad SARS CoV-2 ddPCR Test,reaction,enables
5860,ClinicalTrials.gov,data,processed
5861,ClinicalTrials.gov,data,processed
5862,DMDs,risk,establish
5863,people,health information,determine
5864,ClinicalTrials.gov,data,processed
5865,false postive serological results,whiledetecting antibodies,shown
5866,theinvestigators,different immunoassays,test
5867,coronaviruses,anucleocapsid,display
5868,ClinicalTrials.gov,data,processed
5869,secondaryendpoints,SARS CoV-2 infections,include
5870,ClinicalTrials.gov,data,processed
5871,coronavirus,extensive neuronal damage,cause
5872,inflammation,risk,increase
5873,ClinicalTrials.gov,data,processed
5874,"2019,a new type",inWuhan,broke out
5875,ClinicalTrials.gov,data,processed
5876,ClinicalTrials.gov,data,processed
5877,ClinicalTrials.gov,data,processed
5878,the Covid-19 Outbreak,daily life,influenced
5879,ClinicalTrials.gov,data,processed
5880,ClinicalTrials.gov,data,processed
5881,Thestudy,randomized wait list control,uses
5882,Studies,physical mental benefits,documented
5883,ClinicalTrials.gov,data,processed
5884,Inclusion Criteria:-couples,cessation,followed up
5885,ClinicalTrials.gov,data,processed
5886,disease,individuals,affected
5887,ClinicalTrials.gov,data,processed
5888,pregnant women,sessions,receive
5889,thosein,intervention,receive
5890,Language,English,communicated
5891,ClinicalTrials.gov,data,processed
5892,data,timing,inform
5893,ClinicalTrials.gov,data,processed
5894,negative result,possibility ofinfection,exclude
5895,Reasons,lack,include
5896,patients,early significant CTchanges,emerged
5897,subject,informedconsent,sign
5898,Cin,way,anonymized
5899,limits,difference,required to
5900,ClinicalTrials.gov,data,processed
5901,Feasibility Study,immediate effects,alsoexplore
5902,Emerging data,high prevalence,shows
5903,Feasibility Study,feasibility,evaluate
5904,investigators,short termeffects,evaluate
5905,ClinicalTrials.gov,data,processed
5906,the Municipal Health Committee,outbreak ofviral pneumonia,identified
5907,CQ diphosphate,mortality,The main hypothesisis
5908,hospital,multiprofessional human resources,trained
5909,440 participants,high dosechloroquine,receive
5910,Male female participants,over 18 years,aged
5911,ClinicalTrials.gov,Clinical laboratory data,processed
5912,Especially mesenchymal stromal cells,Especially mesenchymal stromal cells,haveproven
5913,additional immunosuppressive treatment Patients,contraceptives,use
5914,ClinicalTrials.gov,data,processed
5915,ClinicalTrials.gov,data,processed
5916,studies,impact,described
5917,Primary objective Collect,health centres,atassociated
5918,collected dataset,comprehensive characterization,allow
5919,developed structure,rapid assessment,allow
5920,Patients Case eligibility criteria,individuals,included
5921,data,registry,entered at
5922,outcomes,perinatal neonatal events,include
5923,definitions,international criteria,follow
5924,Age,34,range
5925,HT Pulmonary,Chronic Pulmonary Disease,comorbidities
5926,Asthma Hematologic,Chronic Blood Disease,comorbidities
5927,Objective s,prevalence,Determine
5928,selection,distribution,follow
5929,patient,consent,sign
5930,data,personally identifiable information,contain
5931,ClinicalTrials.gov,data,processed
5932,ClinicalTrials.gov,data,processed
5933,approximately 80%,cell phone,reported
5934,ClinicalTrials.gov,data,processed
5935,ClinicalTrials.gov,data,processed
5936,Acute Respiratory Distress Syndrome,hallmark,reflects
5937,Previous studies,shownthat,have
5938,Blood samples,breath particles,exhaled
5939,ClinicalTrials.gov,data,processed
5940,ClinicalTrials.gov,data,processed
5941,Immune mediated lung injury,pivotal role,plays
5942,Tofacitinib,alveolar inflammation byblocking IL-6 signal,mitigate
5943,Inclusion Criteria:-SARS CoV2 Infection,interstitial pneumonia Hospital admission,confirmed
5944,ClinicalTrials.gov,data,processed
5945,ClinicalTrials.gov,data,processed
5946,Pneumonia,intensive care unit,casesin
5947,ClinicalTrials.gov,Exclusion Criteria:-patients data,processed
5948,Efficacy,the 28 days,assessedduring
5949,ClinicalTrials.gov,data,processed
5950,pandemic,manner,altered
5951,ClinicalTrials.gov,data,processed
5952,Dialysis centers,major organizational challenges,face
5953,ClinicalTrials.gov,data,processed
5954,ClinicalTrials.gov,data,processed
5955,Pneumonia,acute respiratory failure,causing
5956,ClinicalTrials.gov,data,processed
5957,Common effects,nausea,include
5958,ClinicalTrials.gov,data,processed
5959,ClinicalTrials.gov,data,processed
5960,public order,daily structure,Closing ofschools
5961,study,differences insubgroups,evaluates
5962,Children and/or parents,onlinequestionnaires,receive
5963,ClinicalTrials.gov,data,processed
5964,total,students,include
5965,ClinicalTrials.gov,data,processed
5966,ClinicalTrials.gov,data,processed
5967,ClinicalTrials.gov,data,processed
5968,ClinicalTrials.gov,data,processed
5969,preliminary uncontrolled study,effect,evaluated
5970,Incomparison,a positive RT-PCR,had
5971,ClinicalTrials.gov,data,processed
5972,ClinicalTrials.gov,data,processed
5973,participant,total,willreceive
5974,Criteria,1,include
5975,ClinicalTrials.gov,data,processed
5976,patient,series,receive
5977,patient,infusion,receive
5978,ClinicalTrials.gov,data,processed
5979,77.1%,fever,had
5980,study,efficacy,determine
5981,subject,inclusion criteria,fulfill
5982,Fever,≥,documented
5983,Subjects,medical treatment,allowed in
5984,Investigator,patients,exclude
5985,Known hypersensitivity,proteins.4,derived
5986,anti - HIV drugs,target effects,have
5987,ClinicalTrials.gov,data,processed
5988,ClinicalTrials.gov,data,processed
5989,ClinicalTrials.gov,data,processed
5990,ClinicalTrials.gov,data,processed
5991,Bats,typical coronavirus hosts,serveas
5992,ClinicalTrials.gov,data,processed
5993,Participants,POCUS,undergo
5994,ClinicalTrials.gov,data,processed
5995,Theprotocol,rapid test,included
5996,assessment,important rolein,plays
5997,query,assignment,allows
5998,primary goal,preliminary evaluation,provide
5999,Inclusion Criteria:-Employees,voluntary request,described
6000,ClinicalTrials.gov,data,processed
6001,novel coronavirus disease,challenge,posing
6002,Inclusion Criteria:-Patients,Hospital,hospitalized
6003,ClinicalTrials.gov,data,processed
6004,Subjects,dose combination,beassigned
6005,ClinicalTrials.gov,data,processed
6006,ClinicalTrials.gov,data,processed
6007,"Efficacy, Safety",Symptomatic SARS CoV-2 Infection,the Prevention of Incident Confirmed
6008,ClinicalTrials.gov,data,processed
6009,patients,decrease,showed
6010,dose escalation,32healthy volunteers,include
6011,Post- menopause subjects,at least 12 months,had
6012,ClinicalTrials.gov,data,processed
6013,Participants,research assistant questions,ask
6014,WeeklyCOVID-19 informational SMS,moderated discussion focus,inform
6015,WelTel staff hasalready,training,conducted
6016,participants,RANAS informed questionnaire,willcomplete
6017,ClinicalTrials.gov,data,processed
6018,investigators,data,collect
6019,ClinicalTrials.gov,data,processed
6020,recent study,positivity,identified
6021,Motta al,11 cases ofsymptomatic infection,reported
6022,METHODS Serological test,high sensitivity,has
6023,transfusion dependent patients,95 % confidence intervals,respective
6024,ClinicalTrials.gov,data,processed
6025,ClinicalTrials.gov,data,processed
6026,Phase II interventional study,last24 weeks,will
6027,ClinicalTrials.gov,data,processed
6028,ClinicalTrials.gov,data,processed
6029,ClinicalTrials.gov,data,processed
6030,ClinicalTrials.gov,data,processed
6031,Guidelines,controlled oxygen,recommend
6032,Guidelines,controlled oxygen,recommend
6033,ClinicalTrials.gov,data,processed
6034,Patients,BEVA Trial,CORIMUNO-19-
6035,ClinicalTrials.gov,data,processed
6036,andto,early severity factors,identify
6037,ClinicalTrials.gov,data,processed
6038,ClinicalTrials.gov,data,processed
6039,therapy-COVID-19 related Acute Respiratory Distress Syndrome,mechanical ventilationExclusion Criteria:-Pregnant woman Uncontrolled sepsis,requiring
6040,ClinicalTrials.gov,data,processed
6041,Inclusion,Informed Consent,Criteria:-signed
6042,ClinicalTrials.gov,data,processed
6043,-33%,gastrointestinal symptoms,developed
6044,Around 2-33%,gastrointestinal symptoms,developed
6045,ClinicalTrials.gov,data,processed
6046,epidemic,major therapeutic challenge,represents
6047,ClinicalTrials.gov,data,processed
6048,threeparticipants,treatment,received
6049,ClinicalTrials.gov,data,processed
6050,Study,pregnant womencohort,included
6051,Study,39 pregnant women,included
6052,"Inclusion Criteria:-Spontaneous pregnancy,-Singleton",SARS CoV-2 positivity,diagnosed
6053,ClinicalTrials.gov,data,processed
6054,Klinikum Graz,Graz,A-8036
6055,ClinicalTrials.gov,data,processed
6056,ClinicalTrials.gov,data,processed
6057,COVID-19,chronic cardiovascular consequences,determine
6058,COVID-19,chronic cardiovascular consequences,determine
6059,ClinicalTrials.gov,data,processed
6060,patient,60 years of age or older,possess
6061,Patient,colchicine,taking
6062,Patient and/or legal representative,informed consent form,signed
6063,ClinicalTrials.gov,data,processed
6064,Subjects,medications(excluding antiviral drugs,receive
6065,） Male,between 18 and 75,aged
6066,subjects,lung volume reduction surgery,had
6067,whichmay,participation,affect
6068,ClinicalTrials.gov,data,processed
6069,ClinicalTrials.gov,data,processed
6070,sudden onset,5 8 days,maydevelop
6071,thevirus,"3,349,786 patients",infected
6072,ClinicalTrials.gov,data,processed
6073,ng/ml,greater risk,had
6074,Previous data fromthe Hellenic Sepsis Study Group,high prognostic utility ofadmission suPAR,shows
6075,ClinicalTrials.gov,data,processed
6076,infection rate,withchemotherapy,be
6077,ClinicalTrials.gov,data,processed
6078,investigators,data includingdemographics,collect
6079,ClinicalTrials.gov,data,processed
6080,pandemic,unprecedented social economic andmental health challenges,brought about
6081,ClinicalTrials.gov,data,processed
6082,Participants,Follow phase,enter
6083,Children,Follow phase,enter
6084,ClinicalTrials.gov,data,processed
6085,publications,increase,demonstrate
6086,published data,low benefit,suggest
6087,ClinicalTrials.gov,published data,processed
6088,participants,written informed consent,sign
6089,ClinicalTrials.gov,data,processed
6090,ICU COVID-19 patients,high risk,show
6091,Highdoses,high efficacy,shown
6092,Inclusion Criteria:-Patient,written Informed Consent.-Age,provided
6093,ClinicalTrials.gov,data,processed
6094,ClinicalTrials.gov,data,processed
6095,data,significantincrease,shows
6096,lines,inflammatorydrugs,testing
6097,ClinicalTrials.gov,data,processed
6098,Prospective Observational Study,Increased Risk,Evaluating
6099,Theexaminator,filtering face pieces,wear
6100,monitoringperiod,maximum duration,have
6101,Previous clinical picture,positive response,defined
6102,ClinicalTrials.gov,data,processed
6103,ClinicalTrials.gov,data,processed
6104,ClinicalTrials.gov,Routineclinical laboratory data,processed
6105,ClinicalTrials.gov,data,processed
6106,LUS scoring,experienced anaesthesia,performed by
6107,ClinicalTrials.gov,data,processed
6108,ClinicalTrials.gov,data,processed
6109,ClinicalTrials.gov,data,processed
6110,Cohort Study,Tracheostomy,Undergoing
6111,ENT UK,guidance regardingsurgical tracheostomy,issued
6112,COVIDTrach,surgical intensive care,brought
6113,Thiswill,unique comprehensive assessment,provide
6114,Thiswill,foundation,lay
6115,ClinicalTrials.gov,data,processed
6116,Prospective Randomized Double Masked Placebo Controlled Trial,preliminary safetyand efficacy,evaluate
6117,severity,severity,defines
6118,Effective contraception,surgical sterilization,includes
6119,ClinicalTrials.gov,data,processed
6120,The bacillus Calmette Guérin,potential,has
6121,ClinicalTrials.gov,data,processed
6122,ClinicalTrials.gov,data,processed
6123,Rapid dissemination,mitigatemortality,help
6124,points,therationale,provide
6125,points,rationale,provide
6126,ClinicalTrials.gov,data,processed
6127,The WHO,disease,named
6128,patients,nasal congestion,mayexhibit
6129,ClinicalTrials.gov,data,processed
6130,ClinicalTrials.gov,data,processed
6131,Personal behaviours,video cameras,recordedusing
6132,ClinicalTrials.gov,data,processed
6133,Epidemic Response Study,diagnostic reliability,evaluate
6134,ClinicalTrials.gov,data,processed
6135,ClinicalTrials.gov,data,processed
6136,Patient,acute respiratory distress syndrome,have
6137,Patient,life expectancy,have
6138,Patient,platelet count,have
6139,Patient,known hypersensitivity,has
6140,ClinicalTrials.gov,data,processed
6141,ClinicalTrials.gov,data,processed
6142,Assessments,theviral detection,include
6143,Pregnant women,positive,testing
6144,ClinicalTrials.gov,data,processed
6145,Humanity,new pandemic,experiencing
6146,ClinicalTrials.gov,data,processed
6147,ClinicalTrials.gov,data,processed
6148,investigators,occurrence,fear
6149,ClinicalTrials.gov,data,processed
6150,studies,coagulopathy disorders,reportedassociated
6151,Pandemic,impacts,had
6152,Patients,consent,give
6153,Chi Square test,patients,include
6154,Exclusion Criteria:-Patients,consent,excluded
6155,ClinicalTrials.gov,data,processed
6156,ClinicalTrials.gov,data,processed
6157,medical drugs,respiratory,receive
6158,ClinicalTrials.gov,data,processed
6159,current COVID-19 pandemic,biggest medicalchallenge,represents
6160,Blood Pressure Endothelium Interaction Study,contact,suspected
6161,PCR,Blood Pressure Endothelium Interaction Study,suspected
6162,ClinicalTrials.gov,data,processed
6163,ClinicalTrials.gov,data,processed
6164,ClinicalTrials.gov,data,processed
6165,ClinicalTrials.gov,data,processed
6166,patient,hospitalization,require
6167,ClinicalTrials.gov,data,processed
6168,The QPlus Cartridge,measurehypocoagulable hypercoagulable conditions,can
6169,ClinicalTrials.gov,data,processed
6170,ClinicalTrials.gov,data,processed
6171,Recent publications,attention,drawn
6172,eight had symptoms of lowerrespiratory tract infection,symptoms,were
6173,interim,use,approved
6174,ClinicalTrials.gov,data,processed
6175,Sub pleural bilateral ground glasspattern,positivity,precede
6176,Previous studies,Previous studies interest,suggest
6177,Adults patients,emergency department,consulting
6178,ClinicalTrials.gov,data,processed
6179,interruption,organization,required
6180,ClinicalTrials.gov,data,processed
6181,patient,approved standard,get
6182,ClinicalTrials.gov,data,processed
6183,patients,treatment,willcomplete
6184,QT,480 msec,prolongation
6185,ClinicalTrials.gov,data,processed
6186,isan,risk,is
6187,healthy people,severe disease fromthe SARS CoV-2 infection,developed
6188,ClinicalTrials.gov,data,processed
6189,participantswill,questionnaire,submit
6190,ClinicalTrials.gov,data,processed
6191,patients,favorable survival outcome,had
6192,ClinicalTrials.gov,data,processed
6193,viral pneumonia,inWuhan,broke out
6194,2019,new coronavirus,is
6195,COVID-19,threat,pose
6196,Subject,total 5x10 ^ 6 cells,receive
6197,Inclusion Criteria:-Laboratory,Covid-19 infection,confirmed
6198,ClinicalTrials.gov,data,processed
6199,severe acute respiratory syndrome,worldwide pandemic,beendeclared
6200,ClinicalTrials.gov,data,processed
6201,Postmortemassessment,pathologic findings consistent withMAS,demonstrated
6202,preliminary data,immunologic link,suggest
6203,Subjects,NYHA Class III IV heart failure,excluded
6204,ClinicalTrials.gov,data,processed
6205,laboratory,Sars Cov-2 cases,confirmed
6206,ClinicalTrials.gov,data,processed
6207,ClinicalTrials.gov,data,processed
6208,single site observational prospective cohort study,safety,assess
6209,Bleeding disorder,contraindication,considered
6210,ClinicalTrials.gov,data,processed
6211,interventional clinical study,400 Adult,includes
6212,ClinicalTrials.gov,data,processed
6213,Purpose,18 and above,volunteersaged
6214,ClinicalTrials.gov,data,processed
6215,Males,≥18,aged
6216,subject,contraindications,postponed for
6217,ClinicalTrials.gov,data,processed
6218,COVID-19,healthcare system,affected
6219,affected people,dry cough,experience
6220,Adults,65 years old.9,aged
6221,ClinicalTrials.gov,data,processed
6222,ClinicalTrials.gov,data,processed
6223,pro - apoptotic caspasesand,PARP-1,estimated by
6224,LC,protective agent,serveas
6225,ClinicalTrials.gov,data,processed
6226,Patients,therapy,received
6227,Patients,therapy,received
6228,Clinical assessments,categoryordinal scale,included
6229,Secondary endpoints,change,comprised
6230,ClinicalTrials.gov,data,processed
6231,Study,pMDI,Delivered
6232,ClinicalTrials.gov,data,processed
6233,Novel Coronavirus,Severe Pneumonia,Induced
6234,Evaluation,severe pneumonia,induced
6235,Known,persons;-4,infected
6236,ClinicalTrials.gov,data,processed
6237,ClinicalTrials.gov,data,processed
6238,Biophytis,BIO101,developing
6239,BIO101,MasR,activates
6240,medically acceptable methods,combined oral contraceptive,Note
6241,ClinicalTrials.gov,data,processed
6242,ClinicalTrials.gov,data,processed
6243,Patients,14,block
6244,ClinicalTrials.gov,data,processed
6245,significant gap,inour knowledge,exists
6246,ClinicalTrials.gov,data,processed
6247,X-Ray,limitations,has
6248,betterimpedance values,improvement,indicate
6249,patient,examination,undergo
6250,ClinicalTrials.gov,data,processed
6251,study,efficacy,compare
6252,around 5%,withextremely forms,evolve
6253,ClinicalTrials.gov,data,processed
6254,ClinicalTrials.gov,data,processed
6255,respiratory rate ≥22 breaths/min).Randomization:-Within 24 hours,SARS CoV-2 infection.-In case,confirmed
6256,ClinicalTrials.gov,data,processed
6257,andto,change,understand
6258,patients,positive airway pressure)5,continue
6259,ClinicalTrials.gov,data,processed
6260,TIMP-2)*(IGFBP7,occurrence,is
6261,ClinicalTrials.gov,data,processed
6262,theinvestigators,understanding,have
6263,investigators,20 subjectsthough The Cleveland Clinic,recruit
6264,Theinvestigators,data,compare
6265,investigators,tomonitor heart rate,measured with
6266,investigatorswill,stage,monitor
6267,ClinicalTrials.gov,data,processed
6268,ClinicalTrials.gov,data,processed
6269,cluster,fromWuhan,diagnosed across
6270,Arduino PG et al,substantial delay,reported
6271,coexistence,incidence oftreatment complications,increase
6272,sample size,confidence interval,produce
6273,ClinicalTrials.gov,data,processed
6274,ClinicalTrials.gov,data,processed
6275,Inclusion Criteria:-Written informed consent Healthy male female adults,18 55 years-,aged
6276,ClinicalTrials.gov,data,processed
6277,subject,body mass index,have
6278,ClinicalTrials.gov,data,processed
6279,Steroids,potent anti - inflammatory activity,exert
6280,Patients,unfractionated heparin,receive
6281,patients,rescue administration ofhigh- dose steroids immune modulatory drugs,receive
6282,Theinvestigators,purpose,explain
6283,PCR,upper limit,fold
6284,ClinicalTrials.gov,data,processed
6285,Studies,support,provide
6286,ClinicalTrials.gov,data,processed
6287,periodic inhaling ofwater,severity,received from
6288,pathway,anon immunological defense mechanism,provide
6289,ClinicalTrials.gov,data,processed
6290,ClinicalTrials.gov,data,processed
6291,ClinicalTrials.gov,data,processed
6292,group,standard treatment,willget
6293,secondgroup,standard treatment,get
6294,Subject,informed consent,provides
6295,ClinicalTrials.gov,data,processed
6296,ClinicalTrials.gov,data,processed
6297,countries,guidelines,followed
6298,ClinicalTrials.gov,data,processed
6299,ClinicalTrials.gov,data,processed
6300,study team,study materials,willsend
6301,Participantswill,100 mg,take
6302,thatwill,up to 15 days,last
6303,ClinicalTrials.gov,data,processed
6304,phase,theapproval,received
6305,theinvestigating clinician,report,draw up
6306,ClinicalTrials.gov,data,processed
6307,Conventional 1H CMR evaluations,T2 maps,include
6308,ClinicalTrials.gov,data,processed
6309,ClinicalTrials.gov,data,processed
6310,ClinicalTrials.gov,data,processed
6311,daily use,level,Assess
6312,daily use,inflammatory parameters,Assess
6313,daily use,depression,Assess
6314,Signature,ICF,approved
6315,ClinicalTrials.gov,data,processed
6316,Montpellier CHU,peak hospitalizations,experienced
6317,barrier measures,adaptation,include
6318,ClinicalTrials.gov,data,processed
6319,ClinicalTrials.gov,data,processed
6320,ClinicalTrials.gov,data,processed
6321,Plexus Corporation,data monitoring,hold
6322,ClinicalTrials.gov,data,processed
6323,Theregistry,consecutive patients,enrolls
6324,Thestudy,new diagnostic therapeutic approach,test
6325,ClinicalTrials.gov,data,processed
6326,Investigators,thegastrointestinal function,evaluate
6327,ClinicalTrials.gov,data,processed
6328,ClinicalTrials.gov,data,processed
6329,ClinicalTrials.gov,data,processed
6330,Serological tests,immune response,detect
6331,called neutralizing antibodies,suchprotection,obtain
6332,data,protective immunity,are
6333,specific treatment,specific treatment,demonstrated
6334,ClinicalTrials.gov,data,processed
6335,ClinicalTrials.gov,data,processed
6336,ClinicalTrials.gov,data,processed
6337,Respiratory infection,mechanical ventilation,require
6338,ClinicalTrials.gov,data,processed
6339,the LPSARS2 Study,testing,Study of
6340,consent process,reason,cover
6341,questionnaire,details,alsorecord
6342,Future studies,testing,involvegenetic
6343,population,frontline healthcare workers,comprise
6344,Seropositive Cases:-Healthcare worker,detectable antibodies,confirmed
6345,Core Group,symptoms,have
6346,Core Comparison Group,clinical symptoms,had
6347,New persistent cough,temperatures,Confirmed
6348,ClinicalTrials.gov,data,processed
6349,Disease,SARS CoV-2,causedby
6350,urban residents,new coronavirus infection,confirmed
6351,ClinicalTrials.gov,data,processed
6352,total enrollment,dramatic effect,had
6353,ClinicalTrials.gov,data,processed
6354,cytokine storm,strongest mechanism,bethe
6355,the World Health Organization,new coronavirus,declared
6356,itproduces,mortality,seems to
6357,high cut semipermeable membranes,bynon selective adsorbent membranes,followed
6358,membranesappear,severity scores,There
6359,Patients,≥ 18 years old.2,aged
6360,ClinicalTrials.gov,data,processed
6361,pandemic,million people,affects
6362,authors,significantproportion,suggested
6363,Patients,encephalopathy,present
6364,infection withSARS CoV-2,encephalitis,cause
6365,cases,nervous system viasystemic circulation,reach
6366,Systemic inflammation,ischemic stroke,alsopromote
6367,Patients,severe forms,develop
6368,Patients withneurodegenerative pathologies,elderly population,represent
6369,SARS CoV-2 infection,certain psychiatric pathologies,worsen
6370,better understanding,management,improve
6371,Knowledge,follow,allowadapting
6372,ClinicalTrials.gov,epidemic area,processed
6373,epidemic,France,affected
6374,mixed investigation unit,chain ofnasopharyngeal swabs,set up
6375,COVID-19 case reporting unit,rapid identification,carried out
6376,ClinicalTrials.gov,data,processed
6377,ClinicalTrials.gov,data,processed
6378,study,burden,identify
6379,follow questionnaire,evolution,evaluate
6380,ClinicalTrials.gov,data,processed
6381,Inclusion,patients,Criteria:-hospitalized
6382,ClinicalTrials.gov,data,processed
6383,treatment,progression,determine
6384,Patients,placebo PO BID,receive
6385,ClinicalTrials.gov,data,processed
6386,ClinicalTrials.gov,data,processed
6387,duration,60 minutes,tailored to
6388,Theseverity,severity,defines
6389,ClinicalTrials.gov,data,processed
6390,trial,Phase,movedfrom
6391,ClinicalTrials.gov,data,processed
6392,ClinicalTrials.gov,data,processed
6393,Performance Status Subject,prior systemic anti - viral treatment,received
6394,ClinicalTrials.gov,data,processed
6395,study population,primary secondary school children,includes
6396,sample size calculation,inclusion,indicated
6397,study population,primary secondary school children,includes
6398,ClinicalTrials.gov,Study data,processed
6399,serologicaltesting visits,testing,involve in
6400,Participants,short follow surveys,fill out
6401,ClinicalTrials.gov,data,processed
6402,Coronaviruses,enteric respiratory diseases,cause
6403,Most human CoVs,mild respiratory disease,cause
6404,Severe Acute Respiratory Syndrome,lethal potential,proven
6405,Epidemiological data,median time,showing
6406,Dexmedetomidine,neuroprotective effects,has
6407,ClinicalTrials.gov,data,processed
6408,ClinicalTrials.gov,data,processed
6409,Investigators,patients,recruit
6410,ClinicalTrials.gov,data,processed
6411,recent evidence,acute andlong term neurological manifestations,highlights
6412,reports,far lack detailed information,publishedthus
6413,Infants,< 18 years,age
6414,ClinicalTrials.gov,data,processed
6415,ULN,1000ng mL.3,ferritin
6416,ClinicalTrials.gov,data,processed
6417,pandemic,the UK,ceasedin
6418,main outcomes,changes,tracking
6419,surveys,approximately 10 minutes,take
6420,main outcomes,changes,tracking
6421,ClinicalTrials.gov,data,processed
6422,Ultrasound,morphologic changes,detect
6423,ClinicalTrials.gov,data,processed
6424,ClinicalTrials.gov,data,processed
6425,antibody surveys,range,report
6426,blood,consent,given
6427,ClinicalTrials.gov,data,processed
6428,ClinicalTrials.gov,data,processed
6429,phenytoin).-Any investigational therapy,systemic exposure,increase
6430,investigator,reason,record
6431,ClinicalTrials.gov,data,processed
6432,ClinicalTrials.gov,data,processed
6433,ClinicalTrials.gov,primary data collection,processed
6434,Patients,standard,receive
6435,Reason,date,start
6436,ClinicalTrials.gov,data,processed
6437,Justification,Background,plan
6438,Thales,world leading capability inthe design,built up
6439,SARS COV-2,huge challenge,placed
6440,research,voids,fill
6441,ClinicalTrials.gov,data,processed
6442,nicotine,penetration,Based on
6443,Obtain,informed consent,written
6444,ClinicalTrials.gov,data,processed
6445,COVID-,low prevalence inocular fluids,has
6446,positive,consent,given
6447,ClinicalTrials.gov,data,processed
6448,role,andseverity,diameters
6449,RT PCR test,limited sensitivity,has
6450,ClinicalTrials.gov,data,processed
6451,Participants,survey,complete
6452,Theinvestigators,blood,collect
6453,ClinicalTrials.gov,data,processed
6454,ClinicalTrials.gov,data,processed
6455,SARS CoV-2 cases,"1,521,252",reached
6456,evolution,common characteristics,Itis
6457,study population,adults,comprise
6458,ClinicalTrials.gov,data,processed
6459,ClinicalTrials.gov,data,processed
6460,cancer treatment,distribution,Patients with
6461,ClinicalTrials.gov,data,processed
6462,ClinicalTrials.gov,data,processed
6463,ClinicalTrials.gov,data,processed
6464,ClinicalTrials.gov,data,processed
6465,ClinicalTrials.gov,data,processed
6466,ClinicalTrials.gov,data,processed
6467,patients,symptoms,defined
6468,ClinicalTrials.gov,data,processed
6469,asymptomatic family close contact,prophylacticivermectin,receive
6470,ClinicalTrials.gov,data,processed
6471,ClinicalTrials.gov,data,processed
6472,Data collection,place,takes
6473,ClinicalTrials.gov,data,processed
6474,SARS COV2 Virus,major impact,had
6475,Researchers,tolearn,want
6476,Researchers,sampling,use at
6477,RDCRN,CCHMC participants,tell
6478,a home kit,gauze,contains
6479,Participants,2020 0299 Impact,protocol
6480,ClinicalTrials.gov,data,processed
6481,ClinicalTrials.gov,data,processed
6482,Patients,6 mg Artemisinin,receive
6483,active agents,prominent anti - oxidant anti - inflammatory aswell,have in
6484,ArtemiC,current status,has
6485,Patients,"up to 12 mg Artemisinin,40 mg Curcumin",receive
6486,ClinicalTrials.gov,data,processed
6487,ClinicalTrials.gov,data,processed
6488,ClinicalTrials.gov,data,processed
6489,Severe acute respiratory coronavirus 2 syndrome,pandemic,causing
6490,ClinicalTrials.gov,data,processed
6491,ClinicalTrials.gov,data,processed
6492,ClinicalTrials.gov,data,processed
6493,studies,efficacy,shown
6494,Vitamin C,expression,blocks
6495,uncontrolled longitudinal study,allpatients,include
6496,ClinicalTrials.gov,data,processed
6497,riboside1.3 Rationale NAD+,circadian rhythm,is
6498,Previous work,efficacious increase,shown
6499,ClinicalTrials.gov,data,processed
6500,data,correlation,releasedshowing
6501,ClinicalTrials.gov,data,processed
6502,Immune suppression,patients,help
6503,ClinicalTrials.gov,data,processed
6504,Individuals,≥ 18 years;Exclusion Inclusion Criteria:-1,aged
6505,ClinicalTrials.gov,data,processed
6506,willbe,4 and 8 weeks,Follow-up visit or phone calls
6507,Patients,continous positive airwaypressure,given
6508,ClinicalTrials.gov,data,processed
6509,ClinicalTrials.gov,data,processed
6510,evaluation procedure,symptom monitoring,includes
6511,COVID-19 infection,patients,admitted
6512,ClinicalTrials.gov,data,processed
6513,COVID-19,complications,causes
6514,ClinicalTrials.gov,data,processed
6515,study,four,includes
6516,aimsthat,effects,probe
6517,ClinicalTrials.gov,data,processed
6518,study investigators,information,collect
6519,ClinicalTrials.gov,data,processed
6520,subjects,following assessmentsat diagnosis,undergo
6521,ClinicalTrials.gov,data,processed
6522,existing prognostic scores,disappointing results,yielded
6523,participant,study,enter
6524,participant,study,enter
6525,ClinicalTrials.gov,data,processed
6526,introduction,attenuated vaccine,reported
6527,BCG,incidence,vaccinereduces
6528,the BCGvaccine,production,increases
6529,vaccine,treatment,administrated
6530,ClinicalTrials.gov,data,processed
6531,The HCP,patient,recommend
6532,ClinicalTrials.gov,data,processed
6533,ClinicalTrials.gov,data,processed
6534,Patients,over17 yearsExclusion Criteria:-Previous enrolment,aged
6535,ClinicalTrials.gov,data,processed
6536,Prospective Observational Autopsy Study,safety andtolerability,evaluate in
6537,nasal swabs,low toxicity,have
6538,Subjects,nasal swabs,apply
6539,testing,thyroid stimulating hormone,include
6540,research related phlebotomy,place,take
6541,ClinicalTrials.gov,data,processed
6542,Female subjects,urine pregnancy test,undergo
6543,Subjects,tests,undergo
6544,subjects,standard,receive
6545,Subjects,tests,undergo
6546,subject,following criteria,satisfy
6547,ClinicalTrials.gov,data,processed
6548,diabetes,specific email,thenreceive
6549,investigators,thismethod,used
6550,investigatorswill,PHQ-9 scale,use
6551,investigators,the Short Mood and FeelingsQuestionnaire,use
6552,Theinvestigators,methodology,used
6553,investigators,demographic information,Analysis
6554,means,deviations,reported
6555,ClinicalTrials.gov,data,processed
6556,Subjects,accordance,assessedin
6557,CT severity scores,patients,determine
6558,ClinicalTrials.gov,data,processed
6559,Elderly patients,worse prognosis,have
6560,ClinicalTrials.gov,data,processed
6561,ClinicalTrials.gov,data,processed
6562,ClinicalTrials.gov,data,processed
6563,ClinicalTrials.gov,data,processed
6564,COVID-19 pandemic,profound impact,having
6565,Criteria:-Working,invited pulmonology units,units
6566,ClinicalTrials.gov,data,processed
6567,ASST,1433 COVID+ patients,treated
6568,study protocol,important aspects,presents
6569,ClinicalTrials.gov,data,processed
6570,examination,only a few minutes,takes
6571,ClinicalTrials.gov,data,processed
6572,SafeBoosC IIIrandomised clinical trial,benefit harms oftreatment,investigates
6573,ClinicalTrials.gov,data,processed
6574,neuromuscular electrical stimulation,anterior muscles,programconsisted of
6575,physiatrists,thepatients,evaluated
6576,ClinicalTrials.gov,data,processed
6577,130subjects,46~59 years,130subjects
6578,Immunosuppressive therapy,corticosteroids,inhaled
6579,ClinicalTrials.gov,data,processed
6580,Present study,efficacy,examined
6581,ClinicalTrials.gov,data,processed
6582,Fluoxetine,extraordinarilystrong evidence,has
6583,ClinicalTrials.gov,data,processed
6584,Female subjects,negative pregnancy test,have
6585,ClinicalTrials.gov,data,processed
6586,ClinicalTrials.gov,data,processed
6587,lymphocyte,0.3 109 L,count
6588,Plasma,300 or as per clinical judgment,glucose
6589,ClinicalTrials.gov,data,processed
6590,ClinicalTrials.gov,data,processed
6591,Ravulizumab,immediate sustained inhibition,causes
6592,TMAand,overall survival,improve
6593,Participant,an unresolved Neisseria Meningitides infection.3,has
6594,ClinicalTrials.gov,data,processed
6595,ClinicalTrials.gov,data,processed
6596,lack,mediumand long term consequences,have
6597,ClinicalTrials.gov,data,processed
6598,Healthcare providers,following,include
6599,ClinicalTrials.gov,data,processed
6600,patients,criteriawill,asked to
6601,ClinicalTrials.gov,data,processed
6602,comorbidities,priority intensive care,linked to
6603,ClinicalTrials.gov,data,processed
6604,outbreak,daily activities,impacted
6605,endoscopy staff,personal protective equipment,use
6606,ClinicalTrials.gov,data,processed
6607,Interferon lambda,betterside effect profile,has
6608,Random blood,20 mmol L. Eligible,glucose
6609,ClinicalTrials.gov,data,processed
6610,Therenin aldosterone angiostensin system,role,play
6611,ClinicalTrials.gov,data,processed
6612,studies,theefficacy,demonstrated
6613,ClinicalTrials.gov,data,processed
6614,ClinicalTrials.gov,data,processed
6615,participants,tobreathe,had
6616,ClinicalTrials.gov,data,processed
6617,exclusion criteria,anaphylactic reaction,apply
6618,ClinicalTrials.gov,data,processed
6619,IVIG,positive effect onsurvival rates,has
6620,patient,informed consent,sign
6621,Patients,high dose therapy,receive
6622,Patients,therapy,receive
6623,rate,recommended increase,increased
6624,ClinicalTrials.gov,data,processed
6625,Patients,intervention.4,undergoes
6626,combination,higher rate,have
6627,ClinicalTrials.gov,data,processed
6628,CorONa Virus edoxabaN ColchicinE,SARS CoV-2 clearance,accelerate
6629,Patients,SARS CoV-2 infection,confirmed
6630,ClinicalTrials.gov,data,processed
6631,ClinicalTrials.gov,data,processed
6632,ClinicalTrials.gov,data,processed
6633,ClinicalTrials.gov,data,processed
6634,ClinicalTrials.gov,data,processed
6635,Related Infections,Risk,Increased
6636,Patient,life expectancy,have
6637,investigator Patient,ECOG Performance Status,have
6638,ClinicalTrials.gov,data,processed
6639,Egyptian population,track,keeping
6640,ClinicalTrials.gov,data,processed
6641,COVID-19,worse clinical outcome,experience
6642,vitD supplementation,overall clinical outcome,alsoimprove
6643,objective,thesignificant health disparity,address
6644,ClinicalTrials.gov,data,processed
6645,Exploratory endpoints,effectsof dornase,explore
6646,COVID-19.By,clearance,administered in
6647,Male female participants,≥ 18 years.2,aged
6648,ClinicalTrials.gov,data,processed
6649,ClinicalTrials.gov,data,processed
6650,ClinicalTrials.gov,data,processed
6651,Serological studies,answers,provide
6652,ClinicalTrials.gov,data,processed
6653,smokers,asignificantly higher percentage,shows
6654,cigarette smoke,inflammatory eosinophilia,attenuates
6655,Changes,interstitial injury patterns,triggers
6656,Uncontrolled eosinophil production,critical role,plays
6657,participants,population,comprise
6658,ClinicalTrials.gov,data,processed
6659,Eligible subjects,informed consent,provide
6660,eligible enrollees,convalescent CoVID-19 plasma,willreceive
6661,ClinicalTrials.gov,data,processed
6662,Description of Ophthalmologic Injuries in Intensive Care,SARS CoV2 Epidemic COVID19,Care
6663,ClinicalTrials.gov,data,processed
6664,ClinicalTrials.gov,data,processed
6665,ClinicalTrials.gov,data,processed
6666,Statistical tests,significance level,usedconsidering
6667,ClinicalTrials.gov,data,processed
6668,ARM,effect,evaluating
6669,ARM,effect,evaluating
6670,ARM,effect,evaluating
6671,research,insight,hoped
6672,Current,cancer related treatment,received
6673,15 minutes,exposure,exposed to
6674,ClinicalTrials.gov,data,processed
6675,Safety and Efficacy of CAStem for Severe COVID-19 Study of Human Embryonic Stem Cells,M Cells,Derived
6676,ill patients,one of the,meet
6677,Childs Pugh,12).5,scores
6678,ClinicalTrials.gov,data,processed
6679,assay,tomography,computed
6680,ClinicalTrials.gov,data,processed
6681,primaryprophylaxis,symptomatic COVID-19infection,"This a double-blind, randomized, placebo-controlled clinical trial to"
6682,study,"1,700 participates inLafayette",enroll up
6683,primary outcome,number,will
6684,Unable,informed consent form,sign
6685,ClinicalTrials.gov,data,processed
6686,OT,excellent therapeutic index,exhibits
6687,patients,OT,receiveintravenous
6688,ClinicalTrials.gov,data,processed
6689,Passive Immunity Trial,COVID-19,Treat
6690,Research personnel,patients,completed by
6691,ClinicalTrials.gov,data,processed
6692,institution,de - identified data,collect
6693,ClinicalTrials.gov,data,processed
6694,Patients,over 18 years,aged
6695,ClinicalTrials.gov,data,processed
6696,ClinicalTrials.gov,data,processed
6697,ClinicalTrials.gov,data,processed
6698,ClinicalTrials.gov,Inclusion,processed
6699,fever,final outcome,measured by
6700,fever,final outcome,measured by
6701,six weeks,patient,contact
6702,Sealed Envelope,patient numbers,generate
6703,Descriptive frequency,table,follow up
6704,ClinicalTrials.gov,data,processed
6705,ClinicalTrials.gov,data,processed
6706,thetranslation,covid-19 infection,is
6707,Theinvestigator,written informed consent,obtain
6708,ClinicalTrials.gov,data,processed
6709,COVID-19 pandemic,threat,represents
6710,ClinicalTrials.gov,data,processed
6711,ClinicalTrials.gov,data,processed
6712,Pilot Study,efficay,investigates
6713,investigatorswill,randomized double blind controlled Trial,undertake
6714,Gautret study,limitations,has
6715,ClinicalTrials.gov,data,processed
6716,Wewill,brainstem disruption,explore
6717,ClinicalTrials.gov,data,processed
6718,Phase,™,Covax-19
6719,Ability,written informed consent.6,give
6720,ClinicalTrials.gov,data,processed
6721,the Dutch Society of Radiology,standardized assessment scheme,developed
6722,system,level,proposes
6723,the Dutch Society of Radiology,standardized assessment scheme,developed
6724,system,level,proposes
6725,national early warning scale,low risk,grants
6726,qCSI,risk,predicts
6727,conditions,therisks,known
6728,method,calculation,approaches
6729,ClinicalTrials.gov,data,processed
6730,ClinicalTrials.gov,data,processed
6731,suggeststhat cod liver oil,COVID-19,prevent
6732,ClinicalTrials.gov,data,processed
6733,Patients,study agent,receive
6734,patients,standard,receive
6735,ClinicalTrials.gov,data,processed
6736,ClinicalTrials.gov,Tertiary center data,processed
6737,CoV-2)that,Coronavirus Disease 2019,causes
6738,toovercome immune response,degree,determines
6739,decreasing number ofanti inflammatory cytokines,finding,supports
6740,Previous studies,immunomodulating,shown
6741,ClinicalTrials.gov,data,processed
6742,participants whoexperience disease progression,data,defined
6743,Participants,visits,complete
6744,Sites,results,have
6745,ClinicalTrials.gov,data,processed
6746,ClinicalTrials.gov,data,processed
6747,ClinicalTrials.gov,data,processed
6748,ClinicalTrials.gov,data,processed
6749,Allpatients,initial chest CT scan,had
6750,Group,initial chestCT scan,had
6751,chest CT scan,ground glass opacities,presented
6752,ClinicalTrials.gov,data,processed
6753,ClinicalTrials.gov,data,processed
6754,COVID-19 viral pandemic,significant global losses,caused
6755,Covid-19 viral pandemic,significant global losses,caused
6756,Similar testing allowance,inScotland,follow
6757,ClinicalTrials.gov,data,processed
6758,previous experiment,safety,showed
6759,trial,60patients,recruit
6760,patients,conventional therapy,receive
6761,Patients,doses,receive
6762,Patients,doses,receive
6763,ClinicalTrials.gov,data,processed
6764,ClinicalTrials.gov,data,processed
6765,ClinicalTrials.gov,data,processed
6766,Prospective Observational Cohort Study,data,collect
6767,ClinicalTrials.gov,data,processed
6768,patients,SARS Cov-2 infection,confirmed
6769,ClinicalTrials.gov,data,processed
6770,ClinicalTrials.gov,data,processed
6771,Inclusion Criteria:-Age,documented positive test,hospitalized within
6772,ClinicalTrials.gov,data,processed
6773,ClinicalTrials.gov,data,processed
6774,"3,95,048",cases,were
6775,India,large numberof persons,has
6776,Recent studies,risingprevalence,reported
6777,incidence,increasing trend,shows
6778,12%,diabetes,haddiabetes
6779,statistician,access,anonymised
6780,ClinicalTrials.gov,data,processed
6781,ClinicalTrials.gov,data,processed
6782,Naive individuals,baseline blood sample,contribute
6783,subjects,baseline online personal health,complete
6784,subjects,brief online symptom survey,complete
6785,ClinicalTrials.gov,data,processed
6786,ClinicalTrials.gov,data,processed
6787,product,duringmeasurement,calculated
6788,Paradoxical septummotion,RV performance,assesses
6789,Patients,mechanical ventilation,requiringinvasive
6790,ClinicalTrials.gov,data,processed
6791,ClinicalTrials.gov,data,processed
6792,infection,excessive host immune response,cause
6793,ClinicalTrials.gov,data,processed
6794,scientific publications,potential contaminations,described
6795,SARS CoV-2,evolution,study
6796,investigations,-T B NK lymphocytes subpopulation,include
6797,HLA DR subpopulation,byflow cytometry,studied
6798,study,notably measurement,ant
6799,immunity investigation,identification,enable
6800,A.An optional visit,place,take
6801,ClinicalTrials.gov,data,processed
6802,trial,phases,has
6803,aftereach group,TSC,receive
6804,participants,the initial 5 days,continue at
6805,Participants,injection injection site,see
6806,participants,blood,undergo
6807,ClinicalTrials.gov,data,processed
6808,et al   ,decreased morbidity mortality rates,reported
6809,patients,ofacute cholecystitis,Study population
6810,Patients,18 yo,aged
6811,investigators,epidemiological clinical surgical data,willdifferentiate
6812,surgeons,patients recruitment,included in
6813,patients,ofacute cholecystitis,admitted to
6814,ClinicalTrials.gov,data,processed
6815,subject,body mass index,have
6816,ClinicalTrials.gov,data,processed
6817,ClinicalTrials.gov,data,processed
6818,ClinicalTrials.gov,data,processed
6819,Prior diagnosis,physician guidance documents,consult
6820,ClinicalTrials.gov,data,processed
6821,Investigators,animprovement,anticipate
6822,Iloprost,safe profile,showed
6823,ClinicalTrials.gov,data,processed
6824,young doctors,structured questionnaire,fulfilled
6825,ClinicalTrials.gov,data,processed
6826,adjunct immunemodulation therapies,outcomes,improve
6827,LOVIT COVID,rigorous assessments,constitute
6828,ClinicalTrials.gov,data,processed
6829,Best supportive care,ofmedical treatment,consist
6830,Patient,an unresolved Neisseria meningitidis infection5,has
6831,ClinicalTrials.gov,data,processed
6832,ClinicalTrials.gov,data,processed
6833,ClinicalTrials.gov,data,processed
6834,ClinicalTrials.gov,data,processed
6835,Subjects,SOC treatment,undergo
6836,ClinicalTrials.gov,data,processed
6837,patients,sequelae,have
6838,ClinicalTrials.gov,data,processed
6839,ClinicalTrials.gov,Anamnestic data data,processed
6840,patient,investigator opinion,Any reason
6841,ClinicalTrials.gov,data,processed
6842,mediators,protective role,hypothesized
6843,Inclusion Criteria:-Patient,over 18 years,aged
6844,ClinicalTrials.gov,data,processed
6845,deep learning segmentation algorithm,lung parenchyma,expressed
6846,ClinicalTrials.gov,data,processed
6847,ClinicalTrials.gov,lack ofsufficient data,processed
6848,patients,peripheral blood samplesat time,provide
6849,ClinicalTrials.gov,data,processed
6850,Study,total,randomize
6851,ofCOVID-19 infection,blood specimen,have
6852,Participants,monitoring,receive
6853,Participant,known allergies,has
6854,Participant,family history,has
6855,Participant,history,has
6856,ClinicalTrials.gov,data,processed
6857,COVID-19,big impact,has
6858,patients,inpatient rehabilitation,receive
6859,Switzerland,Switzerland,finds
6860,The Federal Council,series,hasissued
6861,outpatient rehabilitation clinics,reducedthe interventions,have
6862,ClinicalTrials.gov,data,processed
6863,ClinicalTrials.gov,data,processed
6864,ClinicalTrials.gov,data,processed
6865,viral gene sequencing,high homology,showed
6866,ClinicalTrials.gov,data,processed
6867,Male female subjects,≥18 years of age2,aged
6868,Patients,droxidopa7,taking
6869,ClinicalTrials.gov,data,processed
6870,Observational Study of the Use of Siltuximab,data,collect
6871,ClinicalTrials.gov,data,processed
6872,severe manifestations,respiratory failure,include
6873,ClinicalTrials.gov,data,processed
6874,Women,highly effective method,using
6875,Body weight,kg.6,≥45
6876,PCR and/or serology,SARS Cov-2 infection,confirmed
6877,Investigator,determination,make
6878,ClinicalTrials.gov,data,processed
6879,ClinicalTrials.gov,data,processed
6880,Long term Evolution,study,Follow
6881,Impact and Predictors of Possible Lasting Damage:,study,Follow
6882,studies,problem,addressed
6883,frequencies,percentages,expressed
6884,Inclusion,respiratory failure,Criteria:-acute
6885,ClinicalTrials.gov,data,processed
6886,previous work,antimalarial,indicated
6887,ClinicalTrials.gov,Data,processed
6888,ClinicalTrials.gov,data,processed
6889,ClinicalTrials.gov,data,processed
6890,ClinicalTrials.gov,data,processed
6891,LB1148,7.5 g tranexamic acid,contains
6892,placebo,PEG,contains
6893,Patient,radiographic evidence,has
6894,Patients,orders.4,intubate
6895,ClinicalTrials.gov,data,processed
6896,ClinicalTrials.gov,data,processed
6897,ClinicalTrials.gov,data,processed
6898,ClinicalTrials.gov,data,processed
6899,studies,high prevalence,reported
6900,ClinicalTrials.gov,data,processed
6901,Therapeutic Plasma Exchange,Role,Have
6902,the World Health Organization,coronavirus disease,declared
6903,deaths,"450,686 with a morality of 5.37%",confirmed in
6904,Egypt,"50,437confirmed cases",has
6905,Main symptoms,fever,include
6906,Common laboratory findings,lymphopenia,include
6907,Chest computedtomographic scans,typical pattern,show
6908,Options,immunomodulators,include
6909,Persistent worsening,oxygen O2 requirements,increased
6910,ClinicalTrials.gov,data,processed
6911,Control group:196 patients,8/8 hours,placebo
6912,196 patients,nitazoxanide 500mg 8 / 8 hours,received
6913,196 patients,placebo,received
6914,ClinicalTrials.gov,data,processed
6915,ClinicalTrials.gov,data,processed
6916,Patients,high risk ofcardiovascular adverse events,have
6917,therapies,effects,havecardiovascular
6918,ClinicalTrials.gov,data,processed
6919,ClinicalTrials.gov,data,processed
6920,study,sixty seven,include
6921,"30 min,-blood oxygen saturation",> 50%,infiltrates
6922,ClinicalTrials.gov,data,processed
6923,World Health Organization,new SARS CoV-2 infection,declared
6924,SARS CoV-2,more than two million,infected
6925,Previous reports,effect,analyzed
6926,ClinicalTrials.gov,data,processed
6927,Theseinvestigational modalities,Therapeutic plasma exchange,include
6928,Hospitalized COVID-19 patients,Study Duration,aged
6929,Therapeutic plasma exchange,treatment,tostandard
6930,300 or lung infiltrates > 50% of the lung field).3,> 50%,infiltrates
6931,ormore 100 F,> 48 hours,defined
6932,Allpatients,Methylprednisolone 1 mg,received
6933,ClinicalTrials.gov,data,processed
6934,ClinicalTrials.gov,data,processed
6935,understanding,considerableknowledge,gained
6936,Complex anddelicately balanced interaction,cellular andhumoral components,involve
6937,ClinicalTrials.gov,data,processed
6938,crirical patients,oxygen therapy,need
6939,Inclusion Criteria:-COVID 19 patients,oxygen,need
6940,therapyExclusion Criteria:-patients,oxygen therapy,need
6941,ClinicalTrials.gov,data,processed
6942,ClinicalTrials.gov,data,processed
6943,Inclusion Criteria:-Man,75 overSARS CoV2 infection,aged
6944,ClinicalTrials.gov,data,processed
6945,19 positive mothers newborn mothers,condition,had
6946,ClinicalTrials.gov,data,processed
6947,Medable,observational study protocolunder,enable
6948,workmay,new tools,include
6949,ClinicalTrials.gov,data,processed
6950,Anosmia,onset,reported
6951,ClinicalTrials.gov,data,processed
6952,Participants,NA-831 Atazanavir,receive
6953,ClinicalTrials.gov,data,processed
6954,COVID-19,"than30,000 deaths",caused
6955,20 additional mls,visit.-Endobronchial samples,-Blood samples
6956,member,patient,screen
6957,ClinicalTrials.gov,data,processed
6958,ACEI ARB based regimens,cause mortality,compare
6959,pandemic,">129,000 Americans",killed
6960,ACEI ARB use,ACE2 expression,increases
6961,ACEI/ARB,1.1 and 2.1,aims
6962,ClinicalTrials.gov,data,processed
6963,patient,written informed consent,given
6964,ClinicalTrials.gov,data,processed
6965,COVID-19 pandemic,sanitary capacity,overwhelmed
6966,vagus nerve,thebrainstem,connects
6967,ClinicalTrials.gov,data,processed
6968,Switzerland,high prevalence,have
6969,viral load,possible transmission,assess
6970,ClinicalTrials.gov,data,processed
6971,ClinicalTrials.gov,data,processed
6972,Global confinement,social economic fieldsof human activity,impacts
6973,Clinical behavior,capabilities,exceeds
6974,20%,disease,estimated
6975,oropharyngeal spray,infection proportion,reduce
6976,pharmaceutical service,code,dispense
6977,ClinicalTrials.gov,data,processed
6978,ClinicalTrials.gov,data,processed
6979,Participants,telephone follow,have
6980,ClinicalTrials.gov,data,processed
6981,Severe infiltrationof pulmonary tissue,alveolar gas exchange,affects
6982,ClinicalTrials.gov,data,processed
6983,An Observational Cohort Study,Late Outcomes,Determine
6984,SARS CoV-2,Coronavirus Disease 2019,causes
6985,ClinicalTrials.gov,data,processed
6986,INOpulse technology,targeted pulsatile delivery,provides
6987,Known history,ventricular dysfunction,left
6988,Patients,hemoptysis,reporting
6989,ClinicalTrials.gov,data,processed
6990,Phase 2 Study,impact,assess
6991,ClinicalTrials.gov,data,processed
6992,Coronavirus Disease 2019,exaggerated inflammatory response,induce
6993,suggestive,pneumonia,acquired
6994,ClinicalTrials.gov,data,processed
6995,ClinicalTrials.gov,data,processed
6996,ClinicalTrials.gov,Clinical data mortality status,processed
6997,ClinicalTrials.gov,data,processed
6998,ClinicalTrials.gov,data,processed
6999,contact information,toNorwegian ICUs,admitted
7000,national observational study,survival rates,describe
7001,toNorwegian ICUS,different aims,has
7002,health related domains,bothmental physical cognitive health,capture
7003,ClinicalTrials.gov,data,processed
7004,the Covid-19 Pandemic,3 million people,affected
7005,health care,heightened anxiety,experience
7006,investigators,behavioural interpersonalrelationship changes,reassess for
7007,ClinicalTrials.gov,data,processed
7008,Genetic sequencing,similarity,demonstrated
7009,Recruited subjects,adult patients,include
7010,subjects,written informed consent,give
7011,potential additional future testing,immune response,Willingness to
7012,ClinicalTrials.gov,data,processed
7013,SC group patients,care,will
7014,ClinicalTrials.gov,data,processed
7015,ClinicalTrials.gov,data,processed
7016,long term memory,recollection,contains
7017,Participants,set,provide
7018,sample size,1000 participants,reach
7019,ClinicalTrials.gov,data,processed
7020,psychiatric patients,COVID-19 outbreak,experience
7021,role,lithium treatment,plays
7022,ClinicalTrials.gov,data,processed
7023,ClinicalTrials.gov,data,processed
7024,ClinicalTrials.gov,data,processed
7025,ClinicalTrials.gov,data,processed
7026,Millions of women will,birth,give
7027,ClinicalTrials.gov,data,processed
7028,≥2 L,SpO2 ≥92%,defined
7029,ClinicalTrials.gov,data,processed
7030,present study,theeffectiveness,evaluate
7031,ClinicalTrials.gov,data,processed
7032,ClinicalTrials.gov,data,processed
7033,design,152 patients,included
7034,Investigators,mortality,recorded
7035,patients,informed consent,previouslysigned
7036,ClinicalTrials.gov,data,processed
7037,CKD,4,stage
7038,ClinicalTrials.gov,data,processed
7039,ClinicalTrials.gov,data,processed
7040,ClinicalTrials.gov,data,processed
7041,ClinicalTrials.gov,data,processed
7042,Patients,ASU treatment protocol,receiving
7043,ClinicalTrials.gov,data,processed
7044,shortweekly follow questionnaire,questions,includes
7045,study population,patients,Methods
7046,ClinicalTrials.gov,data,processed
7047,ClinicalTrials.gov,data,processed
7048,ClinicalTrials.gov,data,processed
7049,the Research Centre,Signature Bank project,implemented
7050,Analyses,scientific reasons,consider
7051,Indicators,rates practices,includerecruitment
7052,Peersupport groups,solutionsto,explore
7053,Peer support groups,andpreferences,needs
7054,ClinicalTrials.gov,data,processed
7055,Conventionalcoagulation tests,5%,reflect
7056,ClinicalTrials.gov,data,processed
7057,ClinicalTrials.gov,data,processed
7058,coronavirus pandemic,healthcare,changed
7059,sub - set havealready,assessment,undertaken
7060,ClinicalTrials.gov,data,processed
7061,study,surfactant,willintroduce
7062,ClinicalTrials.gov,data,processed
7063,set,quality,increase
7064,ClinicalTrials.gov,data,processed
7065,main objective,training load management,describe in
7066,main objective,training load management,describe in
7067,ClinicalTrials.gov,data,processed
7068,ClinicalTrials.gov,data,processed
7069,SARS CoV-2 virus,pandemic infection,caused
7070,Participants,baseline survey,Eligibility
7071,Participants,ID code,get
7072,Participants,theonline survey,complete
7073,Participants,series,complete
7074,surveys,range,assess
7075,target population,healthy adults,includes
7076,ClinicalTrials.gov,data,processed
7077,ClinicalTrials.gov,data,processed
7078,ClinicalTrials.gov,data,processed
7079,outbreak lockdown measures,significant concerns,raised
7080,ClinicalTrials.gov,data,processed
7081,ClinicalTrials.gov,data,processed
7082,presence,theirperception,explore
7083,ClinicalTrials.gov,data,processed
7084,Zinc supplement use Multivitamine use,vitamin supplements,taken
7085,ClinicalTrials.gov,data,processed
7086,ClinicalTrials.gov,data,processed
7087,ClinicalTrials.gov,data,processed
7088,ClinicalTrials.gov,data,processed
7089,confirmed COVID-19 infection,o,confirmed
7090,ClinicalTrials.gov,data,processed
7091,ClinicalTrials.gov,data,processed
7092,patients,life threatening heart problems,develop
7093,study,multisysteminvolvement,assess
7094,ClinicalTrials.gov,data,processed
7095,ClinicalTrials.gov,data,processed
7096,ClinicalTrials.gov,data,processed
7097,Egypt,"slightly 82,000 confirmed COVID-19 cases",reported
7098,newpandemic,health organizations,injuring
7099,Inclusion Criteria:-This study,1064 patients,included
7100,ClinicalTrials.gov,data,processed
7101,recent reports,novel insights,provided
7102,patients,significantly higher hospital mortality rates,had
7103,patients,favorable outcomes,had
7104,Inclusion Criteria:-Laboratory,COVID-19Exclusion Criteria:-None,confirmed
7105,ClinicalTrials.gov,data,processed
7106,patients,theseparameters,screened
7107,patients,standard procedure,undergoa
7108,ClinicalTrials.gov,data,processed
7109,study,comprehensive understanding,provide
7110,trial population,ofseverely ill patients,estimated to
7111,Regional Anticoagulation Modalities,66 patients,requires
7112,Intervention,aminimal psychoeducational intervention,receive
7113,Patients,thequestionnaires,answer
7114,The national Health Research Ethics Committee,asnot,assessed
7115,participatingpatients,written informed consent,provide
7116,results,number,have
7117,ClinicalTrials.gov,data,processed
7118,protocol,efficacy,evaluate
7119,predominant modes,COVID-19 infection,"contact.1,2"
7120,Therapeutic plasma exchange,immediate scientifically groundedintervention,offers
7121,Ruxolitinib,mice demonstratedclinical amelioration,treated
7122,Patients,methodology2,accepted
7123,RCT trial,unacceptable risk,Clinical assessment
7124,Current enrollment,CRS,induced
7125,ClinicalTrials.gov,data,processed
7126,ClinicalTrials.gov,data,processed
7127,ClinicalTrials.gov,data,processed
7128,ClinicalTrials.gov,data,processed
7129,bedridden status andcritical illness,prothrombotic milieu,constitute
7130,ClinicalTrials.gov,data,processed
7131,High quality data,policy planning,allow
7132,investigator led non - commercial non - interventional study,patient identifiable information,collect
7133,centre,elective cancer surgeryInclusion,performing
7134,ClinicalTrials.gov,data,processed
7135,patient,steroid,continued
7136,ClinicalTrials.gov,data,processed
7137,Aim-II,remote patient monitoring,evaluate
7138,IV,association,Aim
7139,ClinicalTrials.gov,data,processed
7140,recent government advice,use,supports
7141,Relevant belief related factors,attitudestowards,include
7142,mental imagery exercises,wearing,increase
7143,ClinicalTrials.gov,data,processed
7144,ClinicalTrials.gov,data,processed
7145,ClinicalTrials.gov,data,processed
7146,combination,progression,reducethe
7147,Inhalation,local anti - inflammatory antifibrotic effects,produces
7148,ClinicalTrials.gov,data,processed
7149,corticosteroid,>10 mg/day,use
7150,ClinicalTrials.gov,data,processed
7151,ClinicalTrials.gov,data,processed
7152,Trial,clinicalimpact,evaluate
7153,ClinicalTrials.gov,data,processed
7154,ClinicalTrials.gov,data,processed
7155,ClinicalTrials.gov,data,processed
7156,accurate fast evaluation,optimal treatment care,allow
7157,Investigators team,development,contributed
7158,investigators,patient clinical status,expect to
7159,ClinicalTrials.gov,data,processed
7160,Hong Kong public healthcare system,tremendous pressure,facing
7161,ClinicalTrials.gov,data,processed
7162,patient,degree,report
7163,ClinicalTrials.gov,data,processed
7164,ClinicalTrials.gov,data,processed
7165,ClinicalTrials.gov,data,processed
7166,ClinicalTrials.gov,data,processed
7167,ClinicalTrials.gov,data,processed
7168,ClinicalTrials.gov,data,processed
7169,ClinicalTrials.gov,data,processed
7170,Chest ultrasound,Chest ultrasound value,demonstrated
7171,Chest ultrasound,Chest ultrasound value,shown
7172,Italian article,clinical case,describes
7173,ClinicalTrials.gov,data,processed
7174,patient medical records,thefollowing:1,include
7175,ClinicalTrials.gov,data,processed
7176,ClinicalTrials.gov,data,processed
7177,healthy volunteers,study,beincluded
7178,Human Glucose,Protein,measured through
7179,ClinicalTrials.gov,data,processed
7180,Person,at least one,presented
7181,ClinicalTrials.gov,data,processed
7182,Inclusion,cancer diagnosis,confirmed
7183,ClinicalTrials.gov,data,processed
7184,ClinicalTrials.gov,data,processed
7185,ongoing COVID-19 pandemic,millions of humans worldwide and has,affects
7186,open label controlled trial,hospitalizedadults,randomize
7187,ClinicalTrials.gov,data,processed
7188,infection,ongoingpandemic,caused
7189,"note,93.3 %",decline,saw
7190,ClinicalTrials.gov,data,processed
7191,arm,use,evaluate
7192,ClinicalTrials.gov,data,processed
7193,coagulopathy,intravascular coagulation,disseminated
7194,authors,dosage,noted
7195,ClinicalTrials.gov,data,processed
7196,ClinicalTrials.gov,data,processed
7197,current SARS CoV-2 pandemic,high burden,has
7198,Therenin angiotensin system,important role,plays
7199,Virus spike protein,complex,binds to
7200,Adult,SARS CoV-2-infected patients,hospitalized
7201,Theactive treatment arm,valsartan,Intervention
7202,Theactive treatment arm,matching placebo,receive
7203,ClinicalTrials.gov,data,processed
7204,Treatment,up to 28 days,beextended
7205,Male female patients,≥ 18 years.-3,aged
7206,ClinicalTrials.gov,data,processed
7207,ClinicalTrials.gov,data,processed
7208,Chinese scientists,genomeinformation,shared
7209,Xiyanping injection,anti - inflammatory immune regulation effects,has
7210,total,cases nationwide(Hubei Province,confirmed
7211,Xiyanping injection,anti - inflammatory immune regulation effects,has
7212,ClinicalTrials.gov,data,processed
7213,ClinicalTrials.gov,data,processed
7214,COVID-19,clusters,caused
7215,ClinicalTrials.gov,data,processed
7216,500 cells,bilirubin,count
7217,Local laws,use,require
7218,ClinicalTrials.gov,data,processed
7219,patients,pneumonia,develop
7220,Excessiveand,immune system response,uncontrolled
7221,"AT2),which",development,determines
7222,Cytokinerelease syndrome,emergence,threatens
7223,key components,disruption,include
7224,ClinicalTrials.gov,data,processed
7225,Patients,andwill,receive
7226,Enrolled patients,saline,receive
7227,patients,"these criteria, open-label clazakizumab 25 mg IV",discussed
7228,ClinicalTrials.gov,data,processed
7229,ClinicalTrials.gov,data,processed
7230,ClinicalTrials.gov,data,processed
7231,ClinicalTrials.gov,data,processed
7232,ClinicalTrials.gov,data,processed
7233,ClinicalTrials.gov,data,processed
7234,Online Support Groups,COVID-19,Address
7235,negativeconsequences,impairment,include
7236,individuals,anxiety athigher rates,exhibit
7237,ClinicalTrials.gov,data,processed
7238,FNI participants,increased quality,demonstrated
7239,an RCT,effects,investigated
7240,FNI infants,lowerrisk,had
7241,FNI infants,levels,lower
7242,investigators,randomized controlled trial,conducting
7243,a singleton-Mother,English,speak
7244,ClinicalTrials.gov,data,processed
7245,ClinicalTrials.gov,data,processed
7246,world,coronavirus CoV-2 pandemic,experiencing
7247,Six (75%,hospital,left
7248,trial,effect,/IIIclinical
7249,ClinicalTrials.gov,data,processed
7250,investigator,participants,select
7251,investigator,participants,divide
7252,investigator,improvement intemperature,compare
7253,ClinicalTrials.gov,data,processed
7254,Gives,consent,informed
7255,ClinicalTrials.gov,data,processed
7256,ARDS,mechanical ventilation,oftenrequires
7257,Researchers,potential therapeutic role,studying
7258,ClinicalTrials.gov,data,processed
7259,ClinicalTrials.gov,data,processed
7260,organ,mechanical ventilation,Pregnancy Disease
7261,ClinicalTrials.gov,data,processed
7262,pregnant postpartum women,high risk pregnancyward,included
7263,neonatal imaging exams,tomography,21
7264,pregnantand,women,Methods
7265,ClinicalTrials.gov,data,processed
7266,ClinicalTrials.gov,data,processed
7267,SARS CoV-2 infection,cytopathic effects,induces
7268,ClinicalTrials.gov,data,processed
7269,ClinicalTrials.gov,Recent preliminary data,processed
7270,ClinicalTrials.gov,Recent preliminary data,processed
7271,ConvalescentPlasma,huge activity,shown
7272,A. Patient,informed consent,sign
7273,antineoplastic treatment,immunotherapy molecular therapy- oncological surgery,chemotherapy-
7274,ClinicalTrials.gov,data,processed
7275,fluidity,processing times,considered to
7276,health crisis,limited theuse,have
7277,delays,impact,possiblyhad
7278,fluidity,processing times,considered to
7279,health crisis,use,limited
7280,Thedelays,impact,had
7281,Inclusion Criteria:-Patients,≥,aged
7282,ClinicalTrials.gov,data,processed
7283,Surgical sterilization,a minimumof 6 weeks,occurred
7284,confirmatory follicle,hormone levelsof,Females
7285,Male participants,1,have
7286,Platelet,"125,000",count
7287,AST)/alanine aminotransferase,ULN).6,Aspartate aminotransferase
7288,ClinicalTrials.gov,data,processed
7289,ClinicalTrials.gov,data,processed
7290,ClinicalTrials.gov,data,processed
7291,ClinicalTrials.gov,data,processed
7292,Imaging,key role,is
7293,Previous reports,key role,havehighlighted
7294,ClinicalTrials.gov,data,processed
7295,COVID-19,amortality risk,poses
7296,15-20%,severe respiratory symptoms necessitating hospital admission,develop
7297,Patients,investigational drug,stop
7298,ClinicalTrials.gov,data,processed
7299,ClinicalTrials.gov,data,processed
7300,ClinicalTrials.gov,data,processed
7301,ClinicalTrials.gov,data,processed
7302,NPH patientdataset,114 patients,includes
7303,MIMIC dataset,114 patients,included
7304,Inclusion Criteria:-Patients,18 years,aged
7305,ClinicalTrials.gov,data,processed
7306,difficulty,social distancing hygiene recommendations,Because of
7307,ClinicalTrials.gov,data,processed
7308,Pneumonia,viral pandemic,causing
7309,modulators,decreasein viral carriage,have
7310,ClinicalTrials.gov,data,processed
7311,ClinicalTrials.gov,data,processed
7312,Pneumonia,direct infection,result
7313,ClinicalTrials.gov,data,processed
7314,Virologic measures,proportions,included
7315,ClinicalTrials.gov,data,processed
7316,Participants,unit,receive
7317,Patient,intubation,require
7318,ClinicalTrials.gov,data,processed
7319,Brigham Networkwill,study population,comprise
7320,30- 90-day bleeding outcomes,major,include
7321,Thrombotic outcomes,symptomatic VTE,include
7322,Participating sites,IRB approval,obtain
7323,Additional measured variables,VTE related riskfactors,include
7324,ClinicalTrials.gov,Data,processed
7325,ClinicalTrials.gov,data,processed
7326,ClinicalTrials.gov,data,processed
7327,Virtually COVID-19 RNA assays,centralized laboratories,require
7328,Samples,inlocations,collected
7329,thesedelays,risk,thought to
7330,minimally trained staff,seeif,perform
7331,participant,sample,give
7332,participant registerbut,sample,donate
7333,ClinicalTrials.gov,data,processed
7334,weekly supplementation,tothose,assessed at
7335,ClinicalTrials.gov,data,processed
7336,BLD-2660,fibrosis damage,attenuated
7337,Female subjects,oocytes,donate
7338,ClinicalTrials.gov,data,processed
7339,ClinicalTrials.gov,data,processed
7340,ClinicalTrials.gov,data,processed
7341,COVID-19 pandemic,substantial pressure,places
7342,Theinconveniences,conventional finger probe,established
7343,recent interest,ear canal,promoted
7344,attribute,ear canal,hasestablished
7345,continuous monitoring,earlier warning ofdeterioration,provide
7346,ClinicalTrials.gov,data,processed
7347,study,diagnostic performance,compares
7348,rhino pharynges samples,specific antibodies,The qualitative detection ofspecific SARS CoV-2 antigens by
7349,CoV-2,S protein,detect
7350,ClinicalTrials.gov,data,processed
7351,ClinicalTrials.gov,data,processed
7352,ClinicalTrials.gov,data,processed
7353,research,inpatients,called
7354,ClinicalTrials.gov,data,processed
7355,use,droplet risk,transform
7356,ClinicalTrials.gov,data,processed
7357,Baseline eligibility,informed consent,checklistfollows
7358,Subjects,theirresults,report
7359,symptoms CDC,immediate medical care for].2,Constant
7360,ClinicalTrials.gov,data,processed
7361,ClinicalTrials.gov,data,processed
7362,Coronavirus Disease 2019,global health crisis,caused
7363,previous hospitalization,at least one,have
7364,ClinicalTrials.gov,data,processed
7365,ClinicalTrials.gov,data,processed
7366,Secretary,beginning,declared
7367,ill patients,over 18 years,aged
7368,ClinicalTrials.gov,data,processed
7369,group,adifferent treatment,receives
7370,ClinicalTrials.gov,data,processed
7371,Coronavirus disease,"1,273,712 infections",caused
7372,ClinicalTrials.gov,data,processed
7373,ClinicalTrials.gov,data,processed
7374,People,different susceptibility,have
7375,patients,differentcytokine profile,have
7376,pandemichas,million people,affected
7377,pandemichas,million people,affected
7378,bindings,dendritic cells,macrophages
7379,Treg,activation results,expressed in
7380,KIRs binding,patients,infected
7381,ClinicalTrials.gov,data,processed
7382,study,anadaptive design,adopt
7383,Patients,treatment,start
7384,ClinicalTrials.gov,data,processed
7385,Biospecimens,serum,include
7386,ClinicalTrials.gov,data,processed
7387,Subject,positive SARS CoV-2,had
7388,ClinicalTrials.gov,data,processed
7389,scientific taskforce,comprehensive cohort study,oversee
7390,ClinicalTrials.gov,data,processed
7391,Quantitative,normal distribution,presented in
7392,ClinicalTrials.gov,data,processed
7393,Health care providers,physicians,include
7394,Inclusion Criteria:-Health care providers,physicians,include
7395,ClinicalTrials.gov,data,processed
7396,Methods,PCR+ SARS CoV2-patients,included
7397,patients,patients,invited
7398,lung,Tomography,computed
7399,ClinicalTrials.gov,data,processed
7400,ClinicalTrials.gov,data,processed
7401,ClinicalTrials.gov,data,processed
7402,protocol,access,provides
7403,Participant,unresolved Neisseria meningitidis infection4,has
7404,ClinicalTrials.gov,data,processed
7405,Patients,increased risk,have
7406,Patients,increased risk,have
7407,ClinicalTrials.gov,data,processed
7408,27%,0.8 % occurrence,thatis
7409,ClinicalTrials.gov,data,processed
7410,ClinicalTrials.gov,data,processed
7411,Investigators,prospective cohort study,conduct
7412,volunteers,daily exposures,report
7413,Investigators,enrollment,seek
7414,ClinicalTrials.gov,data,processed
7415,ClinicalTrials.gov,data,processed
7416,ClinicalTrials.gov,data,processed
7417,published data,adult population,concerned
7418,Patient,maintenance treatment,appears
7419,2020).To,presentation,describe
7420,ClinicalTrials.gov,data,processed
7421,ClinicalTrials.gov,data,processed
7422,patients,series,complete
7423,ClinicalTrials.gov,data,processed
7424,Patients,one or more of the following:1,have
7425,Patients,uncontrolled disease,have
7426,ClinicalTrials.gov,data,processed
7427,ClinicalTrials.gov,data,processed
7428,ClinicalTrials.gov,data,processed
7429,Infection,human COVID-19,causes
7430,Dipyridamole,platelet,has
7431,ClinicalTrials.gov,data,processed
7432,disproportionate level,concerns,hasraised
7433,ClinicalTrials.gov,data,processed
7434,drug,half life,has
7435,every 3,total,weeksfor
7436,participants,the gold standard test PCR,have
7437,artemether,QT interval prolongation,causing
7438,ClinicalTrials.gov,data,processed
7439,COVID-19 outbreak,impact,having
7440,ClinicalTrials.gov,data,processed
7441,Subject,diagnosis,has
7442,Subject,immunomodulators,taking
7443,Subject,live attenuated vaccine,received
7444,ClinicalTrials.gov,data,processed
7445,ClinicalTrials.gov,data,processed
7446,ClinicalTrials.gov,data,processed
7447,ClinicalTrials.gov,data,processed
7448,ClinicalTrials.gov,data,processed
7449,ClinicalTrials.gov,data,processed
7450,patients,essential healthcare,need
7451,Collected data,clinical data,includeroutine
7452,Endpoints,death,include
7453,ClinicalTrials.gov,data,processed
7454,ClinicalTrials.gov,data,processed
7455,ClinicalTrials.gov,data,processed
7456,ClinicalTrials.gov,data,processed
7457,objective,oxygenation,optimizing
7458,use,blood flow,hypothesized
7459,study procedures,less than 4 hours,take
7460,ClinicalTrials.gov,data,processed
7461,Inflammatory markers,COVID-19 RT PCR,beobtained on
7462,ClinicalTrials.gov,data,processed
7463,ClinicalTrials.gov,data,processed
7464,Ivermectinhad,promising results,shown
7465,Ivermectinhad,new hope,open
7466,Prospective Covid-19 Seroconversion Study,effect,compare
7467,ClinicalTrials.gov,data,processed
7468,ClinicalTrials.gov,data,processed
7469,ClinicalTrials.gov,data,processed
7470,Secondary Outcomes of the Study To,statistical correlation,understand
7471,Diagnostic test,interventional study(Categorical variable,based
7472,Interventional studies,2020.Observational studies,andcompleted before
7473,ClinicalTrials.gov,data,processed
7474,ClinicalTrials.gov,data,processed
7475,ACTT-3,combination,evaluate
7476,serum,forsecondary research,samples
7477,infection control,ability,limit
7478,The Day 22visit,laboratory tests,have
7479,the Study,different investigational therapeutic agents,compare
7480,One independent Dataand Safety Monitoring Board,combination,evaluate
7481,serum,forsecondary research,samples
7482,infection control,ability,limit
7483,The Day 22visit,laboratory tests,have
7484,subjects,series,undergo
7485,subject,visit,is
7486,key secondary outcome,treatment related improvements,evaluates
7487,stage,different secondary endpoints,prioritize
7488,Subject,criteria,meets
7489,Subject,positive test,has
7490,Platelet,"50,000 microliter.8",count
7491,ClinicalTrials.gov,data,processed
7492,ClinicalTrials.gov,data,processed
7493,investigator,safety,evaluate
7494,Patients,careful observation,remainunder
7495,investigator,safety,evaluatethe
7496,ClinicalTrials.gov,data,processed
7497,ClinicalTrials.gov,data,processed
7498,ClinicalTrials.gov,data,processed
7499,COVID-19,different parts,affect
7500,Participants,neurological exam,have
7501,Participants,pen paper tests,complete
7502,Participants,smell test,complete
7503,Participants,blood samples,give
7504,Participants,magnetic resonance imaging,have
7505,Participants,contrast dye,get
7506,Participants,lumbar puncture,have
7507,Participants,tests,repeat
7508,The NIH Clinical Center,breadth,provides
7509,Enrollment,avisit,include
7510,The NIH Clinical Center,50 participants,enroll
7511,ClinicalTrials.gov,data,processed
7512,ClinicalTrials.gov,data,processed
7513,ClinicalTrials.gov,data,processed
7514,additional histopathological microbiological virologic study,clinical,provide
7515,ClinicalTrials.gov,data,processed
7516,ClinicalTrials.gov,data,processed
7517,Observational Study of Neurologic Function,effect,measure
7518,ClinicalTrials.gov,data,processed
7519,ClinicalTrials.gov,data,processed
7520,ClinicalTrials.gov,data,processed
7521,ClinicalTrials.gov,data,processed
7522,Gold Standard SARS CoV-2 COVID-19 infection,criterion,confirmed
7523,ClinicalTrials.gov,data,processed
7524,Women,highly effective method,using
7525,Laboratory,SARS CoV-2 infection,confirmed
7526,Investigator,determination,make
7527,ClinicalTrials.gov,data,processed
7528,ClinicalTrials.gov,data,processed
7529,infection,light symptoms,causes
7530,investigators,patients,include
7531,investigators,analysis,include
7532,nasopharyngeal swab,estimate,obtain
7533,ClinicalTrials.gov,data,processed
7534,Investigators,product labels,attached
7535,ClinicalTrials.gov,data,processed
7536,Boswellia Serrata gum,havebroad antiviral activity,extract
7537,Chinese traditional Medicine,licorice,are
7538,Licorice,antithrombin antiplatelet effects,has
7539,Licorice,hypercoagulation,alleviates
7540,Licorice,high safety margins,is
7541,monoammonium glycyrrhizinate injection orglycyrrhizic acid,protective influence,shown
7542,studies,role,investigate
7543,signs,dyspnea,This treatment showedimprovement of
7544,Diagnosis,the following criteria:1,follow
7545,Viral specific IgG antibody,titration,reaches
7546,patients,investigations:1,have
7547,B. serrate,volatile oils,contains
7548,Boswellia serrata Gum Resin,terpenoids,contains
7549,ClinicalTrials.gov,data,processed
7550,Study,impact,determine
7551,prospective cohort study,both qualitative(interview,include
7552,investigators,patientswith,identify
7553,Surveys,EQ-5D-5Lprofile,include
7554,ClinicalTrials.gov,data,processed
7555,ClinicalTrials.gov,data,processed
7556,ClinicalTrials.gov,data,processed
7557,real pandemic,enormous challengeto,represents
7558,Genetic analyses,Genome Wide Association Studies,include
7559,ClinicalTrials.gov,data,processed
7560,Subject,oral informed consent,provides
7561,Subject,invasive mechanical ventilation,requires
7562,Subject,documented hereditary fructose intolerance,known
7563,ClinicalTrials.gov,data,processed
7564,short term impact,colonoscopy,follow up
7565,Head,Eye protection,cover
7566,ClinicalTrials.gov,data,processed
7567,atorvastatin,progression,reduce
7568,ClinicalTrials.gov,data,processed
7569,Angiotensing,enzyme type,is
7570,Severe acute respiratory syndromecoronavirus,2,uses
7571,ACEi,Covid-19 infection andseverity,known
7572,ClinicalTrials.gov,data,processed
7573,ClinicalTrials.gov,data,processed
7574,Clinically significant abnormal laboratory value,potential risk,indicating
7575,ClinicalTrials.gov,data,processed
7576,90,atenrollment,documented
7577,ClinicalTrials.gov,data,processed
7578,ClinicalTrials.gov,data,processed
7579,Inclusion Criteria:-Male,18 70 years.-An understanding,aged
7580,ClinicalTrials.gov,data,processed
7581,discharged patients,certain clinicalsymptoms,exhibits
7582,ClinicalTrials.gov,data,processed
7583,ClinicalTrials.gov,data,processed
7584,pilot study,safety,assess
7585,AstraZeneca,mAbs,developing
7586,child,potential,Contraceptive
7587,ClinicalTrials.gov,data,processed
7588,Eightpatients,Viremia,had
7589,patient,virus,cleared
7590,ClinicalTrials.gov,data,processed
7591,Inhaled Epoprostenol,Dedicated Delivery System,Delivered
7592,ClinicalTrials.gov,data,processed
7593,ClinicalTrials.gov,data,processed
7594,100 mg L,15,count
7595,ClinicalTrials.gov,data,processed
7596,ClinicalTrials.gov,data,processed
7597,new virus,global pandemic,causing
7598,tohalf,help,require
7599,ClinicalTrials.gov,data,processed
7600,Intervention,inpatient,target
7601,Viral adherence tohost cell membrane associated ACE2,proximity,facilitates
7602,PP,lung,reduces
7603,PP,uniformity,promotes
7604,ClinicalTrials.gov,data,processed
7605,subjects,standard,receive
7606,brequinargroup,5 daily doses,receive
7607,subjects,standard,receive
7608,Blood chemistry tests,bloodurea nitrogen,include
7609,Hematology tests,hemoglobin,include
7610,ClinicalTrials.gov,data,processed
7611,ClinicalTrials.gov,data,processed
7612,ClinicalTrials.gov,data,processed
7613,ClinicalTrials.gov,data,processed
7614,ClinicalTrials.gov,data,processed
7615,ClinicalTrials.gov,data,processed
7616,study population,COVID 19 patients,include
7617,ClinicalTrials.gov,data,processed
7618,thesignificant decrease,new infectious respiratory disease,made
7619,Positive RT PCR)-Newly,symptomatic patients.-Adults,diagnosed
7620,ClinicalTrials.gov,data,processed
7621,ClinicalTrials.gov,data,processed
7622,100th patient,Visit,performed
7623,ClinicalTrials.gov,data,processed
7624,ClinicalTrials.gov,data,processed
7625,Adults,Hospitalization,Requiring
7626,ClinicalTrials.gov,data,processed
7627,ClinicalTrials.gov,data,processed
7628,the National Health Commission of China,details,released
7629,patients,SARS CoV-2-specific NAbs,developed
7630,Neutralizing antibodies,important roles,play
7631,Virus-specific NAbs,viralinfection,block
7632,ClinicalTrials.gov,data,processed
7633,Heparin,thrombocytopenia,induced
7634,Platelet,"100,0008",count
7635,ClinicalTrials.gov,data,processed
7636,inflammasomes,important role,have
7637,ClinicalTrials.gov,data,processed
7638,Patients,high risk,present
7639,Subjects,15 mg,receive
7640,APPEX-19,follow,has
7641,Experimental,label,approved for
7642,18 years,active moderate severe COVID-19,have
7643,-Subject,history,has
7644,ClinicalTrials.gov,data,processed
7645,Only 5%,severe or critical Coronavirus disease2019,develop
7646,numbers,respiratory distress,developacute
7647,ClinicalTrials.gov,data,processed
7648,multicentric study,efficacy,assess
7649,AstraZeneca,mAbs,developing
7650,Participants,COVID-19 symptoms,had
7651,ClinicalTrials.gov,data,processed
7652,vitamin D supplementation,important outcomes,improve
7653,vitamin D supplementation,therapeutic effects,The investigatorsspeculate
7654,ClinicalTrials.gov,data,processed
7655,ClinicalTrials.gov,data,processed
7656,ClinicalTrials.gov,data,processed
7657,COVID-19,quicklyworldwide,spread
7658,patients,lung inflammation,developoverwhelming
7659,the World Health Organization,1.914.916 confirmed cases,reported
7660,patients,overwhelming lung inflammation,develop
7661,ClinicalTrials.gov,data,processed
7662,ClinicalTrials.gov,data,processed
7663,Chinese scientists,genomeinformation,shared
7664,randomized parallel andproof,safety,evaluate
7665,Men,≥18,aged
7666,women,negative pregnancy test,have
7667,ClinicalTrials.gov,data,processed
7668,ClinicalTrials.gov,data,processed
7669,ClinicalTrials.gov,data,processed
7670,ClinicalTrials.gov,data,processed
7671,ClinicalTrials.gov,data,processed
7672,tramadol,ahypocoagulable effect,reported
7673,tramadol,hemostatic parameters,affect
7674,LDH level andto,cardio protective effect,provide
7675,Tramadol,property,antitussive
7676,Tramadol,low risk,has
7677,patients,intense emotional andbehavioral reactions,experience
7678,effects,Tramadol use,favor
7679,Inclusion Criteria:-Newly,symptomatic COVID-19 patients,diagnosed
7680,ClinicalTrials.gov,data,processed
7681,ClinicalTrials.gov,De identified data,processed
7682,Study participantswill,10 mg,receive
7683,ClinicalTrials.gov,data,processed
7684,ClinicalTrials.gov,data,processed
7685,5 cases,LPV r monotherapy,received
7686,2 had their,conditionsworsened,haddecrease in
7687,published evaluations,reduced viral load,show
7688,study upshot,benefit,demonstrated
7689,ClinicalTrials.gov,data,processed
7690,MSCs,pathological changes,reduce
7691,clinical trial,20patients,recruit
7692,ClinicalTrials.gov,data,processed
7693,symptoms,fever,include
7694,Individuals,immunosuppressants,taken
7695,ClinicalTrials.gov,data,processed
7696,healthcare teams,clinical organizational technical challenges,face
7697,study,negative psychological impact onhealthcare workers,reported
7698,Participants,self reportedquestionnaires,complete
7699,Assessmentwill,socio demographic characteristics,provide
7700,physician,ina medical care unit,informed of
7701,data manager,data,collects
7702,ClinicalTrials.gov,data,processed
7703,research group,thrombo inflammatory state,reported
7704,Tantry et,mechanistic link,al.proposed
7705,commonconventional coagulation tests,prothrombin time,include
7706,Thromboelastography,platelet function,assess
7707,ClinicalTrials.gov,data,processed
7708,Ketone bodies,ATP production,maintain
7709,ClinicalTrials.gov,data,processed
7710,pandemic,important impact,has
7711,ClinicalTrials.gov,data,processed
7712,health care workers,bolus,receive
7713,externaldatabases,enrolment,Use of
7714,concurrent randomised trial;-has,vaccine,received
7715,ClinicalTrials.gov,data,processed
7716,"3/16/2020,the epidemic",100 countries,affects
7717,ClinicalTrials.gov,data,processed
7718,"2019,a new type",inWuhan,broke out
7719,patients,contraindications,meet
7720,patients,drugs,take
7721,ClinicalTrials.gov,data,processed
7722,infusion,4 hours,exceed
7723,Inclusion Criteria:-Male,COVID-19,confirmed
7724,ClinicalTrials.gov,data,processed
7725,patients,criteria,meeting
7726,ClinicalTrials.gov,data,processed
7727,absolute lymphocyte,250 cells,count
7728,ClinicalTrials.gov,data,processed
7729,Radiological examinations,important role,play
7730,ClinicalTrials.gov,data,processed
7731,ClinicalTrials.gov,data,processed
7732,Background,unpredictable risk,have
7733,participants,blood samples,give
7734,related vaccination.-This protocol,treatment,collected in
7735,currentor,donors,resolved
7736,Immunosuppressive treatments,normal B cells,decrease
7737,ClinicalTrials.gov,data,processed
7738,Time,between 0 and 13 days,hospitalizationranged
7739,General VL behavior,anegative slope,showed
7740,patients,detectable viral RNA,show
7741,percentage difference,behavior,the patients
7742,Known HIV infection,300 cell/µL.6,count
7743,Patients,chronic diseases,decompensated
7744,ClinicalTrials.gov,data,processed
7745,Suspected,bacterial,uncontrolled
7746,ClinicalTrials.gov,data,processed
7747,inhealthy adults,18 to 30 years,aged
7748,ClinicalTrials.gov,data,processed
7749,Themost common changes,lymphopenia,include
7750,definitive diagnosis,positive molecular test,requires
7751,interstitial infiltrations;complete resolution,several weeks,takes
7752,multitude,immediatetreatment,need
7753,Endothelial cells,crucial role,play
7754,thistreatment,less than one hour,requires
7755,TREATMENT DELIVERYThe patient,radiation treatment,undergo
7756,50 years Patients,3-Suggestive picture finding,score
7757,ClinicalTrials.gov,data,processed
7758,COVID-19 pandemic,major disruption,caused
7759,safe effective vaccine forCOVID-19 prevention,significant public health impact,have
7760,ClinicalTrials.gov,data,processed
7761,candidate cohort,small cohort,include
7762,study,delivery,enable
7763,Child Pugh,10)-Hemoglobin,score
7764,ClinicalTrials.gov,data,processed
7765,Participants,1 2 units,receive
7766,Participants,standard,receive
7767,ClinicalTrials.gov,data,processed
7768,recombinant human DNaseI,identical primary amino acid sequence,has
7769,Diagnosed Patient Group I. Dornase Alpha,group ii,treated
7770,Patient Group,group ii,treated
7771,ClinicalTrials.gov,data,processed
7772,Canada,important dangerous phase,entering
7773,proposal,tool,offers
7774,proposed digital technology,individuals,screen
7775,ofthe proposed app,ofthe proposed app acoustic analysis,use
7776,ClinicalTrials.gov,data,processed
7777,ClinicalTrials.gov,data,processed
7778,Steroids,benefits,shown
7779,ClinicalTrials.gov,data,processed
7780,investigators,small trial,plan
7781,investigators,interleukin-1receptor antagonist,testing
7782,ClinicalTrials.gov,data,processed
7783,participating study,separate IRB approved protocol,haveits
7784,Laboratory,acute novel Coronavirus nCoV infection,proven
7785,ClinicalTrials.gov,data,processed
7786,acute respiratory illness,novel SAR CoV-2,causedby
7787,the Wuhan Municipal Health Committee,outbreak,identified
7788,Potential donors,followingself identification,recruiting
7789,local study coordinator,study data,collect
7790,ClinicalTrials.gov,data,processed
7791,Colchicine Plus Phenolic Monoterpenes,COVID-19,Treat
7792,ClinicalTrials.gov,data,processed
7793,drugs combininganti inflammatory antiviral effects,symptoms,reduce
7794,Inclusion Criteria:-COVID-19,Age 18 years,infected
7795,ClinicalTrials.gov,data,processed
7796,Outcome measures,incidence,include
7797,hospitals,marked increase,haveseen
7798,investigators,data,validate
7799,ClinicalTrials.gov,data,processed
7800,ClinicalTrials.gov,data,processed
7801,ClinicalTrials.gov,data,processed
7802,observational studies,significant association,shown
7803,vitamin D supplementation,risk,canreduce
7804,Participants,4-week supply,receive
7805,Participants,ane mail address,have
7806,Participants,dried blood spot samples,provide
7807,TishconCorporation,study capsules,donating
7808,ClinicalTrials.gov,data,processed
7809,ClinicalTrials.gov,data,processed
7810,ClinicalTrials.gov,data,processed
7811,duration,month study treatment,subjectincludes
7812,Trial population,ofboth genders,consist
7813,50 patients,standard therapy,receive
7814,100 mg,2capsules,caps
7815,50 patients,standard therapy,receive
7816,ClinicalTrials.gov,data,processed
7817,development,aroundtwo years,take
7818,COVID-19integration,active function,requires
7819,Mindell,alkaline effect,has
7820,The more LTR,study,accordingto
7821,literature,possible hypotension effect,are
7822,groups,routineregime,receive
7823,investigator,values,assessed by
7824,ClinicalTrials.gov,data,processed
7825,severe patients,definition,meet
7826,Patients,retinitis;heart failure,pigmented
7827,ClinicalTrials.gov,data,processed
7828,confidence intervals,statistical adjustments,Effect estimates
7829,Atazanavir,major protease activity,blocked
7830,daclatasvir,production,inhibited
7831,Sofosbuvir,EC50 values,showed
7832,Platelets,"50,000",<
7833,Corrected Q,T,interval
7834,ClinicalTrials.gov,data,processed
7835,Demographic,age,included
7836,Subjects,lung structural damage,ofsignificant
7837,Subjects,lung volume reduction,received
7838,ClinicalTrials.gov,data,processed
7839,patient,capacity,obtained from
7840,protocol,pregnant subjects,exclude
7841,ClinicalTrials.gov,data,processed
7842,multidisciplinary team,survey,developed
7843,ClinicalTrials.gov,data,processed
7844,ClinicalTrials.gov,data,processed
7845,subject,28-day follow phone,randomized to
7846,ClinicalTrials.gov,data,processed
7847,ClinicalTrials.gov,data,processed
7848,study,anti - viral effect,corroborated
7849,5 cases,LPV r monotherapy,received
7850,2 had their,conditionsworsened,haddecrease in
7851,published evaluations,reduced viral load,show
7852,study upshot,benefit,demonstrated
7853,ClinicalTrials.gov,data,processed
7854,ClinicalTrials.gov,data,processed
7855,ClinicalTrials.gov,data,processed
7856,study,participants,allows
7857,ClinicalTrials.gov,data,processed
7858,outbreak,becomepandemic,has
7859,ClinicalTrials.gov,data,processed
7860,Treatment Study,efficacy,evaluate
7861,chemotherapy,Influenza B infection,confirmed
7862,ClinicalTrials.gov,data,processed
7863,subjects,series ofefficacy safety laboratory assessments,undergo
7864,Day 22 Day 60 visits,laboratory tests orcollection,have
7865,Acceptable methods,barrier contraceptives,include
7866,ClinicalTrials.gov,data,processed
7867,Genetic sequencing,similarity,demonstrated
7868,subjects,written informed consent,give
7869,ClinicalTrials.gov,data,processed
7870,C5a blockade,mortality andprevent ARDS,This hypothesis
7871,Eligible patients,patients,include
7872,ClinicalTrials.gov,data,processed
7873,Entry,enrollment,guarantee
7874,investigator,eligibility,confirmed
7875,Clinical laboratory data,serum chemistries,include
7876,Telephone,brief survey,include
7877,ClinicalTrials.gov,data,processed
7878,WOCBP,highly effective forms,use
7879,ClinicalTrials.gov,data,processed
7880,Hospitalised symptomatic COVID-19 patients,following inclusioncriteria:1,meet
7881,ClinicalTrials.gov,data,processed
7882,Patients,interval prolongation)3,QTc
7883,ClinicalTrials.gov,data,processed
7884,Inclusion Criteria:-General population,participate duplicate answers incomplete answers,refuse
7885,ClinicalTrials.gov,data,processed
7886,participant,continued hypoxemia,permitted
7887,ClinicalTrials.gov,data,processed
7888,ClinicalTrials.gov,data,processed
7889,Subjects,written informed consent prior conduct,provide
7890,Non - cardiogenic bilateral pulmonary edema,lung,collapsed
7891,ClinicalTrials.gov,data,processed
7892,Coronavirus disease,global pandemic,caused
7893,acute endothelial dysfunction,ischemic events,produce
7894,ClinicalTrials.gov,data,processed
7895,similar lack,patients,affect
7896,ClinicalTrials.gov,data,processed
7897,BET stage,combination,evaluate
7898,BET stage,combination,evaluate
7899,subjects,aseries,undergo
7900,Day 22 Day 60 visits,laboratory tests orcollection,have
7901,Acceptable methods,barrier contraceptives,include
7902,ClinicalTrials.gov,data,processed
7903,innovative measurements,directnon invasive assessments,provide
7904,ClinicalTrials.gov,data,processed
7905,active agent,broad activity,demonstrated
7906,ClinicalTrials.gov,data,processed
7907,study,extensive retrospective data collection,consists
7908,main SARS Cov-2 outbreak,acute myocarditisand,exhibited
7909,ClinicalTrials.gov,data,processed
7910,eachsite,representation,have
7911,ClinicalTrials.gov,data,processed
7912,ClinicalTrials.gov,data,processed
7913,ClinicalTrials.gov,data,processed
7914,analyzescarried,recommendations,follow
7915,ClinicalTrials.gov,data,processed
7916,ClinicalTrials.gov,data,processed
7917,investigators,electronic nose,COVID-19 in
7918,ClinicalTrials.gov,data,processed
7919,Collection,Convalescent Plasma,COVID-19
7920,protocol,administration,involve
7921,ClinicalTrials.gov,data,processed
7922,IL-6 axistherapies,COVID-19 mortality,reduce
7923,low dose tocilizumab,timeto clinical recovery,establish
7924,Excedrin ®,40,[
7925,ClinicalTrials.gov,data,processed
7926,ClinicalTrials.gov,data,processed
7927,Participants,medical history,have
7928,Participants,blood,give
7929,Participants,computed tomography scan,have
7930,Participants,ultrasoundof,have
7931,Participants,6-minute walk test,take
7932,Participants,balance movement tests,take
7933,Participants,surveys,complete
7934,Participants,smell test,take
7935,Participants,different smells,identify
7936,Participants,memory,have
7937,Participants,activity monitor,wear
7938,Theywill,education classes,attend
7939,Participants,activity monitor,wear
7940,Participants,aerobic exercise,perform
7941,Participants,weekly education sessions,have
7942,Male,18 80 years2,aged
7943,Ongoing tobacco and/or nicotine product,14,use
7944,population,study entrycriteria,enrolled in
7945,ClinicalTrials.gov,data,processed
7946,Participants,inpatient medical treatment,receiveregular
7947,Participants,lasertreatments,receive
7948,ClinicalTrials.gov,data,processed
7949,lung specimens,diffuse alveolar damage,seen whileautopsy
7950,ClinicalTrials.gov,data,processed
7951,ClinicalTrials.gov,data,processed
7952,ClinicalTrials.gov,data,processed
7953,Subjects,informed consent,provides
7954,Hg,oxygen concentration,inspired
7955,subject,therapy.7,Known alpha-1 antitrypsin deficiency for
7956,ClinicalTrials.gov,data,processed
7957,Danish Health Authorities inother countries,different recommendations,have
7958,virus,onsurfaces,known
7959,use,frequency,reduce
7960,participants,authority recommendations,follow
7961,virus,onsurfaces,known
7962,use,frequency ofCOVID-19 infection,reduce
7963,participant,written information,receive
7964,participant,set,receive
7965,ClinicalTrials.gov,data,processed
7966,Willingness,restrictions.9,study
7967,participants,intraarticular,Note
7968,ClinicalTrials.gov,data,processed
7969,Pragmatic,controlled trial,randomized
7970,comorbidities,fortherapeutic support,Variables
7971,Description,incidences,ofaccumulated
7972,drug,highestprobability,calculated
7973,study,risk,has
7974,protocol,evaluation,undergo
7975,protocol,the Helsinki Declaration,follows
7976,thesame Recovery study,results,published
7977,drug,record,have
7978,drug,15 percent superiority,show
7979,drug,objective,meet
7980,Moderate pneumonia,greater 1 Oxygen saturation,score
7981,ClinicalTrials.gov,data,processed
7982,Safety information,adverse events,include
7983,ClinicalTrials.gov,data,processed
7984,study,risk factors,characterize
7985,ClinicalTrials.gov,data,processed
7986,ClinicalTrials.gov,data,processed
7987,patientswill,either 2.5 mg/day,receive
7988,patients,laboratoryassessment,undergo
7989,ClinicalTrials.gov,data,processed
7990,ClinicalTrials.gov,data,processed
7991,ClinicalTrials.gov,data,processed
7992,Laboratory,diagnosis,confirmed
7993,ClinicalTrials.gov,data,processed
7994,HIV positive participants,500 for ≥ 12 months and on astable HIV antiretroviral regimen may be,Note
7995,Participants,contraception requirements,follow
7996,ClinicalTrials.gov,data,processed
7997,ClinicalTrials.gov,data,processed
7998,SARS CoV-2,France,epidemicaffected
7999,The Montpellier University Hospital,clinical pathway,set up
8000,ClinicalTrials.gov,data,processed
8001,COVID-19 pandemic,10 million infections,caused
8002,ClinicalTrials.gov,data,processed
8003,ClinicalTrials.gov,data,processed
8004,Provide,informed consent,written
8005,ClinicalTrials.gov,data,processed
8006,B38-CAP homolog,structural similarity,shares
8007,Invitro recombinant B38-CAP protein,conversion,catalyzed
8008,paper,dose dependent effect,had
8009,ClinicalTrials.gov,data,processed
8010,regulatory agencies,testing,performed in
8011,21 CFR 630.30)Recipient Eligibility,high risk feature,diagnosed with
8012,Peripheral vascular disease,aortic aneurysm,includes
8013,Diabetes,diet-controlled alone)12,excludes
8014,ClinicalTrials.gov,data,processed
8015,ClinicalTrials.gov,data,processed
8016,findings,the Spanish Agency for Medicine and Health Products,led
8017,ClinicalTrials.gov,data,processed
8018,study,focus,include
8019,researchers,researchers,contacted by
8020,Time,symptoms,reported
8021,Unexplained syncope,sudden cardiac death,ofpremature
8022,ClinicalTrials.gov,data,processed
8023,Patients,eligibilitycriteria,screened
8024,ClinicalTrials.gov,data,processed
8025,ClinicalTrials.gov,data,processed
8026,Theymust,highly effective licensed method,using
8027,ClinicalTrials.gov,data,processed
8028,investigators,theaccrual pending safety evaluation,pause
8029,investigators,28 patients,enrolladditional
8030,1500 mm3,"<100,000/mm32",platelets
8031,ClinicalTrials.gov,data,processed
8032,ClinicalTrials.gov,data,processed
8033,study,secondary infection rate,investigate
8034,Additional secondary objectives,determination,include
8035,ClinicalTrials.gov,data,processed
8036,ClinicalTrials.gov,data,processed
8037,Severe patients,access,require
8038,ClinicalTrials.gov,data,processed
8039,ClinicalTrials.gov,data,processed
8040,metabolic ketosis,systemic inflammation,reduces
8041,Coronavirus disease,closer 0.7 % ofconfirmed cases,spread
8042,patients,amean,had amean
8043,theketone body beta hydroxybutyrate,NLRP3 inflammasome mediated production,inhibited
8044,ClinicalTrials.gov,data,processed
8045,salt concentration,solubility limit,reaches
8046,ClinicalTrials.gov,data,processed
8047,Change,Social Distancing Protocols,Loneliness During
8048,dissemination,information,procedureinvolved
8049,interactions,tests,represent
8050,Identifier,data,Clinicaltrials.gov
8051,complementsystem,central role,shown
8052,complementsystem,central role,shown
8053,Identifier,data,Clinicaltrials.gov
8054,Male female patients,≥18,aged
8055,Identifier,data,Clinicaltrials.gov
8056,feasibility,feasibility,Assess
8057,Trained health workers,home care monitoring,conduct
8058,Identifier,data,Clinicaltrials.gov
8059,Identifier,data,Clinicaltrials.gov
8060,Mechanical ventilation,mortality,decreases
8061,Identifier,data,Clinicaltrials.gov
8062,High Dose,Nitric Oxide,Inhaled
8063,Identifier,data,Clinicaltrials.gov
8064,Inclusion Criteria:-COVID-19 infection,disease manifestation,confirmed
8065,Identifier,data,Clinicaltrials.gov
8066,Treatment,12h,occurevery
8067,Identifier,data,Clinicaltrials.gov
8068,Identifier,data,Clinicaltrials.gov
8069,Isoflurane,COVID-19 Patients,Observe
8070,Isoflurane,COVID-19 Patients,Observe
8071,inhalation anesthetics,replication,inhibit
8072,C5-COV patients,additional procedures,have
8073,Severe COVID-19 patients,mechanical ventilationto support lung function,need
8074,technology,nanoneedlebiosensors,uses
8075,analyte specific sensing areaconsists,wider dynamic range,providinga
8076,Identifier,data,Clinicaltrials.gov
8077,armsclinical trial,daily evaluation oftemperature,means
8078,death,theprecise circumstances,transmitted
8079,COVID19,ACE2,use
8080,Identifier,data,Clinicaltrials.gov
8081,cytokine storm,person breathingdifficulties,exacerbates
8082,Identifier,data,Clinicaltrials.gov
8083,IFN,type III interferon,Interferon Lambda
8084,180 mcg,S.C,Lambda
8085,participation,Patients risk,Patients for
8086,standard drink,14 g,contains
8087,cell,"3,000 cells",count
8088,patients,onanticoagulant medications,maintained
8089,Identifier,data,Clinicaltrials.gov
8090,Identifier,data,Clinicaltrials.gov
8091,The aimis,safety,assess
8092,Identifier,data,Clinicaltrials.gov
8093,Identifier,data,Clinicaltrials.gov
8094,Identifier,data,Clinicaltrials.gov
8095,Inclusion Criteria:-Patients,visit,admitted to
8096,Identifier,data,Clinicaltrials.gov
8097,Subjects,additional tests,undergo
8098,Identifier,patient data,Clinicaltrials.gov
8099,Identifier,data,Clinicaltrials.gov
8100,quality,courseof disease,determines
8101,Identifier,data,Clinicaltrials.gov
8102,Imatinib,anti - inflammatory activity,has
8103,results,therapeuticpotential,suggest
8104,investigators,addition,hypothesize
8105,"/dL -AST, ALT",5,phosphatase
8106,Identifier,data,Clinicaltrials.gov
8107,Notable exclusion criteria,admission,include
8108,Notable secondary clinicaloutcomes,30-day mortality,include
8109,Secondary exploratory objectives,eradication,willexamine
8110,Baseline,interval,corrected
8111,Identifier,data,Clinicaltrials.gov
8112,Patient,confirmed positive SARS CoV-2 PCR test result,had
8113,Patient,capacity,have
8114,Identifier,data,Clinicaltrials.gov
8115,study,safety,assess
8116,Identifier,data,Clinicaltrials.gov
8117,Identifier,data,Clinicaltrials.gov
8118,multi center open randomized study,efficacy,evaluate
8119,Pulmonary imaging,lesion progression,shows
8120,Identifier,data,Clinicaltrials.gov
8121,Identifier,data,Clinicaltrials.gov
8122,the Wuhan Municipal Health Committee,outbreak,identified
8123,set,predicted binding,confirmed
8124,famotidine,attractive proven safety,has
8125,Unpublished anecdotal case studies,clinicalbenefits,suggest
8126,ofRemdesivir,known potential risks,outweigh
8127,radiographic,COVID-19 disease,confirmed
8128,imaging,signs,show
8129,Identifier,data,Clinicaltrials.gov
8130,Participants,10-day treatment,undergo
8131,Identifier,data,Clinicaltrials.gov
8132,Identifier,data,Clinicaltrials.gov
8133,COVIDAXIS trial,chemoprophylaxis,evaluates
8134,Identifier,data,Clinicaltrials.gov
8135,Self reported eating habits,validated questionnaires,collectedusing
8136,Identifier,data,Clinicaltrials.gov
8137,Identifier,data,Clinicaltrials.gov
8138,study,effects,evaluates
8139,study,effects,evaluates
8140,COVID psychiatry units,similar feedback,report
8141,TheSARS CoV-2,characteristics,has
8142,Drug repositioning,possible alternative,represents
8143,Identifier,data,Clinicaltrials.gov
8144,Identifier,data,Clinicaltrials.gov
8145,drugs,ACE2 expression,increase
8146,Population,patients,Hospitalized
8147,Classification,criteria,follow
8148,Identifier,data,Clinicaltrials.gov
8149,ClinicalTrials.gov,data,processed
8150,ClinicalTrials.gov,data,processed
8151,study,simulated CPR scenario,forsees
8152,participant,5sequences,perform
8153,Croce,symptoms,"Bianca""-Aged"
8154,ClinicalTrials.gov,data,processed
8155,ClinicalTrials.gov,data,processed
8156,individual,criteria,meet
8157,ClinicalTrials.gov,data,processed
8158,ICU-,chest X ray,follow up
8159,ClinicalTrials.gov,data,processed
8160,Phase II Study,Fostamatinib,Evaluating
8161,Theywill,blood test,have
8162,Theywill,COVID-19 test,have
8163,Theywill,pregnancy test,take
8164,Participants,physical exam,have
8165,patients,organdysfunction,develop
8166,therapies,efficacy,shown
8167,Laboratory,SARS CoV-2 RT PCR test,confirmed
8168,Neutrophil,<1000/microliter9,count
8169,ClinicalTrials.gov,data,processed
8170,hospital presidents,study,approved
8171,ClinicalTrials.gov,data,processed
8172,moderate doses,15 % absolutereduction,Villar et al in
8173,Horby et al,thatdexamethasone,reported
8174,These two RCTs,practice,changeclinical
8175,ClinicalTrials.gov,data,processed
8176,ClinicalTrials.gov,data,processed
8177,COVID-19 outbreak,global public healthemergency,constitutes
8178,ClinicalTrials.gov,data,processed
8179,Prone Positioning,Induced Moderate to Severe ARDS,Combined With
8180,Twenty-nine percent,ARDS,develop
8181,patients,a consistent SpO2<80%,have
8182,ClinicalTrials.gov,data,processed
8183,Bipolar Depression,Electroconvulsive Therapy,A Novel and Practical Accelerated Low-frequency Right-sided Stimulation Protocol
8184,ClinicalTrials.gov,data,processed
8185,ClinicalTrials.gov,data,processed
8186,Adult patients,hospitals,admitted
8187,Inclusion Criteria:-Adult patients,hospitals,admitted
8188,ClinicalTrials.gov,data,processed
8189,Study,success,reports
8190,COVID 19,tocoronavirinae sub family coronaviridae family,belongs
8191,continuously evolving understanding,tremendous agility,demands
8192,African countries,African countries fair share,had
8193,Introduction Coronavirus disease 2019,Introduction Coronavirus disease 2019,developed
8194,real time assays,40 cycles,undergo
8195,Previous studies,increased age pre - existing concurrent cardiovascular orcerebrovascular diseases,opined
8196,Previous studies,increased age pre - existing concurrent cardiovascular orcerebrovascular diseases,opined
8197,Physiotherapy,significant effect,have
8198,ClinicalTrials.gov,data,processed
8199,ClinicalTrials.gov,data,processed
8200,ClinicalTrials.gov,data,processed
8201,uncertainties,psychological effects,used
8202,ClinicalTrials.gov,data,processed
8203,TheFrench government,quantitative target,set
8204,type,technical,has
8205,ClinicalTrials.gov,data,processed
8206,drug,replication,is
8207,nursing homes,measures,taking
8208,modifications,objectives,affect
8209,ClinicalTrials.gov,data,processed
8210,ClinicalTrials.gov,data,processed
8211,65 mmHg Patient,history,reported
8212,ClinicalTrials.gov,data,processed
8213,study,genders,includes
8214,ClinicalTrials.gov,data,processed
8215,ClinicalTrials.gov,data,processed
8216,fact,decrease,identified
8217,SMILE,a top technology dual-source CT scanner(Somatom Force,utilizes
8218,- evaluation,sensitivity andspecificity,improve
8219,ML analysis,predictive algorithm,generate
8220,ClinicalTrials.gov,data,processed
8221,interested participant,research,email
8222,follow,sedentary behaviour measurement,This willserve
8223,Theparticipants,reminder email,receive
8224,Follow,weeks post - intervention,occur
8225,Participants,allsecondary outcomes,recomplete
8226,ClinicalTrials.gov,data,processed
8227,vast majority,mild illness,have
8228,small significant number,andrequire hospitalization,deteriorate
8229,Technologiesfor clinical management,thischallenge,address
8230,Delayed detection ofdeterioration,patient outcomes,worsens
8231,ClinicalTrials.gov,data,processed
8232,Favipiravir,anti - viral activity,shown
8233,unit,250 mL beer,History of
8234,ClinicalTrials.gov,data,processed
8235,patient,2 studies,have
8236,patients,changes,had
8237,ClinicalTrials.gov,obtained anonymized data,processed
8238,ClinicalTrials.gov,data,processed
8239,study,updates,utilizes
8240,ClinicalTrials.gov,data,processed
8241,workersExclusion Criteria:-Intolerance,bitter sensation,taste
8242,ClinicalTrials.gov,data,processed
8243,participants,questions,answered
8244,study,principles,obtained from
8245,short form,informationabout,provides informationabout
8246,Total scorecalculation,sum,included
8247,ClinicalTrials.gov,data,processed
8248,ClinicalTrials.gov,data,processed
8249,clinical trial,safety,evaluate
8250,ClinicalTrials.gov,data,processed
8251,ClinicalTrials.gov,data,processed
8252,study,risk,alsoestimate
8253,ClinicalTrials.gov,data,processed
8254,Compassionate,Open Label Anti - CD14 Treatment,Use
8255,Compassionate,Open Label Anti - CD14 Treatment,Use
8256,attempt resuscitation,status3,intubate
8257,Known HIV,200 cells,count
8258,ClinicalTrials.gov,data,processed
8259,cohort,8 participants,comprise
8260,enrolled participants,study,enrolled
8261,Males,≥18 years old.3,aged
8262,ClinicalTrials.gov,data,processed
8263,Itshould,impact,demonstrate
8264,study group,patients,comprise
8265,ClinicalTrials.gov,data,processed
8266,US).DiaNose system,following elements,made of
8267,ClinicalTrials.gov,data,processed
8268,ClinicalTrials.gov,data,processed
8269,study,safety,assess
8270,ClinicalTrials.gov,data,processed
8271,People,hyper inflammatory response,have
8272,Bruton tyrosine kinase,role,plays
8273,Participants,4 blood samples,give
8274,Participants,stool sample,give
8275,Participants,draws,have
8276,Documented history,7g/,draw
8277,ClinicalTrials.gov,data,processed
8278,ClinicalTrials.gov,data,processed
8279,Mortality,secondary endpoint,willbe
8280,ClinicalTrials.gov,data,processed
8281,ClinicalTrials.gov,data,processed
8282,ClinicalTrials.gov,data,processed
8283,polyphenol inhibitscoronavirus replication,specific molecular targets,supports
8284,ClinicalTrials.gov,data,processed
8285,infection,topneumonia,leads
8286,Participants,study visits,have
8287,population,study entrycriteria,enrolled in
8288,participation,effect,havean
8289,ClinicalTrials.gov,data,processed
8290,ClinicalTrials.gov,data,processed
8291,ClinicalTrials.gov,data,processed
8292,ClinicalTrials.gov,data,processed
8293,information,patient demographics,include
8294,Laboratory,diagnosis,confirmed
8295,300,> 50%,defined
8296,ClinicalTrials.gov,data,processed
8297,Anecdotal,presence,evidencesuggests
8298,Isolated reports,fulminantmyocarditis,described
8299,Angiotensin,2,converting
8300,loss,protective roles,shown
8301,Systematic cardiac autopsy study,pathology,made with
8302,ClinicalTrials.gov,data,processed
8303,Study Chair CTC CLINICAL TRIAL CENTER,date,start
8304,Stoppage criteria,immediate cessation,warrant
8305,Hg diastolic,apart.-Need,recorded on
8306,ClinicalTrials.gov,data,processed
8307,positive patients,55,aged
8308,ClinicalTrials.gov,data,processed
8309,Patients,rapid disease progression,have
8310,thesemanagements,lethal lung injury,treat
8311,Patients,combined treatment,received
8312,ClinicalTrials.gov,data,processed
8313,corona virus,people,infect
8314,positive,participation,stopped
8315,ClinicalTrials.gov,data,processed
8316,ClinicalTrials.gov,data,processed
8317,ClinicalTrials.gov,data,processed
8318,Selected DrugsIvermectin,anti - parasitic effect,has
8319,Ivermectin,established safety profile,has
8320,Warfarin,anticoagulant activities,decrease
8321,Early detection,major difference,make
8322,ClinicalTrials.gov,data,processed
8323,ClinicalTrials.gov,data,processed
8324,ClinicalTrials.gov,data,processed
8325,Male,> 18 years2,aged
8326,ClinicalTrials.gov,data,processed
8327,ClinicalTrials.gov,data,processed
8328,Standard ethiptropic therapy,umifenovir,includes
8329,Pilot Study,period,include
8330,severe chronic cardiovascular disorders,pacemaker device,implanted
8331,ClinicalTrials.gov,data,processed
8332,ClinicalTrials.gov,data,processed
8333,SARS CoV-2 virus,theairway,enters
8334,2020).The SARS CoV-2 virus,airway,enters
8335,ACE2,transformation,catalyzes
8336,angiotensin 1-7,opposite effects,causes
8337,Partial decrease,deviation,resultsin
8338,Telmisartan,10-fold higher blocking potency,has
8339,ClinicalTrials.gov,data,processed
8340,ClinicalTrials.gov,data,processed
8341,Follicle,hormone FSH levels,defined
8342,Prior current infection,throat nose swab,tested
8343,ClinicalTrials.gov,data,processed
8344,virus family,upperrespiratory tract disease,causes
8345,ClinicalTrials.gov,data,processed
8346,Male,18.4,aged
8347,ClinicalTrials.gov,data,processed
8348,Study subjects,screening evaluations,undergo
8349,Bothtreatment arms,remdesivir,receive
8350,remdesivir)-Able,consent,Agree to
8351,ClinicalTrials.gov,data,processed
8352,ClinicalTrials.gov,data,processed
8353,ClinicalTrials.gov,data,processed
8354,Patients,risk,increased
8355,Larger clinical trials,significant efficacy,shown
8356,natural Ta1,improvement,demonstrated
8357,ClinicalTrials.gov,data,processed
8358,severely ill patients,theconvalescent plasma treatment,interrupted
8359,symptom,less than 10 days,Time
8360,ClinicalTrials.gov,data,processed
8361,acute respiratory illness,novel SAR CoV-2,causedby
8362,the Wuhan Municipal Health Committee,outbreak,identified
8363,patient,immune response,develops
8364,virus,entry,is
8365,local study coordinator,study data,collect
8366,ClinicalTrials.gov,data,processed
8367,SARS CoV,out- break,caused
8368,ClinicalTrials.gov,data,processed
8369,Patients,level care,need
8370,ClinicalTrials.gov,data,processed
8371,Marital Status,regular employment status,includes
8372,ClinicalTrials.gov,data,processed
8373,study,singular intramuscular administration,evaluate
8374,ClinicalTrials.gov,data,processed
8375,Long term outcomes,daily living status,collect
8376,ongoing pandemic,worldwide increasein hospitalization,caused
8377,study,survivors,enroll
8378,ClinicalTrials.gov,data,processed
8379,Chloroquine Phosphate Prophylactic Use,Patients,Exposed to
8380,Efficacy,Patients,Exposed to
8381,Health Care Workers,COVID-19 patients,exposed to
8382,ClinicalTrials.gov,data,processed
8383,Participantswill,detailed medical history,provide
8384,ClinicalTrials.gov,data,processed
8385,lung,organ function,compromising
8386,⍺ 1-AR antagonist prazosin,cytokine stormand,prevents
8387,ClinicalTrials.gov,data,processed
8388,Patients,confirmed diagnosis,have
8389,ClinicalTrials.gov,data,processed
8390,data sharing andsequencing data,development,facilitated
8391,at least 30%,critical care admission,required
8392,ClinicalTrials.gov,data,processed
8393,Secondary outcomes,personal decisions,include
8394,ClinicalTrials.gov,data,processed
8395,study personnel,proper PPE,have
8396,patientwill,respiratory filter,placed into
8397,patient willthen,90 minutesof hyperbaric oxygen,receive
8398,ClinicalTrials.gov,data,processed
8399,participants,focused lung ultrasoundexamination,undergo
8400,ClinicalTrials.gov,data,processed
8401,Marshallese,online telephone survey,complete
8402,Criteria:-,inclusion criteria,meet
8403,ClinicalTrials.gov,data,processed
8404,data,important information,reveal
8405,Users,free app,download
8406,ClinicalTrials.gov,data,processed
8407,Study participantswill,2 mg/day,receive
8408,ClinicalTrials.gov,data,processed
8409,ACTT-2,combination,evaluate
8410,infection control,ability,limit
8411,Day 22 visit,laboratory tests,nothave
8412,Open Label Single Center Study,different investigational therapeutic agents,compare
8413,ACTT-2,combination,evaluate
8414,infection control,ability,limit
8415,Day 22 visit,laboratory tests,nothave
8416,subjects,series,undergo
8417,subject,visit,is
8418,stage,different secondary endpoints,mayprioritize
8419,absolute lymphocyte,200 cells microliter,Lymphopenia (
8420,ClinicalTrials.gov,data,processed
8421,ClinicalTrials.gov,data,processed
8422,2020 theInternational Health Regulations Emergency Committee,"outbreak a""public health emergency",declared
8423,Spanish President,nationalemergency,outbreak
8424,studies,presence,reported
8425,ClinicalTrials.gov,data,processed
8426,Participants,sampling,undergointensive
8427,ClinicalTrials.gov,data,processed
8428,ClinicalTrials.gov,data,processed
8429,Frontline NHS staff,highest likelihood,contacthave
8430,Frontline NHS staff,highest likelihood,contacthave
8431,Participants,brief questions,complete
8432,ClinicalTrials.gov,data,processed
8433,Sphingosine-1-phosphate receptor,controlvascular leakage,ligands
8434,ClinicalTrials.gov,data,processed
8435,CALAVI US,safety,investigate
8436,Suspected,bacterial,uncontrolled
8437,aspartate aminotransferase,≥,limit of
8438,ClinicalTrials.gov,data,processed
8439,ClinicalTrials.gov,data,processed
8440,Participants,1 capsule,take
8441,doctors,information,collect
8442,Inclusion Criteria:-Age,written informed consent,hospitalised
8443,ClinicalTrials.gov,data,processed
8444,COVID-19 disease,worldwide attention,received
8445,strong arguments,study ofprobiotics,support
8446,participant,questionnaire thatwill focus,complete
8447,ClinicalTrials.gov,data,processed
8448,ClinicalTrials.gov,data,processed
8449,term cytokine storm,attention,captured
8450,investigators,successful phase 1b clinicaltrial,completed
8451,The SOC,Clexane,include
8452,ClinicalTrials.gov,data,processed
8453,ClinicalTrials.gov,data,processed
8454,Group,exchange transfusion,receive
8455,methyl,1 mg/ IV,Steroid
8456,ECG,daily.3,changes
8457,ClinicalTrials.gov,data,processed
8458,PROTECT open label randomised basket trial,effectiveness ofhydroxychloroquine,assess
8459,toCOVID-19.The master PROTECT protocol,core components,describes
8460,ClinicalTrials.gov,data,processed
8461,ClinicalTrials.gov,data,processed
8462,Treatment groups,Hyperbaric Oxygen Therapy,undergo
8463,Bothpopulations,inpatient medical treatment,receive
8464,patients,hyperbaric oxygen therapy,undergo
8465,ClinicalTrials.gov,data,processed
8466,ClinicalTrials.gov,data,processed
8467,duration,7 days study treatment,subjectincludes
8468,patients,theirclinical signs,document
8469,patients,clinical signs,document
8470,willbe,Physical examination,performed
8471,patients,patients clinical signs,document
8472,ClinicalTrials.gov,data,processed
8473,Therapeutic Plasmapheresis,Confirmed Diagnosis,confirmed
8474,current outbreak,more than two million,left
8475,ClinicalTrials.gov,data,processed
8476,ClinicalTrials.gov,data,processed
8477,ClinicalTrials.gov,data,processed
8478,Systematic Assessment,COVID-19,Patients Who Died From virologically confirmed
8479,Systematic Assessment,COVID-19,Patients Who Died From virologically confirmed
8480,ClinicalTrials.gov,data,processed
8481,Manifestations,shortness,include
8482,ClinicalTrials.gov,data,processed
8483,Prospective Observational Cohort Study,Long term Pulmonary Extrapulmonary Effects,Investigate
8484,Prospective Observational Cohort Study,Long term Pulmonary andExtrapulmonary Effects,Investigate
8485,nation wide Swiss COVID-19 lung group,meticulously characterizedprospective cohort study,establishes
8486,Inclusion Criteria:-Signed,informed consent.-All adult patients,written
8487,precluding,consent,informed
8488,ClinicalTrials.gov,data,processed
8489,ClinicalTrials.gov,data,processed
8490,Low dose lung radiotherapy,survival,improve
8491,Coronavirus disease,high mortality rate,carry
8492,ClinicalTrials.gov,data,processed
8493,Eligible participants,plasma,receive
8494,participants,series,undergo
8495,participantscan,longitudinal samples,provide
8496,Laboratory,diagnosis,confirmed
8497,ClinicalTrials.gov,data,processed
8498,ClinicalTrials.gov,data,processed
8499,invasive mechanical ventilation,participants,inhospitalized
8500,Subject,informed consent,provides
8501,Subject,known anaphylactic reaction,had
8502,Subject,therapy.7,Known alpha-1 antitrypsin deficiency for
8503,Platelet,"75,000 mm3",count
8504,Subject,history,has
8505,ClinicalTrials.gov,data,processed
8506,outcomes,thromboembolic venous disease,is
8507,investigator led non - commercial non - interventional study,patient identifiable information,collect
8508,ClinicalTrials.gov,data,processed
8509,ClinicalTrials.gov,data,processed
8510,National Cohort Study,adults,enroll
8511,Allparticipants,series,undergo
8512,ClinicalTrials.gov,data,processed
8513,ClinicalTrials.gov,data,processed
8514,ClinicalTrials.gov,data,processed
8515,ClinicalTrials.gov,data,processed
8516,pandemic,patients,threatens
8517,Thehost immunity,progress,determines
8518,associatedcytokine storm,lungs,affects
8519,participants,written consent,sign
8520,assessment,nutritional screening,include
8521,Criteria:-Tube,24 hours participation,feeding
8522,ClinicalTrials.gov,data,processed
8523,Immunoprophylaxis,irreplaceable protection,represents
8524,results,promise,shown
8525,evidence,safetyof convalescent plasma treatments,confirmed
8526,ClinicalTrials.gov,data,processed
8527,Primary secondary evaluations,assessment,include
8528,ClinicalTrials.gov,data,processed
8529,patients,atypical blood clots,have
8530,Participants,treatments,receive
8531,ClinicalTrials.gov,data,processed
8532,ClinicalTrials.gov,data,processed
8533,SARS CoV-2 virus,pandemic,caused
8534,data,theresponse,affect
8535,people,SARS CoV-2 virus,learn
8536,Participants,30-minute visits,have
8537,participants,online survey aboutthemselves,take
8538,ClinicalTrials.gov,data,processed
8539,patients,acardiovascular disease,got
8540,ClinicalTrials.gov,data,processed
8541,subjects,symptomsconsistent,Follow-upwould consist of
8542,ClinicalTrials.gov,data,processed
8543,randomized double blind placebo controlled trial,subjects,enroll
8544,Subjects,Screening,complete
8545,randomized double blind placebo controlled trial,subjects,enroll
8546,Subjects,Screening,complete
8547,COVID-19 outcomes,orrespiratory conditions,collected
8548,IL-1 IL-6 IL-10 TNF α,upper limit,defined
8549,ClinicalTrials.gov,data,processed
8550,ClinicalTrials.gov,data,processed
8551,investigators,arandomized double blind placebo controlled study design,employ
8552,ClinicalTrials.gov,data,processed
8553,ClinicalTrials.gov,data,processed
8554,ClinicalTrials.gov,data,processed
8555,the Sponsor,dose regimen,evaluate
8556,female subject,one of the following conditions,meet
8557,Provides,informed consent,signed
8558,ClinicalTrials.gov,data,processed
8559,Observationsfrom Study,conduct,inform
8560,Observationsfrom,conduct,inform
8561,Laboratory,infection,confirmed
8562,Presence,"50,000 per mm3",platelets
8563,ClinicalTrials.gov,data,processed
8564,ClinicalTrials.gov,data,processed
8565,Rationally adjustment,microbiological diagnosis,antibiotherapyrequires
8566,investigators,rapid molecular test,performed
8567,ClinicalTrials.gov,data,processed
8568,ClinicalTrials.gov,data,processed
8569,ClinicalTrials.gov,data,processed
8570,Study,treatment,evaluates
8571,Investigator,data collection,maintain
8572,ALT)/aspartate aminotransferase,over 5 times the ULN;4,elevated
8573,COVID-19,immediate treatment,beused
8574,ClinicalTrials.gov,data,processed
8575,COVID-19 pandemic,major disruption,caused
8576,safe effective vaccinefor COVID 19 prevention,significant global public health impact,have
8577,Inclusion Criteria:-Participants,18 to 55 years,aged
8578,ClinicalTrials.gov,data,processed
8579,patients,huge ongoing challenge,pose
8580,Allparticipants,standard care,receive
8581,ClinicalTrials.gov,data,processed
8582,Somelimited observational trials,benefitof hydroxychloroquine,shown
8583,ClinicalTrials.gov,data,processed
8584,the HCoV-19,nervous system,involve
8585,MSCs,positive role,playa
8586,Participant,informed consent,signed
8587,ClinicalTrials.gov,data,processed
8588,COVID-19 patients,high prevalence,havea
8589,ClinicalTrials.gov,data,processed
8590,ClinicalTrials.gov,data,processed
8591,ClinicalTrials.gov,data,processed
8592,ClinicalTrials.gov,data,processed
8593,Study D822FC00005,Phamacokinetics Safety tolerability ofAcalabrutinib suspension,investigate
8594,ClinicalTrials.gov,data,processed
8595,study,different investigational therapeutic agents,compare
8596,study,different investigational therapeutic agents,compare
8597,subjects,study visit,have
8598,infection control,theability,limit
8599,Day 22 visit,tests,havelaboratory
8600,subjects,series,undergo
8601,subject,visit,is
8602,ClinicalTrials.gov,data,processed
8603,ClinicalTrials.gov,data,processed
8604,HCWs,infection,is
8605,studies,COVID-19 Infection,investigated
8606,ClinicalTrials.gov,data,processed
8607,ClinicalTrials.gov,data,processed
8608,ClinicalTrials.gov,data,processed
8609,ClinicalTrials.gov,data,processed
8610,COVID-19and,outcomes,compare
8611,COVID-19 - Cytokine Storm,attention,captured
8612,publications,importantpart,indicated
8613,Infection,outcomes,andcompare
8614,ClinicalTrials.gov,data,processed
8615,researchers,clinical trials,havecarried out
8616,Trials,usedantivirals,have
8617,patients,2x10 ^ 6 cells,receive
8618,Cell Lab,dose Administration,issue
8619,ClinicalTrials.gov,data,processed
8620,Project,tests,evaluate
8621,cough andto,patients,intended for
8622,use,management,improve
8623,ClinicalTrials.gov,data,processed
8624,ClinicalTrials.gov,data,processed
8625,ClinicalTrials.gov,data,processed
8626,ClinicalTrials.gov,data,processed
8627,outbreakstarted,outbreakstarted,recognized
8628,fromprimary cases,identification,permit
8629,households.a household study design,evaluation,includes
8630,Medical staff,appropriate protective medical gear.3,use
8631,ClinicalTrials.gov,data,processed
8632,Project,single arm phase,includes
8633,emergency conditions,registration,prevented
8634,participants,dose,receive
8635,conditions,it)4,allow it)4
8636,ClinicalTrials.gov,data,processed
8637,ClinicalTrials.gov,data,processed
8638,ClinicalTrials.gov,data,processed
8639,whowill,changes,measure
8640,Chlorine,"3,000 ppm",dioxide
8641,researchers,complete virus vaccine,aim
8642,the Russian Ministry of Health,Russian hospitals,provided
8643,Chloroquine phosphate,apparent efficacy,shown
8644,Biochemistry,cell protection,defines
8645,Chlorine dioxide,viruses,removes
8646,New studies,New studies viability,demonstrate
8647,Nucleic acids,chain,consistof
8648,chlorine dioxide,genetic mutations,cause
8649,Orally administered chlorine dioxide,COVID infection,eliminates
8650,ClinicalTrials.gov,data,processed
8651,ClinicalTrials.gov,data,processed
8652,ClinicalTrials.gov,data,processed
8653,LTCH units,outbreak,randomized to
8654,ClinicalTrials.gov,data,processed
8655,ClinicalTrials.gov,data,processed
8656,clinical condition,rapidly2,Any patient
8657,ClinicalTrials.gov,data,processed
8658,ClinicalTrials.gov,data,processed
8659,Around 30%,hyper inflammatory statewhose progression,prevented by
8660,ClinicalTrials.gov,data,processed
8661,ClinicalTrials.gov,data,processed
8662,ClinicalTrials.gov,data,processed
8663,Platelet,"20,000 μL2",counts
8664,ClinicalTrials.gov,data,processed
8665,available kits,byHVD,supplied
8666,assay,entirecoronavirus genome,surveying
8667,Coronavirus variants,throughantigenic shift,emerge
8668,Ion Torrent targetednext generation sequencing,streamlined research workflow,enables
8669,ClinicalTrials.gov,data,processed
8670,Patient sampling locations,nasopharynx,includethe
8671,Operating room environmental locations,areas patient care arena,include
8672,normal environmental cleaning,place,used after
8673,normal environmental cleaning,place,used after
8674,ClinicalTrials.gov,data,processed
8675,Previous severe allergic reactions,occurred.7,have
8676,known suspected diseases,acute respiratory diseases,include
8677,ClinicalTrials.gov,data,processed
8678,Study,Demographic variables,considered
8679,risk factors,andmechanical ventilation,mcL
8680,Study,hospitalized patients,include
8681,ClinicalTrials.gov,data,processed
8682,Nitazoxanide,SARs CoV-2,inhibited
8683,Nitazoxanide,excellent drug drug interaction profile,has
8684,investigators,Nitazoxanide,propose
8685,persons,anenhanced risk group,constitute
8686,Phase 2b/3 clinical trial,thatoral administration,found
8687,Nitazoxanide,glycosylation,inhibit
8688,Nitazoxanide,inhibitoryactivity,exhibits
8689,investigators,randomised placebo controlled trialrecruiting,perform
8690,rate,hospitalisation rates,determine
8691,Patients,patient being.4,compromise
8692,ClinicalTrials.gov,data,processed
8693,ClinicalTrials.gov,data,processed
8694,ClinicalTrials.gov,data,processed
8695,Smoking,changes,causes
8696,COVID-19,smokers,understand
8697,Participants,6 monthly visits,have
8698,participants,blood tests,have
8699,Blood,saliva sample,provide
8700,Blood,questionnaires,complete
8701,Participants,monthly visits,have
8702,Participants,blood draws,have
8703,Participants,final visit,have
8704,Participants,blood tests,have
8705,smokers,higher risk,Early evidence in
8706,DNA methylation profiles,history,healthywith
8707,ClinicalTrials.gov,data,processed
8708,ClinicalTrials.gov,data,processed
8709,investigators,relationship,willexplore
8710,ClinicalTrials.gov,data,processed
8711,ClinicalTrials.gov,data,processed
8712,ClinicalTrials.gov,data,processed
8713,ClinicalTrials.gov,data,processed
8714,ClinicalTrials.gov,data,processed
8715,Proneposition,dependent lung regions,relieves
8716,ClinicalTrials.gov,data,processed
8717,COVID-19 pandemic,tremendous pressures,put
8718,biomarkers,increased erythrocyte sedimentation rates,include
8719,centers,utility,evaluated
8720,ClinicalTrials.gov,data,processed
8721,high doseThe iSRC,safety data,review
8722,WOCBP,negative urine pregnancy test,have
8723,ClinicalTrials.gov,data,processed
8724,Severe cases,typical course,mimic
8725,Early application ofthe GO2 PEEP MOUTHPIECE,outcomes,improve
8726,ClinicalTrials.gov,data,processed
8727,Participants,LY3819253,receive
8728,ClinicalTrials.gov,data,processed
8729,Evaluate,adverse reactions,ruxolitinib
8730,ClinicalTrials.gov,data,processed
8731,ClinicalTrials.gov,data,processed
8732,Study,600 adults,included
8733,Time,symptoms date,reported
8734,ClinicalTrials.gov,data,processed
8735,respiratory,globalpopulation,affected
8736,ClinicalTrials.gov,data,processed
8737,ClinicalTrials.gov,data,processed
8738,Study,safety,evaluate
8739,ClinicalTrials.gov,data,processed
8740,clinical characteristics,respiratory symptoms,include
8741,Critical illness,ICU support5,needs
8742,COVID-19,210 countries,spread
8743,arms,standard care,COVID-19
8744,ClinicalTrials.gov,data,processed
8745,CT,compatible pneumonia Suspected COVID-19 infection,showing
8746,ClinicalTrials.gov,data,processed
8747,subjects,series,undergo
8748,Inclusion Criteria:-Subject,written informed consent,provides
8749,ClinicalTrials.gov,data,processed
8750,Tracheobronchitis,the Main Sign of Respiratory Involvement,Constitute
8751,ClinicalTrials.gov,data,processed
8752,ClinicalTrials.gov,data,processed
8753,ClinicalTrials.gov,data,processed
8754,ClinicalTrials.gov,data,processed
8755,The NIV,intubtion rate,reduce
8756,The NIV,intubtion rate,reduce
8757,critically ill COVID-19 patients,intubtion,avoid
8758,ClinicalTrials.gov,data,processed
8759,TXA,infectivity andvirulence,hypothesized
8760,patients,apixaban 5 mg p.o . BID,receive
8761,Contact,ofdaily phone contact,consist
8762,ClinicalTrials.gov,data,processed
8763,ClinicalTrials.gov,data,processed
8764,Project,incorporation,pilot
8765,ClinicalTrials.gov,data,processed
8766,ClinicalTrials.gov,data,processed
8767,Convalescent Plasma,Disease Progression,Prevent
8768,ClinicalTrials.gov,data,processed
8769,Chinese scientists,genomeinformation,shared
8770,Thalidomide,angiogenesis,has
8771,total,cases nationwide(Hubei Province,confirmed
8772,Thalidomide,angiogenesis,has
8773,ClinicalTrials.gov,data,processed
8774,ClinicalTrials.gov,data,processed
8775,positive SARS CoV-2 carriage,written consent,given
8776,ClinicalTrials.gov,data,processed
8777,ill patients,one of the,meeting
8778,ClinicalTrials.gov,data,processed
8779,ClinicalTrials.gov,data,processed
8780,> 40 milligram,informed consent,provides
8781,ClinicalTrials.gov,data,processed
8782,ClinicalTrials.gov,data,processed
8783,ClinicalTrials.gov,data,processed
8784,subsequent follow phase,23 +3 days,comprises
8785,lung,>50%,infiltrates
8786,Subject,SoC treatment,receive
8787,ClinicalTrials.gov,data,processed
8788,Patients,COVID disease,Patient population
8789,median duration,impact,Evaluate
8790,ClinicalTrials.gov,data,processed
8791,ClinicalTrials.gov,data,processed
8792,ClinicalTrials.gov,data,processed
8793,Age,changeof status,predicted
8794,collaborators,recruitment,committedto
8795,ClinicalTrials.gov,data,processed
8796,patients,great benefit fromcorticosteroids,derive
8797,ClinicalTrials.gov,data,processed
8798,ClinicalTrials.gov,data,processed
8799,ClinicalTrials.gov,data,processed
8800,Participant,laboratory confirmed SARS CoV-2 infection,has
8801,ClinicalTrials.gov,data,processed
8802,the World Health Organization,coronavirus disease,declared
8803,deaths,"508,055 with a morality of 5.37%",confirmed in
8804,Egypt,"68,311confirmed cases",has
8805,Main symptoms,fever,include
8806,Common laboratory findings,lymphopenia,include
8807,Chestcomputed tomographic scans,typical pattern,show
8808,Atpresent,available therapeuticdrugs,repurposing
8809,Studies,light,shed
8810,(N=19,significantly better clinical outcomes,showed
8811,lung,> 50%,infiltrates
8812,ClinicalTrials.gov,data,processed
8813,NIRS,balance,reflects
8814,ClinicalTrials.gov,data,processed
8815,"more than 350,000",1,known to
8816,ClinicalTrials.gov,data,processed
8817,ClinicalTrials.gov,data,processed
8818,Hong Kong,"nearly 1,000 documented cases",seen
8819,Professor David SC HUI,publishedmultiple follow examinations,has
8820,COVID-19 patients,intensive care,require
8821,ManySARS survivors,post - traumatic stress disorder,developed
8822,Trauma,significant long term morbidity anddecreased quality,experienced
8823,patients,similar fate,suffer
8824,knowledge,SARS experience,gainedfrom
8825,ClinicalTrials.gov,data,processed
8826,Meplazumab,associated cytokine storm syndrome,inhibit
8827,total number,Stage 1 Day 29 visit procedures,stopped
8828,5 × ULN,5 ×,phosphatase
8829,ClinicalTrials.gov,data,processed
8830,Severe acute respiratory syndrome coronavirus,coronavirus disease,causes
8831,people,symptoms,have
8832,participants,bloodsamples,provide
8833,ClinicalTrials.gov,data,processed
8834,Subjects,informed consent,provide
8835,Subjects,laboratory confirmed SARS CoV-2 infection,have
8836,ClinicalTrials.gov,data,processed
8837,receptor availability,multi - organ involvement,suggests
8838,ClinicalTrials.gov,data,processed
8839,Subjects,symptoms,exhibit
8840,Subjects,at least one,have
8841,Subjects,documented positive test,have
8842,Health condition,safety,deemed to
8843,ClinicalTrials.gov,data,processed
8844,majority,mild symptoms,progress to
8845,Numerous preclinical studies,role,addressed
8846,Recent studies,antiviral activities,documented
8847,ClinicalTrials.gov,data,processed
8848,ClinicalTrials.gov,data,processed
8849,ClinicalTrials.gov,data,processed
8850,ClinicalTrials.gov,data,processed
8851,Prevention and/or treatment,large impact,have
8852,Previous study,2 arms,have
8853,Arm,patients,recruit
8854,Primary analysis,logistic regression,include
8855,ClinicalTrials.gov,data,processed
8856,ClinicalTrials.gov,data,processed
8857,100 g,20.1 gof protein,contain
8858,group,5 meals,needs
8859,vitamin D,functioning,modulates
8860,Investigators,contexts,examine
8861,Investigators,participant acts,like
8862,Patients,increased demand,have
8863,Selenium supplementation,viral rate3,reduces
8864,Selenium supplementation,the BMI,improves
8865,Selenium supplementation,COVID-19 related mortality6,postponed
8866,Nutrition education,health status8,improves
8867,acute cause,person,consider
8868,Clinical monitoring,episode,had
8869,ClinicalTrials.gov,data,processed
8870,hazard ratio,treatment,favor
8871,Inclusion Criteria:-19 years or,hospitalizationExclusion Criteria:-Sinonasal tumor Hypersensitivity,require
8872,ClinicalTrials.gov,data,processed
8873,Clinical studies,improvements,shown
8874,Inclusion Criteria:-Patients,≥,aged
8875,ClinicalTrials.gov,data,processed
8876,Patients,covalescent plasma,receive
8877,Patients,extracorporeal oxygenation,bestratified
8878,ClinicalTrials.gov,data,processed
8879,ClinicalTrials.gov,data,processed
8880,Secondary outcomes,clinical deterioration requiringadmission,include
8881,Inclusion Criteria:-Adult participant,tomography angiography,computed
8882,ClinicalTrials.gov,data,processed
8883,ClinicalTrials.gov,data,processed
8884,uric acid -Renal functions,function testsRandomization method,generated by
8885,Computer generatedrandom numbers,participants,randomize
8886,ClinicalTrials.gov,data,processed
8887,ClinicalTrials.gov,data,processed
8888,individuals,"SARS CoV-2,adults",affected
8889,ClinicalTrials.gov,data,processed
8890,sites,patients,enroll
8891,excess cytokines,secondaryhemophagocytic lymphhistiocytosis,proposed
8892,Cobas SARS-CoV-2 real time RT-PCR,nasopharyngeal swab sample,Confirmed COVID-19 disease
8893,patient,capacity,obtained from
8894,protocol,pregnant subjects,exclude
8895,ClinicalTrials.gov,data,processed
8896,randomized controlled trials,randomized controlled trials efficacy,demonstrated
8897,majority,majority,represent
8898,Patients,trial,continuethe
8899,ClinicalTrials.gov,data,processed
8900,ClinicalTrials.gov,data,processed
8901,Study,population,presents
8902,Patients,treatment,have
8903,ClinicalTrials.gov,data,processed
8904,Eligible participants,male female participants,include
8905,Inclusion CriteriaParticipants,following criteria,satisfy
8906,ClinicalTrials.gov,data,processed
8907,Study,data,obtain
8908,Additional data,response strategies,beobtained on
8909,characterized cohort,characterization,enable
8910,outcomes,longitudinallyfor,recruited throughout
8911,logistic regression,self reported baselinehealth status,include
8912,ClinicalTrials.gov,data,processed
8913,laboratoryparameters,assessment,facilitate
8914,Study,90 patients,enrolled
8915,ClinicalTrials.gov,data,processed
8916,Implications,ICOLS,the Lifestyle Changes and Supports Used
8917,Thequestions,changes,investigates
8918,ClinicalTrials.gov,data,processed
8919,Subjects,one of the followingtreatments,receive
8920,ClinicalTrials.gov,data,processed
8921,COVID-19 pandemic,challenge,presents
8922,Participants,questionnaire,complete
8923,Participants,blood sample,give
8924,Participants,theirblood sample,contacted by
8925,COVID-19 pandemic,challenge,presents
8926,protocol,identifiable participants,enroll
8927,Patient/Participants,toparticipate,invited
8928,ClinicalTrials.gov,data,processed
8929,ClinicalTrials.gov,data,processed
8930,ClinicalTrials.gov,data,processed
8931,ClinicalTrials.gov,data,processed
8932,infections,6million persons,approaching
8933,investigators,effect,compare
8934,Aparticipant involvement,up to 33 days,last
8935,ClinicalTrials.gov,data,processed
8936,ClinicalTrials.gov,data,processed
8937,ClinicalTrials.gov,data,processed
8938,Subject,ongoing medical history,has
8939,ClinicalTrials.gov,data,processed
8940,outbreak,byinfection,caused
8941,ClinicalTrials.gov,data,processed
8942,ClinicalTrials.gov,outcome data,processed
8943,ClinicalTrials.gov,data,processed
8944,Patients,instructional video,view
8945,Patients,breathing techniques,thenperform
8946,ClinicalTrials.gov,data,processed
8947,ClinicalTrials.gov,data,processed
8948,pandemic,unprecedented challenges,poses
8949,ClinicalTrials.gov,data,processed
8950,ClinicalTrials.gov,data,processed
8951,participating patients,providedaccording,receive
8952,patient,treatment,know
8953,ClinicalTrials.gov,data,processed
8954,ClinicalTrials.gov,data,processed
8955,ClinicalTrials.gov,data,processed
8956,Fisetin treatment,deterioration,determine
8957,Plasma,300 or as per clinical judgment,glucose
8958,ClinicalTrials.gov,data,processed
8959,Longitudinal Observational Study,Heart Hive,uses
8960,Patients,interruption,experienced
8961,ClinicalTrials.gov,data,processed
8962,ClinicalTrials.gov,data,processed
8963,the World HealthOrganization,global pandemic,declared
8964,Preliminary epidemiological reports,increasedrisk,showed
8965,studies,refutedthese claims,have
8966,population,patients,include
8967,Inclusion Criteria,patients,Include
8968,ClinicalTrials.gov,data,processed
8969,Child Pugh,C,Severe liver disease
8970,ClinicalTrials.gov,data,processed
8971,ClinicalTrials.gov,data,processed
8972,Trial,18 to 59 Years,Aged
8973,ClinicalTrials.gov,data,processed
8974,Adults 18yo hospitalised patients,COVID-19 infection,confirmed
8975,ClinicalTrials.gov,data,processed
8976,laboratory,COVID-19;3,confirmed
8977,i. Chest radiograph,bilateral opacities,showing
8978,i. Chest radiograph,bilateral opacities,showing
8979,Patients,result,have
8980,Patients,assay,have
8981,ClinicalTrials.gov,data,processed
8982,ClinicalTrials.gov,data,processed
8983,Potential participants,remote eligibility,undergo
8984,ClinicalTrials.gov,data,processed
8985,ClinicalTrials.gov,data,processed
8986,data donations frominternal external health care professionals,anonymized dataabout patients,a de-identifiedcentralized registry
8987,ClinicalTrials.gov,data,processed
8988,researchers,40 patients,treat
8989,surveys,COVID-19 symptoms severity,assess
8990,ClinicalTrials.gov,data,processed
8991,ClinicalTrials.gov,data,processed
8992,research team,6-week intervention,piloted
8993,pandemic,potential,presents
8994,ClinicalTrials.gov,data,processed
8995,Effective contraception,surgicalsterilization,includes
8996,ClinicalTrials.gov,data,processed
8997,patients,escalatingpharmacologic AA,receive
8998,66 subjects,escalatingpharmacologic AA treatments,randomized
8999,ClinicalTrials.gov,data,processed
9000,the World Health Organization,firstrecommendations,made
9001,WHODirector-General Tedros Adhanom Ghebreyesus,SARS CoV-2.5 outbreak,declares
9002,Mortality,up to 61%,beenreported
9003,100%,antibodies,detected
9004,Risks,TRALI,include
9005,Rare complications,transmission ofinfectious diseases,include
9006,national transfusion center,guidelines,published
9007,COVID-19 infection,high rate,had
9008,COVID-19 infection,highest rate,presented
9009,proposed treatments,adequate margin,have
9010,proposed treatments,adequate safety profile,have
9011,Ratio,CoV-2,toinspired
9012,ClinicalTrials.gov,data,processed
9013,inclusion visit,followingexamination,included
9014,"physical examination,- vital signs,- weight,- CBC laboratory testresult,-Chest X ray or CT chest Blood",-Pro BNP,assay
9015,nasoparyngeal swab willbe,1 2 day,performed
9016,ClinicalTrials.gov,data,processed
9017,Patients,symptoms,exhibit
9018,Patients,documented SARS CoV-2 RNA positive test virus,have
9019,Patients,100 × 10⁹/L);6,count
9020,ClinicalTrials.gov,data,processed
9021,gold standard,application,requires
9022,aerosols,potential harms,pose
9023,use,problems,solve
9024,ClinicalTrials.gov,data,processed
9025,ClinicalTrials.gov,data,processed
9026,ClinicalTrials.gov,data,processed
9027,Findings,new insight,provide
9028,required information,demographic data,includes
9029,ClinicalTrials.gov,data,processed
9030,Tele rehabilitation group,exercise program,perform
9031,Home exercise group,exercises,perform
9032,physiotherapist,patients,made
9033,ClinicalTrials.gov,data,processed
9034,Randomized Controlled Trial,safety,assess
9035,AZD1656,additional benefits,have
9036,Blood,level,glucose
9037,ClinicalTrials.gov,data,processed
9038,Laboratory,COVID-19;3,confirmed
9039,time,more than 4,exceed
9040,TBIL>=2,normal upper limit,times
9041,ClinicalTrials.gov,data,processed
9042,ClinicalTrials.gov,data,processed
9043,severe COVID-19 pneumonia,levilimab,receive
9044,investigator,arescue therapy - open label LVL,administer
9045,300 mmHg imaging,lesion progression,showed
9046,ClinicalTrials.gov,data,processed
9047,ClinicalTrials.gov,data,processed
9048,ClinicalTrials.gov,data,processed
9049,Participants,at least 1,have
9050,ClinicalTrials.gov,data,processed
9051,ClinicalTrials.gov,data,processed
9052,effectiveness,systematic incorporation inpost ICU rehabilitation protocols,proving
9053,ClinicalTrials.gov,data,processed
9054,ClinicalTrials.gov,data,processed
9055,ClinicalTrials.gov,data,processed
9056,control group,protectiveequipment,use
9057,firstintervention team,daily diet,receive
9058,ClinicalTrials.gov,data,processed
9059,study,efficacy,willevaluate
9060,PVP,1:30,used
9061,ClinicalTrials.gov,data,processed
9062,efficacy,patients,inhospitalized
9063,fever,fever,have
9064,aPTT,blood cell count creatinine levels,started on
9065,hypersensitivity,thrombocytopenia -Presence,induced
9066,ClinicalTrials.gov,data,processed
9067,New York Heart Association functional class Taking medications,antipsychotic antidepressant medications,include
9068,ClinicalTrials.gov,data,processed
9069,Subject,guardianship,protected
9070,ClinicalTrials.gov,data,processed
9071,ClinicalTrials.gov,data,processed
9072,treatment,care,include
9073,cases,cases,found
9074,Early research inthis laboratory,UC MSCs,used
9075,McGill RAAS COVID-19 Trial,48 patients,recruit
9076,ClinicalTrials.gov,data,processed
9077,Chinese scientists,genomeinformation,shared
9078,randomized controlled double blind trial,ofremdesivir,evaluate
9079,Chinese scientists,genomeinformation,shared
9080,randomized controlled double blind trial,ofremdesivir,evaluate
9081,Laboratory,COVID-19.3,confirmed
9082,e.g. Child Pugh,≥ C,Severe liver disease
9083,ClinicalTrials.gov,data,processed
9084,ClinicalTrials.gov,data,processed
9085,large epidemic,available hospital capacity,challenge
9086,nurses,emergency rooms,Study population
9087,Secondary endpoints,number,include
9088,exclusion category,subjects,comprises
9089,ClinicalTrials.gov,data,processed
9090,HCW,baseline assessment,get
9091,HCW,baseline assessment,get
9092,ClinicalTrials.gov,data,processed
9093,treatment,lung inflammation,reduce
9094,decay,sequentiallyunder treatment,I. Describe
9095,Patients,baricitinib,receive
9096,Patients,(PO) PO,receive
9097,Women,highly effective methods,use
9098,1000 mm^3-Absolute lymphocyte,200 mm^3-Hemoglobin 8 g dl Estimated glomerular filtration rate,count
9099,ClinicalTrials.gov,data,processed
9100,Recent observations,role,suggested
9101,ClinicalTrials.gov,data,processed
9102,COVID.The investigators,implementation,shown to
9103,percentage,LUS training module,measured by
9104,ClinicalTrials.gov,data,processed
9105,ClinicalTrials.gov,data,processed
9106,ClinicalTrials.gov,data,processed
9107,ClinicalTrials.gov,data,processed
9108,ROS based inactivation,toseveral reasons,reported
9109,COVID 2019,visible luminescenceof porphyrin,induced
9110,Title,existential threat tohealth care systems,presents
9111,Multiple therapeutic prophylactic agents,clinical trial,currentlyundergoing
9112,event thatthe spleen,event thatthe,expected in
9113,Munster,subnormalhaemoglobin levels,have
9114,36.4%,manifestationsincluding,experienced
9115,ClinicalTrials.gov,data,processed
9116,Participants,final study visitafter hospitalization,have
9117,ClinicalTrials.gov,data,processed
9118,ClinicalTrials.gov,data,processed
9119,Safety immunogenicity month study,daily pillof therapeutic vaccine,administered
9120,ClinicalTrials.gov,data,processed
9121,ClinicalTrials.gov,data,processed
9122,Patients,supportive care,receive
9123,patients,Stage,complete
9124,Twotelephonic,assessments,performed on
9125,Male female patients,21 to 80 years,aged
9126,fallopian tube,coil,without
9127,ClinicalTrials.gov,data,processed
9128,The FDA,an Emergency UseAuthorization,authorized
9129,ClinicalTrials.gov,data,processed
9130,Efficacy and Safety of 72-hour Infusion of Prostacyclin,Pulmonary Endotheliopathy,Induced
9131,Common symptoms,fever,include
9132,iloprost infusion,endothelial function andintegrity,Evidence support
9133,Standard Operation Procedure,specific procedures,addressprotocol
9134,ClinicalTrials.gov,data,processed
9135,Participants,6-week supply,receive
9136,study,place,take
9137,uterus,ovaries,removed
9138,diagnosis,oxaloacetate supplement,taking
9139,ClinicalTrials.gov,data,processed
9140,ClinicalTrials.gov,data,processed
9141,ClinicalTrials.gov,data,processed
9142,ClinicalTrials.gov,data,processed
9143,participants,computed tomographyimaging,complete
9144,ClinicalTrials.gov,data,processed
9145,intestinal tract,nervous systems,liverand
9146,powercalculations,data,used
9147,ClinicalTrials.gov,patient identifiable data,processed
9148,non - ventilatory strategies,intrapulmonary shunt,reduce
9149,studyhas,almitrine,investigated
9150,consecutive patients,doses,received
9151,investigators,COVID-19 patients,studied
9152,emergency conditions,design,impeded
9153,COVID-19 patients,HbThe recorded parameters,referred to
9154,ClinicalTrials.gov,data,processed
9155,The patient's Treating Physicianshould,suggested treatment guidelines,follow
9156,ClinicalTrials.gov,data,processed
9157,ClinicalTrials.gov,data,processed
9158,Subjects,exposure,documented
9159,ClinicalTrials.gov,data,processed
9160,ClinicalTrials.gov,data,processed
9161,study design,harmonisation,allow
9162,recruiting sites,option,have
9163,Participant,treatment,received
9164,ClinicalTrials.gov,data,processed
9165,ClinicalTrials.gov,data,processed
9166,ClinicalTrials.gov,data,processed
9167,participants,non - specific supportive treatment,receive
9168,ClinicalTrials.gov,data,processed
9169,Antiarrhythmics,Anti - cancer,sotalol
9170,Arsenic trioxide,Antidepressants,vandetanib
9171,ClinicalTrials.gov,data,processed
9172,Subjects,Screening,complete
9173,subject participation,maximum,bea
9174,Patients,masks,face
9175,Liver function,5x normal.7,tests
9176,ClinicalTrials.gov,data,processed
9177,ClinicalTrials.gov,data,processed
9178,SOC,1mg kginjection,receive
9179,Provide,informed consent,written
9180,ClinicalTrials.gov,data,processed
9181,Men,18-75 years.2,aged
9182,ClinicalTrials.gov,data,processed
9183,the Ministry of HigherEducation,quarantine hospitals,dedicated
9184,the Ministry of Higher Education,quarantine hospitals,dedicated
9185,forms,data,complement
9186,ClinicalTrials.gov,data,processed
9187,Changes,FiO2 requirement).IVc,decreased
9188,Patients,second infusion,mayreceive
9189,Patients,IV,receive
9190,Patients,secondinfusion,receive
9191,Patients,standard,receive
9192,ClinicalTrials.gov,data,processed
9193,Subjects,informed consent,considered
9194,ClinicalTrials.gov,data,processed
9195,Inclusion,positive,Criteria:-tested
9196,ClinicalTrials.gov,data,processed
9197,ClinicalTrials.gov,data,processed
9198,ClinicalTrials.gov,data,processed
9199,hydroxychloroquine sulfate,virus load,revealed
9200,Chest imaging,mild pneumonia symptoms Patients,chest)-documented
9201,ClinicalTrials.gov,data,processed
9202,ClinicalTrials.gov,data,processed
9203,Patients,quinolones,taking
9204,ClinicalTrials.gov,data,processed
9205,Study,place,take
9206,Participants,pre - loaded syringes,receive
9207,ClinicalTrials.gov,data,processed
9208,Patients,best availablestandard,receive
9209,ClinicalTrials.gov,data,processed
9210,The World Health Organization,COVID-19 outbreak,declared
9211,ClinicalTrials.gov,data,processed
9212,pandemic,thewhole world health system,puts
9213,patients,lymphopenia,show
9214,Patients,information,taken
9215,pandemic,thewhole world health system,puts
9216,patients,lymphopenia,show
9217,ClinicalTrials.gov,data,processed
9218,lopinavir ritonavir,viral load fromrespiratory specimen,This studyinvestigate
9219,ClinicalTrials.gov,data,processed
9220,Retrospective Study,Severity,Quantificate
9221,Retrospective Study,Severity,Quantificate
9222,ClinicalTrials.gov,data,processed
9223,research,6 volunteers,recruit
9224,subject,subject workusing protective costume,perform
9225,ClinicalTrials.gov,data,processed
9226,Patients,14 days,have
9227,Subject,concomitant bacterial respiratory infection,has
9228,Subject,history,has
9229,Subject,adrenocorticosteroids,using
9230,ClinicalTrials.gov,data,processed
9231,outbreak,global pandemic,led
9232,unknown role,plasma,study
9233,Project,priority,addresses
9234,Specimen collection,DNA,include
9235,ClinicalTrials.gov,data,processed
9236,ClinicalTrials.gov,data,processed
9237,ClinicalTrials.gov,data,processed
9238,ClinicalTrials.gov,data,processed
9239,Randomized Clinical Trial,nasal administration,evaluates
9240,Approximately 30%,admission,require
9241,reducing,peripheral inflammation,used at
9242,18 years of age or older,positive diagnostic sample,have
9243,ClinicalTrials.gov,data,processed
9244,The World Health Organization,Coronavirus,declared
9245,The World Health Organization,unprecedented global situation,facing
9246,ClinicalTrials.gov,data,processed
9247,the FDA,Authorization,granted
9248,ClinicalTrials.gov,data,processed
9249,WOCBP,negative pregnancy test,be
9250,ClinicalTrials.gov,data,processed
9251,Effective contraception,surgical sterilization,includes
9252,ClinicalTrials.gov,data,processed
9253,Theperformance,calibration,include
9254,Peripheral blood,cells(PBMC,Serum
9255,ClinicalTrials.gov,data,processed
9256,Chloroquine,COVID-19,AdmItted With
9257,Open Label Cluster Randomized Controlled Trial,COVID-19,AdmItted With
9258,study subject,receiveonly supportive care,Intervention
9259,patients,renal impairment,adjusted
9260,general practitioner,note,receive
9261,ClinicalTrials.gov,data,processed
9262,ClinicalTrials.gov,data,processed
9263,patients,considerable GI adverse effects,modified
9264,ClinicalTrials.gov,data,processed
9265,Thiswould,warming,include
9266,ClinicalTrials.gov,data,processed
9267,component,dose levels,evaluate
9268,The United States,highest totals,has
9269,3 disease,acute respiratory distress syndrome,includes
9270,TREG cells,aprotective effect,mediate
9271,component,dose levels,evaluate
9272,The United States,highest totals,has
9273,3 disease,acute respiratory distress syndrome,includes
9274,TREG cells,aprotective effect,mediate
9275,powerful counter - regulatorypopulation,Th1 cell predominance,described
9276,Clinical trials,TREG Th2-type cells,evaluated
9277,low frequency,eitherGATA3,express
9278,T cells,increase,have
9279,CD103,cooperate tomaintain immune tolerance,cells
9280,Inaddition,engraftment,increased
9281,RAPA-501 cells,suitable candidate,These resultssuggest
9282,RAPA-501 cells,HMC3 cell secretion,reduced
9283,randomized cohorts,therapy,continue
9284,Childs Pugh,12).5,score
9285,Patients,>450 milliseconds,interval
9286,Effective forms,Abstinence,include
9287,ClinicalTrials.gov,data,processed
9288,ClinicalTrials.gov,data,processed
9289,Female subjects,negative serum pregnancy test,have
9290,rate,>50%,infiltrates
9291,subjects,onanticoagulant medications,(INR) ≥1.5
9292,ClinicalTrials.gov,data,processed
9293,Study,efficacy,assess
9294,Eligible patients,single i.v infusion,receive
9295,Male female patients,≥18 years,aged
9296,Current participation,COVID-19 therapies,approved
9297,ClinicalTrials.gov,data,processed
9298,Previous studies,todetermine maternal perinatal outcome,collected in
9299,research project,incollaborative research,engage
9300,ClinicalTrials.gov,data,processed
9301,investigators,intervention,considerapplying
9302,investigators,use,identifiedis
9303,Patients,criteria,meeting
9304,Participant,consent,retires
9305,ClinicalTrials.gov,data,processed
9306,ClinicalTrials.gov,data,processed
9307,severe patients,ARDS development,considered for
9308,ClinicalTrials.gov,data,processed
9309,ClinicalTrials.gov,data,processed
9310,ClinicalTrials.gov,data,processed
9311,recently infected chronichaemodialysis patients,higher risk,stand
9312,ClinicalTrials.gov,data,processed
9313,ClinicalTrials.gov,data,processed
9314,ClinicalTrials.gov,data,processed
9315,Hospitalized COVID-19 patients,≥18 years of age,aged
9316,patients,≥18 years of age,aged
9317,ClinicalTrials.gov,data,processed
9318,Study timepoints,screening enrollment,include
9319,Hydroxychloroquine,long history,has
9320,ClinicalTrials.gov,data,processed
9321,ClinicalTrials.gov,data,processed
9322,ClinicalTrials.gov,data,processed
9323,ClinicalTrials.gov,data,processed
9324,Coagulopathy,approximately 20%,afflicts
9325,Number,11,alive
9326,Number,thrombocytopenia,induced
9327,LMWH options,Tinzaparin,include
9328,laboratory,diagnosis,confirmed
9329,ClinicalTrials.gov,data,processed
9330,centre,50 and200 consecutive patients,recruit
9331,ClinicalTrials.gov,data,processed
9332,ClinicalTrials.gov,data,processed
9333,ClinicalTrials.gov,data,processed
9334,Phase,TD-0903,Treat Symptomatic Acute Lung Injury
9335,conditions,a. New York Heart Association class IV Heart Failure b. Hepatic dysfunction,include
9336,ClinicalTrials.gov,data,processed
9337,Participants,questionnaires,complete
9338,ClinicalTrials.gov,data,processed
9339,WHO,SARS CoV-2 outbreak,declared
9340,patients,severe cardiovasculardamage,have
9341,Anothermarker,extracellular vesicles,circulating
9342,patients,severe cardiovascular damage,have
9343,coagulopathy wasfound,PT aPTT ratio,disturbed
9344,71.4%of non - survivors,criteria,met
9345,Endothelial dysfunction,major role,have
9346,marker,extracellular vesicles,becirculating
9347,ClinicalTrials.gov,data,processed
9348,patient,unit,receive
9349,Vitalant,unit,providing
9350,ClinicalTrials.gov,data,processed
9351,Coronavirus disease-2019,quoted inpatient mortality,has
9352,Excedrin ®,40,[
9353,ClinicalTrials.gov,data,processed
9354,COVID-19 pandemic,largeimpact,having
9355,studywill,minimum,recruit
9356,research team,information,collate
9357,research team,changes,analyse
9358,Participants,test antibody test,confirmed
9359,TwoInclusion Criteria:-The participant,confirmed COVID-19 test,had
9360,ClinicalTrials.gov,data,processed
9361,Patients,high mortality,have
9362,approach,clotformationenough,inhibit
9363,pandemic,wholeworlds health system,puts
9364,patients,lymphopenia,show
9365,centers,empiric anticoagulation,apply
9366,Bivalirudin,fibrinolytic activities,has
9367,ClinicalTrials.gov,data,processed
9368,Child,Exclusion Criteria,meeting
9369,ClinicalTrials.gov,data,processed
9370,Stem Cell Educator Therapy,Viral Inflammation,Treat
9371,SCE therapy,human multipotent cordblood stem cells,uses
9372,human multipotent cordblood stem cells,CB-SC,distinguish
9373,Subjectswho,criteria,scheduled for
9374,ClinicalTrials.gov,data,processed
9375,study,experimental control group,have
9376,ClinicalTrials.gov,data,processed
9377,ClinicalTrials.gov,data,processed
9378,Theassessment,lung volume,includes
9379,thestudy,data,provide
9380,Adult patients,18,befollowed up
9381,ClinicalTrials.gov,data,processed
9382,confirmed rheumatic disease Patients,follow,lost
9383,ClinicalTrials.gov,data,processed
9384,ClinicalTrials.gov,data,processed
9385,Preliminary reports,potentialefficacy,suggest
9386,administration ofhydroxychloroquine,clinical outcomes,improve
9387,ClinicalTrials.gov,data,processed
9388,ClinicalTrials.gov,data,processed
9389,physical psychological changes,someproblems,cause
9390,ClinicalTrials.gov,data,processed
9391,Tuberculosis,allergic history,burdened
9392,condition,completion,prevent
9393,ClinicalTrials.gov,data,processed
9394,ClinicalTrials.gov,data,processed
9395,ClinicalTrials.gov,data,processed
9396,ClinicalTrials.gov,data,processed
9397,Introduction,global public health problem,pose
9398,ClinicalTrials.gov,primary efficacy data,processed
9399,ClinicalTrials.gov,data,processed
9400,ClinicalTrials.gov,data,processed
9401,uncertainty aroundprioritization,public attention,generated
9402,brief educationalintervention,perception,is
9403,Demographic behavioral access questions,historical comparison,provide
9404,follow surveys,ascertain exposure,willadditional
9405,investigators,astratified randomization scheme,execute
9406,Participants,post - intervention surveywith repeat assessment,receive
9407,Key health behavior themes,experience,paid to
9408,Trial milestones,recruitment,include
9409,Additionalmilestones,submission,include
9410,ClinicalTrials.gov,data,processed
9411,ClinicalTrials.gov,data,processed
9412,recent papers,obesity,recognized
9413,Thesecondary end points,patient compliance,evaluating
9414,secondary end points,patient compliance,evaluating
9415,standard,recent guidelines,respect
9416,patient,7-days food diary,send
9417,patient,7-days food diary,send
9418,administration,APA guidelines,follow
9419,psychologist,questionnaires results,discuss
9420,psychologist,sessions contents,summarized
9421,diet changes,timing,follow up
9422,ClinicalTrials.gov,data,processed
9423,video dance class program,frequencyof sessions,have
9424,research,couldhelp,expected
9425,Exclusion,recent surgeries,Criteria:-performing
9426,ClinicalTrials.gov,data,processed
9427,Patients,higher incidence,had
9428,COVID-19 epidemic,"440,000 personsand",affected
9429,Patients,higher incidence,had
9430,ClinicalTrials.gov,data,processed
9431,investigators,survey predictions,willcompare
9432,ClinicalTrials.gov,data,processed
9433,Healthcare workers,COVID-19,acquire
9434,ClinicalTrials.gov,data,processed
9435,Patients,acute respiratory distress,develop
9436,Glycine,expression,diminishes
9437,Control group,habitual management,receive
9438,ClinicalTrials.gov,data,processed
9439,Secondary Immunological disorder,systemic pathology,generate
9440,OBJECTIVESBetter,1,understand
9441,counts,10xgenomics protocol,purified
9442,investigators,comparisons,analyses
9443,ClinicalTrials.gov,data,processed
9444,FDA,Critical COVID-19,defined
9445,patients,roomair,assessed by
9446,patients,theclinical definitions,meet
9447,ClinicalTrials.gov,data,processed
9448,cohort,30 patients,include
9449,ClinicalTrials.gov,data,processed
9450,ClinicalTrials.gov,data,processed
9451,Participants,film footage,view
9452,film(analogue trauma,intrusive memories,predicted
9453,participants,fewer intrusivememories,predicted
9454,ClinicalTrials.gov,data,processed
9455,Coronavirus Disease,unprecedented challenge,represents
9456,ClinicalTrials.gov,data,processed
9457,Participants,basic demographics survey,complete
9458,control group willnot,behavior intervention,receive
9459,single instance,place,take
9460,Subjects,second set,fill out
9461,ClinicalTrials.gov,data,processed
9462,AE report,intensity,include
9463,phase II,93 contacts,needed in
9464,The PrincipalInvestigators,appropriate medical research records,maintain
9465,study team memberswill,access,have
9466,Authorised representatives,documents,mayinspect
9467,clinical study site,records,permit
9468,hours,he/,call
9469,ClinicalTrials.gov,data,processed
9470,investigators,individuals,approach
9471,ClinicalTrials.gov,data,processed
9472,Data analysis,theimpact,test
9473,hospitals,existing support resources,are
9474,participants,brief assessment,complete
9475,Participants,10 discrete negative positive emotional words,rate
9476,ClinicalTrials.gov,data,processed
9477,medical students,access,have
9478,ClinicalTrials.gov,data,processed
9479,Growing evidences,usefulness,showing
9480,investigators,standardization,propose
9481,LUS COVID team,standardized approach,developed
9482,LUS COVID team,scoring system,proposed
9483,clinicians,20 cases,shared
9484,Methods,appropriateultrasound equipment,represent
9485,operators,agreed tested standardized images acquisition protocol,follow
9486,white lung).The darkening,loss,appear with
9487,highly scattering environment,peculiar pattern.- Score,canexplain
9488,scanned area,dense largely extended white lung,shows
9489,ClinicalTrials.gov,data,processed
9490,ClinicalTrials.gov,data,processed
9491,sector,trainee demographics,includes
9492,sector,trainee demographics,includes
9493,Inclusion Criteria:-The Survey,surgeons,targeting
9494,ClinicalTrials.gov,data,processed
9495,Althoughprevious researches,effect,is
9496,previous researches,effect,is
9497,ClinicalTrials.gov,data,processed
9498,ClinicalTrials.gov,data,processed
9499,Patients,investigational History,receiving
9500,ClinicalTrials.gov,data,processed
9501,Thecommon clinical manifestations,fever,included
9502,2016).In respiratory system conditions,wide ranging andfundamental roles,has
9503,ClinicalTrials.gov,data,processed
9504,ClinicalTrials.gov,data,processed
9505,ClinicalTrials.gov,data,processed
9506,Patients,rapid disease progression,have
9507,confirmedthat thalidomide,H1N1 lung injury,treat
9508,Patients,rapid disease progression,have
9509,ClinicalTrials.gov,data,processed
9510,Information,appetite,assessed via
9511,ClinicalTrials.gov,data,processed
9512,trial,pilot phase,has
9513,Secondary aims,collection,include
9514,ClinicalTrials.gov,data,processed
9515,Patients,daily assessment,have
9516,COVID-19.The study,following data,collect
9517,Vitals,FiO2,include
9518,Patients,clinical assessment,have
9519,Patients,1 hour ECG continuous recordings,have
9520,ClinicalTrials.gov,data,processed
9521,ClinicalTrials.gov,data,processed
9522,COVID-19 patients,tothe ICU,admitted
9523,Virchow triad,major risk factors,describes
9524,ClinicalTrials.gov,data,processed
9525,studywill,clazakizumab,compare
9526,ClinicalTrials.gov,data,processed
9527,ClinicalTrials.gov,data,processed
9528,prior echocardiogram,ejection fraction,the upper limit of
9529,ClinicalTrials.gov,data,processed
9530,Child Pugh,≥ C,score
9531,ClinicalTrials.gov,data,processed
9532,male penis,female vagina,no sexual intercourse
9533,-Acceptable forms,monogamousrelationship,include
9534,ClinicalTrials.gov,data,processed
9535,ClinicalTrials.gov,data,processed
9536,bilateral lung,thatextends,infiltrates
9537,ClinicalTrials.gov,data,processed
9538,ClinicalTrials.gov,data,processed
9539,Propolis,anti - inflammatory immunomodulatory anti - oxidant properties,has
9540,Propolis components,inhibitoryeffects,proven in
9541,ClinicalTrials.gov,data,processed
9542,novel coronavirus,Severe Acute Respiratory Syndrome Coronavirus 2,termed
9543,efforts,trials ofhydroxychloroquine,include
9544,ClinicalTrials.gov,data,processed
9545,subjects,series oflaboratory,undergo
9546,study team,studyessential document,update
9547,Recruitmentefforts,dissemination,include
9548,The Ethics Committee,recruitment process,approve
9549,main secondary analyses,effects,assess
9550,Theinvestigator,documents,maintain
9551,Investigator,monitoring,permit
9552,Thestatistician,subject security data,analyze
9553,ClinicalTrials.gov,data,processed
9554,Preliminary data,angiotensin II receptor blockers,shows
9555,ARBs,limitviral titre organ injury,could
9556,angiotensin II receptor blockers,severity ormortality,determine
9557,Modulation,need,decreases
9558,Interventions,quarantine,include
9559,critically ill COVID-19 patients,similar mortality rates,have
9560,ARBs,viral titre andorgan injury,limit
9561,Adult,patients,hospitalized
9562,ClinicalTrials.gov,data,processed
9563,purpose,insight,provide
9564,Investigators,data,providesimilar
9565,ClinicalTrials.gov,data,processed
9566,ClinicalTrials.gov,data,processed
9567,ClinicalTrials.gov,data,processed
9568,Subjects,positive test,have
9569,ClinicalTrials.gov,data,processed
9570,Genetic Factors,Response,Influencing
9571,ClinicalTrials.gov,data,processed
9572,Clinical Study,Patients,confirmed
9573,X-ray and/or CT,pneumonia4,diagnosed
9574,ClinicalTrials.gov,data,processed
9575,Patient,French,speaking
9576,ClinicalTrials.gov,data,processed
9577,ClinicalTrials.gov,data,processed
9578,Male,≥,aged
9579,ClinicalTrials.gov,data,processed
9580,ClinicalTrials.gov,data,processed
9581,SPY COVID TRIAL,enrollment,begin
9582,ClinicalTrials.gov,data,processed
9583,Patients,clinical assessment,receive
9584,Early intubation,noninvasive support,overescalating
9585,Hospitalists,care,physiciansdirect
9586,Disadvantages,allowance ofunblinded design,include
9587,SARS CoV-2 positive,RT PCR reverse transcription polymerase chain reaction)3,approved
9588,ClinicalTrials.gov,data,processed
9589,patients,Sofosbuvir plus Ledipasvir.-Group II OCH group,received
9590,patients,Oseltamivir plus HCQ & Azithromycin,received
9591,FDA,Anti - HCV drug,Sofosbuvir plusLedipasvir
9592,ClinicalTrials.gov,data,processed
9593,Percutaneous electrical nerve field stimulation,novel non - invasive methodof VNS,provides
9594,Unpublished studies,markeddecrease,demonstrated
9595,ClinicalTrials.gov,data,processed
9596,Macrophages,a vitamin Dreceptor,have
9597,Recruited subjects,25 mcg,begiven
9598,ClinicalTrials.gov,data,processed
9599,positron emission tomography,tomography,computed
9600,ClinicalTrials.gov,data,processed
9601,Inclusion Criteria:-Adults,≥,aged
9602,ClinicalTrials.gov,data,processed
9603,ClinicalTrials.gov,data,processed
9604,ClinicalTrials.gov,data,processed
9605,Supportive care,outcomes,improve
9606,The World Health Organization,outbreak apandemic,declared
9607,high quality clinical trials,regimenother,demonstrated
9608,Supportivecare,outcomes,improve
9609,ClinicalTrials.gov,data,processed
9610,Inclusion Criteria,COVID-19,overcome
9611,ClinicalTrials.gov,data,processed
9612,interested participants,study team member,contact
9613,Participantswill,swab,have
9614,Participants,questionnaires,complete
9615,asymptomatic high risk subjects,SARS CoV2 status unknown)2,tested
9616,individual,all thefollowing criteria:1,meet
9617,ClinicalTrials.gov,data,processed
9618,ClinicalTrials.gov,data,processed
9619,Observations,rate,include
9620,ClinicalTrials.gov,data,processed
9621,ClinicalTrials.gov,data,processed
9622,ClinicalTrials.gov,data,processed
9623,Patient,frequent prolonged use,requires
9624,patient,Gilbert syndrome,Total bilirubin
9625,platelets,100 × 109 / L,count
9626,ClinicalTrials.gov,data,processed
9627,Participants,3 study visits,have
9628,participants,blood saliva sample,give
9629,CoV-2 antibodies,short survey tocollect data,complete
9630,Participation,3 to 4 weeks,lasts
9631,2 4 weeks untilthe participant,2 consecutive negative RT PCR results,has
9632,ClinicalTrials.gov,data,processed
9633,Virtually COVID-19 RNA assays,centralized laboratories,require
9634,Samples,inlocations,collected
9635,thesedelays,risk,thought to
9636,ClinicalTrials.gov,data,processed
9637,number,patients,collected
9638,primary analysis,randomized patients,include
9639,investigators,study drug,present
9640,ClinicalTrials.gov,data,processed
9641,Thorax,tomography severity score,computed
9642,ClinicalTrials.gov,data,processed
9643,ClinicalTrials.gov,data,processed
9644,Managementof acute hypoxemic respiratory failure,mechanicalventilation,includes
9645,ClinicalTrials.gov,data,processed
9646,the WHO,pandemic,considered
9647,severe acute respiratory syndrome,diseasetransmission,involved
9648,ClinicalTrials.gov,data,processed
9649,Patients,treatment group,Aare
9650,patients,group,becontrolled
9651,informed consent Patient,diagnosis,received
9652,Pneumonia -pulmonary consolidations,50%of lungs,involving
9653,ClinicalTrials.gov,data,processed
9654,ClinicalTrials.gov,data,processed
9655,the World HealthOrganization,the World HealthOrganization,designated
9656,the WHO,disease,designated
9657,ClinicalTrials.gov,data,processed
9658,ClinicalTrials.gov,data,processed
9659,ClinicalTrials.gov,data,processed
9660,ClinicalTrials.gov,data,processed
9661,ClinicalTrials.gov,data,processed
9662,the FDA,use,tracked
9663,Extracted information,1,include
9664,blood bank technical staff,compatible blood type non - therapeutic units,select
9665,investigators,information,keep
9666,information,1,includes
9667,ClinicalTrials.gov,data,processed
9668,Knowledge,COVID-19,Regarding
9669,Knowledge,COVID-19,Regarding
9670,ClinicalTrials.gov,data,processed
9671,butfew reports,combination therapy,assessed
9672,ClinicalTrials.gov,data,processed
9673,ClinicalTrials.gov,data,processed
9674,Inclusion Criteria:-Have,acute illness,had
9675,ClinicalTrials.gov,data,processed
9676,investigators,national COVID-19 prevalence survey,conducting
9677,ClinicalTrials.gov,data,processed
9678,procedures,positivity,result
9679,ClinicalTrials.gov,data,processed
9680,ClinicalTrials.gov,data,processed
9681,ClinicalTrials.gov,data,processed
9682,Participants,plasma,donate
9683,machine,plasma,separate
9684,Participants,3 20 plasma donations,have
9685,Participation,up to 240 days,last
9686,Enrolled subjects,baseline physicaland laboratory examination,receive
9687,ClinicalTrials.gov,data,processed
9688,ClinicalTrials.gov,data,processed
9689,ClinicalTrials.gov,data,processed
9690,Participants,longitudinal assessments,willundergo
9691,aparticipant,escalation,collected within
9692,ClinicalTrials.gov,immunologic data,processed
9693,Known hypersensitivity,80 and,polysorbate
9694,ClinicalTrials.gov,data,processed
9695,group,drug,receive
9696,group,drug,receive
9697,second stage,20 volunteers,include
9698,subject,negative result,test for
9699,subject,systolic blood pressure less than 100 mm Hg,has
9700,subject,10 cigarettes,smokes
9701,ClinicalTrials.gov,data,processed
9702,Our HCW,higherexposure,have
9703,COVID-19Exclusion Criteria:-Refusal,informed consent,Inclusion Criteria:-Healthcare workers of
9704,ClinicalTrials.gov,data,processed
9705,Patients,collection collection,undergo
9706,ClinicalTrials.gov,data,processed
9707,open labelsafety trial,substantive benefit,suggested
9708,ClinicalTrials.gov,data,processed
9709,medical literature,reflections,reports
9710,rapid spread,fears,raised
9711,inclusion,place,take
9712,virology laboratory,report,edit
9713,ClinicalTrials.gov,data,processed
9714,ClinicalTrials.gov,data,processed
9715,spleen,injection contraindication Faint,cause
9716,ClinicalTrials.gov,data,processed
9717,clinical management,infectionprevention control measures,includes
9718,Study,theimprovement,measure
9719,ClinicalTrials.gov,data,processed
9720,Hydroxychloroquinetreatment,viral nucleic acid mediated activation,inhibit
9721,ClinicalTrials.gov,data,processed
9722,ClinicalTrials.gov,data,processed
9723,ClinicalTrials.gov,data,processed
9724,ClinicalTrials.gov,data,processed
9725,The united states,highest number,has
9726,ClinicalTrials.gov,data,processed
9727,second questionnaire.a second questionnaire,questions,contain
9728,Exclusion Criteria:-Changes,present,taste
9729,ClinicalTrials.gov,data,processed
9730,ClinicalTrials.gov,data,processed
9731,ClinicalTrials.gov,data,processed
9732,ClinicalTrials.gov,data,processed
9733,Patients,9 study visits,attend
9734,ClinicalTrials.gov,data,processed
9735,ClinicalTrials.gov,data,processed
9736,duration,7 days study treatment,includes
9737,Trial population,ofboth genders,consist
9738,Daily procedures,pharyngeal swab forqPCR diagnostics,include
9739,ClinicalTrials.gov,vitro data,processed
9740,ClinicalTrials.gov,data,processed
9741,retail pharmacists,public community,shouldprovide
9742,online survey link,questions,include
9743,Post,pharmacist.2,graduated
9744,Inclusion Criteria:-Post,pharmacist,graduated
9745,Exclusion Criteria:-under,students,graduated
9746,ClinicalTrials.gov,data,processed
9747,Participants,collection,undergo
9748,ClinicalTrials.gov,data,processed
9749,ClinicalTrials.gov,data,processed
9750,ClinicalTrials.gov,data,processed
9751,protocol,access,provides
9752,Safetyoutcomes,adverse events,include
9753,ClinicalTrials.gov,data,processed
9754,Participants,symptomatic COVID-19,whodevelop
9755,ClinicalTrials.gov,data,processed
9756,ABL1,inearly stages,shown
9757,CoV-2,inhibitory effect,proteases
9758,Pneumonia,positive test,confirmed
9759,ClinicalTrials.gov,data,processed
9760,ClinicalTrials.gov,data,processed
9761,covid-19 pathology,coagulation impairment,induce
9762,infection,release,stimulates
9763,ClinicalTrials.gov,data,processed
9764,Covid 19,infection,causes
9765,themajority,mild,expected
9766,recent multi - continentretrospective study,association,demonstrated
9767,Negative pregnancy test,age4,bearing
9768,ClinicalTrials.gov,data,processed
9769,study questionnaire,questions,includes
9770,study population,healthcare workers,include
9771,ClinicalTrials.gov,data,processed
9772,thePilot Stage,300 participants,include
9773,data,insights,providevaluable
9774,ClinicalTrials.gov,data,processed
9775,mass spectometry,consistent ionization patterns,"Additionally, the peptides of"
9776,administration,decrease,showed
9777,11%of adults,decrease,reported
9778,study,adecrease,showed
9779,82.4%,frequency,decrease
9780,SARS CoV-2,significant lung damage,suggested
9781,addition,signs andsymptoms,reduce
9782,ClinicalTrials.gov,data,processed
9783,ClinicalTrials.gov,data,processed
9784,Study timepoints,Day 1 screening enrollment,include
9785,HEALTH SYSTEM,inclusion criteria,meeting
9786,UNMHS HCWs,MD/DO,include
9787,Study PI's,study enrollment,consider
9788,Current medications,concomitant use,exclude
9789,ClinicalTrials.gov,data,processed
9790,second stage,20 volunteers,include
9791,subject,negative result,test for
9792,subject,systolic blood pressure less than 100 mm Hg,has
9793,subject,10 cigarettes,smokes
9794,ClinicalTrials.gov,data,processed
9795,series,higher sensitivity,reported
9796,ClinicalTrials.gov,data,processed
9797,approach,option,provides
9798,ClinicalTrials.gov,data,processed
9799,evaluable patients,ultralow dose lung radiation therapy(ULD WLRT,received
9800,ClinicalTrials.gov,data,processed
9801,clinical presentations,viral pneumonia1,In
9802,total numberof patients,confirmed cases,risen
9803,patients,different susceptibilityand severity levels,have
9804,ClinicalTrials.gov,data,processed
9805,pandemic,naive world population,affects
9806,ClinicalTrials.gov,data,processed
9807,exacerbated inflammatory reaction,inflammatory process,caused
9808,Male,≥,aged
9809,ClinicalTrials.gov,data,processed
9810,thecore management,infection prevention,includes
9811,Otherpossible mechanisms,antibody dependent cellular cytotoxicity,include
9812,Study,Non-randomized open Label trialB.,population1
9813,testing,Kits,ELISA
9814,procedure,column,-Doctor fills donor assessment form before
9815,apheresis technologist,donor age,enters
9816,desired component,select reinfusion,returned to
9817,Patients,consecutivetransfusions,receive
9818,clinical team,complete independent control,have
9819,tothe ERC.PI,data,monitor
9820,ClinicalTrials.gov,data,processed
9821,Exclusion,"workers,-workers",criteria:-interim
9822,ClinicalTrials.gov,data,processed
9823,Early data,particularly high risk ofthrombotic risk,indicate
9824,significant proportion,biological inflammatory syndrome,amarked
9825,ClinicalTrials.gov,data,processed
9826,aimsto,natural history,"This randomized, open-label, prospective, parallel-group controlled clinical study"
9827,ClinicalTrials.gov,data,processed
9828,observational study,patients,include
9829,ClinicalTrials.gov,data,processed
9830,India,edge,isat
9831,HCQ,anti viraleffect,has
9832,Recently published clinical trial,HCQ canbe,suggested
9833,Thecontrol group,HCQ,receive
9834,groups,standard care,receive
9835,chloroquine analogue,rays,given
9836,COVID-19 cases,COVID-19 cases,confirmed
9837,screening,individuals,infected
9838,groups,standard care,receive
9839,ClinicalTrials.gov,data,processed
9840,Inclusion,disease refractory shock,Criteria:-confirmed
9841,ClinicalTrials.gov,data,processed
9842,Inclusion Criteria:-Being,18-Fever 100.4 F,tested
9843,ClinicalTrials.gov,data,processed
9844,Parents,primary school education,had
9845,Parents,severe mental physical illness,have
9846,ClinicalTrials.gov,data,processed
9847,Colombia,"2,800 infected cases",has
9848,ClinicalTrials.gov,data,processed
9849,study,COVID-19 participants,include
9850,ClinicalTrials.gov,data,processed
9851,Qualifyingactivities,presence,include
9852,ClinicalTrials.gov,data,processed
9853,ClinicalTrials.gov,data,processed
9854,study,impact,investigates
9855,ClinicalTrials.gov,data,processed
9856,participants,follow study visits,have
9857,infection control,ability,limit
9858,Day 22 visit,laboratory tests,nothave
9859,absolute lymphocyte,200 cells,Lymphopenia (
9860,Received cytotoxic biologic treatments,therapies,targeted
9861,ClinicalTrials.gov,data,processed
9862,novel coronavirus,outbreak,caused
9863,ClinicalTrials.gov,data,processed
9864,clinical team,appropriate patients,identify
9865,Safety outcomes,monitoring,include
9866,lung,> 50%,infiltrates
9867,ClinicalTrials.gov,data,processed
9868,Thetesting,kind,include
9869,sample size calculation,inclusion,indicated
9870,Eachparticipant sample,unique code,have
9871,Study population,health care workers,include
9872,ClinicalTrials.gov,data,processed
9873,remaining ones,"an""exhausted phenotype",Patients with
9874,ClinicalTrials.gov,data,processed
9875,allergic rhinitis,spray therapy,corticosteroid
9876,ClinicalTrials.gov,data,processed
9877,patients,fever,found
9878,Inactivated Virus Vaccine,virus,inactivates
9879,ClinicalTrials.gov,data,processed
9880,practice,risk,wellincrease
9881,investigators,randomized trial comparingstandard prophylactic dose,designed
9882,ClinicalTrials.gov,data,processed
9883,ClinicalTrials.gov,data,processed
9884,Females,negative urine beta human chorionic gonadotropin hormone hCG pregnancy test,have
9885,ClinicalTrials.gov,data,processed
9886,ClinicalTrials.gov,data,processed
9887,ClinicalTrials.gov,data,processed
9888,paediatric population,mild asymptomatic form,present
9889,Thisstudy,frequency,asses
9890,sample,80 children,thereforeinclude
9891,questionnaire,relevant variables,extract
9892,ClinicalTrials.gov,data,processed
9893,ClinicalTrials.gov,data,processed
9894,ClinicalTrials.gov,data,processed
9895,COVID-19,unprecedented international crisis,caused
9896,COVID19-HOPE trial,patients,randomize
9897,secondary endpoints,clinicalfailure,include
9898,ClinicalTrials.gov,data,processed
9899,ClinicalTrials.gov,data,processed
9900,WHO,novel coronavirus,nominated
9901,ClinicalTrials.gov,data,processed
9902,ClinicalTrials.gov,data,processed
9903,spleen,injection contraindication Faint,cause
9904,ClinicalTrials.gov,data,processed
9905,protocol,94 consecutive adults,recruit
9906,control group,standard treatment,receive
9907,experimental group,care,recivestandard
9908,ClinicalTrials.gov,data,processed
9909,results,24 hrs,take
9910,patterns,information,offer
9911,final diagnostic model,fair discrimination betweenbacterial chest infections,permitted
9912,ClinicalTrials.gov,data,processed
9913,Coronavirus,containment,caused
9914,Somecountries,major screening strategy,used
9915,self survey,stress,assess
9916,Screening questionnaire,31questions,includes
9917,ClinicalTrials.gov,data,processed
9918,studies,"a""cytokine storm",suggested
9919,ClinicalTrials.gov,data,processed
9920,ClinicalTrials.gov,data,processed
9921,study,randomized placebo controlled double blinded design,utilize
9922,ClinicalTrials.gov,data,processed
9923,Novel coronavirus disease,acute lunginjury,causes
9924,Pulmonary imaging,diffuse exudative lesions,showed
9925,Patients,treatment,need
9926,ClinicalTrials.gov,data,processed
9927,outcome measures,new onset cardiac arrhythmia,include
9928,2 million populations,"150,000 deaths",wereinfected
9929,ClinicalTrials.gov,data,processed
9930,available data,association,confirm
9931,selective blockade,thepulmonary inflammatory response,wehypothesized
9932,ClinicalTrials.gov,available data,processed
9933,Theinvestigator,nature,explain
9934,Patients,between 18 and 80 years,aged
9935,ClinicalTrials.gov,available data,processed
9936,results,improvement,allow
9937,ClinicalTrials.gov,data,processed
9938,Study,Primary Objective,objectives
9939,management,written oral informed consent,"18 years,-any gender,-COVID-19 diagnosis"
9940,ClinicalTrials.gov,data,processed
9941,ClinicalTrials.gov,data,processed
9942,ClinicalTrials.gov,data,processed
9943,ClinicalTrials.gov,data,processed
9944,Thisresearch,passive administration,proposes
9945,Thepatients,infection,confirmed
9946,ClinicalTrials.gov,data,processed
9947,one hundred eighty,weekly doses,willreceive
9948,following criteria,standard clinical practice,Note
9949,ClinicalTrials.gov,data,processed
9950,ClinicalTrials.gov,data,processed
9951,Prospective Clinical Study,information,collectthe
9952,Follow assessment,clinical events,includes
9953,ClinicalTrials.gov,data,processed
9954,ClinicalTrials.gov,data,processed
9955,ClinicalTrials.gov,data,processed
9956,ClinicalTrials.gov,data,processed
9957,ClinicalTrials.gov,data,processed
9958,limited number,strict use,requires
9959,ClinicalTrials.gov,data,processed
9960,ClinicalTrials.gov,data,processed
9961,ClinicalTrials.gov,data,processed
9962,ClinicalTrials.gov,data,processed
9963,onset,hugeimpact,had
9964,ClinicalTrials.gov,data,processed
9965,ClinicalTrials.gov,data,processed
9966,ClinicalTrials.gov,data,processed
9967,PEP flute,positive effects,hypothesized
9968,investigators,lower rate,expect
9969,ClinicalTrials.gov,data,processed
9970,global spread,cancer patients,affecting
9971,online survey link,questions,include
9972,Patients,capacity,have
9973,ClinicalTrials.gov,data,processed
9974,ClinicalTrials.gov,data,processed
9975,study,profile,report
9976,proportion,specific IgG antibodies,develops
9977,ClinicalTrials.gov,data,processed
9978,ClinicalTrials.gov,data,processed
9979,ClinicalTrials.gov,data,processed
9980,ClinicalTrials.gov,data,processed
9981,ClinicalTrials.gov,Clinical laboratory chest image data,processed
9982,small scale hospital basedclinical studies,potential,indicated
9983,METHODS Robust clinical trials,800 SARS CoV-2,recruit
9984,ClinicalTrials.gov,data,processed
9985,ClinicalTrials.gov,data,processed
9986,Study,consequences,evaluates
9987,ClinicalTrials.gov,data,processed
9988,the World Health Organization,SARS COV2 COVID-19,secreted
9989,ClinicalTrials.gov,data,processed
9990,ClinicalTrials.gov,data,processed
9991,Male,≥,aged
9992,ClinicalTrials.gov,data,processed
9993,ClinicalTrials.gov,data,processed
9994,ClinicalTrials.gov,data,processed
9995,NLP techniques,methods,include
9996,Thetechniques,number,require
9997,ClinicalTrials.gov,data,processed
9998,ClinicalTrials.gov,data,processed
9999,investigators,existing technology,reoriented
10000,Database Analytics Study,early detection,facilitate
10001,ClinicalTrials.gov,data,processed
10002,Xiaoling Xu,tocilizumab,used
10003,ClinicalTrials.gov,data,processed
10004,ClinicalTrials.gov,data,processed
10005,ClinicalTrials.gov,data,processed
10006,ClinicalTrials.gov,data,processed
10007,Participants,non - pregnant adult,include
10008,ClinicalTrials.gov,data,processed
10009,ClinicalTrials.gov,data,processed
10010,study,invitro thrombin platelet aggregation inhibitory activities,investigated
10011,Retinoic acid,potent inhibition,exhibited
10012,retinoic acid,highestinhibition,showed
10013,Age,following conditions,have
10014,ClinicalTrials.gov,data,processed
10015,ClinicalTrials.gov,data,processed
10016,ClinicalTrials.gov,data,processed
10017,Acute Respiratory Distress Syndrome,high mortality,induces
10018,Acute Respiratory Distress Syndrome,high mortality,induces
10019,nasal high flow,need,reduced
10020,ClinicalTrials.gov,data,processed
10021,Routine Biomarkers Blood Leucocytes Count,Diagnosis,Assist
10022,COVID-19,large spectrum,has
10023,Chinese authors,description,extensivelyproposed
10024,Methods Setting Investigator,single center,designed
10025,Likert scale,distribution,allowed
10026,Investigator,extra - pulmonary infectious disease,patientswith
10027,ClinicalTrials.gov,data,processed
10028,epidemic,China,expanded from
10029,ClinicalTrials.gov,data,processed
10030,ClinicalTrials.gov,data,processed
10031,ClinicalTrials.gov,data,processed
10032,subjects,SOC therapy,receive
10033,HCV,14,positive
10034,subject,treatment,Any psychiatric issue for
10035,ClinicalTrials.gov,data,processed
10036,New Corona virus,horrible situation,made
10037,Levamisole,Lymphocytes,increase
10038,drug,levelof TNF,decrease
10039,chemical adjutant,New Corona virus,introduce
10040,ClinicalTrials.gov,data,processed
10041,controlled facility,emergency room,include
10042,ClinicalTrials.gov,data,processed
10043,Clinical Features,Need,Predict
10044,ClinicalTrials.gov,data,processed
10045,ClinicalTrials.gov,data,processed
10046,global escalation,health care system,put
10047,Ivermectin,5000 fold reduction,showed
10048,ClinicalTrials.gov,data,processed
10049,ClinicalTrials.gov,data,processed
10050,available kits,byhvd,supplied
10051,Ion Torrent targetednext generation sequencing,streamlined research workflow,enables
10052,ClinicalTrials.gov,data,processed
10053,ClinicalTrials.gov,data,processed
10054,ClinicalTrials.gov,data,processed
10055,ClinicalTrials.gov,data,processed
10056,ClinicalTrials.gov,data,processed
10057,The Amazon Alexa,survey questions,ask
10058,study coordinator willthen,survey questions,ask
10059,ClinicalTrials.gov,data,processed
10060,ClinicalTrials.gov,data,processed
10061,Inclusion Criteria:-Laboratory,infection,confirmed
10062,ClinicalTrials.gov,data,processed
10063,ClinicalTrials.gov,data,processed
10064,Patients,1 risk factor,have
10065,ClinicalTrials.gov,data,processed
10066,disease,urgent need,prompted
10067,ClinicalTrials.gov,data,processed
10068,Coronoa Virus,ahigh transmission rate,has
10069,ClinicalTrials.gov,data,processed
10070,Study,safety,evaluate
10071,ClinicalTrials.gov,data,processed
10072,Subject,acute,has
10073,ClinicalTrials.gov,data,processed
10074,bias,bias,limit
10075,case control study,relevant information,elicit
10076,ClinicalTrials.gov,data,processed
10077,investigators,efficacyand safety,evaluate
10078,Severe acuterespiratory infection,severe acute respiratory failure,causes
10079,ClinicalTrials.gov,data,processed
10080,currently ongoing world crippling pandemic,thedesperate urgent need,shows
10081,ClinicalTrials.gov,data,processed
10082,N=20,DSF,receive
10083,N=20,DSF 2000,receive
10084,ClinicalTrials.gov,data,processed
10085,Secondary objectives,assessment,include
10086,ClinicalTrials.gov,data,processed
10087,clinical study,less than 4 weeks,Symptoms of
10088,history,start,prito
10089,Positive test,venerea,lues
10090,ClinicalTrials.gov,data,processed
10091,the untreated group,3 placebo capsules,receive
10092,ClinicalTrials.gov,data,processed
10093,PVP-I)disinfectant,better anti - viral activity,has
10094,participant,option,have
10095,ClinicalTrials.gov,data,processed
10096,clinical spectrum,mechanical ventilation,thatnecessitates
10097,histopathological examination,earlyalveolar epithelial lung endothelial injury,show
10098,historically controlled multicenter trial inadults,treated beforedefibrotide availability,controls
10099,posthoc analysis,defibrotide,shown
10100,Defibrotide,endothelial protective properties,demonstrated
10101,Patients,underlying disease processes,showed
10102,Idiopathic pneumonia syndrome,histological evidence,shows
10103,ClinicalTrials.gov,data,processed
10104,Acceptable forms,-Implanted hormonal methods,include
10105,foam gel film cream suppository,negative pregnancy test4,-Have
10106,Subject,written informed consent,provide
10107,ClinicalTrials.gov,data,processed
10108,current protocol,investigator blinded randomized exercise intervention in10 COVID-19 survivors,encompasses
10109,ClinicalTrials.gov,data,processed
10110,challenge,questions,raises
10111,meta themes,experience stories ii,The diversity of
10112,ClinicalTrials.gov,data,processed
10113,variables,administrative data,included
10114,ClinicalTrials.gov,data,processed
10115,Participant,supplemental oxygen,requires
10116,ClinicalTrials.gov,data,processed
10117,tissue macrophages,circulating precursors,recognized to
10118,ClinicalTrials.gov,data,processed
10119,patients,standardtreatment protocol,received
10120,ClinicalTrials.gov,data,processed
10121,the WHO,pandemic,declared
10122,the World Health Organization,firstrecommendations,made
10123,AdhanomGhebreyesus,2019 outbreak,declares
10124,Theabove,possible use,suggests
10125,20 patients,higher mean age,had
10126,Yao et al,comparative study,conducted
10127,proposed treatments,adequate safety profile,have
10128,ClinicalTrials.gov,data,processed
10129,Investigator,data collection,maintain
10130,ALT)/aspartate aminotransferase,over 5 times the ULN;4,elevated
10131,ClinicalTrials.gov,data,processed
10132,Participants,study treatment,receive
10133,Assessments,blood collection,include
10134,ClinicalTrials.gov,data,processed
10135,ClinicalTrials.gov,Background,processed
10136,study,novel therapeutic agent,compare
10137,TACTIC E,efficacy,assess
10138,Treatment,up to 14 days,befor
10139,General Inclusion Criteria:-Be,18,aged
10140,ClinicalTrials.gov,data,processed
10141,authors,high dose treatment regimens,advocate
10142,ClinicalTrials.gov,data,processed
10143,Participants,the NIA/Clinical Research Unit,visit
10144,visit,about 1 hour,take
10145,Participants,medical history medicine review,have
10146,Participants,COVID-19questionnaire,complete
10147,Participants,urine sample,give
10148,Participants,saliva sample,give
10149,Participants,mouth,rinse
10150,Participants,laboratory sampling,repeat
10151,Confirmed Covid-19,adult patients,recovered
10152,ClinicalTrials.gov,data,processed
10153,ClinicalTrials.gov,data,processed
10154,ClinicalTrials.gov,data,processed
10155,China target population,categories,includes
10156,parameters,comprehensive status,provide
10157,ClinicalTrials.gov,data,processed
10158,ClinicalTrials.gov,data,processed
10159,DISmantling COvid,Neutrophil,iNduced
10160,elevated numbers,pooroutcomes,reported
10161,Acute inflammation,information,results
10162,ClinicalTrials.gov,data,processed
10163,Probiorinse,potentially beneficial effects,exert
10164,ClinicalTrials.gov,data,processed
10165,carrageenan sprays,clinical severity,Secondary objectivesare to
10166,Secondary outcome,symptom types,include
10167,ClinicalTrials.gov,data,processed
10168,study,kinetics,investigate
10169,Subjects,subjects,recovered from
10170,ClinicalTrials.gov,data,processed
10171,ClinicalTrials.gov,Data,processed
10172,ClinicalTrials.gov,data,processed
10173,ClinicalTrials.gov,data,processed
10174,ClinicalTrials.gov,data,processed
10175,spectrum,acute respiratory distress syndrome,ranges from
10176,Patients,intravenous dose,receive
10177,Clinical experimental research,strongassociation,established
10178,ClinicalTrials.gov,data,processed
10179,Recent studies,predominate,shown
10180,ClinicalTrials.gov,data,processed
10181,ClinicalTrials.gov,data,processed
10182,ClinicalTrials.gov,data,processed
10183,60%,ARDS criteria,met
10184,ClinicalTrials.gov,data,processed
10185,Inaddition,high incidence,have
10186,ClinicalTrials.gov,data,processed
10187,atotal,Multi center Randomized Blinding Clinical Trial Study,selected
10188,ClinicalTrials.gov,data,processed
10189,samples,secretions)VIII,inoropharyngeal
10190,ClinicalTrials.gov,data,processed
10191,Participants,1000 mg nitazoxanide,receive
10192,Participants,eitherthe SOC,receive
10193,ClinicalTrials.gov,data,processed
10194,50 years.-Patients,symptoms,have
10195,ClinicalTrials.gov,data,processed
10196,purpose,efficacy,assess
10197,Laboratory,COVID-19Exclusion Criteria1,confirmed
10198,ClinicalTrials.gov,data,processed
10199,ClinicalTrials.gov,data,processed
10200,ClinicalTrials.gov,data,processed
10201,epidemic,great burden,pose
10202,COVID-19,broad spectrum,has
10203,Studies,2/3,shown
10204,CoV-2,debut,have
10205,The World Health Organization,global shortage ofpersonal protection supplies,announced
10206,ClinicalTrials.gov,data,processed
10207,Participants,1 2 saliva samples,give
10208,participant,1 2 saliva samples,give
10209,ClinicalTrials.gov,data,processed
10210,ClinicalTrials.gov,data,processed
10211,COVID -19,world,strikes
10212,Bangladesh,Bangladesh havoc,facing
10213,aberrant release,lung damage,causes
10214,Burden,world,strikes
10215,Bangladesh,Bangladesh havoc,facing
10216,Knowledge gap,important role,has
10217,COVID-19 pandemic,COVID-19 pandemic staff,treating
10218,Adults,≥18,aged
10219,RT-PCR,COVID-19,confirmed
10220,ClinicalTrials.gov,data,processed
10221,ClinicalTrials.gov,data,processed
10222,ClinicalTrials.gov,data,processed
10223,Subjects,100 mg ofSTI-5656,receive
10224,ClinicalTrials.gov,data,processed
10225,Exclusion Criteria:-Eligible patients,history,have
10226,ClinicalTrials.gov,data,processed
10227,expanded cohort,safety,Phase
10228,ClinicalTrials.gov,data,processed
10229,number,thousands and is,killed
10230,novel coronavirus,human body,attacks
10231,ClinicalTrials.gov,data,processed
10232,chloroquine,lymphocyte counts,Note
10233,ClinicalTrials.gov,data,processed
10234,ClinicalTrials.gov,data,processed
10235,Patient,supplemental oxygen,receiving
10236,Patient,severe chronic obstructive pulmonary disease,has
10237,Patient,known pregnancy,has
10238,ClinicalTrials.gov,data,processed
10239,Retrospective study,improved survival,highlighted
10240,DAD,organizational phase,isdescribed
10241,ClinicalTrials.gov,data,processed
10242,ClinicalTrials.gov,data,processed
10243,ClinicalTrials.gov,data,processed
10244,dose,4 hours,bewithin
10245,ClinicalTrials.gov,data,processed
10246,2001).Several studies,psychological impact,reported
10247,participants,healthcare staff,include
10248,ClinicalTrials.gov,data,processed
10249,Acute Physiologic Chronic Health Evaluation,≥57,score
10250,Participant,extracorporeal membrane oxygenation,receiving
10251,ClinicalTrials.gov,data,processed
10252,ClinicalTrials.gov,data,processed
10253,60 patients,Ang 1-7 subcutaneously 500 mcg/kg,receive
10254,60 patients,Ang 1-7 subcutaneously 500 mcg/kg,receive
10255,current trial,COVID-19 treatments,excludepromising
10256,Moderate lung disease,one of the following criteria,meets
10257,patient characteristics,poor prognosis,portend
10258,ClinicalTrials.gov,data,processed
10259,date ofcollection,swab,performed at
10260,subject,nasal wash aspirate,underwent
10261,ClinicalTrials.gov,data,processed
10262,allergic rhinitis,spray therapy,corticosteroid
10263,ClinicalTrials.gov,data,processed
10264,survey studywill,Epidemic Pandemic Impacts Inventory,utilize
10265,ClinicalTrials.gov,data,processed
10266,"90,000 cells mm3-WBC","3,000 cells",count
10267,ClinicalTrials.gov,data,processed
10268,ClinicalTrials.gov,data,processed
10269,ClinicalTrials.gov,data,processed
10270,ClinicalTrials.gov,data,processed
10271,Inclusion CriteriaPatients,all the following criteria:1,meet
10272,Patient,symptoms,experiencing
10273,Patient,oxygen saturation level,has
10274,Patient,written informed consent,signed
10275,ClinicalTrials.gov,data,processed
10276,numerous reports,importance ofvascular damages,stressed
10277,MPs,ACE1,carry
10278,ClinicalTrials.gov,data,processed
10279,studieshave,effects,investigated
10280,study,new paradigm,develop
10281,ClinicalTrials.gov,data,processed
10282,ClinicalTrials.gov,data,processed
10283,older people,higher levelsof ACE2 expression,shown
10284,itscapacity,gene expression,proposed in
10285,mechanism,lungand endothelial damage,reduce
10286,ClinicalTrials.gov,data,processed
10287,Previous BCG,the Prognosis,Outcome of
10288,Previous BCG,Prognosis,Outcome of
10289,WHO,BCG vaccination,notrecommend
10290,ClinicalTrials.gov,data,processed
10291,study,305 COVID-19 cases,randomlyassigned to
10292,study,305 COVID-19 cases,randomlyassigned to
10293,ClinicalTrials.gov,data,processed
10294,ClinicalTrials.gov,data,processed
10295,recovered individuals,online survey,complete
10296,ClinicalTrials.gov,data,processed
10297,CSL,CSL760,evaluating
10298,viral serology test,live viral bacterial vaccinations,Received
10299,ClinicalTrials.gov,data,processed
10300,studies,shorter hospitalstay lower mortality,showed
10301,Adjunctive tests,hepatitis virus,befor
10302,ClinicalTrials.gov,data,processed
10303,activation,significant role,plays
10304,Immune cells,production,enhance
10305,main cause,late phase,whilein
10306,current physician,blood test,collected to
10307,ClinicalTrials.gov,data,processed
10308,ClinicalTrials.gov,data,processed
10309,Healthy people,years,aged
10310,Healthy people,years,aged
10311,ClinicalTrials.gov,data,processed
10312,study,40 symptomatic outpatients,enroll
10313,ClinicalTrials.gov,data,processed
10314,ClinicalTrials.gov,data,processed
10315,ClinicalTrials.gov,data,processed
10316,patients,presence,ambulantlyon
10317,ClinicalTrials.gov,data,processed
10318,Efficacy,treatments,approved
10319,PRRs,membrane bound Toll like receptors,include
10320,SARS coronavirus,positive sense RNA genome,asinglestranded
10321,Type 1 interferons,antiviral activity,have
10322,TLRs,important role,play
10323,TLR3,type IIFN,induces
10324,cells31 CYP26 Inhibitors,Retinoid Signaling,targeted
10325,Muscle Cells32 Itraconazole,inhibitive properties,has
10326,Fluconazol oritraconazol,cytochrome,inhibit
10327,application,dose dependent protein expression,demonstrated
10328,patients,totalcumulative dose,received
10329,Respiratoryfungal diseases therapy,challenges,facing
10330,ClinicalTrials.gov,data,processed
10331,ClinicalTrials.gov,data,processed
10332,Theavailability,mitochondrial metabolism,impacts
10333,ClinicalTrials.gov,data,processed
10334,ClinicalTrials.gov,data,processed
10335,ClinicalTrials.gov,data,processed
10336,transplanted T cells,recipient target tissues,acute graft vs
10337,ClinicalTrials.gov,data,processed
10338,study participation,unreasonable burden,Other critical health condition
10339,ClinicalTrials.gov,data,processed
10340,ClinicalTrials.gov,data,processed
10341,ClinicalTrials.gov,data,processed
10342,post covid syndrome,cases,confirmed
10343,ClinicalTrials.gov,data,processed
10344,ClinicalTrials.gov,data,processed
10345,TMPRSS2inhibitors,SARS CoV cell entry,prevent
10346,treatmentof cystic fibrosis mucolytic action,lung function deterioration,The most potent such inhibitors
10347,vasoactive agents,7 at time of drug infusion,required);-Hemoglobin
10348,ClinicalTrials.gov,data,processed
10349,university hospital,information technology system,developed
10350,ClinicalTrials.gov,data,processed
10351,Published reports,evidence,suggest
10352,Participants,Groups 1 and 2,form
10353,ClinicalTrials.gov,data,processed
10354,Zinc Supplementation,Clinical Efficacy,Enhance
10355,ClinicalTrials.gov,data,processed
10356,ClinicalTrials.gov,data,processed
10357,Inflammatory diseases,onset,favour
10358,Antiplatelet agents,cornerstone,represent
10359,use,inflammation respiratory function,improve
10360,higher efficacy,treatment,considered
10361,COVID-19)patients,unitary pathophysiological interpretation,Severe respiratory failure
10362,multiple bilateral vascular occlusions,segmental subsegmental branches,involvingthe
10363,Early initiation,presentation,mitigate
10364,ClinicalTrials.gov,data,processed
10365,ClinicalTrials.gov,data,processed
10366,ClinicalTrials.gov,data,processed
10367,COPID19,agreater level,require
10368,ClinicalTrials.gov,data,processed
10369,COVID-19,major impact,had
10370,ClinicalTrials.gov,data,processed
10371,ClinicalTrials.gov,data,processed
10372,ClinicalTrials.gov,data,processed
10373,Patients,40 80 years2,aged
10374,ClinicalTrials.gov,data,processed
10375,A Cross Sectional Study,men,includes
10376,ClinicalTrials.gov,data,processed
10377,link,information,gather
10378,study group,HCWs,include
10379,ClinicalTrials.gov,data,processed
10380,investigators,early treatment,hypothesized
10381,ClinicalTrials.gov,data,processed
10382,ClinicalTrials.gov,data,processed
10383,ClinicalTrials.gov,data,processed
10384,ClinicalTrials.gov,data,processed
10385,ClinicalTrials.gov,data,processed
10386,ClinicalTrials.gov,data,processed
10387,ClinicalTrials.gov,data,processed
10388,ofthe infected patients,mild symptoms,have
10389,ClinicalTrials.gov,data,processed
10390,Damage,suspected dysautonomic episodes,explain
10391,patients,continuous recording,have
10392,ClinicalTrials.gov,data,processed
10393,COVID-19,people,understood
10394,ClinicalTrials.gov,data,processed
10395,patients,intestinal symptoms,experienced
10396,ClinicalTrials.gov,data,processed
10397,cases,high risk,fatal
10398,ClinicalTrials.gov,data,processed
10399,WHO,Pandemic,declared
10400,WHO,Pandemic,declared
10401,ClinicalTrials.gov,data,processed
10402,TH,injury,reduce
10403,results,study,support
10404,Patients,deep sedation,receive
10405,Patients,light sedation,receive
10406,Comprehensive metabolic panel,basic electrolytes,includes
10407,8h,new samples,send
10408,CBC,every 12h,Make
10409,electronic versions,to severe ARDS,designed to
10410,up to 90 days,determination,include
10411,Skin process,cooling device,precludes
10412,>20%,21,burns over
10413,ClinicalTrials.gov,data,processed
10414,ClinicalTrials.gov,data,processed
10415,Ultrasound imaging,clinical utilityin COVID-19 patients,demonstrated
10416,Ultrasound imaging,clinical utilityin COVID-19 patients,demonstrated
10417,ClinicalTrials.gov,data,processed
10418,baseline assessments,nasopharyngeal swab,include
10419,center,support,provide
10420,follow,screening,includes
10421,ClinicalTrials.gov,data,processed
10422,ClinicalTrials.gov,data,processed
10423,women,highly effective methods,Women of
10424,ClinicalTrials.gov,data,processed
10425,ClinicalTrials.gov,data,processed
10426,ClinicalTrials.gov,data,processed
10427,ClinicalTrials.gov,data,processed
10428,Investigators,multicenter pilot study,recentlyperformed
10429,Thisstudy,ultraprotective ventilation,demonstrated
10430,ClinicalTrials.gov,data,processed
10431,health professionals,notable role,taking on
10432,studies,emotional responses,analysed
10433,ClinicalTrials.gov,data,processed
10434,ClinicalTrials.gov,data,processed
10435,COVID-19 pandemic,unwanted variation,exposed
10436,study,work packages,have
10437,ClinicalTrials.gov,data,processed
10438,Different genetic markers,role,play
10439,understanding,comprehension,help
10440,findings,valuable information,provide
10441,Routine diagnostic analysis Routine Laboratory testing,complete blood picture,includes
10442,Routine molecular diagnostic analysis Routine molecular Laboratory testing,Real-time PCR Detection,includes
10443,Exclusion Criteria:--patients,symptoms,have
10444,ClinicalTrials.gov,data,processed
10445,ClinicalTrials.gov,data,processed
10446,majority,CT scan,received
10447,investigatos,correlation,study
10448,ClinicalTrials.gov,data,processed
10449,pathology,strong negativeimpact,have
10450,ClinicalTrials.gov,data,processed
10451,Persons,≥60,aged
10452,ClinicalTrials.gov,data,processed
10453,ClinicalTrials.gov,data,processed
10454,European Observational Study,twoparts,comprises
10455,ClinicalTrials.gov,data,processed
10456,investigators,100 healthcare Provider volunteers,enrolling
10457,investigation,revenuesbefore,compare
10458,Physicians,devastating hits,taken
10459,health insurance companies,record profits,actuallypredicting
10460,good fortune,untold expense,comes at
10461,ClinicalTrials.gov,data,processed
10462,ClinicalTrials.gov,data,processed
10463,CHM,400 medicinal substances,includes
10464,Theinvestigators,pragmatic clinic data,have
10465,ClinicalTrials.gov,data,processed
10466,/ week,apotential effect,has
10467,ClinicalTrials.gov,data,processed
10468,ClinicalTrials.gov,data,processed
10469,Participants,hydroxychloroquine,receive
10470,ClinicalTrials.gov,data,processed
10471,20-30%,care and/or mechanical ventilation,hospitalized
10472,group B patients,colchicine,treated under
10473,eg cyclosporine,chemotherapy,considered by
10474,ClinicalTrials.gov,data,processed
10475,Receipt,18,given
10476,Site employees,PIs,include
10477,ClinicalTrials.gov,data,processed
10478,ClinicalTrials.gov,data,processed
10479,Patient,following laboratory values,meet
10480,Patient,adequate renal hepatic function,have
10481,ClinicalTrials.gov,data,processed
10482,investigators,asthe regional plastic,serve
10483,study,follow,forms
10484,Augment,current telemedicine capabilities,replace
10485,3D system,realistic accurate representation,give
10486,Method,Controlled Trial,Randomised
10487,study,data,generate
10488,ClinicalTrials.gov,data,processed
10489,ClinicalTrials.gov,data,processed
10490,ClinicalTrials.gov,data,processed
10491,ClinicalTrials.gov,data,processed
10492,Studies,reportedreduction viral load,have
10493,largest study,treatment,involved
10494,ClinicalTrials.gov,data,processed
10495,protocol,randomised trial,describes
10496,study,subsequentrandomisation,allows
10497,ClinicalTrials.gov,data,processed
10498,patients,questionnaire,answered
10499,ClinicalTrials.gov,data,processed
10500,ClinicalTrials.gov,data,processed
10501,Study staff,medical chart review totrack receipt,conduct
10502,patients,highershared decision,report
10503,patients,lessdecisional conflict,have
10504,ClinicalTrials.gov,data,processed
10505,order,immune response,performed in
10506,ClinicalTrials.gov,data,processed
10507,center,local Principal Investigator,willidentify
10508,ClinicalTrials.gov,data,processed
10509,large epidemic,available hospital capacity,challengethe
10510,participants,participants treatment allocation,receive
10511,allhealth care providers,information,performed to
10512,Data,medical history,includes
10513,Data,eligibility confirmation,includes
10514,participants,unsolicited AEs,report
10515,individual,s41586,found in
10516,participants,symptoms,be
10517,exclusion category,subjects,subjects with
10518,ClinicalTrials.gov,data,processed
10519,ClinicalTrials.gov,data,processed
10520,interventional,patientidentifiable information,collect
10521,ClinicalTrials.gov,data,processed
10522,ClinicalTrials.gov,data,processed
10523,Patients,particularlybad outcome,have
10524,International Cohort Study,metabolic stress,proposes
10525,ClinicalTrials.gov,data,processed
10526,registry,consecutive patients,include
10527,ClinicalTrials.gov,data,processed
10528,ClinicalTrials.gov,data,processed
10529,heparin,throughmultiple mechanisms,thought
10530,investigators,asmarkers,assess
10531,Acute opacities,effusions,include
10532,use,tobramycin,nebulised
